0001019687-11-002503.txt : 20110810 0001019687-11-002503.hdr.sgml : 20110810 20110810083351 ACCESSION NUMBER: 0001019687-11-002503 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20110630 FILED AS OF DATE: 20110810 DATE AS OF CHANGE: 20110810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Integrated Healthcare Holdings Inc CENTRAL INDEX KEY: 0001051488 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 870573331 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-23511 FILM NUMBER: 111022685 BUSINESS ADDRESS: STREET 1: 1301 N. TUSTIN AVENUE CITY: SANTA ANA STATE: CA ZIP: 92705 BUSINESS PHONE: 714-953-3503 MAIL ADDRESS: STREET 1: 1301 N. TUSTIN AVENUE CITY: SANTA ANA STATE: CA ZIP: 92705 FORMER COMPANY: FORMER CONFORMED NAME: Integrated Healthcare Holdings DATE OF NAME CHANGE: 20040816 FORMER COMPANY: FORMER CONFORMED NAME: FIRST DELTAVISION INC DATE OF NAME CHANGE: 19971216 10-Q 1 ihh_10q-063011.htm FORM 10-Q ihh_10q-063011.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
 (Mark One)
  
x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
   
  For the quarterly period ended June 30, 2011; or
   
o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ________ to ________
  
Commission File Number 0-23511


INTEGRATED HEALTHCARE HOLDINGS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

NEVADA
87-0573331
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)
(I.R.S. EMPLOYER IDENTIFICATION NO.)

1301 NORTH TUSTIN AVENUE
SANTA ANA, CALIFORNIA
92705
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
(ZIP CODE)

(714) 953-3503 (Registrant's telephone number, including area code)


(Former name, former address and former fiscal year, if changed since last report)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o
Accelerated filer o
Non-accelerated filer o
Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

There were 255,307,262 shares outstanding of the registrant's common stock as of August 1, 2011.


 
 
 
 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
FORM 10-Q
 
TABLE OF CONTENTS
 
   
   
Page
     
PART I - FINANCIAL INFORMATION
     
Item 1.
Financial Statements:
3
     
 
Condensed Consolidated Balance Sheets as of June 30 and March 31, 2011 - (unaudited)
3
     
 
Condensed Consolidated Statements of Operations for the three months ended June 30, 2011 and 2010 - (unaudited)
4
     
 
Condensed Consolidated Statement of Stockholders’ Deficiency for the three months ended June 30, 2011 – (unaudited)
5
     
 
Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2011 and 2010 – (unaudited)
6
     
 
Notes to Condensed Consolidated Financial Statements - (unaudited)
7
     
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
23
     
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
33
     
Item 4.
Controls and Procedures
33
     
PART II - OTHER INFORMATION
     
Item 1.
Legal Proceedings
34
     
Item 1A.
Risk Factors
34
     
Item 6.
Exhibits
34
     
 
Signatures
35
   
 
2

 
 
PART I - FINANCIAL INFORMATION
   
Item 1.  Financial statements
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in 000's, except par value)
(unaudited)

   
June 30,
2011
   
March 31,
2011
 
             
ASSETS
           
Current assets:
           
Cash and cash equivalents
  $ 14,847     $ 20,539  
Restricted cash
    12       24  
Accounts receivable, net of allowance for doubtful accounts of $22,008 and $20,076, respectively
    46,312       52,538  
Inventories of supplies, at cost
    6,095       5,945  
Due from governmental payers
    3,420       4,352  
Prepaid insurance
    2,282       3,108  
Prepaid income taxes
    5,200       -  
Prepaid expenses - hospital quality assurance fees
    15,100       -  
Hospital quality assurance fees receivable
    -       1,815  
Other prepaid expenses and current assets
    8,695       8,885  
Total current assets
    101,963       97,206  
                 
Property and equipment, net
    53,580       54,251  
Debt issuance costs, net
    182       445  
                 
Total assets
  $ 155,725     $ 151,902  
                 
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
               
Current liabilities:
               
Revolving line of credit
  $ 20,000     $ 19,081  
Accounts payable
    40,169       43,968  
Accrued compensation and benefits
    17,011       18,707  
Accrued insurance retentions
    15,373       16,642  
Unearned revenue - hospital quality assurance fees
    17,245       -  
Income taxes payable
    6,494       12,800  
Other current liabilities
    6,244       7,261  
Total current liabilities
    122,536       118,459  
                 
Debt, noncurrent
    45,000       45,000  
Warrant liability, noncurrent
    3,437       167  
Capital lease obligations, net of current portion of $1,140 and $1,131, respectively
    6,548       6,837  
Total liabilities
    177,521       170,463  
                 
Commitments, contingencies, and subsequent event
               
                 
Stockholders' deficiency:
               
Integrated Healthcare Holdings, Inc. stockholders' deficiency:
               
Common stock, $0.001 par value; 800,000 shares authorized; 255,307 shares issued and outstanding
    255       255  
Additional paid in capital
    62,911       62,911  
Receivable from stockholders
    (882 )     (882 )
Accumulated deficit
    (82,150 )     (79,280 )
Total Integrated Healthcare Holdings, Inc. stockholders' deficiency
    (19,866 )     (16,996 )
Noncontrolling interests
    (1,930 )     (1,565 )
Total stockholders' deficiency
    (21,796 )     (18,561 )
                 
Total liabilities and stockholders' deficiency
  $ 155,725     $ 151,902  
    
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
   
 
3

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(amounts in 000's, except per share amounts)
(unaudited)
     
 
 
Three months ended June 30,
 
   
2011
   
2010
 
             
Net operating revenues
  $ 89,662     $ 93,919  
                 
Operating expenses:
               
Salaries and benefits
    53,238       51,642  
Supplies
    12,983       12,945  
Provision for doubtful accounts
    9,697       8,908  
Other operating expenses
    14,476       16,140  
Depreciation and amortization
    1,090       1,044  
      91,484       90,679  
                 
Operating income (loss)
    (1,822 )     3,240  
                 
Other expense:
               
Interest expense, net
    (2,843 )     (3,118 )
Loss on warrants
    (3,270 )     (1,900 )
      (6,113 )     (5,018 )
                 
Loss before income tax benefit
    (7,935 )     (1,778 )
Income tax benefit
    5,200       -  
Net loss
    (2,735 )     (1,778 )
Net income attributable to noncontrolling interests (Note 9)
    (135 )     (135 )
                 
Net loss attributable to Integrated Healthcare Holdings, Inc.
  $ (2,870 )   $ (1,913 )
                 
Per Share Data:
               
Loss per common share attributable to Integrated Healthcare Holdings, Inc. stockholders
               
Basic
  $ (0.01 )   $ (0.01 )
Diluted
  $ (0.01 )   $ (0.01 )
Weighted average shares outstanding
               
Basic
    255,307       255,307  
Diluted
    255,307       255,307  
   
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
    
 
4

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIENCY
(amounts in 000's)
   
   
Integrated Healthcare Holdings, Inc. Stockholders
             
                                           
   
Common Stock
   
Additional
Paid-in
   
Receivable
from
   
Accumulated
   
Noncontrolling
       
   
Shares
   
Amount
   
Capital
   
Stockholders
   
Deficit
   
Interests
   
Total
 
                                           
Balance, March 31, 2011
    255,307     $ 255     $ 62,911     $ (882 )   $ (79,280 )   $ (1,565 )   $ (18,561 )
                                                         
Net income (loss)
    -       -       -       -       (2,870 )     135       (2,735 )
                                                         
Noncontrolling interests distributions
    -       -       -       -       -       (500 )     (500 )
                                                         
Balance, June 30, 2011
    255,307     $ 255     $ 62,911     $ (882 )   $ (82,150 )   $ (1,930 )   $ (21,796 )
     
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
   
 
5

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in 000's)
 

 
 
Three months ended June 30,
 
   
2011
   
2010
 
             
Cash flows from operating activities:
           
Net loss
  $ (2,735 )   $ (1,778 )
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
               
Depreciation and amortization of property and equipment
    1,090       1,044  
Provision for doubtful accounts
    9,697       8,908  
Amortization of debt issuance costs
    410       130  
Loss on warrants
    3,270       1,900  
Noncash share-based compensation expense
    -       14  
Changes in operating assets and liabilities:
               
Accounts receivable
    (3,471 )     (5,831 )
Inventories of supplies
    (150 )     (90 )
Due from governmental payers
    932       4,979  
Prepaid income taxes
    (5,200 )     -  
Prepaid expenses - hospital quality assurance fees
    (15,100 )     -  
Hospital quality assurance fees receivable
    1,815       -  
Prepaid insurance, other prepaid expenses and current assets, and other assets
    (1,835 )     (2,496 )
Accounts payable
    (3,799 )     (3,322 )
Accrued compensation and benefits
    (1,696 )     (3,253 )
Unearned revenues - hospital quality assurance fees
    17,245       -  
Income taxes payable
    (6,306 )     -  
Accrued insurance retentions and other current liabilities
    418       1,098  
Net cash provided by (used in) operating activities
    (5,415 )     1,303  
                 
Cash flows from investing activities:
               
Decrease (increase) in restricted cash
    12       (6 )
Additions to property and equipment
    (419 )     (571 )
Net cash used in investing activities
    (407 )     (577 )
                 
Cash flows from financing activities:
               
Proceeds from revolving line of credit, net
    919       -  
Noncontrolling interests distributions
    (500 )     (1,250 )
Payments on capital lease obligations
    (289 )     (200 )
Net cash provided by (used in) financing activities
    130       (1,450 )
                 
Net decrease in cash and cash equivalents
    (5,692 )     (724 )
Cash and cash equivalents, beginning of period
    20,539       10,159  
Cash and cash equivalents, end of period
  $ 14,847     $ 9,435  
                 
Supplemental information:
               
Cash paid for interest
  $ 2,191     $ 1,701  
Cash paid for income taxes
  $ 6,300     $ -  
  
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
   
 
6

 

INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
   
NOTE 1 - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION - The accompanying unaudited condensed consolidated financial statements of Integrated Healthcare Holdings, Inc. and its wholly owned subsidiaries (the "Company") have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial reporting. Accordingly, the accompanying statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, these statements include all adjustments that are of a normal and recurring nature necessary to present fairly the Company’s consolidated financial position, results of operations and cash flows. The results of operations for the three months ended June 30, 2011 are not necessarily indicative of the results for the entire 2012 fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2011 filed with the SEC on June 24, 2011.
 
The Company has determined that Pacific Coast Holdings Investment, LLC ("PCHI") (Note 9), is a variable interest entity as defined by GAAP and, accordingly, the financial statements of PCHI are included in the accompanying unaudited condensed consolidated financial statements.
 
All significant intercompany accounts and transactions have been eliminated in consolidation. Unless otherwise indicated, all amounts included in these notes to the consolidated financial statements are expressed in thousands (except per share amounts, percentages and stock option prices and values).
 
LIQUIDITY - As of June 30 and March 31, 2011, the Company had a total stockholders’ deficiency of $21.8 million and $18.6 million, respectively, and a working capital deficit of $20.6 million and $21.3 million, respectively.  For the three months ended June 30, 2011 and 2010, the Company had a net loss of $2.9 million and $1.9 million, respectively. At June 30, 2011, the Company had no additional availability under its revolving credit facility (Note 3).

DESCRIPTION OF BUSINESS - Effective March 8, 2005, the Company acquired four hospitals (the "Hospitals") from subsidiaries of Tenet Healthcare Corporation (the "Acquisition"). The Company owns and operates the four community-based hospitals located in southern California, which are:
     
 
282-bed Western Medical Center in Santa Ana
 
188-bed Western Medical Center in Anaheim
 
178-bed Coastal Communities Hospital in Santa Ana
 
114-bed Chapman Medical Center in Orange
   
RECLASSIFICATION FOR PRESENTATION - Certain amounts previously reported have been reclassified to conform to the current period's presentation with no impact on the reported net loss of the Company.
 
CONCENTRATION OF RISK - The Hospitals are subject to licensure by the State of California and accreditation by the Joint Commission. Loss of either licensure or accreditation would impact the ability to participate in various governmental and managed care programs, which provide the majority of the Company's revenues.
 
Substantially all net operating revenues come from external customers. The largest payers are Medicare and Medicaid, which combined accounted for 55% and 57% of the net operating revenues for the three months ended June 30, 2011 and 2010, respectively. No other payers represent a significant concentration of the Company's net operating revenues.
    
The Company receives all of our inpatient services revenue from operations in Orange County, California. The economic conditions of this market could affect the ability of our patients and third-party payers to reimburse us for our services, through its effect on disposable household income and the tax base used to generate state funding for Medicaid programs.
   
 
7

 
  
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
   
USE OF ESTIMATES - The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Principal areas requiring the use of estimates include third-party cost report settlements, income taxes, accrued insurance retentions and self-insurance reserves, and net patient receivables. Management regularly evaluates the accounting policies and estimates that are used. In general, management bases the estimates on historical experience and on assumptions that it believes to be reasonable given the particular circumstances in which its Hospitals operate. Although management believes that all adjustments considered necessary for fair presentation have been included, actual results may materially vary from those estimates.
 
REVENUE RECOGNITION - Net operating revenues are recognized in the period in which services are performed and are recorded based on established billing rates (gross charges) less estimated discounts for contractual allowances, principally for patients covered by Medicare, Medicaid, managed care, and other health plans. Gross charges are retail charges based on the Company’s Charge Description Master. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and therefore are not displayed in the unaudited condensed consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the federal government and state government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop-loss payments). Because Medicare requires that a hospital's gross charges be the same for all patients (regardless of payer category), gross charges are also what the Hospitals charge all other patients prior to the application of discounts and allowances.
 
Revenues under the traditional fee-for-service Medicare and Medicaid programs are based primarily on prospective payment systems. Discounts for retrospectively cost based revenues and certain other payments, which are based on the Hospitals' cost reports, are estimated using historical trends and current factors. Cost report settlements for retrospectively cost-based revenues under these programs are subject to audit and administrative and judicial review, which can take several years until final settlement of such matters are determined and completely resolved. Estimates of settlement receivables or payables related to a specific year are updated periodically and at year end and at the time the cost report is filed with the fiscal intermediary. Typically no further updates are made to the estimates until the final Notice of Program Reimbursement is received, at which time the cost report for that year has been audited by the fiscal intermediary. There could be several years’ time lag between the submission of a cost report and receipt of the Final Notice of Program Reimbursement. Since the laws, regulations, instructions and rule interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates recorded by the Hospitals could change by material amounts. The Company has established settlement receivables of $994 and $456 as of June 30 and March 31, 2011, respectively, which are included as due from government payers in the accompanying unaudited condensed consolidated balance sheets.
 
The Hospitals receive supplemental payments from the State of California to support indigent care (Medi-Cal Disproportionate Share Hospital payments or "DSH") and from the California Medical Assistance Commission ("CMAC") under the SB 1100 and SB 1255 programs. The Hospitals received supplemental payments of $4.9 million and $11.1 million during the three months ended June 30, 2011 and 2010, respectively. The related revenue recorded for the three months ended June 30, 2011 and 2010, was $3.4 million and $6.4 million, respectively. As of June 30 and March 31, 2011, estimated DSH receivables were $2.4 million and $3.9 million, respectively, which are included as due from government payers in the accompanying unaudited condensed consolidated balance sheets.

The following is a summary of due from governmental payers:
   
   
June 30,
 2011
   
March 31,
 2011
 
Medicare
 
$
994
   
$
456
 
Medicaid
   
2,426
     
3,896
 
   
$
3,420
   
$
4,352
 
  
Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers. The payers are billed for patient services on an individual patient basis. An individual patient's bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. The Hospitals estimate the discounts for contractual allowances utilizing billing data on an individual patient basis. Management believes the estimation and review process allows for timely identification of instances where such estimates need to be revised. The Company does not believe there were any adjustments to estimates of individual patient bills that were material to its net operating revenues.
    
 
8

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
     
The Hospitals provide charity care to patients whose income level is below 300% of the Federal Poverty Level. Patients with income levels between 300% and 350% of the Federal Poverty Level qualify to pay a discounted rate under AB 774 based on various government program reimbursement levels. Patients without insurance are offered assistance in applying for Medicaid and other programs they may be eligible for, such as state disability, Victims of Crime, or county indigent programs. Patient advocates from the Hospitals' Medical Eligibility Program ("MEP") screen patients in the hospital and determine potential linkage to financial assistance programs. They also expedite the process of applying for these government programs. The estimated costs (based on direct and indirect costs as a ratio of gross uncompensated charges associated with providing care to charity patients) for the three months ended June 30, 2011 and 2010 were approximately $1.3 million and $1.9 million, respectively.
 
Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending under the MEP, with appropriate contractual allowances recorded. If the patient does not qualify for Medicaid, the receivables are reclassified to charity care and written off, or they are reclassified to self-pay and adjusted to their net realizable value through the provision for doubtful accounts. Reclassifications of Medicaid pending accounts to self-pay do not typically have a material impact on the results of operations as the estimated Medicaid contractual allowances initially recorded are not materially different than the estimated provision for doubtful accounts recorded when the accounts are reclassified. All accounts classified as pending Medicaid, as well as certain other governmental receivables, over the age of 90 days were reserved in contractual allowances as of June 30 and March 31, 2011 based on historical collections experience.
 
The Company receives payments for indigent care under California section 1011. As of June 30 and March 31, 2011, the Company established a receivable in the amount of $1.4 million and $1.6 million, respectively, related to discharges deemed eligible to meet program criteria.
 
The Company is not aware of any material claims, disputes, or unsettled matters with any payers that would affect revenues that have not been adequately provided for in the accompanying unaudited condensed consolidated financial statements.
 
PROVISION FOR DOUBTFUL ACCOUNTS - The Company provides for accounts receivable that could become uncollectible by establishing an allowance to reduce the carrying value of such receivables to their estimated net realizable value. The Hospitals estimate this allowance based on the aging of their accounts receivable, historical collections experience for each type of payer and other relevant factors. There are various factors that can impact the collection trends, such as changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients, volume of patients through the emergency department, the increased burden of copayments to be made by patients with insurance and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends and the estimation process.
 
The Company's policy is to attempt to collect amounts due from patients, including copayments and deductibles due from patients with insurance, at the time of service while complying with all federal and state laws and regulations, including, but not limited to, the Emergency Medical Treatment and Labor Act ("EMTALA"). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, until the legally required medical screening examination is complete and stabilization of the patient has begun, services are performed prior to the verification of the patient's insurance, if any. In nonemergency circumstances or for elective procedures and services, it is the Hospitals' policy, when appropriate, to verify insurance prior to a patient being treated.

CASH AND CASH EQUIVALENTS - The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.

Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All of the non-interest bearing cash balances were fully insured at June 30, 2011 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, and the Company’s non-interest bearing cash balances may again exceed federally insured limits.

INVENTORIES OF SUPPLIES - Inventories of supplies are valued at the lower of weighted average cost or market.
   
 
9

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
   
PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and any impairment write-downs related to assets held and used. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Capital leases are recorded at the beginning of the lease term as property and equipment and a corresponding lease liability is recognized. The value of the property and equipment under capital lease is recorded at the lower of either the present value of the minimum lease payments or the fair value of the asset. Such assets, including improvements, are amortized over the shorter of either the lease term or their estimated useful life, where applicable.
 
The Company uses the straight-line method of depreciation for buildings and improvements, and equipment over their estimated useful lives of 25 years and 3 to 15 years, respectively.
 
LONG-LIVED ASSETS - The Company evaluates its long-lived assets for possible impairment whenever circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future cash flows. However, there is an evaluation performed at least annually. Fair value estimates are derived from established market values of comparable assets or internal calculations of estimated undiscounted future net cash flows. The estimates of future net cash flows are based on assumptions and projections believed by the Company to be reasonable and supportable. These assumptions take into account patient volumes, changes in payer mix, revenue, and expense growth rates and changes in legislation and other payer payment patterns.

DEBT ISSUANCE COSTS - On August 30, 2010, the Company entered into a new revolving credit facility (Note 3) under which it incurred debt issuance costs consisting of a $450 origination fee for the Company's $40 million Revolving Line of Credit (new debt) and $469 in legal and other expenses paid to third parties. These amounts are amortized over the credit facility’s three year life using the straight-line method. Subsequently, the $40 million Revolving Line of Credit was reduced to $20 million, resulting in an acceleration of the amortization of the related debt issuance costs.  Debt issuance costs of $410 (including $334 in accelerated amortization) and $130 were amortized during the three months ended June 30, 2011 and 2010, respectively.  At June 30 and March 31, 2011, prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheets included $153 and $300, respectively, as the current portion of debt issuance costs.

FAIR VALUE MEASUREMENTS - The Company's financial assets and liabilities recorded in the unaudited condensed consolidated balance sheets include cash and cash equivalents, restricted cash, receivables, debt, accounts payable, and other liabilities, all of which are recorded at book value which approximates fair value.

GAAP has established a hierarchy for ranking the quality and reliability of the information used to determine fair values and requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

 
Level 1:
Unadjusted quoted market prices in active markets for identical assets or liabilities.
     
 
Level 2:
Unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability.
     
 
Level 3:
Unobservable inputs for the asset or liability.

The Company utilizes the best available information in measuring fair value.  Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company currently has no financial or nonfinancial assets or liabilities subject to fair value measurement on a recurring basis except for warrants issued in April 2010 (Note 4).
   
 
10

 
  
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
   
The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis and where they are classified within the hierarchy as of June 30, 2011:
   
   
Total
   
Level 1
   
Level 2
   
Level 3
 
                         
Warrant liability
 
$
3,437
     
-
     
-
   
$
3,437
 
         
Warrant liability - fair value measurements using significant unobservable inputs (Level 3)
   
Balance at March 31, 2011 - Fair value of warrants issued and vested
 
$
167
 
Change in fair value of warrant liability included in earnings
 
       3,270
 
         
Balance at June 30, 2011
 
$
3,437
 
  
 WARRANTS - The Company has entered into complex transactions that contain warrants (Notes 3 and 4). If an instrument (or an embedded feature) that has the characteristics of a derivative instrument under this standard is indexed to an entity’s own stock, it is still necessary to evaluate whether it is classified in stockholders’ equity (or would be classified in stockholders’ equity if it were a freestanding instrument). Effective April 1, 2009, the Company adopted this standard, and at the time of adoption, this standard did not have an effect on the Company’s consolidated financial statements.  Subsequent to the Company’s adoption of this standard, the Company issued the April Warrants, which are accounted for as liabilities (Note 4).

LOSS PER COMMON SHARE - Loss per share is calculated under two different methods, basic and diluted. Basic loss per share is calculated by dividing the net loss by the weighted average shares of common stock outstanding during the period. Diluted loss per share is calculated by dividing the net loss by the weighted average shares of common stock outstanding during the period and dilutive potential shares of common stock. Dilutive potential shares of common stock, as determined under the treasury stock method, consist of shares of common stock issuable upon exercise of stock warrants or options, net of shares of common stock assumed to be repurchased by the Company from the exercise proceeds (Note 8).
 
INCOME TAXES - Deferred income tax assets and liabilities are determined based on the differences between the book and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws using the asset and liability method. The Company assesses the realization of deferred tax assets to determine whether an income tax valuation allowance is required. The Company has recorded a 100% valuation allowance on its deferred tax assets.
 
There is a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
 
The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and California. Certain tax attributes carried over from prior years continue to be subject to adjustment by taxing authorities. Penalties or interest, if any, arising from federal or state taxes are recorded as a component of the income tax provision.
   
 
11

 
  
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
   
SEGMENT REPORTING - The Company operates in one line of business, the provision of healthcare services through the operation of general hospitals and related healthcare facilities. The Company's Hospitals generate substantially all of its net operating revenues.
 
The Company's four general Hospitals and related healthcare facilities operate in one geographic region in Orange County, California. The region's economic characteristics, the nature of the Hospitals' operations, the regulatory environment in which they operate, and the manner in which they are managed are all similar. This region is an operating segment, as defined by GAAP. In addition, the Company's general Hospitals and related healthcare facilities share certain resources and benefit from many common clinical and management practices. Accordingly, the Company aggregates the facilities into a single reportable operating segment.
  
SUBSEQUENT EVENTS - The Company’s accompanying unaudited condensed consolidated financial statements are considered issued when filed with the SEC.  The Company has evaluated subsequent events to the filing date of this Form 10-Q with the SEC.

NEW ACCOUNTING STANDARDS – In August 2010, the FASB approved certain modifications to existing accounting standards that will directly affect health care entities in the future. The first change provides clarification to companies in the healthcare industry on the accounting for professional liability insurance. Specifically, it states that receivables related to insurance recoveries should not be netted against the related claim liability and such claim liabilities should be determined without considering insurance recoveries. The second change clarifies that disclosures regarding the level of charity care provided by a health care entity must (i) represent the direct and indirect costs of providing such services, and (ii) include a description of the method used to determine those costs. Additionally, disclosures about charity care must now include information regarding any related reimbursements received by a health care entity. The modified accounting standards are required to be adopted for fiscal years that begin after December 15, 2010. The charity care disclosure change must be applied on a retrospective basis; however, the accounting change for insurance recoveries may be applied on either a prospective or retrospective basis (the Company has applied the accounting change for insurance recoveries on a retrospective basis). The Company adopted the modified accounting standards during the three months ended June 30, 2011, which did not have a material impact on the unaudited condensed consolidated financial statements.

In January 2010, the FASB issued guidance to amend the disclosure requirements related to recurring and nonrecurring fair value measurements. The guidance requires new disclosures on the transfers of assets and liabilities between Level 1 (quoted prices in active market for identical assets or liabilities) and Level 2 (significant other observable inputs) of the fair value measurement hierarchy, including the reasons and the timing of the transfers. Additionally, the guidance requires a rollforward of activities on purchases, sales, issuance, and settlements of the assets and liabilities measured using significant unobservable inputs (Level 3 fair value measurements). Disclosures regarding transfers are required beginning January 1, 2010 and the Level 3 rollforward is to be disclosed in reporting periods beginning after December 15, 2010.
 
NOTE 2 - PROPERTY AND EQUIPMENT

Property and equipment consists of the following:
 
   
June 30,
 2011
   
March 31,
 2011
 
             
Buildings
 
$
34,637
   
$
34,624
 
Land and improvements
   
13,523
     
13,523
 
Equipment
   
13,635
     
13,266
 
Construction in progress
   
1,404
     
1,375
 
Assets under capital leases
   
11,218
     
11,218
 
     
74,417
     
74,006
 
Less accumulated depreciation
   
(20,837
)
   
(19,755
)
                 
Property and equipment, net
 
$
53,580
   
$
54,251
 
  
Accumulated depreciation on assets under capital leases as of June 30 and March 31, 2011 was $4.1 million and $3.7 million, respectively.
  
 
12

 
  
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
   
The Hospitals are located in an area near active and substantial earthquake faults. The Hospitals carry earthquake insurance with a policy limit of $50.0 million. A significant earthquake could result in material damage and temporary or permanent cessation of operations at one or more of the Hospitals.
 
The State of California has imposed new hospital seismic safety requirements. Under these new requirements, the Hospitals must meet stringent seismic safety criteria in the future. In addition, there could be other remediation costs pursuant to this seismic retrofit.
         
The State of California has introduced a new seismic review methodology known as HAZUS. The HAZUS methodology may preclude the need for some structural modifications. All four Hospitals requested HAZUS review and received a favorable notice pertaining to structural reclassification. All Hospital buildings, with the exception of one (an administrative building), have been deemed compliant until January 1, 2030 for both structural and nonstructural retrofit.  The Company does not have an estimate of the cost to remediate the seismic requirements for the administrative building as of June 30, 2011.

There are additional requirements that must be complied with by 2030. The costs of meeting these requirements have not yet been determined. Compliance with seismic ordinances will be costly and could have a material adverse effect on the Company's cash flow.  In addition, remediation could possibly result in certain environmental liabilities, such as asbestos abatement.

NOTE 3 - DEBT

On April 13, 2010 (the “Effective Date”), the Company entered into an Omnibus Credit Agreement Amendment (the “Omnibus Amendment”) with SPCP Group IV, LLC and SPCP Group, LLC (together, “Silver Point”), Silver Point Finance, LLC, as the Lender Agent, PCHI, Ganesha Realty LLC (“Ganesha”), Dr. Chaudhuri and KPC Resolution Company (“KPC”).  KPC and Ganesha are companies owned and controlled by Dr. Chaudhuri, who is the majority shareholder of the Company.  Ganesha is a member of PCHI with a 49% membership interest in PCHI.

The Company entered into the Omnibus Amendment in connection with the Loan Purchase and Sale Agreement, dated as of January 13, 2010, as amended, by and between KPC and the previous lender’s receiver.  Under the Loan Purchase Agreement and as approved by the Court on April 2, 2010, KPC agreed to purchase all of the Credit Agreements from Medical Capital Corporation’s receiver for $70.0 million.  Concurrent with the closing of the Loan Purchase Agreement, KPC sold its interest in the Credit Agreements to Silver Point, and KPC purchased from Silver Point a 15% participation interest in the Credit Agreements.  On April 13, 2010, concurrent with the effectiveness of the Omnibus Amendment and the closing of the Loan Purchase Agreement, Silver Point acquired all of the Credit Agreements, including the security agreements and other ancillary documents executed by the Company in connection with the Credit Agreements, and became the “New Lender” under the Credit Agreements.

The following are material terms of the Omnibus Amendment:
        
 
The stated maturity date under each Credit Agreement was changed to April 13, 2013.  The Credit Agreements were otherwise due to mature on October 8, 2010.
     
 
Affirming release of prior claims between the Company and the previous lender’s receiver, Silver Point agreed to waive any events of default that had occurred under the Credit Agreements and waived claims to accrued and unpaid interest and fees of $6.4 million under the Credit Agreements as of April 13, 2010.
     
 
The $80.0 million Credit Agreement was amended so that the $45.0 million term note (the “$45.0 million Loan”) and $35.0 million non-revolving line of credit note (the “$35.0 million Loan”) will each bear a fixed interest rate of 14.5% per year.  These loans previously bore interest rates of 10.25% and 9.25%, respectively.  In addition, the Company agreed to make certain mandatory prepayments of the $35.0 million Loan when it received proceeds from certain new financing of its accounts receivable or provider fee funds from Medi-Cal under the Hospital Quality Assurance Fee program (“QAF”) (Note 11).  The $35.0 million non-revolving line of credit was refinanced on August 30, 2010 (see below).
       
 
13

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
  
 
The $50.0 million Revolving Credit Agreement was amended so that Silver Point will, subject to the terms and conditions contained therein, make up to $10.0 million in new revolving funds available to the Company for working capital and general corporate purposes.  Each advance under the $50.0 million Revolving Credit Agreement will bear interest at an annual rate of Adjusted LIBOR (calculated as LIBOR subject to certain adjustments, with a floor of 2% and a cap of 5%) plus 12.5%, compared to an interest rate of 24.0% that was previously in effect under the $50.0 million revolving credit agreement.  In addition, the Company agreed to make mandatory prepayments of the $50.0 million Revolving Credit Agreement under the conditions described above with respect to the $80.0 million Credit Agreement.  The financial covenants under the $50.0 million Revolving Credit Agreement were also amended to increase the required levels of minimum EBITDA (as defined in the Omnibus Amendment) from the levels previously in effect under the $50.0 million Revolving Credit Agreement. This $50.0 million revolving line of credit was refinanced on August 30, 2010 (see below).
     
 
The $10.7 million Credit Agreement was amended so that the $10.7 million convertible term note will bear a fixed interest rate of 14.5% per year, compared to the interest rate of 9.25% previously in effect and to eliminate the conversion feature of the loan.  In addition, the Company agreed to make mandatory prepayments of the $10.7 million Credit Agreement under the conditions described above with respect to the $80.0 million Credit Agreement. This $10.7 million term note was refinanced on August 30, 2010 (see below).
  
In connection with the sale of the Credit Agreements, all warrants and stock conversion rights issued to the previous lender were cancelled.  In connection with the Omnibus Amendment, the Company issued new warrants (Note 4).
  
On August 30, 2010, the Company (excluding PCHI) entered into a Credit and Security Agreement (the “New Credit Agreement”) with MidCap Financial, LLC, a commercial finance lender specializing in loans to middle market health care companies, and Silicon Valley Bank (collectively, the “AR Lender”).

Under the New Credit Agreement, the AR Lender committed to provide up to $40.0 million in loans to the Company under a secured revolving credit facility (the “New Credit Facility”), which may be increased to up to $45.0 million upon the Company’s request, if the AR Lender consents to such increase.  Upon execution of the New Credit Agreement, the AR Lender funded approximately $39.7 million of the New Credit Facility, which funds were used primarily to repay approximately $35.0 million in loans outstanding to affiliates of Silver Point (“Term Lender”).  Upon such repayment, each of the Company’s $35.0 million non-revolving line of credit loan, $50.0 million revolving credit agreement and $10.7 million credit agreement with the Term Lender were fully repaid and terminated.  The only loan currently outstanding to the Term Lender consists of a $45.0 million Term Note issued under the Company’s $80.0 million Credit Agreement.

The New Credit Facility is secured by a first priority security interest on substantially all of the Company’s assets, including the equity interests in all of the Company’s subsidiaries (excluding PCHI).  The availability of the AR Lender’s commitments under the New Credit Facility is limited by a borrowing base tied to the Company’s eligible accounts receivable and certain other availability restrictions.

Loans under the New Credit Facility accrue interest at LIBOR (subject to a 2.5% floor) plus 5.0% per annum, subject to a default rate of interest and other adjustments provided for in the New Credit Agreement.  For purposes of calculating interest, all payments the Company makes on the New Credit Facility are subject to a six business day clearance period. The Company also pays a collateral management fee of .0625% per month on the outstanding balance (or a minimum balance amount equal to 85% of the monthly average borrowing base (the “Minimum Balance Amount”), if such amount is greater than the outstanding balance), a monthly minimum balance fee equal to the highest interest rate applicable to the loans if the Minimum Balance Amount is greater that the outstanding balance, and an unused line fee equal to .042% per month of the average unused portion of the New Credit Facility.  The Company paid to the AR Lender a non-refundable origination fee of 1.0% of the AR Lender’s commitments under the New Credit Facility at closing.

The New Credit Agreement contains various affirmative and negative covenants and customary events of default, including payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to similar obligations, events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, and the occurrence of events which have a material adverse effect on the Company.
  
 
14

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
  
Amendment to $80.0 million Credit Agreement – Concurrently with the execution of the New Credit Agreement, on August 30, 2010 the Company entered into an amendment to its existing $80.0 million Credit Agreement, as amended (the “Original Credit Agreement”), with the Term Lender, PCHI, and Ganesha  (the “Amendment”).  Under the Amendment, the Company agreed with the Term Lender to the following material changes to the Original Credit Agreement:
           
 
In the event of a mandatory prepayment of the Company’s accounts receivable based financing facility under the Original Credit Agreement, the outstanding loans under such agreement shall not be required to be prepaid below $10.0 million.  There is also a floor of $10.0 million below which commitments under such accounts receivable based facility would not be mandatorily reduced as a result of such prepayment.
     
 
The Original Credit Agreement was amended to add an affirmative covenant requiring the Company to deliver financial statements and other financial and non-financial information to the Term Lender on a regular basis, and a negative covenant requiring that the Company maintain a minimum fixed charge coverage ratio of 1.0 and minimum levels of earnings before interest, tax, depreciation and amortization (“EBITDA”).
     
 
The Company agreed to the provisions of an Intercreditor Agreement executed on August 30, 2010 by and between the AR Lender and the Term Lender with respect to shared collateral of the Company that is being pledged under both the New Credit Agreement and the Original Credit Agreement.  Under the Intercreditor Agreement, among other things the Term Lender consented to the AR Lender having a first priority lien on substantially all of the Company’s assets while the Term Lender retained a second lien on such assets, in addition to the Term Lender’s first priority lien on the Company’s leased properties owned by PCHI.
    
On October 29, 2010, the Company entered into Amendment No. 1 (the “Amendment”) to the New Credit Agreement, dated as of August 30, 2010, by and among the Company and the AR Lender.

Under the Amendment, the AR Lender committed to increase the total revolving loan commitment amount under the New Credit Agreement from $40.0 million to $45.0 million, and the Company agreed to pay to the AR Lender a non-refundable origination fee of 1.0% of the AR Lender’s increased commitment under the Amendment, or $50.

Also under the Amendment, the AR Lender agreed to allow the inclusion in Eligible Accounts that are used to determine the Company’s Borrowing Base of up to $33.6 million in aggregate federal or state matching payments to the Company related to QAF (Note 11), which amount was increased from $11.8 million for the first matching payment.

In addition, the optional prepayment and permanent commitment reduction provisions of the New Credit Agreement were amended to change the minimum Revolving Loan Commitment Amount to $20.0 million from $5.0 million.  In addition, the prepayment fee calculation under the New Credit Agreement was changed so that the prepayment fee is based on $40.0 million rather than the amount of the permanent revolving loan commitment reduction amount.

Lastly, under the Amendment, in the event the Company permanently reduces its Revolving Loan Commitment Amount to $20.0 million (and assuming there is no Event of Default at the time), the Company would be permitted to transfer funds that are swept into the Lender’s account from the Company’s lockbox accounts to a different bank account designated by the Company. Effective March 1, 2011, the Company reduced its Revolving Loan Commitment Amount to $20.0 million.  Beginning in April 2011, the funds that were previously swept into the Lender’s account were swept directly to the Company’s main account.

As of June 30, 2011, the Company had the following Credit Agreements:
       
 
A $45.0 million Term Note issued under the $80.0 million Credit Agreement, bearing a fixed interest rate of 14.5% per year ($45.0 million outstanding balance at June 30, 2011). If any event of default occurs and continues, the lender can increase the interest rate to 19.5% per year.
     
 
A $20.0 million Revolving Credit Agreement, bearing an interest rate of 5.0% plus LIBOR, with a 2.5% floor, per year (7.5% at June 30, 2011) and an unused commitment fee of 0.625% per year ($20.0 million outstanding balance at June 30, 2011).  For purposes of calculating interest, all payments the Company makes on the New Credit Facility are subject to a six business day clearance period.  As of June 30, 2011, the Company was in compliance with all financial covenants.
        
 
15

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
   
The Company's outstanding debt consists of the following:

   
June 30,
 2011
   
March 31,
 2011
 
             
Current: 
               
Revolving line of credit 
 
$
20,000
   
$
19,081
 
                 
 Noncurrent:
               
 Secured term note
 
$
45,000
   
$
45,000
 
  
NOTE 4 - COMMON STOCK WARRANTS

On April 13, 2010, the Company issued warrants (the “Omnibus Warrants”) to purchase its common stock for a period of three years at an exercise price of $0.07 per share in the following denominations: 139.0 million shares to KPC or its designees and 96.0 million shares to the Term Lender or its designees. The Omnibus Warrants also provide the holders with certain pre-emptive, information and registration rights. As of April 13, 2010, the Company recorded warrant expense and the related warrant liability of $2.9 million, representing fair value.  As of June 30, 2011, the fair value of the Omnibus Warrants was $2.0 million.
 
In addition, on April 13, 2010, the Company issued a three-year warrant (the “Release Warrant”) to acquire up to 170.0 million shares of common stock at $0.07 per share to Dr. Chaudhuri who facilitated a release enabling the Company to recover amounts due from the Company’s prior lender and a $1.0 million reduction in principal of its outstanding debt, among other benefits to the Company. As a result, the Company recorded the fair value of the Release Warrant ($2.1 million) as an offsetting cost of the recovery of amounts due from the Company’s prior lender. The Release Warrant also provides the holder with certain pre-emptive, information and registration rights. As of June 30, 2011, the fair value of the Release Warrant was $1.4 million.

The Omnibus Warrants and the Release Warrant are collectively referred to as the “April Warrants.” The net loss recorded related to the April Warrants for the three months ended June 30, 2011 and 2010 was $3.3 million and $1.9 million, respectively.
 
The fair value of warrants issued by the Company is estimated using the Black-Scholes valuation model, which the Company believes is the appropriate valuation method under the circumstances. Since the Company’s stock is thinly traded, the expected volatility is based on an analysis of the Company's stock and the stock of eight other publicly traded companies that own hospitals.

The risk-free interest rate is based on the average yield on U.S. Treasury notes with maturity commensurate with the terms of the warrants. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not anticipate paying cash dividends in the foreseeable future.  The assumptions used in the Black-Scholes valuation model are as follows.

   
June 30, 2011
   
April 13, 2010
 
             
Expected dividend yield
   
0.0%
     
0.0%
 
Risk-free interest rate
   
0.4%
     
1.7%
 
Expected volatility
   
43.0%
     
68.4%
 
Expected term (in years)
   
1.8
     
3.0
 
    
 
16

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
  
NOTE 5 - INCOME TAXES

The utilization of NOL and credit carryforwards is limited under the provisions of the IRC Section 382 and similar state provisions. Section 382 of the IRC of 1986 generally imposes an annual limitation on the amount of NOL carryforwards that may be used to offset taxable income where a corporation has undergone significant changes in stock ownership. In fiscal year 2009, the Company entered into the amended purchase agreement which resulted in a change in control. The Company conducted an analysis and determined that it is subject to significant IRC Section 382 limitations. For both Federal and State tax purposes, the Company's utilization of NOL and credit carryforwards is subject to significant IRC Section 382 limitations. The Company evaluates its ability to utilize the net operating losses each period with regard to the limitations imposed under IRC 382 and also considering the continuing expiration of statutes of limitation for prior years; and in the prior year determined that a portion of the federal and state net operating losses were no longer realizable, and removed from the schedule of deferreds those net operating losses in excess of the IRC 382 limitation and also considering prior years statutes now closed.
 
The difference between the reported income tax benefit and the amount computed by multiplying income before income tax benefit in the accompanying unaudited condensed consolidated statements of operations for the three months ended June 30, 2011 and 2010 by the statutory federal income tax rate primarily relates to the impact of a full valuation allowance reserving the net deferred assets, permanently nondeductible expenses, state and local income taxes, and variable interest entity.

The Company received QAF (Note 11) payments in the first quarter of the current fiscal year and expects additional payments in subsequent periods.  The application of FIN 18 requires the Company to compute the interim period income tax expense (benefit) by applying the estimated annual effective tax rate to the first quarter income (loss) from continuing operations, which resulted in the recognition of a tax benefit for the first quarter.

The Company evaluated its historical and projected sources of income to determine the extent to which the net deferred tax assets projected at June 30, 2011 could be realized, and based on this analysis the Company concluded that there was not sufficient positive evidence to support the realization of the net deferred tax assets, and therefore will continue to maintain a full valuation allowance against its net deferred assets for the three months ended June 30, 2011.

The Company’s California Enterprise Zone credits are currently under examination by the California taxing authority.  As a result of the examination, the Company recorded a liability of approximately $18.9 million for unrecognized tax benefits.  The Company's utilization of these credits is also subject to significant IRC Section 383 limitations, and these limitations have been incorporated into the tax provision calculation.

PCHI TAX STATUS - PCHI is a limited liability company. PCHI's taxable income or loss will flow through to its owners and be their separate responsibility. Accordingly, the accompanying unaudited condensed consolidated financial statements do not include any amounts for the income tax expense or benefit, or liabilities related to PCHI's income or loss.
  
 
17

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
  
NOTE 6 - STOCK INCENTIVE PLAN

The Company's 2006 Stock Incentive Plan (the "Plan"), which is shareholder-approved, permits the grant of share options to its employees and board members for up to a maximum aggregate of 12.0 million shares of common stock. In addition, as of the first business day of each calendar year in the period 2007 through 2015, the maximum aggregate number of shares shall be increased by a number equal to one percent of the number of shares of common stock of the Company outstanding on December 31 of the immediately preceding calendar year. Accordingly, as of June 30, 2011, the maximum aggregate number of shares under the Plan was 21.0 million. The Company believes that such awards better align the interests of its employees with those of its shareholders. In accordance with the Plan, incentive stock options, nonqualified stock options, and performance based compensation awards may not be granted at less than 100 percent of the estimated fair market value of the common stock on the date of grant. Incentive stock options granted to a person owning more than 10 percent of the voting power of all classes of stock of the Company may not be issued at less than 110 percent of the fair market value of the stock on the date of grant. Option awards generally vest based on 3 years of continuous service (1/3 of the shares vest on the twelve month anniversary of the grant date, and an additional 1/12 of the shares vest on each subsequent fiscal quarter-end of the Company following such twelve month anniversary). Certain option awards provide for accelerated vesting if there is a change of control, as defined. The option awards have 7-year contractual terms.
  
When the measurement date is certain, the fair value of each option grant is estimated on the date of grant using the Black-Scholes valuation model. Since there is limited historical data with respect to both pre-vesting forfeiture and post-vesting termination, the expected life of the options was determined utilizing the simplified method, whereby the expected term is calculated by taking the sum of the vesting term plus the original contractual term and dividing that quantity by two.

The Company recorded $0 and $14.0 of compensation expense relative to stock options during the three months ended June 30, 2011 and 2010, respectively. No options were exercised during the three months ended June 30, 2011 and 2010. A summary of stock option activity for the three months ended June 30, 2011 is presented as follows.
  
   
Shares
   
Weighted-
 average
 exercise
 price
   
Weighted-
 average
 grant date
 fair value
 
Weighted-
 average
 remaining
 contractual
 term
 (years)
     
Aggregate
 intrinsic
 value
                             
Outstanding, March 31, 2011
   
8,370
   
$
0.18
                   
Granted
   
-
   
$
-
   
$
-
           
Exercised
   
-
   
$
-
                   
Forfeited or expired
   
(20
)
 
$
0.25
                   
Outstanding, June 30, 2011
   
8,350
   
$
0.18
         
3.4
   
-
Exercisable at June 30, 2011
   
8,350
   
$
0.18
         
3.4
   
$
-
 
All outstanding options were fully vested as of June 30 and March 31, 2011.
  
NOTE 7 - RETIREMENT PLAN

The Company has a 401(k) plan for its employees. All employees with 90 days of service are eligible to participate, unless they are covered by a collective bargaining agreement which precludes coverage. The Company matches employee contributions up to 3% of the employee's compensation, subject to IRS limits. During the three months ended June 30, 2011 and 2010, the Company incurred expenses of $774 and $758, respectively, which are included in salaries and benefits in the accompanying unaudited condensed consolidated statements of operations.  At June 30 and March 31, 2011, accrued compensation and benefits in the accompanying unaudited condensed consolidated balance sheets included $1.6 million and $3.8 million, respectively, in accrued employer contributions.
   
 
18

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
    
NOTE 8 - INCOME PER SHARE

Income per share is calculated under two different methods, basic and diluted. Basic income per share is calculated by dividing the net income by the weighted average shares of common stock outstanding during the period. Diluted income per share is calculated by dividing the net income by the weighted average shares of common stock outstanding during the period and dilutive potential shares of common stock. Dilutive potential shares of common stock, as determined under the treasury stock method, consist of shares of common stock issuable upon exercise of stock warrants or options, net of shares of common stock assumed to be repurchased by the Company from the exercise proceeds.

Since the Company incurred losses for the three months ended June 30, 2011 and 2010, the potential shares of common stock, consisting of approximately 412 million and 437 million shares, respectively, issuable under warrants and stock options, have been excluded from the calculations of diluted loss per share for those periods.
 
NOTE 9 - VARIABLE INTEREST ENTITY

Concurrent with the close of the Acquisition, PCHI simultaneously acquired title to substantially all of the real property acquired by the Company in the Acquisition. The Company received $5.0 million and PCHI guaranteed the Company's $45.0 million Term Note. The Company remains primarily liable as the borrower under the $45.0 million Term Note notwithstanding its guarantee by PCHI; this note is cross-collateralized by substantially all of the Company's assets and all of the real property of the Hospitals. All of the Company's operating activities are directly affected by the real property that was sold to PCHI, which is a related party entity that is affiliated with the Company through common ownership and control. As of June 30, 2011, PCHI was owned 51% by various physician investors and 49% by Ganesha (Dr. Chaudhuri and Mr. Thomas). A company is required to consolidate the financial statements of any entity that cannot finance its activities without additional subordinated financial support, and for which one company provides the majority of that support through means other than ownership. Effective March 8, 2005, the Company determined that it provided the majority of financial support to PCHI through various sources including lease payments, remaining primarily liable under the $45.0 million Term Note, and cross-collateralization of the Company's non-real estate assets to secure the $45.0 million Term Note. Accordingly, the financial statements of PCHI are included in the accompanying unaudited condensed consolidated financial statements.
  
PCHI's assets, liabilities, and accumulated deficit are set forth below.

   
June 30,
 2011
   
March 31,
 2011
 
             
Cash
 
$
199
   
$
330
 
Property, net
   
41,951
     
42,273
 
Other
   
142
     
70
 
Total assets
 
$
42,292
   
$
42,673
 
                 
                 
Debt (as guarantor)
 
$
45,000
   
$
45,000
 
Other
   
617
     
634
 
Total liabilities
   
45,617
     
45,634
 
                 
Deficiency
   
(3,325
)
   
(2,961
)
Total liabilities and accumulated deficit
 
$
42,292
   
$
42,673
 
   
As noted above, PCHI is a guarantor on the $45.0 million Term Note should the Company not be able to perform.  PCHI's total liabilities represent the Company's maximum exposure to loss.
 
PCHI rental income and the Company’s related rental expense of $1.9 million and $1.7 million were eliminated upon consolidation for the three months ended June 30, 2011 and 2010, respectively.
 
The Company has a lease commitment to PCHI (Note 12). Additionally, the Company is responsible for seismic remediation under the terms of the lease agreement (Note 2).
   
 
19

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
   
NOTE 10 - RELATED PARTY TRANSACTIONS

PCHI - The Company leases substantially all of the real property of the acquired Hospitals from PCHI. PCHI is owned by various physician investors and Ganesha, which is managed by Dr. Chaudhuri. As of June 30 and March 31, 2011, Dr. Chaudhuri and Mr. Thomas are the beneficial holders of an aggregate of 447.5 million shares of the outstanding stock of the Company. As described in Note 9, PCHI is a variable interest entity and, accordingly, the Company has consolidated the financial statements of PCHI in the accompanying unaudited condensed consolidated financial statements.
 
NOTE 11 - HOSPITAL QUALITY ASSURANCE FEE PROGRAM

In October 2009, the Governor of California signed legislation supported by the hospital industry to impose a provider fee on general acute care hospitals that, combined with federal matching funds, would be used to provide supplemental Medi-Cal payments to hospitals. The state submitted the plan to the Centers for Medicare and Medicaid Services (“CMS”) for a required review and approval process, and certain changes in the plan were required by CMS. Legislation amending the fee program to reflect the required changes was passed by the legislature and signed by the Governor on September 8, 2010. Among other changes, the legislation leaves distribution of “pass-through” payments received by Medi-Cal managed care plans that will be paid to hospitals under the program to the discretion of the plans.  

The hospital quality assurance fee program (“QAF”) created by this legislation initially provided payments for up to 21 months retroactive to April 2009 and expiring on December 31, 2010 (“2010 QAF”). During fiscal year 2011, the Company recognized $87.2 million in revenue from the state for the 2010 QAF of which $1.8 million was received in April 2011 and is reflected as a receivable in the accompanying unaudited condensed consolidated balance sheet as of March 31, 2011.  All other amounts had been received during fiscal year 2011. As of March 31, 2011, $378.6 of the other expenses relating to the 2010 QAF was accrued and included in other current liabilities in the accompanying unaudited condensed consolidated balance sheet.

In May 2011, CMS conditionally approved the extension of the QAF for the six month period from January 1 through June 30, 2011 (“2011 QAF”).

Based on the most recent modeling prepared by the California Hospital Association, the Company anticipates making payments for provider fees and other expenses relating to the 2011 QAF of approximately $15.8 million and receiving approximately $31.6 million in net revenues from the state ($18.1 million from the fee-for-service portion and $13.5 million from the managed care portion). As of June 30, 2011, the Company has received $17.2 million from the fee-for-service portion of the 2011 QAF from the state and has paid fees to the state totaling $15.1 million.  Until such time as all final approvals have been received from CMS, the amounts received and paid through June 30, 2011 are reflected as unearned revenue and a prepaid asset, respectively, in the accompanying unaudited condensed consolidated balance sheet as of June 30, 2011.

The Company cannot provide any assurances or estimates in connection with a possible continuation of the QAF program beyond June 30, 2011.
     
NOTE 12 - COMMITMENTS AND CONTINGENCIES

GUARANTEE - At June 30, 2011, the Company accrued $1.8 million for a guarantee extended to a state supported teaching institution to accept the transfer of an uninsured patient for a necessary higher level of care.  The agreement and the institution’s practice are being reviewed.

OPERATING LEASES - On April 13, 2010, the Company and PCHI entered into a Second Amendment to Amended and Restated Triple Net Hospital Building Lease (the “2010 Lease Amendment”).  Under the 2010 Lease Amendment, the annual base rent to be paid by the Company to PCHI was increased from $5.4 million to $7.3 million, but if PCHI refinances the $45.0 million Term Note, the annual base rent will increase to $8.3 million. This lease commitment with PCHI is eliminated in consolidation.
  
 
20

 
  
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
   
CAPITAL LEASES - In connection with the Hospital Acquisition, the Company also assumed the leases for the Chapman facility, which include buildings and land with terms that were extended concurrently with the assignment of the leases to December 31, 2023. The Company leases equipment under capital leases expiring at various dates through December 2015. Assets under capital leases with a net book value of $7.1 million and $7.5 million are included in the accompanying unaudited condensed consolidated balance sheets as of June 30 and March 31, 2011, respectively. Interest rates used in computing the net present value of the lease payments are based on the interest rates implicit in the leases.

INSURANCE - The Company accrues for estimated general and professional liability claims, to the extent not covered by insurance, when they are probable and reasonably estimable. The Company has purchased as primary coverage a claims-made form insurance policy for general and professional liability risks. Estimated losses within general and professional liability retentions from claims incurred and reported, along with incurred but not reported (“IBNR”) claims, are accrued based upon projections and are discounted to their net present value using a weighted average risk-free discount rate of 5%. To the extent that subsequent claims information varies from estimates, the liability is adjusted in the period such information becomes available. As of June 30 and March 31, 2011, the Company had accrued $12.6 million and $14.0 million, respectively, which is comprised of $5.7 million and $6.6 million, respectively, in incurred and reported claims, along with $6.9 million and $7.4 million, respectively, in estimated IBNR.  Estimated insurance recoveries of $2.2 million and $2.7 million are included in other prepaid expenses and current assets in the accompanying unaudited condensed consolidated balance sheets as of June 30 and March 31, 2011, respectively.
  
The Company has also purchased occurrence coverage insurance to fund its obligations under its workers' compensation program. The Company has a "guaranteed cost" policy, under which the carrier pays all workers' compensation claims, with no deductible or reimbursement required of the Company. The Company accrues for estimated workers' compensation claims, to the extent not covered by insurance, when they are probable and reasonably estimable. The ultimate costs related to this program include expenses for deductible amounts associated with claims incurred and reported in addition to an accrual for the estimated expenses incurred in connection with IBNR claims. Claims are accrued based upon projections and are discounted to their net present value using a weighted average risk-free discount rate of 5%. To the extent that subsequent claims information varies from estimates, the liability is adjusted in the period such information becomes available. As of June 30 and March 31, 2011, the Company had accrued $770 and $836, respectively, comprised of $392 and $434, respectively, in incurred and reported claims, along with $378 and $402, respectively, in estimated IBNR.

In addition, the Company has a self-insured health benefits plan for its employees. As a result, the Company has established and maintains an accrual for IBNR claims arising from self-insured health benefits provided to employees. The Company's IBNR accruals at June 30 and March 31, 2011 were based upon projections. The Company determines the adequacy of this accrual by evaluating its limited historical experience and trends related to both health insurance claims and payments, information provided by its insurance broker and third party administrator and industry experience and trends. The accrual is an estimate and is subject to change. Such change could be material to the Company's unaudited condensed consolidated financial statements. As of June 30 and March 31, 2011, the Company had accrued $2.0 million and $1.8 million, respectively, in estimated IBNR. The Company believes this is the best estimate of the amount of IBNR relating to self-insured health benefit claims at June 30 and March 31, 2011.

The Company has also purchased umbrella liability policies with aggregate limits of $25 million. The umbrella policies provide coverage in excess of the primary layer and applicable retentions for insured liability risks such as general and professional liability, auto liability, and workers compensation (employers liability).

As of June 30, 2011, the Company finances various insurance policies at an interest rate of 4.03% per annum. The Company incurred finance charges relating to such policies of $12.4 and $16.7 for the three months ended June 30, 2011 and 2010, respectively. As of June 30 and March 31, 2011, the accompanying unaudited condensed consolidated balance sheets include the following balances relating to the financed insurance policies.

   
June 30,
2011
   
March 31,
2011
 
             
Prepaid insurance
 
$
2,282
   
$
3,108
 
                 
Accrued insurance premiums
 
$
1,523
   
$
1,951
 
(Included in other current liabilities)
               
   
 
21

 
  
INTEGRATED HEALTHCARE HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2011
(UNAUDITED)
 
CLAIMS AND LAWSUITS – The Company and the Hospitals are subject to various legal proceedings, most of which relate to routine matters incidental to operations. The results of these claims cannot be predicted, and it is possible that the ultimate resolution of these matters, individually or in the aggregate, may have a material adverse effect on the Company's business (both in the near and long term), financial position, results of operations, or cash flows. Although the Company defends itself vigorously against claims and lawsuits and cooperates with investigations, these matters (1) could require payment of substantial damages or amounts in judgments or settlements, which individually or in the aggregate could exceed amounts, if any, that may be recovered under insurance policies where coverage applies and is available, (2) cause substantial expenses to be incurred, (3) require significant time and attention from the Company's management, and (4) could cause the Company to close or sell the Hospitals or otherwise modify the way its business is conducted. The Company accrues for claims and lawsuits when an unfavorable outcome is probable and the amount is reasonably estimable.

The following is a summary of material developments in the matter involving Orange County Physicians Investment Network, LLC (“OC-PIN”) that was identified in our Form 10-K filed on June 24, 2011.  There have been no material developments in the other matters identified in the Form 10-K.

On April 24, 2009, a conglomeration of several OC-PIN members led by Ajay G. Meka, M.D. filed a lawsuit against Dr. Shah, other OC-PIN members, and various attorneys, alleging breach of fiduciary duty and seeking damages as well as declaratory and injunctive relief relating to the control of OC-PIN.  After a number of demurrers were filed by the defendants, Plaintiffs filed a Sixth Amended Complaint on May 5, 2011, to which the Company is not a party.  On May 19, 2011, Judge Nancy Wieben-Stock appointed Dr. Anil Shah and Dr. John Glavinovich as interim managers of OC-PIN and signed a formal order to this effect on June 27, 2011.  On July 20, 2011, OC-PIN’s attorney placed a demand on the Company to seat two directors – Mr. Brahmbhatt himself and one AmerZarka, M.D. – on the Board of Directors.  The Company declined this request based on its non-compliance with the Global Settlement Agreement and asked for additional information.  On August 3, 2011, the Company filed a lawsuit in the Orange County Superior Court asking for declaratory relief as to how it must respond to this request.
 
NOTE 13 - SUBSEQUENT EVENT

On July 1, 2011, the Company entered into software and services agreements with McKesson Technologies Inc. (“McKesson”) to upgrade the Company’s information technology systems.
 
Under the agreements, McKesson will provide the Company with a variety of services, including new software implementation and education/training services for the Company’s personnel, software maintenance services and professional services related to movement and migration of data from legacy systems.  McKesson will also furnish to the Company and maintain new hardware to accommodate the upgraded software and systems.  The new hardware will include computers, and servers, among other things, and will include installation, testing and ongoing maintenance.  The Company has entered into the arrangement to enhance its clinical information systems and upgrade its billing and revenue management information systems.
 
The agreements will initially run for a period of five years, and the recurring services may be renewed by the Company for successive periods.  The agreements do not provide that they may be terminated by the Company prior to the initial expiration date.  The agreements provide for one-time fees and recurring fees which aggregate a total of $22.0 million.  Approximately 60% of the fees are for one-time charges, while the balance is for recurring services.
     
 
22

 
 
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

FORWARD-LOOKING INFORMATION

This Quarterly Report on Form 10-Q contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed on June 24, 2011 that may cause our Company's or our industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as may be required by applicable law, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

As used in this report, the terms “we,” “us,” “our,” “the Company,” “Integrated Healthcare Holdings” or “IHHI” mean Integrated Healthcare Holdings, Inc., a Nevada corporation, unless otherwise indicated.

Unless otherwise indicated, all amounts included in this Item 2 are expressed in thousands (except percentages and per share amounts).

OVERVIEW

On March 8, 2005, we completed our acquisition (the "Acquisition") of four Orange County, California hospitals and associated real estate, including: (i) 282-bed Western Medical Center - Santa Ana, CA; (ii) 188-bed Western Medical Center - Anaheim, CA; (iii) 178-bed Coastal Communities Hospital in Santa Ana, CA; and (iv) 114-bed Chapman Medical Center in Orange, CA (collectively, the "Hospitals") from Tenet Healthcare Corporation. The Hospitals were assigned to our four wholly owned subsidiaries formed for the purpose of completing the Acquisition. We also acquired the following real estate, leases and assets associated with the Hospitals: (i) a fee interest in the Western Medical Center at 1001 North Tustin Avenue, Santa Ana, CA, a fee interest in the administration building at 1301 North Tustin Avenue, Santa Ana, CA, certain rights to acquire condominium suites located in the medical office building at 999 North Tustin Avenue, Santa Ana, CA, and the business known as the West Coast Breast Cancer Center; (ii) a fee interest in the Western Medical Center at 1025 South Anaheim Blvd., Anaheim, CA; (iii) a fee interest in the Coastal Communities Hospital at 2701 South Bristol Street, Santa Ana, CA, and a fee interest in the medical office building at 1901 North College Avenue, Santa Ana, CA; (iv) a lease for the Chapman Medical Center at 2601 East Chapman Avenue, Orange, CA, and a fee interest in the medical office building at 2617 East Chapman Avenue, Orange, CA; and (v) equipment and contract rights. At the closing of the Acquisition, we transferred all of the fee interests in the acquired real estate to Pacific Coast Holdings Investment, LLC ("PCHI"), a company owned indirectly by two of our largest shareholders.

SIGNIFICANT CHALLENGES

COMPANY - Our Acquisition involved significant cash expenditures, debt incurrence and integration expenses that has seriously strained our consolidated financial condition. If we are required to issue equity securities to raise additional capital or for any other reasons, existing stockholders will likely be substantially diluted, which could affect the market price of our stock. In April 2010 we issued equity securities to existing shareholders and a new lender (see "WARRANTS”).
 
INDUSTRY - Our Hospitals receive a substantial portion of their revenues from Medicare and Medicaid. The healthcare industry is experiencing a strong trend toward cost containment, as the government seeks to impose lower reimbursement and resource utilization group rates, limit the scope of covered services and negotiate reduced payment schedules with providers. These cost containment measures generally have resulted in a reduced rate of growth in the reimbursement for the services that we provide relative to the increase in our cost to provide such services.
  
Changes to Medicare and Medicaid reimbursement programs have limited, and are expected to continue to have limited, payment increases. Also, the timing of payments made under the Medicare and Medicaid programs is subject to regulatory action and governmental budgetary constraints resulting in a risk that the time period between submission of claims and payment could increase. Further, within the statutory framework of the Medicare and Medicaid programs, a substantial number of areas are subject to administrative rulings and interpretations which may further affect payments.
   
 
23

 
  
Our business is subject to extensive federal, state and, in some cases, local regulation with respect to, among other things, participation in the Medicare and Medicaid programs, licensure and certification of facilities, and reimbursement. These regulations relate, among other things, to the adequacy of physical property and equipment, qualifications of personnel, standards of care, government reimbursement and operational requirements. Compliance with these regulatory requirements, as interpreted and amended from time to time, can increase operating costs and thereby adversely affect the financial viability of our business. Since these regulations are amended from time to time and are subject to interpretation, we cannot predict when and to what extent liability may arise. Failure to comply with current or future regulatory requirements could also result in the imposition of various remedies including (with respect to inpatient care) fines, restrictions on admission, denial of payment for all or new admissions, the revocation of licensure, decertification, imposition of temporary management or the closure of a facility or site of service.
 
We are subject to periodic audits by the Medicare and Medicaid programs, which have various rights and remedies against us if they assert that we have overcharged the programs or failed to comply with program requirements. Rights and remedies available to these programs include repayment of any amounts alleged to be overpayments or in violation of program requirements, or making deductions from future amounts due to us. These programs may also impose fines, criminal penalties or program exclusions. Other third-party payer sources also reserve rights to conduct audits and make monetary adjustments in connection with or exclusive of audit activities.
 
The healthcare industry is highly competitive. We compete with a variety of other organizations in providing medical services, many of which have greater financial and other resources and may be more established in their respective communities than we are. Competing companies may offer newer or different centers or services than we do and may thereby attract patients or customers who are presently our patients or customers or are otherwise receiving our services.
 
An increasing trend in malpractice litigation claims, rising costs of malpractice litigation, losses associated with these malpractice lawsuits and a constriction of insurers have caused many insurance carriers to raise the cost of insurance premiums or refuse to write insurance policies for hospital facilities. Also, a tightening of the reinsurance market has affected property, vehicle, and excess liability insurance carriers. Accordingly, the costs of all insurance premiums have increased.
 
We receive all of our inpatient services revenue from operations in Orange County, California. The economic condition of this market could affect the ability of our patients and third-party payers to reimburse us for our services, through its effect on disposable household income and the tax base used to generate state funding for Medicaid programs. An economic downturn, or changes in the laws affecting our business in our market and in surrounding markets, could have a material adverse effect on our financial position, results of operations, and cash flows.

LIQUIDITY AND CAPITAL RESOURCES

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of obligations in the normal course of business. We had a total stockholders’ deficiency of $21.8 million and a working capital deficit of $20.6 million at June 30, 2011.  For the three months ended June 30, 2011, we had a net loss of $2.9 million.

Key items for the three months ended June 30, 2011 included:
   
 
1.  
Net collectible revenues (net operating revenues less provision for doubtful accounts) for the three months ended June 30, 2011 and 2010 were $80.0 million and $85.0 million, respectively, representing a decrease of 5.9%. The Hospitals serve a disproportionate number of indigent patients and receive governmental revenues and subsidies in support of care for these patients. Governmental revenues include payments from Medicaid, Medicaid DSH, and Orange County, CA (CalOptima). Governmental net revenues decreased $3.8 million for the three months ended June 30, 2011 compared to the three months ended June 30, 2010.
  
Inpatient admissions decreased by 8.6% to 5.3 for the three months ended June 30, 2011 compared to 5.8 for the three months ended June 30, 2010. The decline in admissions is primarily related to reductions in managed care and obstetrics admissions.  Adjusting for the shift to outpatient, adjusted admissions decreased by 4.3% for the three months ended June 30, 2011 compared to the same period in fiscal year 2011.
  
Uninsured patients, as a percentage of gross charges, were 4.8% for the three months ended June 30, 2011 compared to 5.2% for the three months ended June 30, 2010.
     
 
2.  
Operating expenses: Management is working aggressively to reduce costs without reduction in service levels. These efforts have in large part been offset by inflationary pressures. Operating expenses before interest for the three months ended June 30, 2011 were $91.5 million, or 0.9%, higher than during the three months ended June 30, 2010.
   
 
24

 
  
DEBT - On April 13, 2010 (the “Effective Date”), we entered into an Omnibus Credit Agreement Amendment (the “Omnibus Amendment”) with SPCP Group IV, LLC and SPCP Group, LLC (together, “Silver Point”), Silver Point Finance, LLC, as the Lender Agent, PCHI, Ganesha Realty LLC (“Ganesha”), Dr. Chaudhuri and KPC Resolution Company (“KPC”).  KPC and Ganesha are companies owned and controlled by Dr. Chaudhuri, who is our majority shareholder.  Ganesha is a member of PCHI with a 49% membership interest in PCHI.

We entered into the Omnibus Amendment in connection with the Loan Purchase and Sale Agreement, dated as of January 13, 2010, as amended, by and between KPC and the previous lender’s receiver.  Under the Loan Purchase Agreement and as approved by the Court on April 2, 2010, KPC agreed to purchase all of the Credit Agreements from Medical Capital Corporation’s receiver for $70.0 million.  Concurrent with the closing of the Loan Purchase Agreement, KPC sold its interest in the Credit Agreements to Silver Point, and KPC purchased from Silver Point a 15% participation interest in the Credit Agreements.  On April 13, 2010, concurrent with the effectiveness of the Omnibus Amendment and the closing of the Loan Purchase Agreement, Silver Point acquired all of the Credit Agreements, including the security agreements and other ancillary documents executed by us in connection with the Credit Agreements, and became the “New Lender” under the Credit Agreements.

The following are material terms of the Omnibus Amendment:
             
 
The stated maturity date under each Credit Agreement was changed to April 13, 2013.  The Credit Agreements were otherwise due to mature on October 8, 2010.
     
 
Affirming release of prior claims between us and the previous lender’s receiver, Silver Point agreed to waive any events of default that had occurred under the Credit Agreements and waived claims to accrued and unpaid interest and fees of $6.4 million under the Credit Agreements as of April 13, 2010.
     
 
The $80.0 million Credit Agreement was amended so that the $45.0 million term note (the “$45.0 million Loan”) and $35.0 million non-revolving line of credit note (the “$35.0 million Loan”) will each bear a fixed interest rate of 14.5% per year.  These loans previously bore interest rates of 10.25% and 9.25%, respectively.  In addition, we agreed to make certain mandatory prepayments of the $35.0 million Loan when it received proceeds from certain new financing of its accounts receivable or provider fee funds from Medi-Cal under the Hospital Quality Assurance Fee program (“QAF”) (Note 11).  The $35.0 million non-revolving line of credit was refinanced on August 30, 2010 (see below).
     
 
The $50.0 million Revolving Credit Agreement was amended so that Silver Point will, subject to the terms and conditions contained therein, make up to $10.0 million in new revolving funds available to us for working capital and general corporate purposes.  Each advance under the $50.0 million Revolving Credit Agreement will bear interest at an annual rate of Adjusted LIBOR (calculated as LIBOR subject to certain adjustments, with a floor of 2% and a cap of 5%) plus 12.5%, compared to an interest rate of 24.0% that was previously in effect under the $50.0 million revolving credit agreement.  In addition, we agreed to make mandatory prepayments of the $50.0 million Revolving Credit Agreement under the conditions described above with respect to the $80.0 million Credit Agreement.  The financial covenants under the $50.0 million Revolving Credit Agreement were also amended to increase the required levels of minimum EBITDA (as defined in the Omnibus Amendment) from the levels previously in effect under the $50.0 million Revolving Credit Agreement. This $50.0 million revolving line of credit was refinanced on August 30, 2010 (see below).
     
 
The $10.7 million Credit Agreement was amended so that the $10.7 million convertible term note will bear a fixed interest rate of 14.5% per year, compared to the interest rate of 9.25% previously in effect and to eliminate the conversion feature of the loan.  In addition, we agreed to make mandatory prepayments of the $10.7 million Credit Agreement under the conditions described above with respect to the $80.0 million Credit Agreement. This $10.7 million term note was refinanced on August 30, 2010 (see below).
       
 
25

 
  
In connection with the sale of the Credit Agreements, all warrants and stock conversion rights issued to the previous lender were cancelled.  In connection with the Omnibus Amendment, we issued new warrants.
  
On August 30, 2010, we (excluding PCHI) entered into a Credit and Security Agreement (the “New Credit Agreement”) with MidCap Financial, LLC, a commercial finance lender specializing in loans to middle market health care companies, and Silicon Valley Bank (collectively, the “AR Lender”).

Under the New Credit Agreement, the AR Lender committed to provide up to $40.0 million in loans to us under a secured revolving credit facility (the “New Credit Facility”), which may be increased to up to $45.0 million upon our request, if the AR Lender consents to such increase.  Upon execution of the New Credit Agreement, the AR Lender funded approximately $39.7 million of the New Credit Facility, which funds were used primarily to repay approximately $35.0 million in loans outstanding to affiliates of Silver Point (“Term Lender”).  Upon such repayment, each of our $35.0 million non-revolving line of credit loan, $50.0 million revolving credit agreement and $10.7 million credit agreement with the Term Lender were fully repaid and terminated.  The only loan currently outstanding to the Term Lender consists of a $45.0 million Term Note issued under our $80.0 million Credit Agreement.

The New Credit Facility is secured by a first priority security interest on substantially all of our assets, including the equity interests in all of our subsidiaries (excluding PCHI).  The availability of the AR Lender’s commitments under the New Credit Facility is limited by a borrowing base tied to our eligible accounts receivable and certain other availability restrictions.

Loans under the New Credit Facility accrue interest at LIBOR (subject to a 2.5% floor) plus 5.0% per annum, subject to a default rate of interest and other adjustments provided for in the New Credit Agreement.  For purposes of calculating interest, all payments we make on the New Credit Facility are subject to a six business day clearance period. We also pay a collateral management fee of .0625% per month on the outstanding balance (or a minimum balance amount equal to 85% of the monthly average borrowing base (the “Minimum Balance Amount”), if such amount is greater than the outstanding balance), a monthly minimum balance fee equal to the highest interest rate applicable to the loans if the Minimum Balance Amount is greater that the outstanding balance, and an unused line fee equal to .042% per month of the average unused portion of the New Credit Facility.  We paid to the AR Lender a non-refundable origination fee of 1.0% of the AR Lender’s commitments under the New Credit Facility at closing.

The New Credit Agreement contains various affirmative and negative covenants and customary events of default, including payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to similar obligations, events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, and the occurrence of events which have a material adverse effect on us.

Amendment to $80.0 million Credit Agreement – Concurrently with the execution of the New Credit Agreement, on August 30, 2010 we entered into an amendment to its existing $80.0 million Credit Agreement, as amended (the “Original Credit Agreement”), with the Term Lender, PCHI, and Ganesha  (the “Amendment”).  Under the Amendment, we agreed with the Term Lender to the following material changes to the Original Credit Agreement:
                
 
In the event of a mandatory prepayment of our accounts receivable based financing facility under the Original Credit Agreement, the outstanding loans under such agreement shall not be required to be prepaid below $10.0 million.  There is also a floor of $10.0 million below which commitments under such accounts receivable based facility would not be mandatorily reduced as a result of such prepayment.
     
 
The Original Credit Agreement was amended to add an affirmative covenant requiring us to deliver financial statements and other financial and non-financial information to the Term Lender on a regular basis, and a negative covenant requiring that we maintain a minimum fixed charge coverage ratio of 1.0 and minimum levels of earnings before interest, tax, depreciation and amortization (“EBITDA”).
     
 
We agreed to the provisions of an Intercreditor Agreement executed on August 30, 2010 by and between the AR Lender and the Term Lender with respect to shared collateral of ours that is being pledged under both the New Credit Agreement and the Original Credit Agreement.  Under the Intercreditor Agreement, among other things the Term Lender consented to the AR Lender having a first priority lien on substantially all of our assets while the Term Lender retained a second lien on such assets, in addition to the Term Lender’s first priority lien on our leased properties owned by PCHI.
           
 
26

 
  
On October 29, 2010, we entered into Amendment No. 1 (the “Amendment”) to the New Credit Agreement, dated as of August 30, 2010, by and among us and the AR Lender.

Under the Amendment, the AR Lender committed to increase the total revolving loan commitment amount under the New Credit Agreement from $40.0 million to $45.0 million, and we agreed to pay to the AR Lender a non-refundable origination fee of 1.0% of the AR Lender’s increased commitment under the Amendment, or $50.

Also under the Amendment, the AR Lender agreed to allow the inclusion in Eligible Accounts that are used to determine our Borrowing Base of up to $33.6 million in aggregate federal or state matching payments to us related to QAF (Note 11), which amount was increased from $11.8 million for the first matching payment.

In addition, the optional prepayment and permanent commitment reduction provisions of the New Credit Agreement were amended to change the minimum Revolving Loan Commitment Amount to $20.0 million from $5.0 million.  In addition, the prepayment fee calculation under the New Credit Agreement was changed so that the prepayment fee is based on $40.0 million rather than the amount of the permanent revolving loan commitment reduction amount.

Lastly, under the Amendment, in the event we permanently reduce our Revolving Loan Commitment Amount to $20.0 million (and assuming there is no Event of Default at the time), we would be permitted to transfer funds that are swept into the Lender’s account from our lockbox accounts to a different bank account designated by us. Effective March 1, 2011, we reduced our Revolving Loan Commitment Amount to $20.0 million.  Beginning in April 2011, the funds that were previously swept into the Lender’s account were swept directly to our main account.

As of June 30, 2011, we had the following Credit Agreements:
                       
 
A $45.0 million Term Note issued under the $80.0 million Credit Agreement, bearing a fixed interest rate of 14.5% per year ($45.0 million outstanding balance at June 30, 2011). If any event of default occurs and continues, the lender can increase the interest rate to 19.5% per year.
     
 
A $20.0 million Revolving Credit Agreement, bearing an interest rate of 5.0% plus LIBOR, with a 2.5% floor, per year (7.5% at June 30, 2011) and an unused commitment fee of 0.625% per year ($20.0 million outstanding balance at June 30, 2011).  For purposes of calculating interest, all payments we make on the New Credit Facility are subject to a six business day clearance period.  As of June 30, 2011, we were in compliance with all financial covenants.
      
WARRANTS - On April 13, 2010, we issued warrants (the “Omnibus Warrants”) to purchase our common stock for a period of three years at an exercise price of $0.07 per share in the following denominations: 139.0 million shares to KPC or its designees and 96.0 million shares to the Term Lender or its designees. The Omnibus Warrants also provide the holders with certain pre-emptive, information and registration rights. As of April 13, 2010, we recorded warrant expense and the related warrant liability of $2.9 million, representing fair value.  As of June 30, 2011, the fair value of the Omnibus Warrants was $2.0 million.
 
In addition, on April 13, 2010, we issued a three-year warrant (the “Release Warrant”) to acquire up to 170.0 million shares of common stock at $0.07 per share to Dr. Chaudhuri who facilitated a release enabling us to recover amounts due from our prior lender and a $1.0 million reduction in principal of our outstanding debt, among other benefits. As a result, we recorded the fair value of the Release Warrant ($2.1 million) as an offsetting cost of the recovery of amounts due from our prior lender. The Release Warrant also provides the holder with certain pre-emptive, information and registration rights. As of June 30, 2011, the fair value of the Release Warrant was $1.4 million.

The Omnibus Warrants and the Release Warrant are collectively referred to as the “April Warrants.” The loss related to the April Warrants for the three months ended June 30, 2011 and 2010 was $3.3 million and $1.9 million, respectively.
   
 
27

 
  
HOSPITAL QUALITY ASSURANCE FEES PROGRAM - In October 2009, the Governor of California signed legislation supported by the hospital industry to impose a provider fee on general acute care hospitals that, combined with federal matching funds, would be used to provide supplemental Medi-Cal payments to hospitals. The state submitted the plan to the Centers for Medicare and Medicaid Services (“CMS”) for a required review and approval process, and certain changes in the plan were required by CMS. Legislation amending the fee program to reflect the required changes was passed by the legislature and signed by the Governor on September 8, 2010. Among other changes, the legislation leaves distribution of “pass-through” payments received by Medi-Cal managed care plans that will be paid to hospitals under the program to the discretion of the plans.  

The hospital quality assurance fee program (“QAF”) created by this legislation initially provided payments for up to 21 months retroactive to April 2009 and expiring on December 31, 2010 (“2010 QAF”). During fiscal year 2011, we recognized $87.2 million in revenue from the state for the 2010 QAF of which $1.8 million was received in April 2011 and is reflected as a receivable in our unaudited condensed consolidated balance sheet as of March 31, 2011.  All other amounts had been received during fiscal year 2011. As of March 31, 2011, $378.6 of the other expenses relating to the 2010 QAF was accrued and included in other current liabilities in our unaudited condensed consolidated balance sheet.

In May 2011, CMS conditionally approved the extension of the QAF for the six month period from January 1 through June 30, 2011 (“2011 QAF”).

Based on the most recent modeling prepared by the California Hospital Association, we anticipate making payments for provider fees and other expenses relating to the 2011 QAF of approximately $15.8 million and receiving approximately $31.6 million in net revenues from the state ($18.1 million from the fee-for-service portion and $13.5 million from the managed care portion). As of June 30, 2010, we have received $17.2 million from the fee-for-service portion of the 2011 QAF from the state and have paid fees to the state totaling $15.1 million.  Until such time as all final approvals have been received from CMS, the amounts received and paid through June 30, 2011 are reflected as deferred revenue and a prepaid asset, respectively, in our unaudited condensed consolidated balance sheet as of June 30, 2011.

We cannot provide any assurances or estimates in connection with a possible continuation of the QAF program beyond June 30, 2011.

LONG TERM LEASE COMMITMENT WITH VARIABLE INTEREST ENTITY - On April 13, 2010, we and PCHI entered into a Second Amendment to Amended and Restated Triple Net Hospital Building Lease (the “2010 Lease Amendment”).  Under the 2010 Lease Amendment, the annual base rent to be paid to PCHI was increased from $5.4 million to $7.3 million, but if PCHI refinances the $45.0 million Term Note, the annual base rent will increase to $8.3 million.  This lease commitment with PCHI is eliminated in consolidation.
 
COMMITMENTS AND CONTINGENCIES - The State of California has imposed new hospital seismic safety requirements. Under these new requirements, the Hospitals must meet stringent seismic safety criteria in the future. In addition, there could be other remediation costs pursuant to this seismic retrofit.
 
The State of California has introduced a new seismic review methodology known as HAZUS. The HAZUS methodology may preclude the need for some structural modifications. All four Hospitals requested HAZUS review and received a favorable notice pertaining to structural reclassification. All Hospital buildings, with the exception of one (an administrative building), have been deemed compliant until January 1, 2030 for both structural and nonstructural retrofit. We do not have an estimate of the cost to remediate the seismic requirements for the administrative building as of June 30, 2011.
  
There are additional requirements that must be complied with by 2030. The costs of meeting these requirements have not yet been determined. Compliance with seismic ordinances will be costly and could have a material adverse effect on our cash flow.  In addition, remediation could possible result in certain environmental liabilities, such as asbestos abatement.
 
CASH FLOW - Net cash provided by (used in) operating activities for the three months ended June 30, 2011 and 2010 was $(5.4) million and $1.3 million, respectively. Net income, adjusted for depreciation and other non-cash items, excluding the provision for doubtful accounts and net income from noncontrolling interests (not a measurement under accounting principles generally accepted in the United States of America (“GAAP”)), totaled $1.9 million and $1.2 million for the three months ended June 30, 2011 and 2010, respectively. We used $7.5 million and $0 in working capital for the three months ended June 30, 2011 and 2010, respectively. Net cash used in payment of accounts payable, accrued compensation and benefits and other current liabilities was $5.1 million and $5.5 million for the three months ended June 30, 2011 and 2010, respectively. Cash provided by accounts receivable, net of provision for doubtful accounts, was $8.0 million and $3.1 million for the three months ended June 30, 2011 and 2010, respectively.
   
 
28

 
  
Net cash used in investing activities during the three months ended June 30, 2011 and 2010 was $0.4 million and $0.6 million, respectively. During the three months ended June 30, 2011 and 2010, we invested $0.4 million and $0.6 million in cash, respectively, in new equipment.
 
Net cash provided by (used in) financing activities for the three months ended June 30, 2011 and 2010 was $0.1 million and $(1.5) million, respectively.  
   
RESULTS OF OPERATIONS AND FINANCIAL CONDITION

The following table sets forth, for the three months ended June 30, 2011 and 2010, our unaudited condensed consolidated statements of operations expressed as a percentage of net operating revenues.
        
     
Three months ended June 30,
     
2011
 
2010
           
Net operating revenues
 
100.0%
 
100.0%
           
Operating expenses:
       
 
Salaries and benefits
 
59.4%
 
55.0%
 
Supplies
 
14.5%
 
13.8%
 
Provision for doubtful accounts
 
10.8%
 
9.5%
 
Other operating expenses
 
16.1%
 
17.2%
 
Depreciation and amortization
 
1.2%
 
1.1%
     
102.0%
 
96.6%
           
Operating income (loss)
 
 (2.0%)
 
3.4%
           
Other expense:
       
 
Interest expense, net
 
 (3.2%)
 
 (3.3%)
 
Loss on warrants
 
 (3.6%)
 
 (2.0%)
     
 (6.8%)
 
 (5.3%)
           
Loss before income tax benefit
 
 (8.8%)
 
 (1.9%)
 
Income tax benefit
 
5.8%
 
0.0%
Net loss
 
 (3.0%)
 
 (1.9%)
 
Net income attributable to noncontrolling interests
 
 (0.2%)
 
 (0.1%)
Net loss attributable to Integrated Healthcare Holdings, Inc.
 
 (3.2%)
 
 (2.0%)
   
THREE MONTHS ENDED JUNE 30, 2011 COMPARED TO THREE MONTHS ENDED JUNE 30, 2010

NET OPERATING REVENUES - Net operating revenues for the three months ended June 30, 2011 decreased 4.5% compared to the same period in fiscal year 2011, from $93.9 million to $89.7 million. Admissions for the three months ended June 30, 2011 decreased 8.6% compared to the same period in fiscal year 2011. The decline in admissions is the combined result of lower obstetrical deliveries and psychiatric admissions. Net operating revenues per admission improved by 4.6% during the three months ended June 30, 2011 as a result of negotiated managed care and governmental payment rate increases. Adjusting for the shift to outpatient, adjusted admissions decreased by 4.3% for the three months ended June 30, 2011 compared to the same period in fiscal year 2011.
 
Essentially all net operating revenues come from external customers. The largest payers are the Medicare and Medicaid programs accounting for 55% and 57% of the net operating revenues for the three months ended June 30, 2011 and 2010, respectively.
 
Uninsured patients, as a percentage of gross charges, decreased to 4.8% from 5.2% for the three months ended June 30, 2011 compared to the three months ended June 30, 2010.
       
 
29

 
  
Although not a GAAP measure, we define "Net Collectible Revenues" as net operating revenues less provision for doubtful accounts. This eliminates the distortion caused by the changes in patient account classification. Net collectible revenues (net operating revenues less provision for doubtful accounts) for the three months ended June 30, 2011 and 2010 were $80.0 million and $85.0 million, respectively, representing a decrease of 5.9%. The Hospitals serve a disproportionate number of indigent patients and receive governmental revenues and subsidies in support of care for these patients. Governmental revenues include payments from Medicaid, Medicaid DSH, and Orange County, CA (CalOptima). Governmental net revenues decreased $3.8 million for the three months ended June 30, 2011 compared to the three months ended June 30, 2010.  

OPERATING EXPENSES - Operating expenses for the three months ended June 30, 2011 increased to $91.5 million from $90.7 million, an increase of $0.8 million, or 0.9%, compared to the same period in fiscal year 2011. Operating expenses expressed as a percentage of net operating revenues for the three months ended June 30, 2011 and 2010 were 102.0% and 96.6%, respectively. On a per admission basis, operating expenses increased 10.6%.
 
Salaries and benefits increased $1.6 million (3.1%) for the three months ended June 30, 2011 compared to the same period in fiscal year 2011. The increase is primarily due to an increase in health insurance ($1.7 million) which was partially offset by lower paid hours due to the decrease in admissions.

Other operating expenses during the three months ended June 30, 2011 decreased to $14.5 million from $16.1 million, a decrease of $1.6 million, or 9.9%, compared to the same period in fiscal 2011, primarily due to an accrual of $1.5 million during the three months ended June 30, 2010 for a guarantee extended to a state supported teaching institution to accept the transfer of an uninsured patient for a necessary higher level of care (the agreement and the institution’s practice are being reviewed).
 
The provision for doubtful accounts for the three months ended June 30, 2011 was $9.7 million compared to $8.9 million for the three months ended March 31, 2010, representing a 9.0% increase.  The primary reason for the increase was related to an increase in patients classified as self-pay as a result of the delay in California field offices processing medical eligibility applications due to State mandatory furloughs and general economic and unemployment conditions.

OPERATING INCOME - The operating income (loss) for the three months ended June 30, 2011 and 2010 was $(1.8) million and $3.2 million, respectively.
 
OTHER EXPENSE - Interest expense for the three months ended June 30, 2011 was $2.8 million compared to $3.1 million for the same period in fiscal year 2011. The decrease primarily related to lower outstanding borrowings under our revolving line of credit, which was partially offset by accelerated amortization of debt issuance costs of $334 as a result of the reduction in our $40 million Revolving Line of Credit to $20 million.
 
On April 13, 2010, we issued warrants which had a fair value at the date of issuance of $5.0 million.  Of the fair value on April 13, 2010, $2.1 million was related to the warrants issued to Dr. Chaudhuri and were a component of the recovery of overswept funds by our previous lender that was recorded during fiscal year 2010.  The remaining $2.9 million was recorded as warrant expense during fiscal year 2011.   As of June 30, 2011, the fair value of the warrants aggregated $3.4 million.  The loss related to the April Warrants for the three months ended June 30, 2011 and 2010 was $3.3 million and $1.9 million, respectively. See “DEBT.”
      
NET LOSS - Net loss for the three months ended June 30, 2011 and 2010 was $2.9 million and $1.9 million, respectively.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

REVENUE RECOGNITION - Net operating revenues are recognized in the period in which services are performed and are recorded based on established billing rates (gross charges) less estimated discounts for contractual allowances, principally for patients covered by Medicare, Medicaid, managed care, and other health plans. Gross charges are retail charges based on our Charge Description Master. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and therefore are not displayed in the consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop-loss payments). Because Medicare requires that a hospital's gross charges be the same for all patients (regardless of payer category), gross charges are also what the Hospitals charge all other patients prior to the application of discounts and allowances.
   
 
30

 
  
Revenues under the traditional fee-for-service Medicare and Medicaid programs are based primarily on prospective payment systems. Discounts for retrospectively cost based revenues and certain other payments, which are based on the Hospitals' cost reports, are estimated using historical trends and current factors. Cost report settlements for retrospectively cost-based revenues under these programs are subject to audit and administrative and judicial review, which can take several years until final settlement of such matters are determined and completely resolved. Estimates of settlement receivables or payables related to a specific year are updated periodically and at year end and at the time the cost report is filed with the fiscal intermediary. Typically no further updates are made to the estimates until the final Notice of Program Reimbursement is received, at which time the cost report for that year has been audited by the fiscal intermediary. There could be several years’ time lag between the submission of a cost report and receipt of the Final Notice of Program Reimbursement. Since the laws, regulations, instructions and rule interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates recorded by the Hospitals could change by material amounts. We have established settlement receivables of $994 and $456 as of June 30 and March 31, 2011, respectively.
 
Our Hospitals receive supplemental payments from the State of California to support indigent care (Medi-Cal Disproportionate Share Hospital payments or "DSH") and from the California Medical Assistance Commission ("CMAC") under the SB 1100 and SB 1255 programs. The Hospitals received supplemental payments of $4.9 million and $11.1 million during the three months ended June 30, 2011 and 2010, respectively. The related revenue recorded for the three months ended June 30, 2011 and 2010, was $3.4 million and $6.4 million, respectively. As of June 30 and March 31, 2011, estimated DSH receivables were $2.4 million and $3.9 million, respectively.

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers. The payers are billed for patient services on an individual patient basis. An individual patient's bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. The Hospitals estimate the discounts for contractual allowances utilizing billing data on an individual patient basis. Management believes the estimation and review process allows for timely identification of instances where such estimates need to be revised. We do not believe there were any adjustments to estimates of individual patient bills that were material to its net operating revenues.

Our Hospitals provide charity care to patients whose income level is below 300% of the Federal Poverty Level. Patients with income levels between 300% and 350% of the Federal Poverty Level qualify to pay a discounted rate under AB 774 based on various government program reimbursement levels. Patients without insurance are offered assistance in applying for Medicaid and other programs they may be eligible for, such as state disability, Victims of Crime, or county indigent programs. Patient advocates from our Hospitals' Medical Eligibility Program ("MEP") screen patients in the hospital and determine potential linkage to financial assistance programs. They also expedite the process of applying for these government programs. The estimated costs (based on direct and indirect costs as a ratio of gross uncompensated charges associated with providing care to charity patients) for the three months ended June 30, 2011 and 2010 were approximately $1.3 million and $1.9 million, respectively.
 
Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending under the MEP, with appropriate contractual allowances recorded. If the patient does not qualify for Medicaid, the receivables are reclassified to charity care and written off, or they are reclassified to self-pay and adjusted to their net realizable value through the provision for doubtful accounts. Reclassifications of Medicaid pending accounts to self-pay do not typically have a material impact on the results of operations as the estimated Medicaid contractual allowances initially recorded are not materially different than the estimated provision for doubtful accounts recorded when the accounts are reclassified. All accounts classified as pending Medicaid, as well as certain other governmental receivables, over the age of 90 days were reserved in contractual allowances as of June 30 and March 31, 2011 based on historical collections experience.
 
We receive payments for indigent care under California section 1011. As of June 30 and March 31, 2011, we established a receivable in the amount of $1.4 million and $1.6 million, respectively, related to discharges deemed eligible to meet program criteria.
 
We are not aware of any material claims, disputes, or unsettled matters with any payers that would affect revenues that have not been adequately provided for in its unaudited condensed consolidated financial statements.
 
PROVISION FOR DOUBTFUL ACCOUNTS - We provide for accounts receivable that could become uncollectible by establishing an allowance to reduce the carrying value of such receivables to their estimated net realizable value. Our Hospitals estimate this allowance based on the aging of their accounts receivable, historical collections experience for each type of payer and other relevant factors. There are various factors that can impact the collection trends, such as changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients, volume of patients through the emergency department, the increased burden of copayments to be made by patients with insurance and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends and the estimation process.
   
 
31

 
  
Our policy is to attempt to collect amounts due from patients, including copayments and deductibles due from patients with insurance, at the time of service while complying with all federal and state laws and regulations, including, but not limited to, the Emergency Medical Treatment and Labor Act ("EMTALA"). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, until the legally required medical screening examination is complete and stabilization of the patient has begun, services are performed prior to the verification of the patient's insurance, if any. In nonemergency circumstances or for elective procedures and services, it is our Hospitals' policy, when appropriate, to verify insurance prior to a patient being treated.
 
INCOME TAXES - Deferred income tax assets and liabilities are determined based on the differences between the book and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws using the asset and liability method. We assess the realization of deferred tax assets to determine whether an income tax valuation allowance is required. We have recorded a 100% valuation allowance on its deferred tax assets.
 
There is a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
 
We and our subsidiaries file income tax returns in the U.S. federal jurisdiction and California. Certain tax attributes carried over from prior years continue to be subject to adjustment by taxing authorities. Penalties or interest, if any, arising from federal or state taxes are recorded as a component of the income tax provision.
 
INSURANCE - We accrue for estimated general and professional liability claims, to the extent not covered by insurance, when they are probable and reasonably estimable. We have purchased as primary coverage a claims-made form insurance policy for general and professional liability risks. Estimated losses within general and professional liability retentions from claims incurred and reported, along with incurred but not reported (“IBNR”) claims, are accrued based upon projections and are discounted to their net present value using a weighted average risk-free discount rate of 5%. To the extent that subsequent claims information varies from estimates, the liability is adjusted in the period such information becomes available. As of June 30 and March 31, 2011, we had accrued $12.6 million and $14.0 million, respectively, which is comprised of $5.7 million and $6.6 million, respectively, in incurred and reported claims, along with $6.9 million and $7.4 million, respectively, in estimated IBNR.  Estimated insurance recoveries of $2.2 million and $2.7 million are included in other prepaid expenses and current assets as of June 30 and March 31, 2011, respectively.
  
We have also purchased occurrence coverage insurance to fund its obligations under its workers' compensation program. We have a "guaranteed cost" policy, under which the carrier pays all workers' compensation claims, with no deductible or reimbursement required of us. We accrue for estimated workers' compensation claims, to the extent not covered by insurance, when they are probable and reasonably estimable. The ultimate costs related to this program include expenses for deductible amounts associated with claims incurred and reported in addition to an accrual for the estimated expenses incurred in connection with IBNR claims. Claims are accrued based upon projections and are discounted to their net present value using a weighted average risk-free discount rate of 5%. To the extent that subsequent claims information varies from estimates, the liability is adjusted in the period such information becomes available. As of June 30 and March 31, 2011, we had accrued $770 and $836, respectively, comprised of $392 and $434, respectively, in incurred and reported claims, along with $378 and $402, respectively, in estimated IBNR.

In addition, we have a self-insured health benefits plan for its employees. As a result, we have established and maintains an accrual for IBNR claims arising from self-insured health benefits provided to employees. Our IBNR accruals at June 30 and March 31, 2011 were based upon projections. We determine the adequacy of this accrual by evaluating its limited historical experience and trends related to both health insurance claims and payments, information provided by its insurance broker and third party administrator and industry experience and trends. The accrual is an estimate and is subject to change. Such change could be material to our consolidated financial statements. As of June 30 and March 31, 2011, we had accrued $2.0 million and $1.8 million, respectively, in estimated IBNR. We believe this is the best estimate of the amount of IBNR relating to self-insured health benefit claims at June 30 and March 31, 2011.

We have also purchased umbrella liability policies with aggregate limits of $25 million. The umbrella policies provide coverage in excess of the primary layer and applicable retentions for insured liability risks such as general and professional liability, auto liability, and workers compensation (employers liability).
  
 
32

 
  
NEW ACCOUNTING STANDARDS

In August 2010, the FASB approved certain modifications to existing accounting standards that will directly affect health care entities in the future. The first change provides clarification to companies in the healthcare industry on the accounting for professional liability insurance. Specifically, it states that receivables related to insurance recoveries should not be netted against the related claim liability and such claim liabilities should be determined without considering insurance recoveries. The second change clarifies that disclosures regarding the level of charity care provided by a health care entity must (i) represent the direct and indirect costs of providing such services, and (ii) include a description of the method used to determine those costs. Additionally, disclosures about charity care must now include information regarding any related reimbursements received by a health care entity. The modified accounting standards are required to be adopted for fiscal years that begin after December 15, 2010. The charity care disclosure change must be applied on a retrospective basis; however, the accounting change for insurance recoveries may be applied on either a prospective or retrospective basis (the Company has applied the accounting change for insurance recoveries on a retrospective basis). We adopted the modified accounting standards during the three months ended June 30, 2011.

In January 2010, the FASB issued guidance to amend the disclosure requirements related to recurring and nonrecurring fair value measurements. The guidance requires new disclosures on the transfers of assets and liabilities between Level 1 (quoted prices in active market for identical assets or liabilities) and Level 2 (significant other observable inputs) of the fair value measurement hierarchy, including the reasons and the timing of the transfers. Additionally, the guidance requires a rollforward of activities on purchases, sales, issuance, and settlements of the assets and liabilities measured using significant unobservable inputs (Level 3 fair value measurements). Disclosures regarding transfers are required beginning January 1, 2010 and the Level 3 rollforward is to be disclosed in reporting periods beginning after December 15, 2010.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As of June 30, 2011, we did not have any investment in or outstanding liabilities under market rate sensitive instruments. We do not enter into hedging instrument arrangements.

ITEM 4.  CONTROLS AND PROCEDURES.

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's reports under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based closely on the definition of "disclosure controls and procedures" in Rule 15d-15(e) under the Exchange Act. The Company's disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching the Company's desired disclosure control objectives. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As of June 30, 2011, the end of the period of this report, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and the Company's Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based on that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that as of June 30, 2011 the Company's disclosure controls and procedures were effective to ensure that the information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

During the quarter ended June 30, 2011, there were no changes in the Company's internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
  
 
33

 

PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS
 
 
The Company and the Hospitals are subject to various legal proceedings, most of which relate to routine matters incidental to operations. The results of these claims cannot be predicted, and it is possible that the ultimate resolution of these matters, individually or in the aggregate, may have a material adverse effect on the Company's business (both in the near and long term), financial position, results of operations, or cash flows. Although the Company defends itself vigorously against claims and lawsuits and cooperates with investigations, these matters (1) could require payment of substantial damages or amounts in judgments or settlements, which individually or in the aggregate could exceed amounts, if any, that may be recovered under insurance policies where coverage applies and is available, (2) cause substantial expenses to be incurred, (3) require significant time and attention from the Company's management, and (4) could cause the Company to close or sell the Hospitals or otherwise modify the way its business is conducted. The Company accrues for claims and lawsuits when an unfavorable outcome is probable and the amount is reasonably estimable.

The following is a summary of material developments in the matter involving Orange County Physicians Investment Network, LLC (“OC-PIN”) that was identified in our Form 10-K filed on June 24, 2011.  There have been no material developments in the other matters identified in the Form 10-K.

On April 24, 2009, a conglomeration of several OC-PIN members led by Ajay G. Meka, M.D. filed a lawsuit against Dr. Shah, other OC-PIN members, and various attorneys, alleging breach of fiduciary duty and seeking damages as well as declaratory and injunctive relief relating to the control of OC-PIN.  After a number of demurrers were filed by the defendants, Plaintiffs filed a Sixth Amended Complaint on May 5, 2011, to which the Company is not a party.  On May 19, 2011, Judge Nancy Wieben-Stock appointed Dr. Anil Shah and Dr. John Glavinovich as interim managers of OC-PIN and signed a formal order to this effect on June 27, 2011.  On July 20, 2011, OC-PIN’s attorney placed a demand on the Company to seat two directors – Mr. Brahmbhatt himself and one AmerZarka, M.D. – on the Board of Directors.  The Company declined this request based on its non-compliance with the Global Settlement Agreement and asked for additional information.  On August 3, 2011, the Company filed a lawsuit in the Orange County Superior Court asking for declaratory relief as to how it must respond to this request.
      
ITEM 1A.  RISK FACTORS

CONCENTRATION OF BUSINESS - Since our business is currently limited to the Southern California area, any reduction in our revenues and profitability from a local economic downturn would not be offset by operations in other geographic areas.

To date, we have developed our business within only one geographic area to take advantage of economies of scale. Due to this concentration of business in a single geographic area, we are exposed to potential losses resulting from the risk of an economic downturn in Southern California. If economic conditions deteriorate in Southern California, our patient volumes and revenues may decline, which could significantly reduce our profitability.

There are no other material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011.
   
ITEM 6.  EXHIBITS
 
Exhibit Number
 
Description
     
31.1
 
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2
 
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1
 
Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2
 
Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
      
101.INS
 
XBRL Instance Document
101.SCH
 
XBRL Schema Document
101.CAL
 
XBRL Calculation Linkbase Document
101.DEF
 
XBRL Definition Linkbase Document
101.LAB
 
XBRL Label Linkbase Document
101.PRE
 
XBRL Presentation Linkbase Document
    
 
34

 

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
   
         
Dated: August 10, 2011
By:
/s/ Steven R. Blake
   
   
Steven R. Blake
   
   
Chief Financial Officer (Principal Financial Officer)
   
         

 

 
35
EX-31.1 2 ihh_10q-ex3101.htm CERTIFICATION ihh_10q-ex3101.htm

EXHIBIT 31.1
 
CERTIFICATION PURSUANT TO RULE 13a-14 AND 15d-14
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
   
I, Kenneth K. Westbrook, Chief Executive Officer of Integrated Healthcare Holdings, Inc., certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of Integrated Healthcare Holdings, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a)    designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated, or caused such disclosure controls and procedures to be designed under our supervision, subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)    designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)    disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.    The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a)    all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
   
         
Dated: August 10, 2011
By:
/s/ Kenneth K. Westbrook
   
   
Kenneth K. Westbrook
   
   
Chief Executive Officer
   
         
 
EX-31.2 3 ihh_10q-ex3102.htm CERTIFICATION ihh_10q-ex3102.htm
 
    

EXHIBIT 31.2
  
CERTIFICATION PURSUANT TO RULE 13a-14 AND 15d-14
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
 
I, Steven R. Blake, Chief Financial Officer of Integrated Healthcare Holdings, Inc., certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of Integrated Healthcare Holdings, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a)    designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated, or caused such disclosure controls and procedures to be  designed under our supervision, subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)    designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)    disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.    The registrant's other certifying officer and I have disclosed based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a)    all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
  
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
   
         
Dated: August 10, 2011
By:
/s/ Steven R. Blake
   
   
Steven R. Blake
   
   
Chief Financial Officer
   
         
 
EX-32.1 4 ihh_10q-ex3201.htm CERTIFICATION ihh_10q-ex3201.htm

EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
   
In connection with this Quarterly Report on Form 10-Q of Integrated Healthcare Holdings, Inc. (the "Company") for the quarter ended June 30, 2011, as filed with the Securities and Exchange Commission (the "Report"), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i)    the Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(ii)    the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the period indicated
 
This Certificate has not been, and shall not be deemed, "filed" with the Securities and Exchange Commission.

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
   
         
Dated: August 10, 2011
By:
/s/ Kenneth K. Westbrook
   
   
Kenneth K. Westbrook
   
   
Chief Executive Officer
   
         
 
EX-32.2 5 ihh_10q-ex3202.htm CERTIFICATION ihh_10q-ex3202.htm

EXHIBIT 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
  
In connection with this Quarterly Report on Form 10-Q of Integrated Healthcare Holdings, Inc. (the "Company") for the quarter ended June 30, 2011, as filed with the Securities and Exchange Commission (the "Report"), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i)    the Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(ii)    the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the period indicated

This Certificate has not been, and shall not be deemed, "filed" with the Securities and Exchange Commission.

 
 
INTEGRATED HEALTHCARE HOLDINGS, INC.
   
         
Dated: August 10, 2011
By:
/s/ Steven R. Blake
   
   
Steven R. Blake
   
   
Chief Financial Officer
   
         
 
EX-101.INS 6 ihch-20110630.xml XBRL EXHIBIT 0001051488 2011-06-30 0001051488 2011-03-31 0001051488 2011-04-01 2011-06-30 0001051488 2010-04-01 2010-06-30 0001051488 us-gaap:CommonStockMember 2011-03-31 0001051488 us-gaap:AdditionalPaidInCapitalMember 2011-03-31 0001051488 us-gaap:OtherAdditionalCapitalMember 2011-03-31 0001051488 us-gaap:RetainedEarningsMember 2011-03-31 0001051488 us-gaap:NoncontrollingInterestMember 2011-03-31 0001051488 us-gaap:RetainedEarningsMember 2011-04-01 2011-06-30 0001051488 us-gaap:NoncontrollingInterestMember 2011-04-01 2011-06-30 0001051488 us-gaap:CommonStockMember 2011-06-30 0001051488 us-gaap:AdditionalPaidInCapitalMember 2011-06-30 0001051488 us-gaap:OtherAdditionalCapitalMember 2011-06-30 0001051488 us-gaap:RetainedEarningsMember 2011-06-30 0001051488 us-gaap:NoncontrollingInterestMember 2011-06-30 0001051488 2010-03-31 0001051488 2010-06-30 0001051488 2011-08-01 iso4217:USD iso4217:USD xbrli:shares xbrli:shares 14847 20539 12 24 46312 52538 22008 20076 6095 5945 3420 4352 2282 3108 5200 15100 1815 8695 8885 101963 97206 53580 54251 182 445 155725 151902 20000 19081 40169 43968 17011 18707 15373 16642 17245 6494 12800 6244 7261 122536 118459 45000 45000 3437 167 6548 6837 1140 1131 177521 170463 255 255 0.001 0.001 800000 800000 255307 255307 255307 255307 62911 62911 882 882 -82150 -79280 -19866 -16996 -1930 -1565 -21796 -18561 155725 151902 89662 93919 53238 51642 12983 12945 9697 8908 14476 16140 1090 1044 91484 90679 -1822 3240 -2843 -3118 -3270 -1900 6113 5018 -7935 -1778 -5200 -2735 -1778 135 135 -2870 -1913 -0.01 -0.01 -0.01 -0.01 255307 255307 255307 255307 255307 255 62911 -882 -79280 -1565 -18561 -2870 135 -500 -500 255307 255 62911 -882 -82150 -1930 -21796 410 130 14 -3471 -5831 -150 -90 932 4979 -5200 -15100 1815 -1835 -2496 -3799 -3322 -1696 -3253 17245 -6306 418 1098 -5415 1303 -12 6 419 571 -407 -577 919 500 1250 289 200 130 -1450 -5692 -724 10159 9435 2191 1701 6300 Integrated Healthcare Holdings Inc 10-Q --03-31 255307262 1867760 false 0001051488 Yes No Smaller Reporting Company No 2011 Q1 2011-06-30 <div style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 1 - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BASIS OF PRESENTATION - The accompanying unaudited condensed consolidated financial statements of Integrated Healthcare Holdings, Inc. and its wholly owned subsidiaries (the "Company") have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial reporting. Accordingly, the accompanying statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, these statements include all adjustments that are of a normal and recurring nature necessary to present fairly the Company&#8217;s consolidated financial position, results of operations and cash flows. The results of operations for the three months ended June 30, 2011 are not necessarily indicative of the results for the entire 2012 fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended March 31, 2011 filed with the SEC on June 24, 2011.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has determined that Pacific Coast Holdings Investment, LLC ("PCHI") (Note 9), is a variable interest entity as defined by GAAP and, accordingly, the financial statements of PCHI are included in the accompanying unaudited condensed consolidated financial statements.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All significant intercompany accounts and transactions have been eliminated in consolidation. Unless otherwise indicated, all amounts included in these notes to the consolidated financial statements are expressed in thousands (except per share amounts, percentages and stock option prices and values).</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIQUIDITY - As of June 30 and March 31, 2011, the Company had a total stockholders&#8217; deficiency of $21.8 million and $18.6 million, respectively, and a working capital deficit of $20.6 million and $21.3 million, respectively.&#160;&#160;For the three months ended June 30, 2011 and 2010, the Company had a net loss of $2.9 million and $1.9 million, respectively. At June 30, 2011, the Company had no additional availability under its revolving credit facility (Note 3).</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DESCRIPTION OF BUSINESS - Effective March 8, 2005, the Company acquired four hospitals (the "Hospitals") from subsidiaries of Tenet Healthcare Corporation (the "Acquisition"). The Company owns and operates the four community-based hospitals located in southern California, which are:</font> </div><br/><table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font></font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">282-bed Western Medical Center in Santa Ana</font></font> </div> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">188-bed Western Medical Center in Anaheim</font></font> </div> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">178-bed Coastal Communities Hospital in Santa Ana</font></font> </div> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">114-bed Chapman Medical Center in Orange</font></font> </div> </td> </tr> </table><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RECLASSIFICATION FOR PRESENTATION - Certain amounts previously reported have been reclassified to conform to the current period's presentation with no impact on the reported net loss of the Company.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONCENTRATION OF RISK - The Hospitals are subject to licensure by the State of California and accreditation by the Joint Commission. Loss of either licensure or accreditation would impact the ability to participate in various governmental and managed care programs, which provide the majority of the Company's revenues.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Substantially all net operating revenues come from external customers. The largest payers are Medicare and Medicaid, which combined accounted for 55% and 57% of the net operating revenues for the three months ended June 30, 2011 and 2010, respectively. No other payers represent a significant concentration of the Company's net operating revenues.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company receives all of our inpatient services revenue from operations in Orange County, California. The economic conditions of this market could affect the ability of our patients and third-party payers to reimburse us for our services, through its effect on disposable household income and the tax base used to generate state funding for Medicaid programs.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">USE OF ESTIMATES - The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Principal areas requiring the use of estimates include third-party cost report settlements, income taxes, accrued insurance retentions and self-insurance reserves, and net patient receivables. Management regularly evaluates the accounting policies and estimates that are used. In general, management bases the estimates on historical experience and on assumptions that it believes to be reasonable given the particular circumstances in which its Hospitals operate. Although management believes that all adjustments considered necessary for fair presentation have been included, actual results may materially vary from those estimates.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REVENUE RECOGNITION - Net operating revenues are recognized in the period in which services are performed and are recorded based on established billing rates (gross charges) less estimated discounts for contractual allowances, principally for patients covered by Medicare, Medicaid, managed care, and other health plans. Gross charges are retail charges based on the Company&#8217;s Charge Description Master. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and therefore are not displayed in the unaudited condensed consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the federal government and state government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop-loss payments). Because Medicare requires that a hospital's gross charges be the same for all patients (regardless of payer category), gross charges are also what the Hospitals charge all other patients prior to the application of discounts and allowances.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenues under the traditional fee-for-service Medicare and Medicaid programs are based primarily on prospective payment systems. Discounts for retrospectively cost based revenues and certain other payments, which are based on the Hospitals' cost reports, are estimated using historical trends and current factors. Cost report settlements for retrospectively cost-based revenues under these programs are subject to audit and administrative and judicial review, which can take several years until final settlement of such matters are determined and completely resolved. Estimates of settlement receivables or payables related to a specific year are updated periodically and at year end and at the time the cost report is filed with the fiscal intermediary. Typically no further updates are made to the estimates until the final Notice of Program Reimbursement is received, at which time the cost report for that year has been audited by the fiscal intermediary. There could be several years&#8217; time lag between the submission of a cost report and receipt of the Final Notice of Program Reimbursement. Since the laws, regulations, instructions and rule interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates recorded by the Hospitals could change by material amounts. The Company has established settlement receivables of $994 and $456 as of June 30 and March 31, 2011, respectively, which are included as due from government payers in the accompanying unaudited condensed consolidated balance sheets.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Hospitals receive supplemental payments from the State of California to support indigent care (Medi-Cal Disproportionate Share Hospital payments or "DSH") and from the California Medical Assistance Commission ("CMAC") under the SB 1100 and SB 1255 programs. The Hospitals received supplemental payments of $4.9 million and $11.1 million during the three months ended June 30, 2011 and 2010, respectively. The related revenue recorded for the three months ended June 30, 2011 and 2010, was $3.4 million and $6.4 million, respectively. As of June 30 and March 31, 2011, estimated DSH receivables were $2.4 million and $3.9 million, respectively, which are included as due from government payers in the accompanying unaudited condensed consolidated balance sheets.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following is a summary of due from governmental payers:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 30,</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;2011</font> </div> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March 31,</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;2011</font> </div> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Medicare</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">994</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">456</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Medicaid</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,426</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,896</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,420</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,352</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> </table><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers. The payers are billed for patient services on an individual patient basis. An individual patient's bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. The Hospitals estimate the discounts for contractual allowances utilizing billing data on an individual patient basis. Management believes the estimation and review process allows for timely identification of instances where such estimates need to be revised. The Company does not believe there were any adjustments to estimates of individual patient bills that were material to its net operating revenues.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Hospitals provide charity care to patients whose income level is below 300% of the Federal Poverty Level. Patients with income levels between 300% and 350% of the Federal Poverty Level qualify to pay a discounted rate under AB 774 based on various government program reimbursement levels. Patients without insurance are offered assistance in applying for Medicaid and other programs they may be eligible for, such as state disability, Victims of Crime, or county indigent programs. Patient advocates from the Hospitals' Medical Eligibility Program ("MEP") screen patients in the hospital and determine potential linkage to financial assistance programs. They also expedite the process of applying for these government programs. The estimated costs (based on direct and indirect costs as a ratio of gross uncompensated charges associated with providing care to charity patients) for the three months ended June&#160;30,&#160;2011 and 2010 were approximately $1.3 million and $1.9 million, respectively.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending under the MEP, with appropriate contractual allowances recorded. If the patient does not qualify for Medicaid, the receivables are reclassified to charity care and written off, or they are reclassified to self-pay and adjusted to their net realizable value through the provision for doubtful accounts. Reclassifications of Medicaid pending accounts to self-pay do not typically have a material impact on the results of operations as the estimated Medicaid contractual allowances initially recorded are not materially different than the estimated provision for doubtful accounts recorded when the accounts are reclassified. All accounts classified as pending Medicaid, as well as certain other governmental receivables, over the age of 90 days were reserved in contractual allowances as of June 30 and March 31, 2011 based on historical collections experience.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company receives payments for indigent care under California section 1011. As of June 30 and March 31, 2011, the Company established a receivable in the amount of $1.4 million and $1.6 million, respectively, related to discharges deemed eligible to meet program criteria.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is not aware of any material claims, disputes, or unsettled matters with any payers that would affect revenues that have not been adequately provided for in the accompanying unaudited condensed consolidated financial statements.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PROVISION FOR DOUBTFUL ACCOUNTS - The Company provides for accounts receivable that could become uncollectible by establishing an allowance to reduce the carrying value of such receivables to their estimated net realizable value. The Hospitals estimate this allowance based on the aging of their accounts receivable, historical collections experience for each type of payer and other relevant factors. There are various factors that can impact the collection trends, such as changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients, volume of patients through the emergency department, the increased burden of copayments to be made by patients with insurance and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends and the estimation process.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company's policy is to attempt to collect amounts due from patients, including copayments and deductibles due from patients with insurance, at the time of service while complying with all federal and state laws and regulations, including, but not limited to, the Emergency Medical Treatment and Labor Act ("EMTALA"). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, until the legally required medical screening examination is complete and stabilization of the patient has begun, services are performed prior to the verification of the patient's insurance, if any. In nonemergency circumstances or for elective procedures and services, it is the Hospitals' policy, when appropriate, to verify insurance prior to a patient being treated.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CASH AND CASH EQUIVALENTS - The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All of the non-interest bearing cash balances were fully insured at June 30, 2011 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, and the Company&#8217;s non-interest bearing cash balances may again exceed federally insured limits.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INVENTORIES OF SUPPLIES - Inventories of supplies are valued at the lower of weighted average cost or market.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and any impairment write-downs related to assets held and used. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Capital leases are recorded at the beginning of the lease term as property and equipment and a corresponding lease liability is recognized. The value of the property and equipment under capital lease is recorded at the lower of either the present value of the minimum lease payments or the fair value of the asset. Such assets, including improvements, are amortized over the shorter of either the lease term or their estimated useful life, where applicable.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company uses the straight-line method of depreciation for buildings and improvements, and equipment over their estimated useful lives of 25 years and 3 to 15 years, respectively.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LONG-LIVED ASSETS - The Company evaluates its long-lived assets for possible impairment whenever circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future cash flows. However, there is an evaluation performed at least annually. Fair value estimates are derived from established market values of comparable assets or internal calculations of estimated undiscounted future net cash flows. The estimates of future net cash flows are based on assumptions and projections believed by the Company to be reasonable and supportable. These assumptions take into account patient volumes, changes in payer mix, revenue, and expense growth rates and changes in legislation and other payer payment patterns.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DEBT ISSUANCE COSTS - On August 30, 2010, the Company entered into a new revolving credit facility (Note 3) under which it incurred debt issuance costs consisting of a $450 origination fee for the Company's $40 million Revolving Line of Credit (new debt) and $469 in legal and other expenses paid to third parties. These amounts are amortized over the credit facility&#8217;s three year life using the straight-line method. Subsequently, the $40 million Revolving Line of Credit was reduced to $20 million, resulting in an acceleration of the amortization of the related debt issuance costs.&#160;&#160;Debt issuance costs of $410 (including $334 in accelerated amortization) and $130 were amortized during the three months ended June 30, 2011 and 2010, respectively.&#160;&#160;At June 30 and March 31, 2011, prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheets included $153 and $300, respectively, as the current portion of debt issuance costs.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FAIR VALUE MEASUREMENTS - The Company's financial assets and liabilities recorded in the unaudited condensed consolidated balance sheets include cash and cash equivalents, restricted cash, receivables, debt, accounts payable, and other liabilities, all of which are recorded at book value which approximates fair value.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">GAAP has established a hierarchy for ranking the quality and reliability of the information used to determine fair values and requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="top" width="5%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="top" width="7%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 1:</font> </div> </td> <td valign="top" width="88%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unadjusted quoted market prices in active markets for identical assets or liabilities.</font> </div> </td> </tr> <tr> <td align="left" valign="top" width="5%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="top" width="7%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="top" width="88%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td align="left" valign="top" width="5%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="top" width="7%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 2:</font> </div> </td> <td valign="top" width="88%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability.</font> </div> </td> </tr> <tr> <td align="left" valign="top" width="5%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="top" width="7%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="top" width="88%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td align="left" valign="top" width="5%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="top" width="7%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 3:</font> </div> </td> <td valign="top" width="88%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unobservable inputs for the asset or liability.</font> </div> </td> </tr> </table><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company utilizes the best available information in measuring fair value.&#160;&#160;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company currently has no financial or nonfinancial assets or liabilities subject to fair value measurement on a recurring basis except for warrants issued in April 2010 (Note 4).</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and where they are classified within the hierarchy as of June 30, 2011:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font> </div> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 1</font> </div> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 2</font> </div> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 3</font> </div> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="52%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant liability</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,437</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,437</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> </table><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant liability - fair value measurements using significant unobservable inputs (Level 3)</font></font> </div><br/><table cellpadding="0" cellspacing="0" width="60%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="80%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at March 31, 2011 - Fair value of warrants issued and vested</font> </div> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="top" width="15%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">167</font> </div> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td colspan="2" valign="bottom" width="81%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Change in fair value of warrant liability included in earnings</font> </div> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="15%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,270</font> </div> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="80%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="80%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at June 30, 2011</font> </div> </div> </td> <td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="top" width="15%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,437</font> </div> </div> </td> <td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> </table><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;WARRANTS - The Company has entered into complex transactions that contain warrants (Notes 3 and 4). If an instrument (or an embedded feature) that has the characteristics of a derivative instrument under this standard is indexed to an entity&#8217;s own stock, it is still necessary to evaluate whether it is classified in stockholders&#8217; equity (or would be classified in stockholders&#8217; equity if it were a freestanding instrument). Effective April 1, 2009, the Company adopted this standard, and at the time of adoption, this standard did not have an effect on the Company&#8217;s consolidated financial statements.&#160;&#160;Subsequent to the Company&#8217;s adoption of this standard, the Company issued the April Warrants, which are accounted for as liabilities (Note 4).</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LOSS PER COMMON SHARE - Loss per share is calculated under two different methods, basic and diluted. Basic loss per share is calculated by dividing the net loss by the weighted average shares of common stock outstanding during the period. Diluted loss per share is calculated by dividing the net loss by the weighted average shares of common stock outstanding during the period and dilutive potential shares of common stock. Dilutive potential shares of common stock, as determined under the treasury stock method, consist of shares of common stock issuable upon exercise of stock warrants or options, net of shares of common stock assumed to be repurchased by the Company from the exercise proceeds (Note 8).</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INCOME TAXES - Deferred income tax assets and liabilities are determined based on the differences between the book and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws using the asset and liability method. The Company assesses the realization of deferred tax assets to determine whether an income tax valuation allowance is required. The Company has recorded a 100% valuation allowance on its deferred tax assets.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There is a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and California. Certain tax attributes carried over from prior years continue to be subject to adjustment by taxing authorities. Penalties or interest, if any, arising from federal or state taxes are recorded as a component of the income tax provision.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SEGMENT REPORTING - The Company operates in one line of business, the provision of healthcare services through the operation of general hospitals and related healthcare facilities. The Company's Hospitals generate substantially all of its net operating revenues.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company's four general Hospitals and related healthcare facilities operate in one geographic region in Orange County, California. The region's economic characteristics, the nature of the Hospitals' operations, the regulatory environment in which they operate, and the manner in which they are managed are all similar. This region is an operating segment, as defined by GAAP. In addition, the Company's general Hospitals and related healthcare facilities share certain resources and benefit from many common clinical and management practices. Accordingly, the Company aggregates the facilities into a single reportable operating segment.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SUBSEQUENT EVENTS - The Company&#8217;s accompanying unaudited condensed consolidated financial statements are considered issued when filed with the SEC.&#160;&#160;The Company has evaluated subsequent events to the filing date of this Form 10-Q with the SEC.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEW ACCOUNTING STANDARDS &#8211; In August&#160;2010, the FASB approved certain modifications to existing accounting standards that will directly affect health care entities in the future. The first change provides clarification to companies in the healthcare industry on the accounting for professional liability insurance. Specifically, it states that receivables related to insurance recoveries should not be netted against the related claim liability and such claim liabilities should be determined without considering insurance recoveries. The second change clarifies that disclosures regarding the level of charity care provided by a health care entity must (i)&#160;represent the direct and indirect costs of providing such services, and (ii)&#160;include a description of the method used to determine those costs. Additionally, disclosures about charity care must now include information regarding any related reimbursements received by a health care entity.&#160;The modified accounting standards are required to be adopted for fiscal years that begin after December&#160;15, 2010. The charity care disclosure change must be applied on a retrospective basis; however, the accounting change for insurance recoveries may be applied on either a prospective or retrospective basis (the Company has applied the accounting change for insurance recoveries on a retrospective basis). The Company adopted the modified accounting standards during the three months ended June 30, 2011, which did not have a material impact on the unaudited condensed consolidated financial statements.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In January&#160;2010, the FASB issued guidance to amend the disclosure requirements related to recurring and nonrecurring fair value measurements. The guidance requires new disclosures on the transfers of assets and liabilities between Level 1 (quoted prices in active market for identical assets or liabilities) and Level 2 (significant other observable inputs) of the fair value measurement hierarchy, including the reasons and the timing of the transfers. Additionally, the guidance requires a rollforward of activities on purchases, sales, issuance, and settlements of the assets and liabilities measured using significant unobservable inputs (Level 3 fair value measurements). Disclosures regarding transfers are required beginning January&#160;1, 2010 and the Level 3 rollforward is to be disclosed in reporting periods beginning after December&#160;15, 2010.</font> </div><br/> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 64.8pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 2 - PROPERTY AND EQUIPMENT</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Property and equipment consists of the following:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 30,</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">2011</font></font> </div> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March 31,</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">2011</font></font> </div> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Buildings</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">34,637</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">34,624</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Land and improvements</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,523</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,523</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Equipment</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,635</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,266</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Construction in progress</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,404</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,375</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Assets under capital leases</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,218</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,218</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,417</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,006</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less accumulated depreciation</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(20,837</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(19,755</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div> </div> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property and equipment, net</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">53,580</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">54,251</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> </table><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accumulated depreciation on assets under capital leases as of June 30 and March 31, 2011 was $4.1 million and $3.7 million, respectively.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Hospitals are located in an area near active and substantial earthquake faults. The Hospitals carry earthquake insurance with a policy limit of $50.0 million. A significant earthquake could result in material damage and temporary or permanent cessation of operations at one or more of the Hospitals.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The State of California has imposed new hospital seismic safety requirements. Under these new requirements, the Hospitals must meet stringent seismic safety criteria in the future. In addition, there could be other remediation costs pursuant to this seismic retrofit.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The State of California has introduced a new seismic review methodology known as HAZUS. The HAZUS methodology may preclude the need for some structural modifications. All four Hospitals requested HAZUS review and received a favorable notice pertaining to structural reclassification. All Hospital buildings, with the exception of one (an administrative building), have been deemed compliant until January 1, 2030 for both structural and nonstructural retrofit.&#160;&#160;The Company does not have an estimate of the cost to remediate the seismic requirements for the administrative building as of June 30, 2011.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There are additional requirements that must be complied with by 2030. The costs of meeting these requirements have not yet been determined. Compliance with seismic ordinances will be costly and could have a material adverse effect on the Company's cash flow.&#160;&#160;In addition, remediation could possibly result in certain environmental liabilities, such as asbestos abatement.</font> </div><br/> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 3&#160;- DEBT</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 13, 2010 (the &#8220;Effective Date&#8221;), the Company entered into an Omnibus Credit Agreement Amendment (the &#8220;Omnibus Amendment&#8221;) with SPCP Group IV, LLC and SPCP Group, LLC (together, &#8220;Silver Point&#8221;), Silver Point Finance, LLC, as the Lender Agent, PCHI, Ganesha Realty LLC (&#8220;Ganesha&#8221;), Dr. Chaudhuri and KPC Resolution Company (&#8220;KPC&#8221;).&#160;&#160;KPC and Ganesha are companies owned and controlled by Dr. Chaudhuri, who is the majority shareholder of the Company.&#160;&#160;Ganesha is a member of PCHI with a 49% membership interest in PCHI.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company entered into the Omnibus Amendment in connection with the Loan Purchase and Sale Agreement, dated as of January 13, 2010, as amended, by and between KPC and the previous lender&#8217;s receiver.&#160;&#160;Under the Loan Purchase Agreement and as approved by the Court on April 2, 2010, KPC agreed to purchase all of the Credit Agreements from Medical Capital Corporation&#8217;s receiver for $70.0 million.&#160;&#160;Concurrent with the closing of the Loan Purchase Agreement, KPC sold its interest in the Credit Agreements to Silver Point, and KPC purchased from Silver Point a 15% participation interest in the Credit Agreements.&#160;&#160;On April 13, 2010, concurrent with the effectiveness of the Omnibus Amendment and the closing of the Loan Purchase Agreement, Silver Point acquired all of the Credit Agreements, including the security agreements and other ancillary documents executed by the Company in connection with the Credit Agreements, and became the &#8220;New Lender&#8221; under the Credit Agreements.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following are material terms of the Omnibus Amendment:</font> </div><br/><table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The stated maturity date under each Credit Agreement was changed to April 13, 2013.&#160;&#160;The Credit Agreements were otherwise due to mature on October 8, 2010.</font></font></font> </div> </div> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td width="90%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Affirming release of prior claims between the Company and the previous lender&#8217;s receiver, Silver Point agreed to waive any events of default that had occurred under the Credit Agreements and waived claims to accrued and unpaid interest and fees of $6.4 million under the Credit Agreements as of April 13, 2010.</font></font> </div> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td width="90%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The $80.0 million Credit Agreement was amended so that the $45.0 million term note (the &#8220;$45.0 million Loan&#8221;) and $35.0 million non-revolving line of credit note (the &#8220;$35.0 million Loan&#8221;) will each bear a fixed interest rate of 14.5% per year.&#160;&#160;These loans previously bore interest rates of 10.25% and 9.25%, respectively.&#160;&#160;In addition, the Company agreed to make certain mandatory prepayments of the $35.0 million Loan when it received proceeds from certain new financing of its accounts receivable or provider fee funds from Medi-Cal under the Hospital Quality Assurance Fee program (&#8220;QAF&#8221;) (Note 11).&#160;&#160;The $35.0 million non-revolving line of credit was refinanced on August 30, 2010 (see below).</font></font> </div> </td> </tr> </table><br/><table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The $50.0 million Revolving Credit Agreement was amended so that Silver Point will, subject to the terms and conditions contained therein, make up to $10.0 million in new revolving funds available to the Company for working capital and general corporate purposes.&#160;&#160;Each advance under the $50.0 million Revolving Credit Agreement will bear interest at an annual rate of Adjusted LIBOR (calculated as LIBOR subject to certain adjustments, with a floor of 2% and a cap of 5%) plus 12.5%, compared to an interest rate of 24.0% that was previously in effect under the $50.0 million revolving credit agreement.&#160;&#160;In addition, the Company agreed to make mandatory prepayments of the $50.0 million Revolving Credit Agreement under the conditions described above with respect to the $80.0 million Credit Agreement.&#160;&#160;The financial covenants under the $50.0 million Revolving Credit Agreement were also amended to increase the required levels of minimum EBITDA (as defined in the Omnibus Amendment) from the levels previously in effect under the $50.0 million Revolving Credit Agreement. This $50.0 million revolving line of credit was refinanced on August 30, 2010 (see below).</font></font></font></font> </div> </div> </div> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td width="90%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The $10.7 million Credit Agreement was amended so that the $10.7 million convertible term note will bear a fixed interest rate of 14.5% per year, compared to the interest rate of 9.25% previously in effect and to eliminate the conversion feature of the loan.&#160;&#160;In addition, the Company agreed to make mandatory prepayments of the $10.7 million Credit Agreement under the conditions described above with respect to the $80.0 million Credit Agreement. This $10.7 million term note was refinanced on August 30, 2010 (see below).</font></font></font> </div> </div> </td> </tr> </table><br/><div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the sale of the Credit Agreements, all warrants and stock conversion rights issued to the previous lender were cancelled.&#160;&#160;In connection with the Omnibus Amendment, the Company issued new warrants (Note 4).</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On August 30, 2010, the Company (excluding PCHI) entered into a Credit and Security Agreement (the &#8220;New Credit Agreement&#8221;) with MidCap Financial, LLC, a commercial finance lender specializing in loans to middle market health care companies, and Silicon Valley Bank (collectively, the &#8220;AR Lender&#8221;).</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the New Credit Agreement, the AR Lender committed to provide up to $40.0 million in loans to the Company under a secured revolving credit facility (the &#8220;New Credit Facility&#8221;), which may be increased to up to $45.0 million upon the Company&#8217;s request, if the AR Lender consents to such increase.&#160;&#160;Upon execution of the New Credit Agreement, the AR Lender funded approximately $39.7 million of the New Credit Facility, which funds were used primarily to repay approximately $35.0 million in loans outstanding to affiliates of Silver Point (&#8220;Term Lender&#8221;).&#160;&#160;Upon such repayment, each of the Company&#8217;s $35.0 million non-revolving line of credit loan, $50.0 million revolving credit agreement and $10.7 million credit agreement with the Term Lender were fully repaid and terminated.&#160;&#160;The only loan currently outstanding to the Term Lender consists of a $45.0 million Term Note issued under the Company&#8217;s $80.0 million Credit Agreement.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The New Credit Facility is secured by a first priority security interest on substantially all of the Company&#8217;s assets, including the equity interests in&#160;all&#160;of the Company&#8217;s subsidiaries (excluding PCHI).&#160; The availability of the&#160;AR Lender&#8217;s commitments under the New Credit Facility is limited by a borrowing base tied to the Company&#8217;s eligible&#160;accounts receivable and certain other availability restrictions.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loans under the New Credit Facility accrue&#160;interest&#160;at LIBOR (subject to a 2.5% floor) plus 5.0% per annum, subject to a default rate of interest and other adjustments provided for in the New Credit&#160;Agreement.&#160;&#160;For purposes of calculating interest, all payments the Company makes on the New Credit Facility are subject to a six business day clearance period. The Company also pays&#160;a collateral management fee of .0625% per month on the outstanding balance (or a minimum balance amount equal to 85% of the monthly average borrowing base (the &#8220;Minimum Balance Amount&#8221;), if such amount is greater than the outstanding balance), a monthly minimum balance fee equal to the highest interest rate applicable to the loans if the Minimum Balance Amount is greater that the outstanding balance,&#160;and an unused line fee equal to .042% per month of the average unused portion of the New Credit Facility.&#160; The Company paid to the AR Lender a non-refundable&#160;origination&#160;fee of 1.0% of the&#160;AR Lender&#8217;s commitments under the&#160;New Credit Facility at closing.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The New Credit Agreement contains various affirmative and negative covenants and customary events of default, including payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to similar obligations, events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, and the occurrence of events which have a material adverse effect on the Company.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment to $80.0 million Credit Agreement</font> &#8211; Concurrently with the execution of the New Credit Agreement, on August 30, 2010 the Company entered into an amendment to its existing $80.0 million Credit Agreement, as amended (the &#8220;Original Credit Agreement&#8221;), with the Term Lender, PCHI, and Ganesha&#160;&#160;(the &#8220;Amendment&#8221;).&#160;&#160;Under the Amendment, the Company agreed with the Term Lender to the following material changes to the Original Credit Agreement:</font> </div><br/><table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In the event of a mandatory prepayment of the Company&#8217;s accounts receivable based financing facility under the Original Credit Agreement, the outstanding loans under such agreement shall not be required to be prepaid below $10.0 million.&#160;&#160;There is also a floor of $10.0 million below which commitments under such accounts receivable based facility would not be mandatorily reduced as a result of such prepayment.</font></font></font></font> </div> </div> </div> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td width="90%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Original Credit Agreement was amended to add an affirmative covenant requiring the Company to deliver financial statements and other financial and non-financial information to the Term Lender on a regular basis, and a negative covenant requiring that the Company maintain a minimum fixed charge coverage ratio of 1.0 and minimum levels of earnings before interest, tax, depreciation and amortization (&#8220;EBITDA&#8221;).</font></font></font> </div> </div> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td width="90%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Company agreed to the provisions of an Intercreditor Agreement executed on August 30, 2010 by and between the AR Lender and the Term Lender with respect to shared collateral of the Company that is being pledged under both the New Credit Agreement and the Original Credit Agreement.&#160;&#160;Under the Intercreditor Agreement, among other things the Term Lender consented to the AR Lender having a first priority lien on substantially all of the Company&#8217;s assets while the Term Lender retained a second lien on such assets, in addition to the Term Lender&#8217;s first priority lien on the Company&#8217;s leased properties owned by PCHI.</font></font></font> </div> </div> </td> </tr> </table><br/><div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 29, 2010, the Company entered into Amendment No. 1 (the &#8220;Amendment&#8221;) to the New Credit Agreement, dated as of August 30, 2010, by and among the Company and the AR Lender.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the Amendment, the AR Lender committed to increase the total revolving loan commitment amount under the New Credit Agreement from $40.0 million to $45.0 million, and the Company agreed to pay to the AR Lender a non-refundable origination fee of 1.0% of the AR Lender&#8217;s increased commitment under the Amendment, or $50.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Also under the Amendment, the AR Lender agreed to allow the inclusion in Eligible Accounts that are used to determine the Company&#8217;s Borrowing Base&#160;of up to $33.6 million in aggregate federal or state matching payments to the Company related to QAF (Note 11), which amount was increased from $11.8 million for the first matching payment.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, the optional prepayment and permanent commitment reduction<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>provisions of the New Credit Agreement were amended to change the minimum Revolving Loan Commitment Amount to $20.0 million from $5.0 million.&#160;&#160;In addition, the prepayment fee calculation under the New Credit Agreement was changed so that the prepayment fee is based on $40.0 million rather than the amount of the permanent revolving loan commitment reduction amount.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lastly, under the Amendment, in the event the Company permanently reduces its Revolving Loan Commitment Amount to $20.0 million (and assuming there is no Event of Default at the time), the Company would be permitted to transfer funds that are swept into the Lender&#8217;s account from the Company&#8217;s lockbox accounts to a different bank account designated by the Company. Effective March 1, 2011, the Company reduced its Revolving Loan Commitment Amount to $20.0 million.&#160;&#160;Beginning in April 2011, the funds that were previously swept into the Lender&#8217;s account were swept directly to the Company&#8217;s main account.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of June 30, 2011, the Company had the following Credit Agreements:</font> </div><br/><table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A $45.0 million Term Note issued under the $80.0 million Credit Agreement, bearing a fixed interest rate of 14.5% per year ($45.0 million outstanding balance at June 30, 2011). If any event of default occurs and continues, the lender can increase the interest rate to 19.5% per year.</font></font></font></font></font> </div> </div> </div> </div> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td width="90%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td width="5%"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="top" width="5%"> <font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#9679;</font> </td> <td width="90%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A $20.0 million Revolving Credit Agreement, bearing an interest rate of 5.0% plus LIBOR, with a 2.5% floor, per year (7.5% at June 30, 2011) and an unused commitment fee of 0.625% per year ($20.0 million outstanding balance at June 30, 2011).&#160;&#160;For purposes of calculating interest, all payments the Company makes on the New Credit Facility are subject to a six business day clearance period.&#160;&#160;As of June 30, 2011, the Company was in compliance with all financial covenants.</font></font></font></font> </div> </div> </div> </td> </tr> </table><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company's outstanding debt consists of the following:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 30,</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;2011</font> </div> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March 31,</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;2011</font> </div> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current:&#160;</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revolving line of credit&#160;</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,000</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,081</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;Noncurrent:</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;Secured term note</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45,000</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45,000</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> </table><br/> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 4 - COMMON STOCK WARRANTS</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 13, 2010, the Company issued warrants (the &#8220;Omnibus Warrants&#8221;) to purchase its common stock for a period of three years at an exercise price of $0.07 per share in the following denominations: 139.0 million shares to KPC or its designees and 96.0 million shares to the Term Lender or its designees. The Omnibus Warrants also provide the holders with certain pre-emptive, information and registration rights. As of April 13, 2010, the Company recorded warrant expense and the related warrant liability of $2.9 million, representing fair value.&#160;&#160;As of June 30, 2011, the fair value of the Omnibus Warrants was $2.0 million.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, on April 13, 2010, the Company issued a three-year warrant (the &#8220;Release Warrant&#8221;) to acquire up to 170.0 million shares of common stock at $0.07 per share to Dr. Chaudhuri who facilitated a release enabling the Company to recover amounts due from the Company&#8217;s prior lender and a $1.0 million reduction in principal of its outstanding debt, among other benefits to the Company.&#160;As a result, the Company recorded the fair value of the Release Warrant ($2.1 million) as an offsetting cost of the recovery of amounts due from the Company&#8217;s prior lender. The Release Warrant also provides the holder with certain pre-emptive, information and registration rights. As of June 30, 2011, the fair value of the Release Warrant was $1.4 million.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Omnibus Warrants and the Release Warrant are collectively referred to as the &#8220;April Warrants.&#8221; The net loss recorded related to the April Warrants for the three months ended June 30, 2011 and 2010 was $3.3 million and $1.9 million, respectively.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The fair value of warrants issued by the Company is estimated using the Black-Scholes valuation model, which the Company believes is the appropriate valuation method under the circumstances. Since the Company&#8217;s stock is thinly traded, the expected volatility is based on an analysis of the Company's stock and the stock of&#160;eight other publicly traded companies that own hospitals.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The risk-free interest rate is based on the average yield on U.S. Treasury notes with maturity commensurate with the terms of the warrants. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not anticipate paying cash dividends in the foreseeable future.&#160;&#160;The assumptions used in the Black-Scholes valuation model are as follows.</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="50%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 30, 2011</font> </div> </td> <td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 13, 2010</font> </div> </td> <td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="50%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom" width="14%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom" width="14%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="50%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected dividend yield</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="10%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.0%</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="10%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.0%</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="50%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk-free interest rate</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="10%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.4%</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="10%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.7%</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="50%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected volatility</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="10%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43.0%</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="10%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68.4%</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="50%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected term (in years)</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="10%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.8</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="10%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.0</font> </div> </div> </td> <td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> </table><br/> <div> &#160;&#160;<br /> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 5 - INCOME TAXES</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The utilization of NOL and credit carryforwards is limited under the provisions of the IRC Section 382 and similar state provisions. Section 382 of the IRC of 1986 generally imposes an annual limitation on the amount of NOL carryforwards that may be used to offset taxable income where a corporation has undergone significant changes in stock ownership. In fiscal year 2009, the Company entered into the amended purchase agreement which resulted in a change in control. The Company conducted an analysis and determined that it is subject to significant IRC Section 382 limitations. For both Federal and State tax purposes, the Company's utilization of NOL and credit carryforwards is subject to significant IRC Section 382 limitations. The Company evaluates its ability to utilize the net operating losses each period with regard to the limitations imposed under IRC 382 and also considering the continuing expiration of statutes of limitation for prior years; and in the prior year determined that a portion of the federal and state net operating losses were no longer realizable, and removed from the schedule of deferreds those net operating losses in excess of the IRC 382 limitation and also considering prior years statutes now closed.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The difference between the reported income tax benefit and the amount computed by multiplying income before income tax benefit in the accompanying unaudited condensed consolidated statements of operations for the three months ended June 30, 2011 and 2010 by the statutory federal income tax rate primarily relates to the impact of a full valuation allowance reserving the net deferred assets, permanently nondeductible expenses, state and local income taxes, and variable interest entity.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company received QAF (Note 11) payments in the first quarter of the current fiscal year and expects additional payments in subsequent periods.&#160;&#160;The application of FIN 18 requires the Company to compute the interim period income tax expense (benefit) by applying the estimated annual effective tax rate to the first quarter income (loss) from continuing operations, which resulted in the recognition of a tax benefit for the first quarter.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company evaluated its historical and projected sources of income to determine the extent to which the net deferred tax assets projected at June 30, 2011 could be realized, and based on this analysis the Company concluded that there was not sufficient positive evidence to support the realization of the net deferred tax assets, and therefore will continue to maintain a full valuation allowance against its net deferred assets for the three months ended June 30, 2011.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s California Enterprise Zone credits are currently under examination by the California taxing authority.&#160;&#160;As a result of the examination, the Company recorded a liability of approximately $18.9 million for unrecognized tax benefits.&#160;&#160;The Company's utilization of these credits is also subject to significant IRC Section 383 limitations, and these limitations have been incorporated into the tax provision calculation.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PCHI TAX STATUS - PCHI is a limited liability company. PCHI's taxable income or loss will flow through to its owners and be their separate responsibility. Accordingly, the accompanying unaudited condensed consolidated financial statements do not include any amounts for the income tax expense or benefit, or liabilities related to PCHI's income or loss.</font> </div><br/> <div> &#160;&#160;<br /> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 6 - STOCK INCENTIVE PLAN</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company's 2006 Stock Incentive Plan (the "Plan"), which is shareholder-approved, permits the grant of share options to its employees and board members for up to a maximum aggregate of 12.0 million shares of common stock. In addition, as of the first business day of each calendar year in the period 2007 through 2015, the maximum aggregate number of shares shall be increased by a number equal to one percent of the number of shares of common stock of the Company outstanding on December 31 of the immediately preceding calendar year. Accordingly, as of June 30, 2011, the maximum aggregate number of shares under the Plan was 21.0 million. The Company believes that such awards better align the interests of its employees with those of its shareholders. In accordance with the Plan, incentive stock options, nonqualified stock options, and performance based compensation awards may not be granted at less than 100 percent of the estimated fair market value of the common stock on the date of grant. Incentive stock options granted to a person owning more than 10 percent of the voting power of all classes of stock of the Company may not be issued at less than 110 percent of the fair market value of the stock on the date of grant. Option awards generally vest based on 3 years of continuous service (1/3 of the shares vest on the twelve month anniversary of the grant date, and an additional 1/12 of the shares vest on each subsequent fiscal quarter-end of the Company following such twelve month anniversary). Certain option awards provide for accelerated vesting if there is a change of control, as defined. The option awards have 7-year contractual terms.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">When the measurement date is certain, the fair value of each option grant is estimated on the date of grant using the Black-Scholes valuation model. Since there is limited historical data with respect to both pre-vesting forfeiture and post-vesting termination, the expected life of the options was determined utilizing the simplified method, whereby the expected term is calculated by taking the sum of the vesting term plus the original contractual term and dividing that quantity by two.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recorded $0 and $14.0 of compensation expense relative to stock options during the three months ended June 30, 2011 and 2010, respectively. No options were exercised during the three months ended June 30, 2011 and 2010. A summary of stock option activity for the three months ended June 30, 2011 is presented as follows.</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="31%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares</font> </div> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted-</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;average</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;exercise</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;price</font> </div> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted-</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;average</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;grant date</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;fair value</font> </div> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted-</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;average</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;remaining</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;contractual</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;term</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;(years)</font> </div> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Aggregate</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;intrinsic</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;value</font> </div> </td> </tr> <tr> <td align="left" valign="bottom" width="31%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" width="8%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="31%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding, March 31, 2011</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,370</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="8%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.18</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="31%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="8%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="8%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="31%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="8%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="31%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Forfeited or expired</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(20</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="8%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.25</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="31%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding, June 30, 2011</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,350</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.18</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.4</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$&#160;</font> </div> </div> </td> <td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font> </div> </div> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="31%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercisable at June 30, 2011</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,350</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.18</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="8%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.4</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font> </div> </div> </td> </tr> </table><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All outstanding options were fully vested as of June 30 and March 31, 2011.</font> </div><br/> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 64.8pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 7 - RETIREMENT PLAN</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has a 401(k) plan for its employees. All employees with 90 days of service are eligible to participate, unless they are covered by a collective bargaining agreement which precludes coverage. The Company matches employee contributions up to 3% of the employee's compensation, subject to IRS limits. During the three months ended June 30, 2011 and 2010, the Company incurred expenses of $774 and $758, respectively, which are included in salaries and benefits in the accompanying unaudited condensed consolidated statements of operations.&#160;&#160;At June 30 and March 31, 2011, accrued compensation and benefits in the accompanying unaudited condensed consolidated balance sheets included $1.6 million and $3.8 million, respectively, in accrued employer contributions.</font> </div><br/> <div> &#160;&#160;&#160;&#160;<br /> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 8 - INCOME PER SHARE</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Income per share is calculated under two different methods, basic and diluted. Basic income per share is calculated by dividing the net income by the weighted average shares of common stock outstanding during the period. Diluted income per share is calculated by dividing the net income by the weighted average shares of common stock outstanding during the period and dilutive potential shares of common stock. Dilutive potential shares of common stock, as determined under the treasury stock method, consist of shares of common stock issuable upon exercise of stock warrants or options, net of shares of common stock assumed to be repurchased by the Company from the exercise proceeds.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since the Company incurred losses for the three months ended June 30, 2011 and 2010, the potential shares of common stock, consisting of approximately 412 million and 437 million shares, respectively, issuable under warrants and stock options, have been excluded from the calculations of diluted loss per share for those periods.</font> </div><br/> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 9 - VARIABLE INTEREST ENTITY</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Concurrent with the close of the Acquisition, PCHI simultaneously acquired title to substantially all of the real property acquired by the Company in the Acquisition. The Company received $5.0 million and PCHI guaranteed the Company's $45.0 million Term Note. The Company remains primarily liable as the borrower under the $45.0 million Term Note notwithstanding its guarantee by PCHI; this note is cross-collateralized by substantially all of the Company's assets and all of the real property of the Hospitals. All of the Company's operating activities are directly affected by the real property that was sold to PCHI, which is a related party entity that is affiliated with the Company through common ownership and control. As of June 30, 2011, PCHI was owned 51% by various physician investors and 49% by Ganesha (Dr. Chaudhuri and Mr. Thomas). A company is required to consolidate the financial statements of any entity that cannot finance its activities without additional subordinated financial support, and for which one company provides the majority of that support through means other than ownership. Effective March 8, 2005, the Company determined that it provided the majority of financial support to PCHI through various sources including lease payments, remaining primarily liable under the $45.0 million Term Note, and cross-collateralization of the Company's non-real estate assets to secure the $45.0 million Term Note. Accordingly, the financial statements of PCHI are included in the accompanying unaudited condensed consolidated financial statements.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PCHI's assets, liabilities, and accumulated deficit are set forth below.</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 30,</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;2011</font> </div> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March 31,</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;2011</font> </div> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">199</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">330</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property, net</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">41,951</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">42,273</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">142</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">70</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total assets</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">42,292</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">42,673</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Debt (as guarantor)</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45,000</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45,000</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">617</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">634</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total liabilities</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45,617</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45,634</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deficiency</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,325</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,961</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div> </div> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total liabilities and accumulated deficit</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">42,292</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">42,673</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> </table><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As noted above, PCHI is a guarantor on the $45.0 million Term Note should the Company not be able to perform.&#160;&#160;PCHI's total liabilities represent the Company's maximum exposure to loss.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PCHI rental income and the Company&#8217;s related rental expense of $1.9 million and $1.7 million were eliminated upon consolidation for the three months ended June 30, 2011 and 2010, respectively.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has a lease commitment to PCHI (Note 12). Additionally, the Company is responsible for seismic remediation under the terms of the lease agreement (Note 2).</font> </div><br/> <div> &#160;&#160;&#160;<br /> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 10 - RELATED PARTY TRANSACTIONS</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PCHI - The Company leases substantially all of the real property of the acquired Hospitals from PCHI. PCHI is owned by various physician investors and Ganesha, which is managed by Dr. Chaudhuri. As of June 30 and March 31, 2011, Dr. Chaudhuri and Mr. Thomas are the beneficial holders of an aggregate of 447.5 million shares of the outstanding stock of the Company. As described in Note 9, PCHI is a variable interest entity and, accordingly, the Company has consolidated the financial statements of PCHI in the accompanying unaudited condensed consolidated financial statements.</font> </div><br/> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 64.8pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 11 - HOSPITAL QUALITY ASSURANCE FEE PROGRAM</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In October 2009, the Governor of California signed legislation supported by the hospital industry to impose a provider fee on general acute care hospitals that, combined with federal matching funds, would be used to provide supplemental Medi-Cal payments to hospitals. The state submitted the plan to the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) for a required review and approval process, and certain changes in the plan were required by CMS. Legislation amending the fee program to reflect the required changes was passed by the legislature and signed by the Governor on September&#160;8, 2010. Among other changes, the legislation leaves distribution of &#8220;pass-through&#8221; payments received by Medi-Cal managed care plans that will be paid to hospitals under the program to the discretion of the plans.&#160;&#160;</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The hospital quality assurance fee program (&#8220;QAF&#8221;) created by this legislation initially provided payments for up to 21&#160;months retroactive to April 2009 and expiring on December&#160;31, 2010 (&#8220;2010 QAF&#8221;). During fiscal year 2011, the Company recognized $87.2 million in revenue from the state for the 2010 QAF of which $1.8 million was received in April 2011 and is reflected as a receivable in the accompanying unaudited condensed consolidated balance sheet as of March 31, 2011.&#160;&#160;All other amounts had been received during fiscal year 2011. As of March 31, 2011, $378.6 of the other expenses relating to the 2010 QAF was accrued and included in other current liabilities in the accompanying unaudited condensed consolidated balance sheet.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In May 2011, CMS conditionally approved the extension of the QAF for the six month period from January 1 through June 30, 2011 (&#8220;2011 QAF&#8221;).</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on the most recent modeling prepared by the California Hospital Association, the Company anticipates making payments for provider fees and other expenses relating to the 2011 QAF of approximately $15.8 million and receiving approximately $31.6 million in net revenues from the state ($18.1 million from the fee-for-service portion and $13.5 million from the managed care portion). As of June 30, 2011, the Company has received $17.2 million from the fee-for-service portion of the 2011 QAF from the state and has paid fees to the state totaling $15.1 million.&#160;&#160;Until such time as all final approvals have been received from CMS, the amounts received and paid through June 30, 2011 are reflected as unearned revenue and a prepaid asset, respectively, in the accompanying unaudited condensed consolidated balance sheet as of June 30, 2011.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company cannot provide any assurances or estimates in connection with a possible continuation of the QAF program beyond June 30, 2011.</font> </div><br/> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTE 12 - COMMITMENTS AND CONTINGENCIES</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">GUARANTEE&#160;- At June 30, 2011, the Company accrued $1.8 million for a guarantee extended to a state supported teaching institution to accept the transfer of an uninsured patient for a necessary higher level of care.&#160;&#160;The agreement and the institution&#8217;s practice are being reviewed.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OPERATING LEASES&#160;- On April 13, 2010, the Company and PCHI entered into a Second Amendment to Amended and Restated Triple Net Hospital Building Lease (the &#8220;2010 Lease Amendment&#8221;).&#160;&#160;Under the 2010 Lease Amendment, the annual base rent to be paid by the Company to PCHI was increased from $5.4 million to $7.3 million, but if PCHI refinances the $45.0 million Term Note, the annual base rent will increase to $8.3 million. This lease commitment with PCHI is eliminated in consolidation.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CAPITAL LEASES - In connection with the Hospital Acquisition, the Company also assumed the leases for the Chapman facility, which include buildings and land with terms that were extended concurrently with the assignment of the leases to December 31, 2023. The Company leases equipment under capital leases expiring at various dates through December 2015. Assets under capital leases with a net book value of $7.1 million and $7.5 million are included in the accompanying unaudited condensed consolidated balance sheets as of June 30 and March 31, 2011, respectively. Interest rates used in computing the net present value of the lease payments are based on the interest rates implicit in the leases.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INSURANCE - The Company accrues for estimated general and professional liability claims, to the extent not covered by insurance, when they are probable and reasonably estimable. The Company has purchased as primary coverage a claims-made form insurance policy for general and professional liability risks. Estimated losses within general and professional liability retentions from claims incurred and reported, along with incurred but not reported (&#8220;IBNR&#8221;) claims, are accrued based upon projections and are discounted to their net present value using a weighted average risk-free discount rate of 5%. To the extent that subsequent claims information varies from estimates, the liability is adjusted in the period such information becomes available. As of June 30 and March 31, 2011, the Company had accrued $12.6 million and $14.0 million, respectively, which is comprised of $5.7 million and $6.6 million, respectively, in incurred and reported claims, along with $6.9 million and $7.4 million, respectively, in estimated IBNR.&#160;&#160;Estimated insurance recoveries of $2.2 million and $2.7 million are included in other prepaid expenses and current assets in the accompanying unaudited condensed consolidated balance sheets as of June 30 and March 31, 2011, respectively.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has also purchased occurrence coverage insurance to fund its obligations under its workers' compensation program. The Company has a "guaranteed cost" policy, under which the carrier pays all workers' compensation claims, with no deductible or reimbursement required of the Company. The Company accrues for estimated workers' compensation claims, to the extent not covered by insurance, when they are probable and reasonably estimable. The ultimate costs related to this program include expenses for deductible amounts associated with claims incurred and reported in addition to an accrual for the estimated expenses incurred in connection with IBNR claims. Claims are accrued based upon projections and are discounted to their net present value using a weighted average risk-free discount rate of 5%. To the extent that subsequent claims information varies from estimates, the liability is adjusted in the period such information becomes available. As of June 30 and March 31, 2011, the Company had accrued $770 and $836, respectively, comprised of $392 and $434, respectively, in incurred and reported claims, along with $378 and $402, respectively, in estimated IBNR.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, the Company has a self-insured health benefits plan for its employees. As a result, the Company has established and maintains an accrual for IBNR claims arising from self-insured health benefits provided to employees. The Company's IBNR accruals at June 30 and March 31, 2011 were based upon projections. The Company determines the adequacy of this accrual by evaluating its limited historical experience and trends related to both health insurance claims and payments, information provided by its insurance broker and third party administrator and industry experience and trends. The accrual is an estimate and is subject to change. Such change could be material to the Company's unaudited condensed consolidated financial statements. As of June 30 and March 31, 2011, the Company had accrued $2.0 million and $1.8 million, respectively, in estimated IBNR. The Company believes this is the best estimate of the amount of IBNR relating to self-insured health benefit claims at June 30 and March 31, 2011.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has also purchased umbrella liability policies with aggregate limits of $25 million. The umbrella policies provide coverage in excess of the primary layer and applicable retentions for insured liability risks such as general and professional liability, auto liability, and workers compensation (employers liability).</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of June 30, 2011, the Company finances various insurance policies at an interest rate of 4.03% per annum. The Company incurred finance charges relating to such policies of $12.4 and $16.7 for the three months ended June 30, 2011 and 2010, respectively. As of June 30 and March 31, 2011, the accompanying unaudited condensed consolidated balance sheets include the following balances relating to the financed insurance policies.</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 30,</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font> </div> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March 31,</font> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font> </div> </td> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid insurance</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,282</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,108</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: #EEEEEE;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued insurance premiums</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,523</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div> </div> </td> <td valign="bottom" width="9%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,951</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="76%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Included in other current liabilities)</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td> </tr> </table><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CLAIMS AND LAWSUITS &#8211;&#160;The Company and the Hospitals are subject to various legal proceedings, most of which relate to routine matters incidental to operations. The results of these claims cannot be predicted, and it is possible that the ultimate resolution of these matters, individually or in the aggregate, may have a material adverse effect on the Company's business (both in the near and long term), financial position, results of operations, or cash flows. Although the Company defends itself vigorously against claims and lawsuits and cooperates with investigations, these matters (1) could require payment of substantial damages or amounts in judgments or settlements, which individually or in the aggregate could exceed amounts, if any, that may be recovered under insurance policies where coverage applies and is available, (2) cause substantial expenses to be incurred, (3) require significant time and attention from the Company's management, and (4) could cause the Company to close or sell the Hospitals or otherwise modify the way its business is conducted. The Company accrues for claims and lawsuits when an unfavorable outcome is probable and the amount is reasonably estimable.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following is a summary of material developments in the matter involving Orange County Physicians Investment Network, LLC (&#8220;OC-PIN&#8221;) that was identified in our Form 10-K filed on June 24, 2011.&#160;&#160;There have been no material developments in the other matters identified in the Form 10-K.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 24, 2009, a conglomeration of several OC-PIN members led by Ajay G. Meka, M.D. filed a lawsuit against Dr. Shah, other OC-PIN members, and various attorneys, alleging breach of fiduciary duty and seeking damages as well as declaratory and injunctive relief relating to the control of OC-PIN.&#160;&#160;After a number of demurrers were filed by the defendants, Plaintiffs filed a Sixth Amended Complaint on May 5, 2011, to which the Company is not a party.&#160;&#160;On May 19, 2011, Judge Nancy Wieben-Stock appointed Dr. Anil Shah and Dr. John Glavinovich as interim managers of OC-PIN and signed a formal order to this effect on June 27, 2011.&#160;&#160;On July 20, 2011, OC-PIN&#8217;s attorney placed a demand on the Company to seat two directors &#8211; Mr. Brahmbhatt himself and one AmerZarka, M.D. &#8211; on the Board of Directors.&#160;&#160;The Company declined this request based on its non-compliance with the Global Settlement Agreement and asked for additional information.&#160;&#160;On August 3, 2011, the Company filed a lawsuit in the Orange County Superior Court asking for declaratory relief as to how it must respond to this request.</font> </div><br/> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">NOTE 13&#160;- SUBSEQUENT EVENT</font></font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 1, 2011, the Company entered into software and services agreements with McKesson Technologies Inc. (&#8220;McKesson&#8221;) to upgrade the Company&#8217;s information technology systems.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the agreements, McKesson will provide the Company with a variety of services, including new software implementation and education/training services for the Company&#8217;s personnel, software maintenance services and professional services related to movement and migration of data from legacy systems.&#160;&#160;McKesson will also furnish to the Company and maintain new hardware to accommodate the upgraded software and systems.&#160;&#160;The new hardware will include computers, and servers, among other things, and will include installation, testing and ongoing maintenance.&#160;&#160;The Company has entered into the arrangement to enhance its clinical information systems and upgrade its billing and revenue management information systems.</font> </div><br/><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The agreements will initially run for a period of five years, and the recurring services may be renewed by the Company for successive periods.&#160;&#160;The agreements do not provide that they may be terminated by the Company prior to the initial expiration date.&#160;&#160;The agreements provide for one-time fees and recurring fees which aggregate a total of $22.0 million.&#160;&#160;Approximately 60% of the fees are for one-time charges, while the balance is for recurring services.</font> </div><br/> EX-101.SCH 7 ihch-20110630.xsd XBRL EXHIBIT 001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - NOTE 2 - PROPERTY AND EQUIPMENT link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - NOTE 3 - DEBT link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - NOTE 4 - COMMON STOCK WARRANTS link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - NOTE 5 - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - NOTE 6 - STOCK INCENTIVE PLAN link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - NOTE 7 - RETIREMENT PLAN link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - NOTE 8 - INCOME PER SHARE link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - NOTE 9 - VARIABLE INTEREST ENTITY link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - NOTE 10 - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - NOTE 11 - HOSPITAL QUALITY ASSURANCE FEE PROGRAM link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - NOTE 12 - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - NOTE 13 - SUBSEQUENT EVENT link:presentationLink link:definitionLink link:calculationLink 000 - Disclosure - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 ihch-20110630_cal.xml XBRL EXHIBIT EX-101.DEF 9 ihch-20110630_def.xml XBRL EXHIBIT EX-101.LAB 10 ihch-20110630_lab.xml XBRL EXHIBIT EX-101.PRE 11 ihch-20110630_pre.xml XBRL EXHIBIT XML 12 R3.htm IDEA: XBRL DOCUMENT  v2.3.0.11
CONDENSED CONSOLIDATED BALANCE SHEET (Parentheticals) (USD $)
Jun. 30, 2011
Mar. 31, 2011
Allowance for doubtful accounts (in Dollars) $ 22,008 $ 20,076
Current portion of Capial Lease Obligation (in Dollars) $ 1,140 $ 1,131
Common stock par value (in Dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 800,000 800,000
Common stock, shares issued 255,307 255,307
Common stock, shares outstanding 255,307 255,307
XML 13 R4.htm IDEA: XBRL DOCUMENT  v2.3.0.11
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (USD $)
3 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Net operating revenues $ 89,662 $ 93,919
Operating expenses:    
Salaries and benefits 53,238 51,642
Supplies 12,983 12,945
Provision for doubtful accounts 9,697 8,908
Other operating expenses 14,476 16,140
Depreciation and amortization 1,090 1,044
[OperatingExpenses] 91,484 90,679
Operating income (loss) (1,822) 3,240
Other expense:    
Interest expense, net (2,843) (3,118)
Loss on warrants (3,270) (1,900)
[OtherExpenses] (6,113) (5,018)
Loss before income tax benefit (7,935) (1,778)
Income tax benefit 5,200  
Net loss (2,735) (1,778)
Net income attributable to noncontrolling interests (Note 9) (135) (135)
Net loss attributable to Integrated Healthcare Holdings, Inc. $ (2,870) $ (1,913)
Loss per common share attributable to Integrated Healthcare Holdings, Inc. stockholders    
Basic (in Dollars per share) $ (0.01) $ (0.01)
Diluted (in Dollars per share) $ (0.01) $ (0.01)
Weighted average shares outstanding    
Basic (in Shares) 255,307 255,307
Diluted (in Shares) 255,307 255,307
XML 14 R1.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Document And Entity Information (USD $)
3 Months Ended
Jun. 30, 2011
Aug. 01, 2011
Document and Entity Information [Abstract]    
Entity Registrant Name Integrated Healthcare Holdings Inc  
Document Type 10-Q  
Current Fiscal Year End Date --03-31  
Entity Common Stock, Shares Outstanding   255,307,262
Entity Public Float $ 1,867,760  
Amendment Flag false  
Entity Central Index Key 0001051488  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Filer Category Smaller Reporting Company  
Entity Well-known Seasoned Issuer No  
Document Period End Date Jun. 30, 2011
Document Fiscal Year Focus 2011  
Document Fiscal Period Focus Q1  
XML 15 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 16 R12.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 6 - STOCK INCENTIVE PLAN
3 Months Ended
Jun. 30, 2011
Shareholders' Equity and Share-based Payments [Text Block]
  
NOTE 6 - STOCK INCENTIVE PLAN

The Company's 2006 Stock Incentive Plan (the "Plan"), which is shareholder-approved, permits the grant of share options to its employees and board members for up to a maximum aggregate of 12.0 million shares of common stock. In addition, as of the first business day of each calendar year in the period 2007 through 2015, the maximum aggregate number of shares shall be increased by a number equal to one percent of the number of shares of common stock of the Company outstanding on December 31 of the immediately preceding calendar year. Accordingly, as of June 30, 2011, the maximum aggregate number of shares under the Plan was 21.0 million. The Company believes that such awards better align the interests of its employees with those of its shareholders. In accordance with the Plan, incentive stock options, nonqualified stock options, and performance based compensation awards may not be granted at less than 100 percent of the estimated fair market value of the common stock on the date of grant. Incentive stock options granted to a person owning more than 10 percent of the voting power of all classes of stock of the Company may not be issued at less than 110 percent of the fair market value of the stock on the date of grant. Option awards generally vest based on 3 years of continuous service (1/3 of the shares vest on the twelve month anniversary of the grant date, and an additional 1/12 of the shares vest on each subsequent fiscal quarter-end of the Company following such twelve month anniversary). Certain option awards provide for accelerated vesting if there is a change of control, as defined. The option awards have 7-year contractual terms.

When the measurement date is certain, the fair value of each option grant is estimated on the date of grant using the Black-Scholes valuation model. Since there is limited historical data with respect to both pre-vesting forfeiture and post-vesting termination, the expected life of the options was determined utilizing the simplified method, whereby the expected term is calculated by taking the sum of the vesting term plus the original contractual term and dividing that quantity by two.

The Company recorded $0 and $14.0 of compensation expense relative to stock options during the three months ended June 30, 2011 and 2010, respectively. No options were exercised during the three months ended June 30, 2011 and 2010. A summary of stock option activity for the three months ended June 30, 2011 is presented as follows.

   
Shares
   
Weighted-
 average
 exercise
 price
   
Weighted-
 average
 grant date
 fair value
 
Weighted-
 average
 remaining
 contractual
 term
 (years)
     
Aggregate
 intrinsic
 value
                             
Outstanding, March 31, 2011
   
8,370
   
$
0.18
                   
Granted
   
-
   
$
-
   
$
-
           
Exercised
   
-
   
$
-
                   
Forfeited or expired
   
(20
)
 
$
0.25
                   
Outstanding, June 30, 2011
   
8,350
   
$
0.18
         
3.4
   
-
Exercisable at June 30, 2011
   
8,350
   
$
0.18
         
3.4
   
$
-

All outstanding options were fully vested as of June 30 and March 31, 2011.

XML 17 R17.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 11 - HOSPITAL QUALITY ASSURANCE FEE PROGRAM
3 Months Ended
Jun. 30, 2011
Other Parent Company Disclosures
NOTE 11 - HOSPITAL QUALITY ASSURANCE FEE PROGRAM

In October 2009, the Governor of California signed legislation supported by the hospital industry to impose a provider fee on general acute care hospitals that, combined with federal matching funds, would be used to provide supplemental Medi-Cal payments to hospitals. The state submitted the plan to the Centers for Medicare and Medicaid Services (“CMS”) for a required review and approval process, and certain changes in the plan were required by CMS. Legislation amending the fee program to reflect the required changes was passed by the legislature and signed by the Governor on September 8, 2010. Among other changes, the legislation leaves distribution of “pass-through” payments received by Medi-Cal managed care plans that will be paid to hospitals under the program to the discretion of the plans.  

The hospital quality assurance fee program (“QAF”) created by this legislation initially provided payments for up to 21 months retroactive to April 2009 and expiring on December 31, 2010 (“2010 QAF”). During fiscal year 2011, the Company recognized $87.2 million in revenue from the state for the 2010 QAF of which $1.8 million was received in April 2011 and is reflected as a receivable in the accompanying unaudited condensed consolidated balance sheet as of March 31, 2011.  All other amounts had been received during fiscal year 2011. As of March 31, 2011, $378.6 of the other expenses relating to the 2010 QAF was accrued and included in other current liabilities in the accompanying unaudited condensed consolidated balance sheet.

In May 2011, CMS conditionally approved the extension of the QAF for the six month period from January 1 through June 30, 2011 (“2011 QAF”).

Based on the most recent modeling prepared by the California Hospital Association, the Company anticipates making payments for provider fees and other expenses relating to the 2011 QAF of approximately $15.8 million and receiving approximately $31.6 million in net revenues from the state ($18.1 million from the fee-for-service portion and $13.5 million from the managed care portion). As of June 30, 2011, the Company has received $17.2 million from the fee-for-service portion of the 2011 QAF from the state and has paid fees to the state totaling $15.1 million.  Until such time as all final approvals have been received from CMS, the amounts received and paid through June 30, 2011 are reflected as unearned revenue and a prepaid asset, respectively, in the accompanying unaudited condensed consolidated balance sheet as of June 30, 2011.

The Company cannot provide any assurances or estimates in connection with a possible continuation of the QAF program beyond June 30, 2011.

XML 18 R8.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 2 - PROPERTY AND EQUIPMENT
3 Months Ended
Jun. 30, 2011
Property, Plant and Equipment Disclosure [Text Block]
NOTE 2 - PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

   
June 30,
 2011
   
March 31,
 2011
 
             
Buildings
 
$
34,637
   
$
34,624
 
Land and improvements
   
13,523
     
13,523
 
Equipment
   
13,635
     
13,266
 
Construction in progress
   
1,404
     
1,375
 
Assets under capital leases
   
11,218
     
11,218
 
     
74,417
     
74,006
 
Less accumulated depreciation
   
(20,837
)
   
(19,755
)
                 
Property and equipment, net
 
$
53,580
   
$
54,251
 

Accumulated depreciation on assets under capital leases as of June 30 and March 31, 2011 was $4.1 million and $3.7 million, respectively.

The Hospitals are located in an area near active and substantial earthquake faults. The Hospitals carry earthquake insurance with a policy limit of $50.0 million. A significant earthquake could result in material damage and temporary or permanent cessation of operations at one or more of the Hospitals.

The State of California has imposed new hospital seismic safety requirements. Under these new requirements, the Hospitals must meet stringent seismic safety criteria in the future. In addition, there could be other remediation costs pursuant to this seismic retrofit.

The State of California has introduced a new seismic review methodology known as HAZUS. The HAZUS methodology may preclude the need for some structural modifications. All four Hospitals requested HAZUS review and received a favorable notice pertaining to structural reclassification. All Hospital buildings, with the exception of one (an administrative building), have been deemed compliant until January 1, 2030 for both structural and nonstructural retrofit.  The Company does not have an estimate of the cost to remediate the seismic requirements for the administrative building as of June 30, 2011.

There are additional requirements that must be complied with by 2030. The costs of meeting these requirements have not yet been determined. Compliance with seismic ordinances will be costly and could have a material adverse effect on the Company's cash flow.  In addition, remediation could possibly result in certain environmental liabilities, such as asbestos abatement.

XML 19 R14.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 8 - INCOME PER SHARE
3 Months Ended
Jun. 30, 2011
Earnings Per Share [Text Block]
    
NOTE 8 - INCOME PER SHARE

Income per share is calculated under two different methods, basic and diluted. Basic income per share is calculated by dividing the net income by the weighted average shares of common stock outstanding during the period. Diluted income per share is calculated by dividing the net income by the weighted average shares of common stock outstanding during the period and dilutive potential shares of common stock. Dilutive potential shares of common stock, as determined under the treasury stock method, consist of shares of common stock issuable upon exercise of stock warrants or options, net of shares of common stock assumed to be repurchased by the Company from the exercise proceeds.

Since the Company incurred losses for the three months ended June 30, 2011 and 2010, the potential shares of common stock, consisting of approximately 412 million and 437 million shares, respectively, issuable under warrants and stock options, have been excluded from the calculations of diluted loss per share for those periods.

XML 20 R19.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 13 - SUBSEQUENT EVENT
3 Months Ended
Jun. 30, 2011
Subsequent Events [Text Block]
NOTE 13 - SUBSEQUENT EVENT

On July 1, 2011, the Company entered into software and services agreements with McKesson Technologies Inc. (“McKesson”) to upgrade the Company’s information technology systems.

Under the agreements, McKesson will provide the Company with a variety of services, including new software implementation and education/training services for the Company’s personnel, software maintenance services and professional services related to movement and migration of data from legacy systems.  McKesson will also furnish to the Company and maintain new hardware to accommodate the upgraded software and systems.  The new hardware will include computers, and servers, among other things, and will include installation, testing and ongoing maintenance.  The Company has entered into the arrangement to enhance its clinical information systems and upgrade its billing and revenue management information systems.

The agreements will initially run for a period of five years, and the recurring services may be renewed by the Company for successive periods.  The agreements do not provide that they may be terminated by the Company prior to the initial expiration date.  The agreements provide for one-time fees and recurring fees which aggregate a total of $22.0 million.  Approximately 60% of the fees are for one-time charges, while the balance is for recurring services.

XML 21 R15.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 9 - VARIABLE INTEREST ENTITY
3 Months Ended
Jun. 30, 2011
Business Combination Disclosure [Text Block]
NOTE 9 - VARIABLE INTEREST ENTITY

Concurrent with the close of the Acquisition, PCHI simultaneously acquired title to substantially all of the real property acquired by the Company in the Acquisition. The Company received $5.0 million and PCHI guaranteed the Company's $45.0 million Term Note. The Company remains primarily liable as the borrower under the $45.0 million Term Note notwithstanding its guarantee by PCHI; this note is cross-collateralized by substantially all of the Company's assets and all of the real property of the Hospitals. All of the Company's operating activities are directly affected by the real property that was sold to PCHI, which is a related party entity that is affiliated with the Company through common ownership and control. As of June 30, 2011, PCHI was owned 51% by various physician investors and 49% by Ganesha (Dr. Chaudhuri and Mr. Thomas). A company is required to consolidate the financial statements of any entity that cannot finance its activities without additional subordinated financial support, and for which one company provides the majority of that support through means other than ownership. Effective March 8, 2005, the Company determined that it provided the majority of financial support to PCHI through various sources including lease payments, remaining primarily liable under the $45.0 million Term Note, and cross-collateralization of the Company's non-real estate assets to secure the $45.0 million Term Note. Accordingly, the financial statements of PCHI are included in the accompanying unaudited condensed consolidated financial statements.

PCHI's assets, liabilities, and accumulated deficit are set forth below.

   
June 30,
 2011
   
March 31,
 2011
 
             
Cash
 
$
199
   
$
330
 
Property, net
   
41,951
     
42,273
 
Other
   
142
     
70
 
Total assets
 
$
42,292
   
$
42,673
 
                 
                 
Debt (as guarantor)
 
$
45,000
   
$
45,000
 
Other
   
617
     
634
 
Total liabilities
   
45,617
     
45,634
 
                 
Deficiency
   
(3,325
)
   
(2,961
)
Total liabilities and accumulated deficit
 
$
42,292
   
$
42,673
 

As noted above, PCHI is a guarantor on the $45.0 million Term Note should the Company not be able to perform.  PCHI's total liabilities represent the Company's maximum exposure to loss.

PCHI rental income and the Company’s related rental expense of $1.9 million and $1.7 million were eliminated upon consolidation for the three months ended June 30, 2011 and 2010, respectively.

The Company has a lease commitment to PCHI (Note 12). Additionally, the Company is responsible for seismic remediation under the terms of the lease agreement (Note 2).

ZIP 22 0001019687-11-002503-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001019687-11-002503-xbrl.zip M4$L#!!0````(`$A$"C^9;:,#V9P``!:H!@`1`!P`:6AC:"TR,#$Q,#8S,"YX M;6Q55`D``\=Z0D['>D).=7@+``$$)0X```0Y`0``[%WI<]M&LO_^JM[_,*O= M3255IH2#IVRSBJ8DFQM94D1ZG;PO6R`P)"\(Q MHI=/;6=]IDB2>D8LU],L'9\$3Y[3NZ3F\T;\`O]P_RRX&3WJNQUOO\,QFI7F M+MG#T9TSBK\CR1U5CEXB&WV3@$,V&V+K5#OL::FO2M&S)K'^*(!.;R\U-X9N M%CS\ZS4\S2%?:]I.")S>$.%V[:XB#XHT&3P1O6#@E!9=K)^N[8=47/`0;Y[->/UW-]@[=:YV#7<>!O"+VA-,Y==OL>KQ"C M>4[M]/;$)=N=217)KFT8@8;T]TZ3\3 M]W:E2O_R+?IPS`\>Q)9'O/WX<`$N$8->7!$8+@P*3L@2Z6@Z^_ED+(%$4D_N M#H=OSN+7>/IG,8/HT@X[Q#:2+)DJO'&@]'Y'E=Z<1=<.E.+W`AG/0B$C2DFA MY4!H^:/F_"6$5L'3&@NM_.?*L;?R9,=D7MC?LLU!4,>[@.`:*J`+H^W-67P5 M(?YI;!G.5);**TN*E25]Z\J2:BA+:DE9W>1P^@^DV:UMS3U;_^,C MWBZQQ)FCO.Y!WJ@ MKU_^Z0-.6C#8%OS3G3P1]V0<9BU^]R)>E7).7#N+OR_1?:11_?0^0D\L?XJG+]V7K MKS9W:6?I1DE9K,+DY?NRWSVG'FFK*FJ73E^_+EM_$_*4=2W93ELPOFKXO M$W[=&4P[MNNE;/=2_7SY.4P[EDPN!TE?-/_5%UMJ:>HF#Q(._!<0NQUK!TL/ M\L1??Z/[.$D7'[+ROK[0OD4"B7W7X!/(%FNN[^!QN'5[_FE^\>8LNHAB>O1] M[M\\N3OLS#>:0_=90Z(&>0")$U+0%V[\+6THL/F17P5"'"725)+T+[!E;XD5 MW1/Q8+T`YRZ%ZPKDC+FD:1TT'"DW<&; MLUKD\YB5*1>NJH.CFNBZ M[ZQC>&9IXAOL37W'@8>/UU.WK_*J*F+2%J!B%?64GCH\$I!IVH^TR^3* M=BYL?^FM?#/[?F.5*8HD\0CK18O[Y'-(^?1R68EUTU9YR#)8[ M!^_8$@UD2>H^38;0D$.0IMN$;['DJLR/W(I\%]H3;I")>C#Z,CP9S1S/"Q^Y M?-K!_*]YN))[LI1V/2&+<=DX.%[O\E#NY7M#12IG\\SI78;9E+> M_LZ$V15HA)9&.[HNT2CS]-3>,#$<\YFT!:@D,765GGP@.EEW;C;#1O&B(@ MJ?M6RGPNY+< M'V6G($GR(K^JC:.L3AOU!5.A4AR7VYUI[S&^QR;]GN.::$MB$H_@%K+&`*[% MD$HYI4-6(VAE-<9`&C2`!NIU?!Q7@RT47NI`39A/1+\%&"5ZZ?>[2FT845R] MQS!3\EM0QD`1A>TD>?&8"N#J]A:SJKDQE'YWU!7H(\V@+3`EUE&&?+0M0),M MS<.'VQS??:7;317JN5P$"CH>5K&6!DI?;@"KU0BH*#VUS^Z-:[)FZKFUKO<#.]@(OO;@^:I`C>U)F5BGFD>NI/U0'K0-K'FGDKE2**C_H'0^K+`*I<@-87,!J4DT, M>HHLC(*BZ5$ECB52#Z0NOUQ2R)&V)!)OR_;`+&,*7(BUQI9>5^8G]]PBYML3 M#S(=_=RU)3X92:OP"5LL&^YN*CVN"$R338^K&EQ+]C^.XWJG.;<.Z[DQV)/1 MYGH"R&''O;(:U).Q="I)LA!2'L]"HS0!6J"Y]H&R)]R)[VULA_P7&S'`<(>^ MLA)G-U&Q MRQO;-+#C!JV6-[:'Y_[2U1VR8P5.O'W58$>*7V2OQ?,9(9?M6K4'.=UI##,2 M?^NSU;H+O**]J<>KMC-4Y!X7A0I>_1,;>PQ:W@#32ER(-B,QV#)[WX_/Q2EEEEV.,7')]' M2FX*";.W-L=R>H.RC%-F/^]X8/5V-&L"FVLF=L,M@SEV'HC.VI6*\.2?$I1* M;*-^GT]M8DX91ZT/*/\DGE2KA#J21[4!76M+VP%5AKM>83])&PKJJ0K?EREF M)%KOJ8VHJH9Z!Q+2I'5D9#;G$HQ2'MQ=7Y5U4%\.=WUXKY MWSGV`Z$?%@G:/]M0QJ@_2BX[YW)K"5A5+0U'R>Z_RL#87@)M+:$-.8%.;W?T MPX?$+*^!^W2[?']N$3MA?^@1T"I[5C^Q"ET'V@7>.4"*+0C#XY,M397_9?]L M16G2B`-6P"P[\S@2666=2?PF:BUD!V6&RFUG0-)O2C@;IGF(=NCJX*B7@,J`OLD`>-'HO['B;75)FW5GRM+96IRB`1 MB$IX9L-D`Y"550AU=Q.0+.ZW&9/ZLJRFTDH&4[F&O72<_@(>(GJ003FX_8V]@&_0S%#?;O6O'$P4A-?.3R MQ=`+(O%:\V5O:1Y.H/7ZS6HX(+_1>KL*SH<`R=D)$1/+@'#57LM#5^:_X:W( M6-`6W0+DZ@MTK4".EF>P\=ZV#?HP.!H.O[V/&I46CF:Y]/U):.[N(W0$7:*NP%6P,-\-:>26S-U3; MQQJ=R5;R\5KU+?Z>5(218]<>N,H:'-7`5@*MSBE=E3M&5*4(7]D!7LU`5E5B M=\1WDU1"60:SZHEOQ^^V%3#,;CZ+'VZQ;[&3.ARNC&8M>R7R7/D M:K$7;[.*I8U.)ZE]Y%N-_B.U4)`J0*HDJZ8"50YH2I)9'NQH@J_=`J4IA3*X-,O^`I'8\O%_L$/GLJ[C!<>"K*UOIJ<\'/G7X M42N!,7F\4BG/2CZ<.HFHS2'75Z5"[\CE7@[\<+)5>^&ZFVP_+.%8*=/40%F] M[7A4#V9ZB9A.AEA7O(&-=_M/+M7_H2%U`O.EA_;"0Z\K)]>(*S(7+VZW@+S& MO%D]&GB)4R2/A&\G#!W9J.S&`JQ&JL\[HM!W4E7M=^46%!JAS_#QH8VP_.G3YQ?KJO+-CK!WT?CSIQ`)_I=FSOV\UCI7-].4=D?\7N`-=@+ M]K):`E]9\0/^QX'J8J\`OTH@LF=Y&IP?AT;X3NC./@/.;LSPF M*1P7MN[33+/8[ZKSEZ7.+P$'_O5Q@G!X.N85<77-_`UKSF7PL]^5F72B'YHL MHC9.:[3)866IGV84-]@H]`B-:OR$)K_S(7OK5Z:M-?KIBOY@T)=X(!S=I"$F M8!^#VNC*U-:5M;\"5CB@GR`PS@@TA3N.9LXL`S_]C/>5.?"_5YE+;9Q58.@* M4"/1_7QK3<]G]-W*;'^COX)81DUHN7_;IF]YFK._(B;M/*O*\<;F&::H"#FQ M6U-P[[7M5%?H'-P#WD,'61#]\5S-VO/L$Z3'`MZ?L6G^;-F/UASRKFU!)40[ MR)PCI?C)99WL1O?_C3M[W7B\M?%YW)]>S]S3DR\2W&%E^:S_[L\1[*T\\(+5Y./LVMXT2-;F#18^!$!;LV*`=S<+BXC$!$&&770 MQ>5\>C^[6\QN;]#M%7KW:3Z[N9S/T>3F`LT_??PXN?^-7I^#3+.KV71RLPBH M1#0FT^GMIYO%[.8]NKN]GDUGEW,JVAF532`XNP=J8[?@[TOG+/IK6ID'92RI M75XC@/)^=M.YOKP"73#)F;IG-Q>7-W!%[=-+UX"^\R%4F'RJ]`[OW0?7XA=# M._WNNQY9[;.F.L)2N699,+/<@%GNDV9Y-YG/Y@<='7B"QN_N+^<@V(19IH,6 M&XPT70\B7)#<-=\@M"8"CS7HSJN1M(Q^&`WPS"IR?I`B\GYDKY"PM,KBB6JM M5[38.D60[Q$!`H\;VS3W".(=O._Z2Y<81&,--3]Z&P&90.XP3`?_^`EMM`>, MEAA;:$[Z@86K!I2E6T MLL$7:,MTN/(HI8SR^G$>>5[8"(4*V3+6<8)\ICIVD/G#!=P!US M_XJA2#@"9U##1I;M`6UZDAT\9II)EPB%(!8@V`9GXU`IX!V0Q\%L`=E`RSVB M>F(P*1\3>P);BCSJ%-R#<;!WQ*+4@2&XN[9FMQEV-ZLK3@`..=(,.C2#Z]X& MRD=:]`-!#?`">I-"3XKG4.,X5"<65#7PM(5U[+I0?"#/IMY%LP%::<0!AQ$Z M:.2:VG;W^N]#11Z\=O/&TZPK$S[$51% M1W3\*O\D57P,+R+E;1R,$53?WL9%4*("&DA&&*G2*T13$M,/-7\D-3'W&5T3 MJ-1U=B)(Y`P1A)`I4/;`"RA%!:2EZ1[MH;80#+X%M:8H#I6'GJ3=W(WMF^!W M%(S&1C\0^-VW6#MG,/PI,C'5]&#AO(EJ/#%4`D8J2YR(>PBGS05*!:`AQR]G2)OX@?MQI.ED1'9[17.^0TE+VBD_Q>(6N MKZ=1]+Z;?IA%X?M'>B0R&OWT"A'P,?0`(XTU49!P`28SZ#";&R`&:<7P1"$6 M//15F.JX\)[Q;9%SP_"EH-BH3WET3J&0UE6-\2KR2?12TXG=%G1Y0^76UE`U`FV M]#UE\P]%/AVB+3'-J#3]ASP\[:>5$3[`*J\=IMM5F(9.EN[1H^W\0<.>'NP@ MAAR\@+R42RS@!OQ5,?G3`+7\BD7_@R M_*>CE';B"RFX:.(E+9``D.5KV5!P1Q_E(>U!(V;0`)FM(7T0R&'S/P<_V.8# MTW;0R;""%$O?"7.DFC,,7P:B>"!RBS%)X_$K,QT4?-E$:_A@+`ZI4:5>TJA: MT`^4FB*M;-]!&]ME8R.8IH>S\@_1Q<,LU;&WR4D]N.`")MPIQ^*V9*:V`R5R M,+'D2+/6I&"V%!(/9C\15/O12I=AU+N#&1'-0[0FHL`A:V[I)L*^LZ3?@W&" M@%.$*3&;$5S;I_G00E/-)%"P6T1[A1XW!#0'H,^/*;?925=HN=9MTW9")P"* M,$]F?T4Z-LT='4_6.KPK<7?S6FM_1R\5IET^ MT(3G"--A`"]?V;H\6_DC*-C`<>A61!MTDC//*/@+L@!%024:R$DS]X) M[",0#]65<%A#P+I!IPYMIKQ1?S!*::\-5?(Z&TD"I655UC#P2U7C?FA5WM9Y MP3\)LF7?;2&?Y!)7ADIGF4X!T9_/,%6E4?$CIE,$$]&M2)K7+32':8J&)I96 MYA!9ZQWBI7!0%/E,<,_)>_DE!'WE$)07)EXBPW.YU'-&!GDX/"8R0$S88+(M M310B\[V$AI?0\!(:_@*A85`0&MC:.0T)X4R,3@NCF>.A=,C10(6"0FC`L=?('#(W8+`L=%V\+2@IKAU6`=%:63X8H$AN$E7>+[]=>GG;88-HY^('8OFONPRX7NG:G/:2VWED/D(-U M4W-=LB)TV]:FFT^T6>6P%Q7TK]+M(6(;/V@[VWWM9J+WCFO\"S;;+1N1[4[3 MV?9]T/80XN`7V/.Z`5XVDZH[R_3V9@KP[SE/2?2UW<_F/X?];(( MGEHJ((8)72;FF-M.BN(CZU/Y__;>AKF-&UD7_BMX]WAOV74I1I3DKR2;*EJ6 M'65MR9'DY.R]=>L4.`.2B(ES*2<\R`!4G`)`$0`#;)+L&SPF-2E<"DTZ,P M,ZAS%CK/LTG.9X4)5L_5C2UZ\8S_0=<0319/G;;2%@@K-8IJ1(2#_)NP,K:] M+L&@E9AAZ+X94]00.[*Z-9^A,1Y3"'5\(CZC(PU;'<%"X*^YROMR-CKA^03O MK\[Y`A/M41B4FH1_T(DK_2)CPP@P_@C32#I34LD$>$H/K/OTZ3_IZ:?/_VFX M9,E\X=MMV,/OWN`,LWU.VE[;2::R$C` MGHN>!=OJ(%#`[F9 M-E.9QSN(T0O#F(#9N9"S495C4J/*AVS&J<\2])/][3$=F@1N9,\9_P3R"CLWHZ-YLKJ* MHIK-E9"J1.U:*)?Z643JQU!5_2]9E@ MB!+30$TB>"&2\4[]:1L:4#_FES1,JOP3@[MY4_NPS]XW^Z(N*N3&2*E7AKEP M=0:%?3$"B!V9.PS-^DV6O;LHA"9*[=?7+7HV3R!XJ153.T MW2+:5FTWR;)C]C=#V39\R838JD?,T?ZFI*>.XYKB1H,LR&**WY%4#)ZIS*G'DQQ#&]&4/(PG MC+*##5\XD;JX+D6N+OZ@,:ZX#W@MNR)9ZID[5<1^M=_06IRQLR)T=56NN_%F M>I8K8SN^O58J;[TR\ANFE%[&Y@E/`?3>VNO1U"FY3.H_J<2P+@"UG&3K;LBR+*II2ZT[+V$`BU:#3KM;=SW#LY M=D"DL>'[3JRF7,P1R^NY:;WN*!`S5"HF&3C1I;GYTFA%I<$IMS!702`0+!VW M&8L8:>82$=@]]642 M%JG@I@NV27,O0S^K$V5M1J_%"D2SJ#`!L1N\!$4YWZ&(I)G#DSY[)2*.YDL] M3V.O:9IWUV9XR;C++21`)5HS,(H[NGE&QNELP5AX3B_2M^B<] M9VP*6R1%1ES=#2PTG*0>4"ZFCA%H[`!)PM3JS)M=S>?SA"ZQ*2.XP2T"S!JK M@M:[D=;3.JQC^Q$/DZ>:\SH_?"S$#K#-CM9<_G!5>^N-ETKLH5`:=GE&UQ09 MW>G(3!2I%J!B`4B,CFU;UEZW-!4H@.;11%OLZ@6-8L:[ERVY=;2,$34K,;A6 M)6VN5?)$;W'-=G02T&K/&ULX!O!!=6S9OV6.=>34E-1IAL=U`XC(,%AXZ'<_ M?`OOR`E.<<AN]O<1:&DHT(2-0K]31T(Z6:R[V$17U'64Z M70+-=HG>RE'CC(RMX=TM:TK99\0$ZM^YJ@%-Q&!(8;HW2'<\Z^G4`C)7BE09 M=5HK$K7*^E:H^9W$""10.[U%A\IZIT'].Q=%]4U:X:VHGS,W#[JW#$]#>$5T8_J!8AIV92!EMF2Q,O!`] MEE+S`"[4;S;9/K6Z0&MHA==58Y$>26T+PG28*[OTXUS>\:J,@`L=UZVX]366&^(JZ^A6Y^=2S2"\(4) MORIZ+G/6U0FS MDJIV88.&K=#R@`?,9=6&C1H_9>$J>MR5+C[1&_#;QJ4UAF3[>@@RA>7B="*R M-72TQ'G,'KU\>:"N21T\?89F>OLB6V<^[L6V]NVR1B_4UR7Q0F\K^.TS4G5X M>>7-W&Y`T1]1'/&$S&8@@UAV*3>8-VL>=33LJ<$+I!XL2Z$/9VL'0,=7]"&T M7>6A/C1I3J$!6W$4`O$TEA/D`)*\QRAV.X<=$`-;!O0P5?[(\%8OH[)J34Y= M/0W`24V2\Y_-%2UD[N[1"[FZS91,QLT0\$R%Q#S520[?#^OR)&0C=(<\?\4& M@UUU!Q3_O??T:7/TX)SG&W7@TMQ/8935@\[5QD%_8/[BT"RNZI#N^J>4OC-Q M^[ZD*L>A]+XYUJH1S91YH->YBUKKC/0*P.+1?O_`7F2'D1X]:[[0N<]YW47< M97'MF`''M+#Q"C7EH[WV9'!VS672KF&R/A9:Z.>>5-T("SW'&[6N7@,(`Q2N M#87C#+UFW`:J:%%4LQE&EM&Y[NZIQT!4^^J[27G]'JBKE/?APF0[O?#ZQ&([ M&;2I%M?.TQUE90GXWEW9A^'KU\G5Y]&Q'EU>O;ZZ*RFS2CAT2>D$".PW?"LZ8CRAMU)MJ=X MQYN).MBS,_@#BO\6KDD&(ML2@\;-2@6_/F$#\`18#K!\3Q&#W"$_<1AZ20&8 M`S#?/^A9ZXIC:P4CP)5)GE5IO$/E:[YG_W5$/S]T">+;AN7TMAVRY\]\=PF_ MM3"MEIEO*-B^:N'N%.\:/_4AP;4XZ17H.Y'X]5AML-9-SXV7Y#M9=1"O31&O M1]=SQ^:)ULO`9.LS62XGTV[+AZ_,9B]?'@0`OT<`_C!7'1`EJ*V@MAZ0VCIX M^BRHK>V-(%#MVV[\X.]'#VXP9[/@MET2SD@6Z#,K5`F8'[`_`>&^?N]%R\#YF^TS&[\ MZ?C*/3A8R[_=^$VX"_;TD.:!4L:K4H`\+,XJ+&&[1H@J*)5-B9!L=;0]L.5] MMG4.]G;OJZT3E$F@3%"S0Q!;__I7E"SFZQ,5H84U(>A=4C] MKM5EQ5JE\:C"X]+J8+HB&%;\Z0PF4].&>IX+JSB4JH&)K>9CR2=I5DC56'XG MEF*F/NTYQ##%Y+#F@U/C+#<%C[_#RN!46JF0,YEP3Q',5O7,G(J?4ZD+*C-1 MB';%4*J5U]3?L.`LXH6!94U['H M%'&G^@]4KN12QE3'4G\#]D&:XFMFH*'OFZ;&(+X%2PC8Q<3JPKCTGBZI]!`[ MH\5.Z[VF2D26QS+%:@2P+SD5<&8CK*DF3`^/>HDV.:R2!O!'F=MDQ"G%5@%! MP;OWQJQBPK@HM[Z)J:U!;VP53NW@B;^0*JM*FHXE5$BGF>87%B-2E540[!$^1-QEBJ>MR0J$UHK$6E%G%% M-;>H7%M3!BH5JG(:U6F^E%0[^F))8QTP4_")K)Z^*G&J*I10%W.KKK(1#3.& ML$N\^6@$A-7U,6F\NLJ4.Q"6\+]!-PGU6$N_;C30?QVD7UEAR;2NP8J?6'>> M`)^ZY.B"GU=8OUK75&<)4+]3]U5B93C@5+:_NULW-'FC:L2R#UB=!,9]AT_V MV8=Z6%E..Q)IOZ6HR[[1L"@>^T^7CM]%+WHA^[/"Z& MK]CSYP=NB6(S5+=%D"FOY%1J4Q-O5ME9(*XZJTJKSBY5MAV/J1XS;^I`88NN M^3Q9Z`83+LGK2G%4IUW5R30U(ZF\,98C!S$'T9V07H(Q>LRI:VL&4X5Z@3"Z M3T>/_28C$&"2WD/0]:+'J.XTM@BIBV>U!;4I-Z77#OAPF46$`769+K=2IZY_ MY5#[B.:L.H:8ZGRZ%M;[HP_J'T]8$>74JL'PD]9)=6W=UNR02DV9X'E&!?^! M>4"L/@%*(W;0K^H1[#P-:,"T3@750.X0MF:B[3HUFRJRP,7 M1199U:`5-N`J#"H8E#!D?](>J%6,JUM]JS'TL1I'Z[9R78^K*S*D<.8PE\^F MZO:C07_?*4G6*9#5&&EV!Z3E_EM0&JY[4%5,F;@^.QYK&U29 MQ:V9U*:.T1;VQ'NZ*6%3I*UKPW=:(]K*%!GT"GX%`B'2$Y:6NH!]A]O=D:@; M"6DN;1X7NOJMLIW1-LH%3/HO\FP=!L$F(Z)NAZ01"NP^%!M<(D:BRG&5F`8D MG7+.9_5L(EZW>NKLE'FZ-=\X#!&ZJTU.W'=Y8?FX/2-55PS5PK=Y5O-W: MQ*J>ZN<%UU*6FEOK2H*Z<+_=Q2.6I)G1NYWR5LL(U]*-KR-M\QXPS:VA:F8V MW]-])6HNP+8GUC!MJ=%;L,P\Z.%WK@0^7Y@JV]I<:+4[M+C;=;OQ:ZHFX(0\ MO)>[X`XM=*5"W0\GUKV+#-4[7&U)9*?8JU,LL=,FHA[$*M0=@0LI=,G=IFE- MZ++U]YR"3H>YIM!JECM%4Q4Z-[5,':XIU.[`C`:#-0IDMGJ`N)YDW4"%6WQ: M5ZJDLL14IW2PI(1G/19\XYF_AF?/KBN.'H(VB&(!=GVG5&JMW[#IEA"-,Q`! MRB-T!$:\'4:42BOS*^4D4=BA5A@`A!([L&)CE0KCA".N M7-4]87P\%AC,QV`?SDY_.SZW6A[7K\7^V*]//[ZZ>//Q'1L>'IY^/+DP_04- M#^J-51AHM+#/;#/`1'QBBMU3.`,]+Z6O\//1H@$ULIXZ?EVM+57GR[C2E>@! M>'-B'V77F78,MFE:=JPN92S$2P.UENE%#52K34Z`X`Z-A\;YZS'+K.DF@E%+.VP6=Y`5T,"M(#> M2R.P?+&;)45WE7*6:82M_;#2?056K.YQ61L(;MQVI!M:C!:6J]AN,(4+-,<% M(&5`%QD)GV35BMG:$S$>8T<7`A51_%-T"?H_%O1^>:\BOI@D@6`)U6@NF?STN*!NJ^9T^7!&K"1`E4)G<)8 M6:MY6(S82JB\M%W$$N[MM7K&4!\;=10)_\RSJALU2.%4'2#7$F%;@22[I$^EJEU:$9@&OK&*\5F](B8#&; M)-L7&[UV@RII0]!VRI M$(85?NMU%`"M;V'!?4T,WIP""CH$1BX0<>@4_]S9P>'):X8?L*-? M/Q[_-GQWU+5F30-3-CW)?L.M.M&U\BB:1-5 M]Q23*8;\!+4X:TZX,$U`EA4IF([SD:I.892MU3/M/!20B\^1H/2;6+=.-18G MZ9].]-CM%)5BXR_+OH_)#\=^FNW&;G0^YL[+3$2%0S5B`OKM4*8TK>^ZPUG9G&*6,@,'1Z,AR:N3<;GCJG@BBG2]4\(!.1UZ# MET-6NPYP[=96M_V)NT+XXEZ??:R//?3@/9UX0<$016G3)ZX.?G6R0#3H*OS7 MT:HZR,]>"?#62!7"._=[S.EV;J^06@5CZ/<*$X@P-)+3ZQ_M/=WM[>[NJAPN M`=I!EN@@EU;.3DUO'^/5K7B]O7_MC>U.RK_3R*%\@A'N97SJ4MRP;<@D61-^ MCD]^@]F?GAT?G;>W^/0-.__XX<,[^``TSC&HC11]>]WC$5M+26T>4<"A;KF8 M9%>B8EYI]$&8R%&P;`/AR=7?S'?2G:"V@J?'@/ MBX-M^Y#C\5JISAI1E\SK]H/DH-"NX49XG!+2[X`PU:Q2.`Z8D`M,)C!G]!30 M!4F7.8V*)Z)B)\ZN4C?0:K?X!-4`NFPJ$I7I4E'*VC!6W6Z5LP1CY@!25J/L M.EZ5(88N6U+$R;2E=O!Z7:X"._I,YVLEVJTZ'(7J,9N;O" MAH<0#"CM4U)`3RE!L`5@1'L2#'O=SJJ9&MC)0[*:\E%[4MB?]L/$4WUVKJ)Y MR%^K?.P6>ZD&PJ!U\Y+8ICX;+:;P)YI[QT2PUF+MF)I=*S`+O(WGQ8DY5`?0+4''O7D$9Y149W8IV,.1V9*H1#X]B7CS-2:@>-+$K80N^E8>E]E%X:FA$P?$Z&,9+PC]426F%1GF?O>&R0RP% MU4W^.`(N'FT@B?V\R%*U9`QGJHZW2FMT8L!T=F*_&1O#(X$RXRS6L3IUD@2,I`^\ MG$G)5!_'S>3GGCE!US"HS1]@R:MR:IUNM4:R!DK`TBF2QG#4Z.#X_/SC\.3PB!V>GA/8G:9L6$U@HB8@LMO*SF'4YH@R MOKH!>ZYN]PESYRO*,3<:3^>4.<^]J MA<>X1)S9$]W`_-E+S;3Z+$>QJ^9ZS*&2.J@E\TX`@NXRB?H8TQQJ+;$RH_:4 MK&-L(F\K@*(RL-%<((N2X4'KI&OO=,Y*T/I!XWA4M'O)KR26,XHB'?555MD+ ML8H8[;:2KZJ$=E%:UZJL7!F1Z$3/6LK3^9K1=BU&Z2J#`&$]SQ[3^UVL/ M?U'#Z\$N>]QX`(_V]P\Z(%5/$56;-37-%8/]79VX7F^C:HWM>*A?U"?;;_1Y M%C@LU^E*;7MS@MBU9MZ>DDT:%4>M33)]J=W;4Y3NU.T4V_ZD>#I_N>J#3L MP^ZNF[:GDX#-['2S=F6^CYPL[_9.AQ#2373'F^'Q60=X?AN^^WC$WA\-SS^> M';WOGC89H&U=K1&E??S81&)5`$):.?N&R=;K/^X>%#ALI0POWTD)L529RZ@[ M%'ZUUTJ.)K;J-=G88(^H9*9:4CI4LI;6HU,W#&_67=KMD,@HRSYI`YB^T!50 MZQI,884V0N[)#5CY[7#XH;-)>#S53C6>2D!WP$MU&23GZ2>C0.F2B`IY=2.7 M=2!-JRB9HO^CM!9&+RG!N+Z)UFRA:U"KZ"(E-.@$M49V6M*"+J'4!WQ+_2D\ M=;7N#6#J"[@T258H*CF\4M4.+Y!G:/N;:"4F>.=[Q?[WQWM,W/P"NV7C+>=HD:_Y:^>-'9TXW: MT>MJM'R5+?V8FJM_R_85O]I$Q.:Y5.%$QE7NE_J[OLA#-22Z]Z[-3Q,JL_3, M:G/Y=MAF9?V>`+.;!K,/@1(>=-I.6@39VA"."B;,WS5A]H().HB<5SB< MS@_AJ3,Y',T_)[H..\*$?6[*;-3'P/;TEJ0"!*OM`6N6AT")8+4%V0I66Y?G MOZ75MA^LMJVTVAH[8]F6,6/)W-`.^6I&B/HPE'ZNW[4J+9:*W^K4V!%>J^*7 M'*Q?57*G.*'+;:H2 ML\"`ROS&&L<@1'2Y-BV7W+ZULL+5*BAOM]^^*JER"A)]=RWK8&ISK`VLGF9I MYYC;<10Z=:2OG1`E!N(1,4R%ZA%3]66\W30OFTQ3,\85E;/&(^^BJ-3!WA!< MB43=0%.Y5P=/PEGQWQ,4JWHU"87)^BVG2R^S+2OFL^1$5S-`?:1KKB^T>*&3 M]%!(-9(J_&SJ"]K'OGAMUU1)K0^WW7HF39TNE2443GEM%7.]L;V\*<,-6SJZ MX]]'6_OOT6>;J1-ER/^&#GLW(LX-.]5NEE4;4?[P:L/[CC?S(L/ZT-U]O'M' MY"'C02!$$/UO+OJK4V.NW^``"P$6`BP\+%CP-WT+L!!@(<#"`X:%_:\("\&7 M_I9GHS9E[P^PA)4[*[\ATJX\R-IZ8CQ<-GBX*P\"$-C@0:\\"$!@@P>]\B`` M#X(-UO*<6BL8\>@3EA1+XQW@D2S_GOW7$?W\X"')C<(YK733/=]QO^N_'GC\ MUV\=N5@=H-BPM%!WBG?,M;^KM*0EV8O-38W%.@$5;TCE*X=B6RDJ7\BQ6X@: MMT$9;T02R$/M,A.Q3EPJ"/:F"/:C;138EX$M[Y(MT6 MV4"9$%`+`;4M@K*@8^^_C@T!M8U7)BO/=-6'=U,`X_9SO-V9W]GM_O4&I]6^ M/CH\/1M>')^>?*^:UU#SE'JDUAFGF7M3"WYG27V'0K=EL0I6=$E062583*65 MQY2:SO:?M)G&PT%JE);4M;?_=J[J/_OF-_4W('_AQ>YZ9<>":ML4B^N5ZA6R M5*ORTFF:`Z+\IM51U"FZLFP56)GC4E#U2R_,;X8B]1?*&OBX>AMUY%TL.LCR MILCR)GM/2WBL6U\Q,-@F^T SXO:),Y[+Y`]TKW9DV3[VHJ2]$U^#R4O>FE MVY81V*5Y$.K-U1J'U(1VV:MEZC20U^:>Y=O5;0MEI_=H\R-XGF*G\,V-H=QS M_`AJ^1ZK95^5T9O_:[^W]WPW".@6*_@[C>G@Z@U\;<)<]-2 M+/>>2$]OA4KWGDP/2YN M_4ZKE0XVT*%4+PJ3EQF+X(-$?&9ESM,"6V)FJ=WOLADG@B5PF39I%M3&IF#[ ME%%Q\*3/CL?P3QBU*/.*>N8\SG+X2X<#Q&PD8HS3CP4OJUP\4>V"<&K8$26: M\APF(G()=(T*C/5S=S(Q?'K)J2>I]3Y*!X,QL/%0";/B>8Q-B"3\^3.\#E9K MS::93EIBR0N[34QVE<((P#0])E4?HU(F"7!])(J"YPL<2N!)!"\]O;BNIH(: MB:I'K;8O4H\ZS1*8:&&]DHD_*SS">-RT46V&RZHD9B-QLY'D&-]_)7+G1(6S M<2X$D0?SW1KJP08>C<="-7I5W8HHTV;W9<_7M\DP%(^S.79*;5&]1SS!2]I/ M1`S:1/PFL%>O/:'V=L4RIN:L4PZS`&X2-"73;,K3TJ=+?F!4"E)PG%;3"0I> M4:I4/V\OK/-J5`#I1-KJ"M5,TM]/R*P)U^=0P'[$'4ZWA<*O*$KKK,6BAVYS M-*5^03R*P)^F1:`<>59JMRI:U53JVLS##4/.KP.=[T[/SSL[\^'HC!V>OG]_ M>L+.?QZ>'0%\OLN*@LU!GHLI;@N*-$^B*B'^TI!SU6696`+K8MLR-@,XR&+8 M6VP-%9%HQ#*IX/$^>T5_2MQ7=,"W>>-H`4]?2I)>9*!4E.IY^`!_OQ)H9V'/ MJDN1<_=`E5Y`F`K`/\LTC+"L*FM(B*F3'(T%4Y(9S/*UFJX[J\ZT;S!/1TFZ MLUY_HEVQ:&;>T!I!;0X2`EB/6.`=O-_9P]?K/@J`5X!2`J4U`Y;L$,HH)@## MG'*.%WHYBC5ZA%F@[G!8]P4.H=1S"""4+5S-80J@W?)(%H2RZO-:20-R*(0J M>EU"X99XWJC'`&4#BH'4)BB?7,RK'%1S05OK)[K1"6,P#>D/]<3F>18)$1N8 M>K&D]UT`*A]0'9\`(AVUY?AB^-]'YP!.KP6`C#+F8/.`O_CG926$^OLHRS[1J/`2ARM5TSM4\DO>C>9`+IJ&>BK;WK(K+*RK MNSV*%.U`>A_+>:G'2?A5T3RO6YS"!QUTJA-#E)2U>TKB8_@_&@.$,I%_<:W) MNU!NB&Q1%Z2BIE]M\9'Y:_:A36QE+>(+.'8MQ*`G`F:.YEHNG,FA*9R+*,O1 M2N;M@;`5GW3@$RT?HFEK0; MA?*RS.4(U&73%K09QQ["?1"EAS9MGA7Z)?P3B)[;7%1\G@LE%@3,ZDLRU0_G M`ERJ%)PQF$E29(B\H(2%TUMR4H%]K)DF%CO6M'JUFQ%Q];LD=['PRM@<1#1! M">\9HA.=-Z&#Z.91&!^J_0L.V.0]XGO3_8KS=@U:5.&;`68D$!3@U8 M8#Q'#!Y+NK54JPG%*>@>-SAL!OK8/^^#>PY6"Y@\?X"=5<0RJKGV$-`2F#N5 MO,\.14YA@48G6/.I90$MPSQ'SS4#^TX9".#X@'6R$#PO*+@@TTHHGG9-GKI; M+_A;2',2%S0C^6=D-UX!O.>D:/KL@^%(YG&E#2OWT#T&0@'7PM)P#)J167"6 M*V\17V`K3D>0%3HC,F`0)4NU$*-"LS`VE[6/C]Z^QZF[_#!V=&' MT[.+XY.W3DPK`Y`AZP#8$':!X:MQ(T9H)("2]\8OZFW!;TY!_Y?3""T4O-\G M([(+\JR:J%;"Z@U+K(.)2(EKIEDQER6`+LE(+I0;9`T]YI&VATC;+Q'>_\4! M_W\HV,_U<.H%P(XHSN#\H!\"UA'\AQINEQB.+3O3TG,&WL[%I0#9\IL!@05O MBJYF@\99E=>;__,UF^^P9EP?$%6;/XG)DF`%6:S6`X)ZZJ(E0I16#=$36*U8M28S5BH!^&%Z&SG^5H MJE_*/$L)F4WZ=1,/Q9`6]<'6BU7Q01P":)YBJ#2UOT6>`D_YI/:D:X6"Y@/P M?2%G,N$YKI>,:$4H)+[%]X68X'QZ5NS,LNB5W[-@;X?##V`N@6:+8VT!M:)] MBHJ=?79'O%;F=9`DTOH2U!#P3Z1\&G>P$;QM+$NEE6:(<=HSCX"GP3!+E/%( M)"*2SW%G$;;Z;=(/(U130(QDT5H6XY,)4(U0$_]L39-.!7@'3E!+)A0&R')U M4;E#Z&"ZK:W?/KXZ/_KU8Z/BK!KYO08@(K5L9`*3H-/Z\:>T()4S>N):(.BYA)#2N@QX'IQQ,RK\XOAB>OAV>OSUG->(,?$"*'U02FW>STWNY@5^'*F^'YJPXDSM'( M0M;4F#?+XMJOI-T6GU$7H0E?.X]=@3!'*NI8$O8?\#^68(!CB(BK\R&%N(P@ ME\[S%))U^61G(L<_!J([IV5/O)Z/[F]2SKLZ!&FI"OU>@TH(7U,HV! M.J`,=1S-\HBM4$#+!!V#>0JO`7FTKS&!EXS.>9^=@Z=/.":!LU)Y!QT#EX[C#:@LU@T]EC^:01 M"U"2\#(Z2J1P*O*J3\T#PZC/HJPH*7RJWDTZ%>EJG)&>[^G'TGZGOOP&SB@P M<91+ZUA2Z``HJPIB"4]\TP0RX6N%4-/ILZ$VB!3WV63D(]@X1S!L$A))TNS* M7,F#_P<)F"F1:O:@.1IMW&K%:;F0LU&5%UI#*=;66V+OP;+3_'Y;&RG@0:YN M1+*!%9RQB<-Z#C8HRF:.N?$H=@R4`(E5D0L2O1$8H&!`CK&$3N<,">8^&\$' M]8P&3RF7=5(Y-E#H:I/KRG8/P/X(]> M`7_GO6YTQZ*"EA]+Y99.<8^ MKD/HZ"X!V6//J;8ESAI@#)[5ZADXN<4-$,45&(WX_DG42JQC1&4 M`3([!J)Z(7S%>M\3FH`:?X\]M@IRL0RQIHO0G:)<3XS>\Y.,325XKGDT73BR MJK25$7$\J4<[U80J2CG#C_30->5S#9ZEQS*.H>Q7USZ;!EG/G%(\]IO MB-4L:.MAI5+36@R6"J>J!K5;[Y*9DTUA6;3.%5R!4/ET*K*!,])G5LT4VII] M#<5^XTC_C]]5QW] MSYL\FPV&\QRUVD6VOPLZ#__YCY^^6F[YLX/^BQO?>+B!`OE=OWN4)?$7YT*? MG%XRRQW;8A[/3#T=G%_]AX%^SHU\_'G^@8XX0-EM/51O.]<5>A>%BDTM5 MU$H@PQ0)$./O_6;1]<2^G<*,F+CAR>/_FI49:XJ9.YS7WK?K[_#=DL7U`+*!>ILG@[8)+S_&NAS*Z!/%90]NX4_ M^X,`^P'V60"V+[Z5M0BVGA@/EPT>[LJ#`#P( M-EA+;WZ#FJ+/GX4^,=M55>I5)9-X60%O'[DVKP?:EMO`=[+J(&";(F";7+;M MVM:7@_9DDIL&\YK`<;#JK^E+&\LK@3E]65,%I37-BJOO8-MY+5[ M`N.W$4^X[0+U(9:P;=KBG76KRO-NJJ(RHSN,E%U[[?%H$/;ML=GNVZJ#$;%M M1L1@O_=T;S\8$=LB86'5#V?5`4T#F@8T#4>\#T^8-\`MJR\DAB/>[="6#W/5 MP4;80AOAV?[38"-LBX2%53^<50I@16R=%=$[V/5GT@14V3SY"JM^.*L.6+I] M6+K_W!_>"EBZ)?[8G9Z`W;A$0Q#WS?7;AE34==FK5W@F5`@QND-4SZ.T-7FQS'#I@6Z!,0/V`^@'U M`^K?*VS;YA/*C2?NPPRRA%6'T.T]5&?/#WH'@U`.96LD+*SZX:PZH.D6HNGN M;DA-W&[#/QR%;87`;\!1V#M,2UPFW]3+M9I5JN-FC*V9(TDM]+89'QY`\"`$ M1N^`2B$P>M]MG\=[N[T7RRIK/AAT"QRY*<3M9E\'_ M.)6\\=:V@<]8-F:_5*E@^[O,:NQG!GO/\VC*]@<]MK<[&+`K>.#107_`9C)) M<'R,C3S:[S\W?^BUYY*+8BZB4EZ*9-%?$35IB=0WVEL/=BW;X*^SPQ=3X;[O MYZR@_8.=RP4#`E!ZML1]P+]P$$^>,TX4I[TIJE%1\K24/'&8$[Y83O^L^"?! MQKQ*RJ+/X(76&R*>YPO[:S(MJIRGD6CO\94LIXRS>9;(:,$2.9,E,M6CI[O] M7<,6?39D!=!5CF4$LW&79;TDRJHD1KZ!*>'"9K#"'&;/8C[C$[6H4LSF6GLM;&%'"\V`1FPF!-(@E^D$F:7]9A;E MDI@.^0\'&U=EE8L^.T[=]?$XELA7]-+<<.\(EHR_,YQ2K)$XR@I`X7F5%Q5( M`"LSA^G*J2SJB>2BS+.Q++T,&+CO[W)?"M2-JP@8D!/_-&2_E.+*V9B9**=9 MG"799,$^I=D5:E3V\_#_?#S7B(G_;'UKQA==`P:58S&@[V.>ML6;QS-X.;R6D^8R@SSIP7[A[T*D8->@-($:)1!&J0*UY MIO(+3RO4#62S@%6#9`;S>FJO"LF3FA+N^)?N,(T(-N9M_2_<]T.8"$\7X!&B M69R5:JJ@B&$[Y$QQ7GN52`N$`22Q@0;%#PT#-D!&$Z^5TS64:EMRREI;HKT" M?"R!CUQTN0#-+`/R)`W6_I13,"9(G8R$9DO@3^+ZT:(C:,B+"C"4)H#=0BU$ M$D>*K#4V\1(RU4*4W5EI>0`E!@QV/[D2'([4<_"\.*OT'-!N+*1LGV957 M<(Y32V=:ZM&=%LX%QBOD"*;76(.1@BDFTDN99RG2"IT9R4 M"T<_9P12F<$_1K`R?.SFFO7'[ZIB9\+Y_'MS9/PA`1@:IG'=>N^U+*(D`RM9 M7(C/Y2L4EY]HVW[\_W9VV/_]_?UO^__O__YW-*\^_R=]^C+^Z_GEY#^+]./K MZNKM\_SE\W_O_?'Q8E$DSR^COW:37\K__=V[%\-WZ?CS\\GI?X--_]^_?YK] M_G[T+)X]EZ]_>Q[MBI/H[)?]V:=17,U/_N2?_G>2R<4HBY\=9;^\6OSGUY>G M9\G^+^+%^S?[W\4#'K\816>_OGWW-$U_>7'U_&#_\/GS5W^]^T_QVW]&[WX5 M?XSRLA"[K\7GHW^_KD[^FIXL?OEC?G3Z-,E&177R[^%K\>+Y;/ABMOOJW>_Y M](_Q_W[QOY/Y[.G;/Q;%\%__^G_L\/QL9^BY&/+K#':0F_G(GQ MO_X1[?W/FSR;#8;S'('K(MO?!23#?_[CIPV,JGX)(OVNWSS*DOB+(RTGIQ=' M+BKN-\*UPUX?O;K8;)-QX[SL4[=_"S"A3-A@GY3H+GN,^EG1^,7>WNX/1X2$ MJ'M?`Y34'PQ^>-*S7$GFPB-`%D`J.>N@_<%*.)VEP*@O_D.?0%> MDTT$.C`]^V7G,@%=P#YDLOV>7F?)]C?9&Z6`:.0>8C&NX9T@#VXXH8R:#X<_ M'_?86W#@"J>\BJ=5+FEI__YPZ&SOF2BR MI")KU&R-/2X^8(WI56+PG2969L;5$R*+(:*!01TQWW=0O=B`V]X1;#)^LC05U'&*=LP= MC.0J`V3Y4.41N+DJ5G;.$]&`2X_%%#'4WH+QE/9[[F`(?22M'&<@XAXR+8XW M$N456I]:!NBM&`XU`Q>F3SFFQ@*"L1ZX`S.&6@DME[^&O4 MB:@>ZMCZ899C>)+,6M_*R;%[]'RWO^M&&G2PU$>9PRR-JCS'-==^-=I4Z#_H MR2+).EA<,X/%`[AW`(+`;V71DNMFR:Y.;`@`E++QO6=@MJ9?K&BDOM2=#RD% MS@9/_\GF/"]E).K`NU`V_VQW.(HX*1 MH(6!OU#>XRRJU)?%9QBAM.5&`9+L,I*#/G[QZ&F,B``V_#K*4K6(D>]:``$: M5Y]3>4?WJ9R@<&ZB<,9@@&17%"_*1>/E8R!A.=]__X5Q)#JM9:,))>7KM=$U M14VI2"3)'*,!Z41_NFM]4LQYU/VD=32^N^L['+^1;_7EA]Z>O`]U-V'5&7P9 MMU;P]/H[EDMXY"L?+9\]?WNY"6WE# MN[[=V[3TFZ40M"0%9_.FVIWG+;&W.7@%QZ;P?XI2C+V`>:5E8"VO]:O M@D?3CH)=FIO%*/$##)ITHFSEEH6UO^R(9,5X7^=DU?[YS0J,_1G7RB#SS$3EO^R6A(Z*5Y?EBBV`E:Z"4]!FVRN-EFZSJ^K M2S9S\P(K;Q,K!\/HYH;15I@;P_%8XIGP9#G9,;.!LC_1WP,UGN4L2K@$_\^$ M]NQ`@`YY+->^)O:W*M37#GTLM0J:4-P55_F+"R8NR3B`J<:"TA35J?N4=X(< MS4\64;0G7A5*H(71:^(5^ZX)@PA7\;"PSVCWWPAC^/ MGO4/ZIS9E=-J1O%-J!W96F7H+!DBV"P/"NB#S1)8^9ZPB% M=8V@FRQQU1Q1LB(CXV"I?8$:]]'!4VLXC'MCEIWH9%;0]Y9I<_,X';C9&1?J M-HSUAA4+2[-T!VRG++G$<#Q2$*V<2"W0/Z?]IYTCPS4F18E_%.\9T>40-I:? M5UH]M6&3Z_3IP4$?3^O`:%G`",NB/<6J;4Q@5D5M+"8+-L+;%ZTWD94'1LT> MO*LYQ.H.]1*_T7.N%EV7:KC2AJV-W=H`G=%5%)UL"-P:\S++%TNG!.N:\\7, MF*K$:#8;J#/!JRD8UYVCU>:GSM>>YUD$$]&'S68:*#IC2J;19X^R+):O"0S6 MK,+YJ%'I*`9,?3PFEVA^@L'*QF")JI/NG<.>6)9K76N]Z\5@%.Y8,-" M7PQB;X18)C3PYDG.9ZUDFU^';UJL^O@$^'[Y7`8#?S[.18?>+>%:2G!'Z!!+ M>I)=/5G#+/_*AKGZ;,GER0=Q3.<0 MP[EEVK'[KK7LNGOS=:RZ[H[?Y);QVM9:\9U5[*!)MR66YJ; M-]5P;/B-K7G?!K0N!;.SVOSUV?6K3OPFZ'"_7J)N=$FQ(,@JK^7+V@E<]&M@+U%9;8^8KBXM?!+IQF5@T='W;6[0]O1*]J*7Z8PVG1T]3K*,4J;W_JFR3G$;\/>G_WRR@N/G M256PP5X?719*"\^5A\'3KI^U=]#?[:1@MXG.E9EJ.5)X&TI=SFHL=-J8E:D! M9M,:UM1&<)U)N,2G6LX1+6=KF4_E^E)+IN=SJ%8RVRJJ-7S84,B2]%@442Y' MR"VC[-*3LFC_$#-HU].(J"]$L9+XPY4T1F]&^WG`_Q%,"?Y=NWJ^\9R-OY9( MUU"),C%X`MAJ8!86*E-@$#PUZI9+L'_T)<:8)0(<V/_>',1GRB?&#_3;VA$814/+)62+K%ND+6"]SEEX0SD^IU+ M9O2%SJ<7\=;S/6]\6'2K>3!WVQTCN'/?UIU;LL"OXLBV5NS8G(='ECM%ZT8B3RF&SM%GKPFUZ)N,9G%6-QSR;3Y66E`DYF\ MC+@WM)[_5G;5W5C"*\]X7#!?Z]+;)E>_/'8]1]_UQ`+O/B^[R=O#FY=M=KCB M>.U_&1QX9MX>K>,$ MMX%#3PBU0KT`[T'J@QY$0:AN79`VG+0WX;'X;"[F8G&$)TZY M#VQH=\KJMO2)Z8^ANH3V&`U??@*L_-E%]F\3( M<0V;V9?6\9.:ZL0\LBQUP0252^+L?#6G.<2:1I'R3ZP6D'N2-?J9=)^9J*J,IEFG$RFTFLDEK,K/O9'_5R=OSK)4A[R2\ M4S'&'I/C-N$Z\P(Y*$PY!2I29F;A+XN!+U5W]74519_UN%,NP02GPH=@MK8GX"3O M&&YQ&"NK2BQE'.L:E7P\AEF8O+'6`:"=8G0!MF-W6CX0649WVI[:V.ZI5#I_ MZ0L2S+GRD/QF#9YA9"GL+"Z!Z>(;B9M`Y^RH.Q&4$:E+)?)VYF9W1^E! MM'J,/63=LO#MBNV>^+6S=4JS-%(4U,NU)2<\P,&HTC%!/I45`L,C!\N*+B-1 MK2MM$[41N';P22;KLN98OM(JV./9:U4`O^>.9A=2P5,KG)=^!5;%:9@9_83Z MEV6E6CSOQ4G*6`+R`;%<`]$2&W;1*?*J$@04L?0;ZZ]W;"!ZF=+,*AQ0K:7D M[=V@JNUF-T99GJLB(2,Z\).N9FYK\=8T1"(G&`RRJ.=)1+7B+Y9*U'FNNEJ- M30+Q!.5!P$(KD)[F-PQJW-T'/RE9\UU/Q/-:]VVTRS29&D86]3-&L>L M&5U.RC(2&U%:>1#_!O.E=;Y,EX2HMG6BB?*/U/PHK,#JR)QM[6(`KV`^Y;5T M(T`3MRA:R,]L5!62ZE3%O%ME.$H$5ZG80&:9Q:KBSHZ.P.6G>J"P"U-/N))TR2B&>QQAI:^20;0 M7V)\AN"`^(MEB#+V`D;74$XOZ!HA'.P\;`3AH)3K$[S7+WIESZ;VF^FM;9\` M3'95+5C-"$`1F`/I@B%Q3]ECSY*?H'^MI]U9*5+0+--E>)CZ5$ZFJOB9'<8& M,QE\9L),#;K*CY)>\]-9LUZFLY32W;#VLO1T>Q:'8+(3WEHE6YY,5GLMP!,' M>Q9+N#:>VDRS:WJ4>9:77N=BJ0/GZ,N:I$LY@;TQ M03.V+M6'?]2\/D"P\I1PO[$F;C]T8AH,..9F(_2E*3`7#,];,CR;V)I.ZRS8 M)9AE>&V=TXUY;AKF=+$Y%1/U:9V)I5)%8;DPA=QS1=VJTN?.2>L%\\VBQT8Y M^I/*BG4117U+'W&J>^-=3TC%%VY0D]ZUQS<]-'B3P^^O(D?K#4ZK?7UT>'HV MO#@^!>$GG,//FI$Z9:PM\V[UI<[6GM4Z?3#X@35%4+MV@=5MI!TG6Q(7:QT0 MNH/1>:%MN[G5NWE=%!1S(ZF2IBQ*;]+?ZL7:17;)B.D(IUWO6ZFKI$NR=GC3 M#NLL"WZ9LMLHCZUBVFTC^'%'QNUPO*_N^#6%?=NG6,L<:7,<[HU0:77?%+,T MT-!!2*I85H>=EY+/5^'R6I!X$/?F.BE/H2)"J(C@/KE%J6*;-]7N/#=UIO[D M\Y""]Q4&[W8>;/^0W8,VLSHK\66)+3FR:O]XP^>>`"Z&7.+E_,NL0@7UJ6T3 MTKA.I-RA&R(@M+4R'QIZ''\LVK]V75 MG*ZH#Y>FDF$J21VY=/M$[":BVW.MJEN&/S2?AA__UDV5I:C93J[SZX!0V#78 M46NM\^M:49NY>8&5MXF5@TMPGUV"8&1?5_%^:82G=:H60ZSFB: M&`3O9%"M&`J^CX;;I,*S`3`(I<[1Y=WSCA6CV`31!XO-8;>DDY;FS'6UEC:>&S7FP-'@G_N'H.TMPT; M=NO>[429&9Y9_F5UJ_4_:"87MT M*_]0KIM@EK,L1.T;9'46:7/RW=J8%9.RK]ZY.C$?$WI6I=^O'F9Y;C[&MQ-Q`_67&V`((^QX(*=>]PD#Y/N^UK M'8=-]!O49QMP1=V=U-U?(K;?:-K5[;WTW21N91HUO8=/LCX;="CJ9CU[$W(, M=WOSH'P"8O<([]QZUMI`(5.K@$7:8>L6Y"SOWKL9N7CKLL[72<1;<5'7J0.P MY':N7;`/?B\[D27K&B)=TJL/%TT*O.^22'=&C>ZDRGSMB[_F+JWY0YW^V=[^ MKLV#=T2[6=UN'G=[058R-VOG<#N7<6T\KF__=@35(DCERU[#)NY/W1Y,[4&V MB*V_"E,/DZ(;+/42U]GXFB\XIOSY\HZCI"KTY>$C?0>-#)FFTM>\ M8Z$NL+::E#O$[OP[?J#H?V!?!W,76HHO1[N9>N]WA MH1[IT6#0?U%/&"]*44XEW<1TYQ3NW/VMVC3M@D_9'/\-+&#EYB`J@MD'PZA+ M"@9YNG!+F1<4@UY_";]KVHVR)+XVK-1XFAV669%/K8O&-@S4>KFZ349.)UZ6Q;5QVX]J/I"7ZM+GW^]5D-D M#ZC5YR'MUY&[2C();VBKRIQK+X]WCA?H`I6BBMZ"AE>6:O$5K*,'"]>+UK]& MRXLR6?0PQV>=%44PPG:/65';V*.#V:,AIH^QSD]VFK@S+,4P&5XBWF.IA8U'("96J`-_% M;U&;VT+LB*X4X>GG>YZ#.AV0US-H>V@F^ZYA'LNX40PG`ANTHG@YLUTU3V7 M39SMLOF&$]=M'WRXX@@,?]K=;)>70%O-U]=?4<92WG1:N/(,#'_6*NK-'EL% M%I<.51<@[!9:0;_%F$77C()&TY,^.\9#\T5S1\J4%Z(J!$6K\L.RD;!TA$PK MH>H>F"*I$35R`7'`_BC^^(-RG+]F\1 MS&_=KZ15*R#J+S=DE^[LU/!K_]RLB.?*B9D"GVO6\UPMV-UBGTUQSVN88>$/*:]<5WT*1%D%U-8AD;13BM6`5N[UM:5SJZOHW7*GRFUQ2FZ4`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`%S*T[J7=>B[`;*V[I76G@7VU6)J58INMV@<0X`_GQ4'$ MPWEQ8,O-/R\^>!H2LQZ$.@F4"8HV*-H52!44[7UERZ!H@SI9CS(KXS[J0T]Q MX1^_JXJ=">?S[U^+4?E:%E&2%>#'7XC/Y2OD[I]HC!^;;^7RDF,CS..T*/.* MZF`/T_AG$4]D.AEBCTQ92E%XAJ)&.?#+F1C_ZQ_1WO^\`4H,AO,<2W-=9/N[ MOU0I_O,?/VV@*G!HN28WV/V5OYA!3DXOCER')Q[NN`5R;V=3S5.W'[?JH3K8I_KGN^V6FKIUUA7/IVIWN[/YS.4CFJ"O:[?J+^:/##$^SP-*_R:(K-H;"W+U;/SU)8 M)5"[.RHV8>>Z>KNJ;)T+057S"RS9SU,F/HL\D@6V=941W8=\M-O??6XWD#*# M%5.L-J^[$3<-0F.19C.94H_K`NBX_](JQD_/%)[2]/_^<(@=ZW$)JIVN$-0T MB[U\YGN8F=9^>YV!&S.:(7MF,&JLY42V^[RU<]3"XF$B!.?8/T,$Q'E[?5?&I+VX$E83B%2 MZD\PYC)'E5B):XK[=Y?9;B#;#&0JJ'>(C\7^82J['6"L6Q7[,"@@D`^!CET$ M:EK29^DZ<,05%NP@%CA#&99"H+)QZ4PDU)-.;Z@+2SSZLY(`$-7<$O=FU,'S MW:Y@X_5K"\`0DVKXT7CC&^MUWF>'4U[%TRJ7[&J:`?M10PP2"8["03,5*5@N MNF7YDGX;,'&4M4MXG^IA#R`"/+RJ"-:M?7%EOJ;,(>#:R54F]O@@(" M$IE&9K"W_M!F@]/%HXVID)F/\,&:'#?-BY2>FR5Q@8VSF/`-9@ M'CBXPJ59%HNDAVG!T=2C]*RQ1B*1XE+@/.B+?`YX"1R''<*L\40YS3IM?\T8 MD*Y4K,=JL\KL"&B9*'G M2,VJ>"I)L8"]DEVEH%V*.1@?B=N"*KC1-Q667!:?=L:(<.VF=?;^$[N"4<$G MX,I*D=`?/_;/^^Y@%]A#N0+C`[-'M$L'D@4V(W`4VIW@454T/'U$Z`HN9K>_ M&WYB!%=YEK!?8%L`/ZD)@%I`G:%98J7@@>>.\V%S+F/J(!WQ8EJ/!ZQ*4H3_ MF=>V1YP)>L@UH<"'0VL2%C#G"S*]VF/5OCHZ?(*B>"XX54`.O^^'R^0`4C.: M1\&H69\>L84_W34Z@$1JE145ZS;T@4N"70(H@.H%?MO,:HT^I M?WM;>&/S5S<@K?I(GT,L,\V9$P7>QCS7KLAO-_ZMMVH?[-__50\>'@(-7MQZ M"OW71J'=/FS;TO/WE;`1<.4K2]C#7'5`TP>"IEM_'RE@Z98[9K==[S`X9=OF ME)V9!*&E#A9KIPYYF38(_.8IU&!&/!`$NA=.V4$P)+9$PA[FJ@.:/A`TW7JG M;-!_'K!TFYVR<%KVS05Y`QRSZT_+FNL\?IX-$K^!&C78$0\$?NZ!5W:POR2^ M&Y!E`V7L8:XZX.D#P=.M]\N>O5@2Y`IHNBV>63@N"U[9=5X9M5=X+%-5%>Y) M<,VV1JD&4^*!8-`]<,T&_1<>+@FHLGGR]3!7';#T@6#IUKME^_WK[X(')-W0 M2NE?7@/])_VJNJ#Z<1IE,W'!/]]"P73/:GT5H=2BV'=>XMU@!^^LNOE3ML.. M3PY/WQ^QB^%_'_F*FJNOMKB_V:I;P)=[4XFMPJ.ZOU05KVS,3D[?42FR*!>Q M+%G$\WPQSO(KGL=40S"1,XDU^ZJF*&X]%%8,HVJL!142TR50C\\.V;E0I7'W M7^S1Z`6,DG`,:V#F9GN49H1^ZSEK./CGX.6+9VPB4I'S)%DP.9MG15VBS`Q% M%033BB=JVGJ1NK(J5R9)2-G5 M5&`%-!#+?)[I$K)3[LZ*2#?)4L&PB+D64O1$Q\H-=KMT,=HZZ?D* M2/JEP1ULF7`TJUDV^>XJ.ZNYL+=25=A#ML!JMKKR.PROYMG9R5)7G\WF`MDO MG5`=6GA<<-A7W1^`BB#F8@*SUC5HG4VTIJ,%RY0&Q948&:;BR[#?A81/=,'2 M[O*09V1:X>?B\USF-6E1]*M2U0:WI!/+WU(EZ([BH;C5#_1J79U058PF*7"Y MBS,00/.JTE.LM>$4!4)^LEVA/*<9_`HBD'=7EPN.[`(0T-/%HV?9)Y]O\3 $H6F#:YAB+/VMY=G>F(531T#W-KA@: M%")>4LTTJ-`U56@LQ["S`NMYCD1Y)42J:Z(C#Q*,DG9`\-&UW4V)VBY':;6$ MQ6>K4M4-G@$8RWE"A3_U4".!M3ZM@1T.,*_1@L(C5%GEB&L41ND@"Q9Y4',H(H.O4+53F]H9JEVI6E=$5OR8Y8M:)BURY;5Y MT%@'VZ2CX`%8](GW,VKI+$*D[*L1PI%B]V-P[+I>:7IM@R2J"1 M4:R(*DK0$;!>V'Y8?H+E97%U6.6_J;!JAM)].^`)!2>X3)""UG+P4_S[)2Q` MFPWJ`HL[+VS:489RW']+**TN"$(B)O\Z?,,>GV2P-X/!$RRDJYC:U,Z5>5&R M/RN>EQV[5F-O5`%GP`*4*:;T#FZGJF-=U*TYX#-K='=>8",4XL\*!U+ZN%A> ME7<^3\"",&KLS?$)&[QHBT,NJ!E'T3(`R\S@AY(,Y#(Y,^J_`QHN#[/'&CZ> MH(SB)!9&1.J:Y<:N%H!\5#W>=06T\!KI;)'73.$Q:KDG2EDV=D)[@0W@]#S6 MJ6D]`;:6H1)O5N:BH4&LUF1"*>];$C1CJ\9DJTXE>#&YC+2-!4[='ZK8>Y&! M%R):%=W-2(8SL\:BW8A.V."5%6)3&Z=,J& MPZ+T'DO?*D9.?HQV:&QI`\Z-DBHVEF=)/N`5=YHV8"GPHAJ#1R!)]+-"HM@` MU;"R3$2K+JHY6@R:J[EQ1!R!&'O77RLL;5GDRD*XDJ`)M6PYFA1>...`#9R\ MO&4J$YQ#^$)1TJ;"2]MC..KR!C9!RR@(,G@[,MAJQ'`(#`3[D4K.CE`#@.4$ MV/Y_,.Z@_-<"Z[5[/#:EYL#>43Z?^,Q-V[>ZBT4S-+!>T]/(DK\*?)RT-L6:N)VE*!+,R=L`/,O&BI+W8_.'QUH3Z\=Y]BW7?%:M&%HVT.?\DMT"(3; M*0S15(6A[%@014!,A(T!/$=50@.%UD/K2^"'PY^/.RQ_,?QO=GXQO/AXSG88 M?H,VO@Z8-NRJ?;$^?:<3#)L^8/!`36=/AM&*%,@QR3L]*0UULUV+U5[(H[)#RBU1. M<\2SZE3F)^<$YQS[V^E^DT=@KI>+81K3'U^A=?%!^PH/_E3G&G3*%+M*4Q;D(]#&&X"?5R@L#HH43!QN8Y$F]@T.=O=L8#RSVOP!C%^JB"W MLQZ65KCJFFI%1V3ASZ`,1@26V`!)!0NY>5#\B?XY'E6E-!O<92<8;@6?G9=U M&G9J*\V889UVEC794_9:1+1A;']@'I.S&9A"RC:;8T`F5DV,++KUNY-JZ25> M=V!T>BXNXX2E2ZN;G"F&QX9Y>U8C3]_IEA5)T-W4R-4K*MA]KDY_1J+$R`:! M0!-U$84*FP)KM^G4\+EN2945PO0*M02J4`Q*A"!O#+_M.77%E?2HF9029;UI M3.>?Q*=:&BKH6:;*Q6IT?+`S^FM_0;1NB)C MDZ6>)`$*3*Q`X_TJ1=:^L)VWF[$$8?/EE1@&4Z?3GK$.)Y$GH0_B->GS+$%4=.D#!G(J8@5B M[5>3G_B<&D&K`7A45B:EH%D1-L;[HLYM#]?>^GTJT@[6D&ZBOH0JM2+6[0UU M5V)?PV`/I^HM5!:4W334*])-YU!W_2L;B5HM/16O:9^UBU-65!=>S$TJ`;60 M11RE+`QLKVPX&/A\+"3V'FP+#BF9K"CK+ZIX;Q/_:;J#@MH2+@PD-Y_E6U^I'3CI'/UV:"* M)C[:U7V2#\`05+9O8^WH"(0O^R.A+$^*Z+5,B[@R&3'+0N'.IG<:.3N=F=E) MUO`[2JGX#/:`+'Q">OW+NZ_KLV%'1\YF6AG;:P,]1=FKBQ6Q_K:8ME\H40>* M0BCS<&6OT#6X.G0+;=\_7#=/>Q`:3S6[?Q^ZH=2D^#MM2M^_+O4>=MN_ M;]S8[W[)0B!%@(6-A87?!=XR$_'.2HM^?7`(-+7%AE^*G$_6 M*0H>*'LSRAK'XWI@"K2]*6WGN8Q\A`V&0C`4@J'P0.$A&`K!4-A&RMK'=YTY MQ$LZM@22_QV2XW&2EY#Z4/A6N#QHU)N1XNOISB`807-^/?$(FO.N*)L+O)B# MN76!;V^?NG;N2[!`;IFXF-,0N/8."/MX1=G68,&%\%`@Q6;:]2^"77_K6SFL M4_V#IKE]\9!@'LFTD%&@[AU0=UDD(&M;1Y-V?Y`70:]GG5K%MV8%C<^ MOMQ"N0^K_B*$#Q"TV4VS7O3VG_O:9@54V43Y"JL.J++YALVC;313@NK:-M6U MVQ_X6N=N.)\%"`^KOM^K7@])[]NJ'^9>W[=CH;#78=5AU?<&PV\C6'\UE:7H MANI#H'[97%[>-W_VK2I[[6?%X&YL('P]S%6'$,:VA3"6W+,.D+)YPA56'2!E M\TV5$'J_[TP6]%9`\+#JH+>"WOKF@!+T5M!;06^%DZ6PUV'58=7A9.FF)TOA M&D@X72I_.*K[DGD8,E@FFX=@#W/5P=D)SDZ`E+#J$*0+0;IM`I2@MX+>"GHK MK#JL.@1NPEZ'X'O8Z[#J![OJ>X+AMQ%\#],]7V>D^(%;@LDU1HO[^6O>" MR>X;X`?1VB[1"L]3V)U86]#N4NX[/#-W8T-\&G7ZGGQ2Y4*MK^[HN5%\$TV#^O6/W4YF']F M<5:-$O$0Z;3^NJ`0_?5V-KJ`X3`EO=7 M/8;.'=NG)L*J[_^J[TFX*NSU#8X<@IZ]OWIVOW_@X:F@93=/&A_VJ@,&W5\7 M]`:>KVXV)@=3 M*9RN!HW]D#5V.%W=)HE\V*L..'1?;:UPNAK8K]U[/A='5;I/%AKSI@4'!!-PB"@@MZ_U7C%IRIJ@_II`P_A]]&^7?F MGW]S__:?_8T-_*,J2CE>+-W"V]BX"]JX$]BXL_; /$E;"LN;+)LGDIL[1@ M5R(7;%PER8)=BJ(4,>,%R\;F9)'!U]E[GD=3=[#]@3IU[*]BD-:N-QOSXW=5 ML3/A?/[]^93G8IHEL.BVG(O^0%64N2ID+?.R52,58EL5K641)5E2YJ,=A$4P8?CD3 MXW_](]K[GS?`]H/A/,<5763[N[!\_.<_?OIJ&/#LH/]B;>WT13STNW[[",C] MQ7AP\)2-LYP!7S,QFR?90HBBST#"C7@^X3)%C.&37)`@8CZ+01`ST#P745+%0`T:B4]$GP$1ZE7/ M>!E-1;/&[II0A',YJA2057.<__X_<74PR>8Y/L^*'_`MLSF`!<=O]]I3*:K1 M'S![?/[X[)PE<@;$[;/758ZKP,'**:R$S>"%4YA1&L.Z3>J%NVL(&X2:\(_= M'CUMEB33J,J19N(S3D703CQZ_OP`O^^.\^CYTQ<]EHMBK@B;+'J*C$1]&`J) M%\,_6,$3GDL8K1[%C#'2`(C?PHGP*%)3P755*:]B+)J,A(QQ/O0O*@_+K5K* M-95*^"NA,4X[F\.>$>7[EE-4_VM8=C4(JHSV_)!6/9Q57M'+FQVBIU9-OSW0 M=6L!K@2Y`7XOID+0@)I\CP;]9^Y"9S))S!0>[?=?F#^XNP&S,E/7S):W9]5B MT+^G)[]4S_U42TRM,H]XCM)9?!`Y*=HOUHE>@]#'#-Y_T2K9=_Y!-D"IO0"E M=GQR>/K^B'TX.F/G/P_/COQ;N$%J33\X?'?\]N1[]FTUVG$*TNHDKP%H@`@2 M@`$B\R2J$A+/"H0V9^55QF(Y'H->@3G-1#G-XJ('LEO(J`O_*)ZQ3"IXOL]> MX7=0K.&52]\"J@IV0L8U?#!;K0%CE&8$^";^Y4J@"X8VL=)0:E3"/_@:J`,@ M'&S@*CL[;I0(3$MF,-?7:M*^V7J4G'?Z:\ZW`^'>Z:^>KT\W$=E1V<^S$K9* M\F3)T'JQK:^N-ZD>^B&Q*$4^`R:L.01U<2XX8-RBJY]P+8IK>H3^LBC)UO&O M6A9%A4XC6`Y9Z@XF="M?>IZ^?L7SG)/RRXWSU*,ML-_@.'BM]W%XWPQ6`E;& M2(`JF5>@$]'),;MGS(0QH%.7$8?VUH.2CSYF?`Y;_5F",0PF!SL8[+6LDX/] MY^9WA_/4RSH62\WR)$TU2^-8-I+50&;X?,K1LAK:^GE5%''\-B)?*4L5"`"? M&&T"1"X`'OB/&1BT;X+Z!^2V[.C@>AQ'I6D'SII4R]EW&#<7D0#$`N_K:7^W M!7BTD$G%$;8$3M<:0_OYCP[@H64NW068$^P$(+D=:P`WBDM`KWD.2)M+6'`B M"2>YQR+#=XZR/,^N`,T:LX3>VWV1.Y,T*W'#:GL+W=MZ04@V7.(/,"*8KO!= MVRBL-40.6(HWA=`LS`$._E($7[IE;0IY+&G0=EH++-MH\\>?LV(N2Y[HB%/' MXO%LB(X48#P(%1'L/H8J0`?$P"E1B5,%DS]2%FXGV.1,HYSR$O16@5ULR)1" MD$O;7FSJY2 MD1=3.2>:D9N?)4`1.W+>T]$-8MDK[H31<(28/1W\$S?N$G@.A)+-IPOP8B1/ M05XP&)_E:E,.7M+7WH+L@O9L#_3X==YGAU->Q5.PW%6P)4?N!@`IGL"<6&1D ML`#:&#'/?&:'CI80(<:@'-.([)96W`='LNCH&KP\!:;5#PMB;FO3D MQX0!.'@%HA2C(NX&G*PI5/-YEI<]6AZ:#FJ_LU34JP,.`=<(7E(V@=1&_/D? M62X-%\/NZP'--H/7P-%XP=`*?L':X;ZSPB/B571H5$SK!>[S[M-VH,_R6Q2S MN732LU4`9L^NLV;#XRY'-F,9[BDR<"B$B6VAO"7@*(&!I<]0>AKF\),:Z%R: M:]R[%M9ZEENX')=4*,^+0@!NZ0[)MB`&ZV@2A4FHB02H/K%J,L#E441L-`$K MUX_8R_B9:.M&5'T\=*/8:?,ZURZO7^XS>(/QXS-^<(M:NJO-(SUB6D!RQ!@% M$;!7U4Q'36(Q!DPM:8_AZP@?I4>*1B+)KKYH3^CDF44B2>8(;.E$+W]7V^OX M23'G4?>35HK/[JXOF^)&IOB7IS7YSMN=XW9/EHC?$UF1/&*O[,/P]>OCD[=U MHLC>_//]2NT*U%E%'5`3(!2&#GLW(LX-6QM^\PRC%BM$`/XB7R?UZ,XVLPE> M==Z+!YK79<)>G\H3B&Q+S-+:YW>4O!>`)U`GP/+V(88WS<[\8.Y$`.8`S/<. M>E:F]MZ5)W+=9F\\U<+*EZW\AAIL9<+ZUA/CX;+!PUUY$(`'P09KZ M12>WY\]"J<'MNGMXR(OI\CPRAQLWYO+AP[X)O$E^=)"M>W:O=[T>QH')Z)>- MN*4[>/GRVNC0IG%9`/"PZF\IQ1N+*$%M?1F3!;6U;6IK?]]7_'>SN>R>`/AM MA`]NNTM!"!ULFY[XH/.R>TM5!,,[/EUR M=A]P9?,D+*SZX:PZH.G6H>E>;^_Y?D#3K7;&[O0L]\:9:$'@-]=IHPI26^R2 MW909MQ`0;H,R-TS'OO]46K^2_TVH%'!MUL:3`ZH%R@2\#W@?\'Y] MQGKN[QT:#-F-$=F-/F9<2?^#X-5NE5=[D95-;5$?$JEJ(??3/O0PZQ:"Q9U9 M0:']S';*]%:GH06VO+^&)YZ8O/3%&C:>.X,Z"92Y%\R6FZ)H MGVUW:L(#4"<;G[ZP@FVV@L`/,RLFK/K6LNWNVZH?YEZ'53^<50>YWN)5;_2I M5S"&PJKOZ:H#:(95AU7?OU4'N=[B56][="B$@^F7#3BE>"U&Y9*-PI_'O&ZE ME^5/MCEFO.42?R>K#F*X*6*XU8>%@7T9DP7E%9174%[WYP@FE-.X1QHEE-/8>#"X#-KSNY6=G0NXL@D2%E;]<%8=T'0;T=3KM'5V M+J#IQOIDX:978*FPZKM05?=MU0]SK\.J'\ZJ@UQO\:HW/D`=\J[N41#[M1C+ M2(HT6GBY=CO>R6[UWOY;*O[R`;WFZ0A M,I[&C$=1-:L27HJ8Q13^*?TB^O+Q!Z M>CT0=1(H$Q1M4+0KD"HHVOO*EINB:$-/KTU7)RNC0.I#CK*'G\-OH_P[\\^_ MR=[[S];E;_W@\-WQVY/OV1]54BQSX<_GS,9,%X4YZ892DKIX(].GC:WV4SF202_G(A\EF7VB+7G2BK7D M8IZ+0@"QX'TNJ.K7FZ=G_+.<53,F/L/O58Y384E6%/V5D9F6V&XT_WP=!J+] M<&4TAQV`G9%IE,T$!<"L[5=[^6)O\/P'W#`5%--/P%Z(M!!M\,G&[-&@_[)F M-AP/_O"\_L.5@-T3B9S)E`:KYEG:Y:HH2^FDBY?X##`83:JDW^:181Q+W%>>)(M>"VQD0?L$FR\1;W#? M"R&+F8P\;#L3L53\40$K:`X!;"N0"?$7-3$^`::A>=%\W+7@[)9G]BUAAA^_ MJXJ=">?S[U]5!1"W*&`%(^1HF,YK640)H=2%^%R^0M;X28WWHWGJ3$G2!YZ7 MBPO`ZH)'^&3A>11%H81?SL3X7_^(]O[G#:CBP7">([]?9/N[(`#XSW_\I!G4 MIY0\T-S6X*.=5X#?@K-\U2X^R)/YBP^+D].+(W:'!+MMA9T?OAA='K]F' MX=G%?]C%V?#D?'AX<7QZ/1G)7-`YY^S8BY!5Q1L#!M-J-"O#97L*H6O MC!9@%NV48A$)B-.`IS`JTI0H*4T&^BL ML8>'8%F.[W>FG]0NL57Z+5&R"_`22[:$ZU.>%!F(2F4O-0<5/\OGNG_=E! M_\6-PTD;H0@&@%0_GYY_.+X8OF._?@3S"'3!\/S\(ZB#PR/VYNB(?3@[?7LV M?']SE?ZPU<)QZDCN:51F(S"J]G9W7RH`>`M>9IZB4SEFAS!S,,Y2R5D!2P"! M3,1$%@G9/VW&*:KY/,M+A9Q14HH3DOBH:K#/]5FF2:+>M)U:1N<7(*%)V#^@!.;PSB%V0+[(*U`)[F MA&6([N;-O3;E[3?C^L!T`DN%Q1+X6HXJ^ENM^)EKD=.&X3)VP+'-JLG4VKF& MJW(1"?!:::6&YUR&5N8/\0ONC!(&$`$PVH"OY\@Z-G,V#E-[(&LW<&6PC"@7 M>A'UMA?>4,^F>]0;A[@>M[I&QC\KF&<)1G`V]8`;:O"I3J6U[C7=QPW.`&FW.J.;(%'N#9L-U%`;X(\\XQ57P&V#8R(24 M!DFA^#R7.EK)'"C_:? MO^@_JQTB>K>...I().F1K+T?0.K.7@*Y\@I)B[1.HZ2*U39H8*]R--Q;D6E% M9W<;_P[9F4-YGZ\2P')]\_0]7V@)!QN#MJ".*&K#1EM;X'G!YE@J#)'$F;J1 MZD)^5L%E/-206:RD_Q>>5ARLU`'36KH=&(>-N]+&4Q.>`D`JLD@%D]LZ`^-?D9R#1&.4 MZ1,-KI6DCXML[T4%JZX'KH&/)3%ZA&S\68*W(H"I'PV>-@J&1E8PBV.UOMFE MU*/]`0!IH^S`W2Z-@BM<#??XT>!%?]#69/4*S5=A=3NPW)U"N2,,';SFL&?? M"FN91U89K.KA)TYTKN?1X%/N>#ZUJGDTL!7ZM1/UV>3V=KA4P85-R><`2YKV M5N\??>P9"P\[<6MPVVIJ>C7K1^"P!%Q$4(48#"$#(''C:!CN2FJ/#97OI7"4 M+I\J?)#N)'$HE=Q(?*$39 M/G+K.4KU;ZI5I47;S,"[[+/YQ\,;![.]A?=19#-/XD.8^$6D$IN,M'.!M4C(A^S*NN[L(\![;88>G[]\?7[R'!9^S MXVZUS_&JD@G%PM]1FLICG(\;]J*/G,G4KV][E5[3TJ3% M-(,UC_?\?`LZOH+9C?"[N5ZDB2$;=TI3S>3YV$$7BV88?"R,9?KH:?^@A@9X M\-'S_K[YO<=&5&!# M$5(GF0E-E0Z#F6-U*X\-STCLI+4@S#<2YL,AG>HZ.Z8$&73^<=HQ'W'#&P<> M,TX*63OPW:,H(^E)D9'5.M,!(IWM8F)`AU,^AXFQ,8\P&KCH=4;262?L)_D?-CA+1U#$,($I7/FK]!^O2,4AP\^N5P11A:X@#[6RVPIN#:R+I M.IBZM]_W)?3@(=J<1E3'/Q$GVKG;;+ZM0_<,5J`3=%A,MKUQ&>NW`KH\[;LH MA2Y@T7Z3&5I;_QB&&&79)TR+KP1ECC[O#SKT;F62VBDSJ$#M>*X;&N^,=#/G MLF@[E)UHL"=YJ)5C"CRK$VUR(AN=+LO.X0#.MRK-F2C2Q&1%UV1I M=UE\1&BKXV*R_7(YFR=XD=W02>U$P*B;1:%/=*;)-0ETRAQ6F&)ZDB+4C..8<`MSMA,M9T3.A)@*,DO+Q(SS`5N%-,G.1:7U`)6BS%R0I M\,H1Y7^IV"$OX-TC0!PU0?B@A1G.I"CV50&S$XOA+SD\!%8SS81/,'-#37=G MQF,Z)YMUYE-/%?Q^8,8%T6<951HZ.%/)9?&IZ+.CFJYX#4"#BDQO3N5<(%DQ MTTL9*FH9""P(RK$FEW)+>L",60,LC5U13IL'T);!33(/M4X$CE^=G+7R,_0F M=P^ME_2'4H*Z5D6NCNDQVD>^E#LWV'^9>V`%TY8!VT$YX64M M7*?>2*3OSC@7'I5E7D28@L#T])_`-"WN)(6'F:.@;/!WM3P/*R"'J'`/*A<3 MAZX#2,J>:W8)4QACE'Z/;:XR$]2)#<51[=%'`J\UP-.77":*S9LPLS/4DI30 M=@0ZMKS=O2:N[@RE(N$'C:GJ1D/KW%7$?Z`Y(O<8K>3G3JCVT`<'+Y3/I(][N;)/6D'I6XA(NS>T^+4)Q]?> M2PD*^8NOIJ"MWZBM+%*;'XE&;37\9Z"S/G*I,%T`$Y='L%ZN(%>9L_C7JRS_ M)/)"W4\C(0;64)"C@]:='.V+J7!NSJB5U#$Q9*S"4%GIR)Y^I8*+SD%:Q'.0 MF!SM0CHV6C4M(_HD]*FS6A"<"I@0[0-0RKF0LU&5%RK$56??.3GH;`7Y_2;0 M];-STNO6LWS:EDX7L=8T?:I$S9-VH;[MUE&HF4JE,ME8QA&L40:7;)&S?1+7 MX((Z<#:)JJNL#@0IKJ],==@4[Q@@K<'D,2YL0^]Z3O6XTO:C.^$1F`A"N)Y- MGQVJ65UOB[AS\A@FUUDBW6U;;IJL88ET[2"?8;*F(=)QD7UVR9J6B,L(/KMD M34NDJ[:47?+\N7K\T8O]9ZZ=T#8W]E_N^2/8CP[V#ZXQ,988%9Y])"MC__D+ M-:F#W3W/R*X1$13AW\J/,GC1O;O#62&2\8XY'ID*GL#VJ`M,@'I6=GHKLP4_ M$[-YDBV$*(A7,4VQ`,SLO@+#X*`TP2"*N\`PXS+%C/+"A2X+>0`])*$"RJ(G M@V[E`DPR*T".->&+CI7GW#"GU^OY%!CT6BZ(2R)Z?FALA^)B@8%!O#&JPE4Q MP!&/?+?H$%DT=4#9"<1*E3F$B\2P,\H*?*O,T^^!]TPESF.F&.2 M> M(UJKCP`B]7T0'"''.V;F?D:;8VK/H!O2\SH*WCMK;=3W4VMMAW3/.AKI.H'V MZ>SU".R)!MF\+A(I+HF+@;RRT+<@\5:A(;VY"TKV#_Y&L8_.Z4Z3#[="K&M< M:(FE.YB;QQQR?^[4GZIF(]B^A%OF$#DM4D?C'.RO;\(2>&DO_ZE]_"::(=) M*[\^<@D6485U2JS?.T*I7:*V,_18*ZZ\:!X.B<-_NUS.ZN32^IC9G';5JLR= M=FU0Z[>C#LHG3J(P<6#]4JJPLM<_ MZ)I6CP;/^L]O5"Q%I4)T@H7V*=9:7DE'RFXO@F;\:TKGS9(DN\(Q]2/=A&I- MQVZ4N'7V(/UG7^O($Q6D8A&@U!R-['2BN797\S]^4LQYU/VD5>-K=]=7Y>M& MJ7)?7KVK31M3;7UE!:\R7I(LN**HV4W[X+5>NB45S`)UUJ).E*%0&#KLW8@X M-^R%XJ'3-\RJC2BC;%E5A:^RF9Z3+O,#NF!I"D!K?U?6/@Q$+NFJUTJ'8WUR M!K@)8!S`^)[B!!G/?N(PM*D#'`1"`!\$&:^G-:WHC_M<1_72[(WI)?,/^B$N'"VTP-JL[ MRP>5`KLD^F.%Q:]GV)HQ-ZY/QI9;R7>RZB""FR*"6]T@*3#9MK0[VNOMO?"W M%=QL3@L@'E;]+25Y8U$EJ*XO8[*@NK9-=>WW!KLO@NK:YFC#U526HAMKN/-( MP\83]V&R5%CUK2FJ^[;JA[G78=4/9]5!KK=XU>'HY5[X-1O@/`_5I;SKCU[P M.OQ,5K,BN$#W"NN"*&Z**(8XUGUGLHV(8PUZ3_?V`XC?*Q!_F*L.J!)45U!= M#TIUO7SJOR^QV9QV3T!\FX]@@AAOBJYX?*Q+H"Y5$VQEV\LGVZAK[@D"A%6' MR'K8Z[#J![GJ(-=;O.J5MJOZD!J9X^?)QEOS_O[CJV,WPW M_/W\X_'%>=T,;#!PNL_97J(IG97.33AUM5I?BI'975T6% MM1RILT*FYF(:/,GT$FN!ZM+YW0XGK+T][/'@B2Z]J@O.FXJSN$RLW%UB,^YN MORK&8C[C$]6!5E=;1P+_4<43U2P)_EZ(LDR$KE]+3-[A;H<[.NR@)X?U)K$` MMGH1,-78)330M:?JC2/_C.K6%E@R4_4/Z!2CPPKV7=%MFNM@T4K=P$):O4QZ M[/$>$(U7A?!1R%Y=70I>M?,S=0=AA/TG-<&QY9@<2Y#&4C>C3N/.ZDI=-;/I MD>WPNNKN32T&:<:/#_3&>GB)IN[T%,0&ND)M6I(X`)=Y"@HSY=)>262F+`98 MIX>NN*I(7(L>-5M)L3"_B%O-"[IBV^I?X&-XZCA`?4;'_#++2<-U5@=8B27? MF>H6T+0@L,KBRL)J2-!AR:9!@4]'MY3L%A7__&I:]L+7;IQ9520EE4.O9E0R M%E"F!OD8N\!FXLPOV8;HH0+AY6K!C@L)9 MW9:@&>-$E%@!ML?>O3ML-8HZ/=SY<'S2:A6EF@ERF!!J7)#35C^Y-N/E[$V6 MSX!:._\ *HOG!4Q'/OP)1']O>V!1A`E>=.E)K-I]E*$NG0D@9TCW2U)DY/ MU+-<7:TY,/GR+KBIA]"JUZW:ZMV7/>S.!A9&`F"4USW6"W%)]8L5I[$9]7)T MJZ]B.TBJ[3[\`^#T;9^]%Y]XC[WOO^YKON(&%(W%P%[G?78^Y=.>!Q&)0=IO M5$K"V*;`.UF>B@6UDP!#M>GC:/%BCMVA<0UCT-<@8B"]<54J@[@0XA,*HS$* M0%ZN4(]X*CACVQL`=RH\O]"5Y_^H4BI]BS:P%.-.?5ELYIYGB2L>,!>U*J]8 M#<<(%)RE%?7+A"_'8H;Z-R^L7@*VS:>ICF]4)AHG8^-#@MT3Y'A[.FIU"M]0`/T0SOMLEFJE:_=W&G:N3!2S/T M+V!X"78"!LZ"_2[%2*0[YR5(8L>2F,\S2=UAD&.&*7`LL@UM!/[EEVR:LK<) M!VS-+B45X5:UEN7,!\9H=.1%LQ.*&T!4B4S4L2`!^X%:(NL>/LJ&]["IPJ2;=':<-XM3^V_`W-MJ(:&;`"CA3W;>SL8-\2%((4`&@,5@, MYEH$(Q6VE\C>`]5>Y7PZ&X&J*-D4S!:TZM7P7ET(?)/_'Y[7,FV/IF?T*N-Y MW+APS;.OS1R6MDEOO(P(,2Y65$=K4Q1NZ+X7`BKI<6RS1Y6$P![MN^I'>Z7WP89 MM;)KVP?G%74*RO'W'!O2??)AG>HFU:"4AB5.AOPTNT(/>8;SPJK=V)U<\[9O MLS7AOU#5_OA=5>Q,.)]_?UAWQRZ&:7P(`\',18J.S&M9H/E>Y>)"?"Y?H0+^ M28W\HWGZO&["='2)0]1?)&R%7\[$^%__B/;^YPWX%P/09$CNBVQ_%T02__F/ MGS;PJ,\AWYUI>^_@].CO>AVC++'*<)Z<7ARQP7[#R#OL_..K\Z-?/P(9'&8[ M^@W_UN*-Y1D!VV:/?97=.77;,)&"\/9MH1*99`=C@?]L7%Y1ES4R8'+0=MU& M80;5='CE??1O<&H!+2]$-$VS))M@A.`XC?H=CK3]"O-8V[/(6#6?Y#P6;7^^ MT5N=,>T>0*69P8(5BZ(4L]!8^F9\\Q'#0ET@5N$GL^V]9LNO9)+4S5!LKE*= MU=VY4V.[09=<=JC>=#XC@D_!J*(U MPY/4+6.683,,%6R86_MB?Z"-9@[%/I_X+9QW7H.XU?8VY'LSTDFNZVSK1V_UHJDUG(V;';: MH?*<+"S:>&S_EDZ)E=">1`,4^Z2U@$O3L!OF-&A(\4-L4*17D8//G%;""G': MX[7'6`&%08G>K`E52_":X9V!ROI8`K# MWRW@JF/U(#B-\UTW!VH"S_7^5A%VGL*7J7'K6SU MA%2_0-4GISVG.7D/+>1IY)$(A%%_J:$/T66="3HS,R,BD<&'W*%C@;'0N-S0 MD?ZD(@K-B0F'V97`L``00E#@``!#D!``#M76USVK@6_GYG]C]P MLU_NG1T*A*8DF20S!-)N4_+2D#3I[.SL^$6`6ENBDIR$_OJ5C$TPMHPQ$C;9 M[9:;VSLF4N4KEB&`'W(!!Q3?]D$W&X'B'0G?L"(O\:R,"!L<[<&2-JH+# M^KMF7;3QJ[CR%U>,8@?:@OM3PQ%/TA\!P'8JHN&[FX^19X"C$<26D*\F_ER3 M?KIVHMRZCXC#@C[C/[L`Y3!PL8':B7H*.P8=O7?PT^K6S3XIS)K:91F.Y3E^ M3^IQ*R+V@6<&D`WLT$+17CZI`A8XGH.M"(8CNC$F(81CF,`YWO%H=6@8X[_: ME`)&.QXAOAKS1`5F^/UY8%#3[]3!YVJ"P!IP&`VO^)16ZXV@;_^:#%`+O44. M4P6W;>13?/;#@X^&PUND;=8Q")E`-/QB.![0\0C9@&>*1S5OD^@S&L0*;>0_ MQ@2/>H_@CAKU7-=OK0IYMP\_/R#87:(DPROSAXD-R/%.8Z?R!.!PQ,2/@2-8 M6;(;0!F!5C`PXN`ZU%J*67JAEK,6:+2K0J.V96&/MWH#+,`13`=<`J;3(:3A M1?U#*=5)YRM0IKF@3#YI/O(X#/$_3RZ!%BDB[9=^6$39"(A^JV((7+$1("]Z M4KT#(`7MY0%*J4`:3X$>>XL=/^]L?TW`V(`\W*,>"2)SY4K$,$K.?YR3@/5W MBEF_-9Z!ELDYTG[I/4Z4C8#KEC*/$S1_]CP&B`+='B<9K>0]/HVG0(]]57U_ MT;MMPO=O!?\13@+6#Q1[G$!<'NSZD%/#-'J@9+PM"#_3^0H7;_68/&MD!_2E M!4K1_1.#_*@,DC7Q&IT>CP%ADVO'0(QK*!9W8Y'.TA3HI^*5I=,G]_8THB3+ MX-RR=,$`<,7M]Q")\*J#*:.7&%G3;J!)F^6@918H`V6R)7%>E7K0,*$#&00Z M\Y8)*.L9C0"]&G0X55#GXC(1IW92M=)=U\9$1#0;2'0M M(!6]ZLFFA8PFE9G',W?LX`D`-\`1[S,V,ZZ7@Q;O;K-)E($^I=E(WB6(!UZR M#WJ'3B+4MD@CI4J2M5PO7+D!CP!Y.O60(&V'*Y/1),E8KC)'`EFC^D@T#&E#SWD#+>Y-JBI;S) M0M^\4O49MKZ/L,-;I2(MR"8ZM$E`6:N&#;LN1GZC^LK5%C&*G?+D.D4Z4(P8 MU?->V[:A,-5PKOUWZ$&7G0/6$JLO1YU;_Y57GRSL2:?$G+6#S(`(V&<&01`- M*7?YGNOYJ0Z^HH,6U.*+,Z!NA5Y9V)/.G8K\\25FH.^9U")P[$\'+R^2-^.J MTPPH?"&63<<568U/LE75LRQ?M3N>S?O4-28^88P1:'I,&'"+Q8R/$>,L\-:& M_JX20+6,5$66E;`?K,-P>M]1_C;E`B),?)/U"1W#*%L\HTJO.)FR&77=)$L; MV9L)GY=BEFC9F4J*)$N384!MRU.IZM>I4>!1;6$[U(GF35*+V\7629R-Q?Y) M_JQ![96>`L$82/Z(K&>8F'#]@Q>$08M:AGDR4MZI89#1+6%*]_NQ[X['# M!Z1&&18A"O=#F02($:-V'7E-\".DW,[WF'2Q9[*!YX35#9KRJW*\60?R=TO_ M<7_QI?GG'P_6V'O^BO8.[)^MQ^'7";KK>D\?6N2@]6GWV]WMA#JM1^MGW3EG MO]5Z^^T>&CRWAEVV8/=+RZJ#2^OFO.E^-VUO?/G#^/Z; M@^'$Q/:[,WQ^.OGZ^>#JQFF>@_V+]\V:W3#L?=.Z^?RAMX?0^?Y3ZVVSTVJ= M_NQ]I5^^FKW/X)M)&`7U+G@^^]3U+G^.+B?GW\9G5WL.-JEW^:G=!?LMMUTW M[@[VQGW/??N[\6[T^`"^W=?VVL?'?U8Z_9M@KW>YNV!Z'Y&LD_._?1%5,6GE3.ID\Z9RHU@73`FP()3#I#==D7@\]/_54]9A1QN*^;. M5+Y4[PB;632-Z7J8ZHW`YF!RK[GZA@-H4'C2!^016OZN.2V3OP2J1(,\+EPD M#I!Q)8W$RO],":,H'MU4UPEO?.>H=442`5AG`(=KQ"EE09/:MC9+L`K.WB?* M%=WE+",I/@RJ:^7NNH#`1T.<^//!@$CTX"OTX=+CF&JW<`^B-4:,`Q7O,Q`>.SFH; M5%OE"48S@X*^<@H0&.@I/9!!;8V\"2PIG@:O">;-ZAI5_HGS_HJ:KN[%_DWD%JE1E@ROLO,7ROFJ;DN5 MV]P[K?E.<368G@3!S?//@N!]I@NI/@DS8Q<>T:VG9G:.I?LL\KW`&!D$G!K< MU`\8VP**ARL@V'D>9NEOB8&H.#PW+@^`46F,S_ M!MW$\TEUJ+H">DDGD(S:KD)SO-QLC0DD^5N1KWGH+#:"1&,5'0JOA%]PLB\/ M5PLUNIF7."7<9:;I\1-#K"6'M;VBQT]T$&G?-9.X7>&H)O!,#NW?]3=02P,$ M%`````@`2$0*/^[[2?L[%0``;V4!`!4`'`!I:&-H+3(P,3$P-C,P7V1E9BYX M;6Q55`D``\=Z0D['>D).=7@+``$$)0X```0Y`0``[5UM<]LV$OY^,_*[2((@R!3W MY5*9Q"Z?76!?L%B\^JG?[[T!$&#-!D9OMNF9X__:J__U^KTQ6JUO=;-W`6WZ M5]TV[P']#=X#3/^;_GUIV^N7@\'#P\,3G3Y*=!,#@ARL`\)^Z/7[O_;8__[] MKU>,R!@#1N)E[S.E,W(6O<-A[_#HY?'PY>%1[^/=N''X2(/!H.#P>!`\>>$^^?&0_1)Y_.':?/GSQXL7`_>OV M46*F/4B'/1S\_O[R5E^"E=8W(;$UJ#,"Q'Q)W!\OD:[9)H(%^.IE/L'^JQ\\ MUF<_]0^/^L>'3QZ)L661/F/86S+A`9X.O#\>N(#U>J\PLL`-F/?<;WQI;];@ M]0$Q5VN+L>[^ML1@_OK`7.K+/@-[^.QXR(C]A_WRE8J6(,LTF)!.-8M]\NT2 M`/N@QP;^>',1^5ASN321SN0\8'\>9+X]^%4H=U^G&@;07@+;U#6+\#$;'TP` M[Q>0<@%N;?KO%255GM_X`(.:Q'^[I-^^1)8!,#G[VS'MS1T=X@CAXV(\YKP_ M"-:!>J$<:V1Y;J&'\AANWW0YJX.O*V2#8GRX3]:D6&RL87&RPWJ_=UB&]+!. M+?!&+$5^6-M$\<GN!.D.\QY&T#B#-K75%W".\,KU:8LQECM"2)LTK!=E M,\-1#OQE$\FS/5V#!/:`_K*P']FD'P]4#C! MS**59L+*O'IO"X9V28?`NC,#_2WE<@RG#1#662$0N]#T5V`U`[@DOI%7=Y-= M!)N:995CCKVP8XDJJPE--K\N*?$(6^#1!M``1L`8>[M:M.9-!$K-0GJ$A,4B M7H0#"I8V`];K`X?T%YJV_KH-1RAKX(+^DZ1BY'[I7",S]W/]EP=L91H`RR;! M+^Y:U1\>^K'P?W*HA%2K.M-WVBQ#J'4Q[%$(K'U$F",Q8[6)(6MQ<&:3I8$04V8"%Q5&O,+X.&Q>':%D$KIH883#`?'$<1I6K MG$1&A`";C&;$9BEO$4*(41!F%&)>477S$(>$!V8OB>=@EF;-@SHK_9?ZIC#E MW8]@^CET0P8BP*HGJ!E`F3-U//"=)BI#27IH=$-!^W")+4;7U7M>1 M0\>Z`3J@XU)W[`K8/H="5O\\>M%HID6+63&TZK"_%_">CH7PY@H(P3\ROI0Y M4$;SPMA'D>%?E:[M)<`[XD2LWN=0DVF^2\H@#[.P]E<2R!2#M68:%Y`XV"\X MJ%T,"1H=`C^)CP_Y$2_D=]HC$&*%(^-W:K6)(N,#?7LB86_^6B%_:"J\IB`.:#2-,@5PBWA/7,N3N'5)IFDNK'K)%8EC#\;-15V:VLRTZ,<"0F?5K8WT;WX- M*V7*U$T`]4VI#'6I`67F_O=DKLL!$_9&JV\(A&E6V!5(>UV"5E?6J_BN02H< MW%N.;*N'7,_'=+Z9(A,^J71$[OH6RSKGZ%AX=4E'*;9OPY=QGFH;YO8VD&N. M49*>^2\H@RR@^)/^9ZNUA38`W`"+54"%^!$HC?U$)?DZ%413`,"H3UIUIF`' M[!)^8J=**JGNB"03K*CWR14;W(![`!V1;E6UB M-B2(=<:`Y^`5SN-5MN)>OL0CTHS]V$.Q,Y+9AUPTEU=1/,V(I#TVO)Q:1CW= M3!'P^;DN*Y<(+NX`7DW`S-Z%],*F1P8Y>>:C:AQ8",18O47E/*SAZ/9G#5.W MP=ZXNJ-9(B240:F[PLF"+I:.K5K?MS9MS;H$&@'7,\MKB-A)M)^H3(>8 M5UX%(`T[R[R&1[#%D9FQ+:R<&9:FACS6&*U6IKUR2S:A,4;0-N&":H`@X//( M=7<%RP4Q$K247<:\GA+\^?0"&?2.85\(&:X8Q:7`NO8LW*8^OP'-LI>ZAL%O ME"`5,*%140VBX:,@*S-?4E"<,/*7:;(IBJ!+1UQ)?YQ&U[9-LL&*19/5$+&IHP#XTS#D*VL-)1R5HZ[M^!-?"'1 M3@&J;9]A18"+A*,US;!FII'L;%IQMQ$/XR.MA`IGYHX MDVN#LA0Y?Q)5$T$-E:K93JFXM7`O3:F'28H(<#]J:>GK5X-HFYO07YKH?Q-O M`*K:X:AV.*H=3D4QJ'8XJAU.R42+9:$'MAB?(SQ!SLR>.U;RH)#(PI=2#,CU MH@HV;RD':2U;RAF[0P+EMH=B%P2U#[1Z-I5W(17U=*ZQRYKA1E=3@-T6WH+S MRYED.R&C(O#%`E!N0;G#DI%C+ZG/_7WGY`H24(*NLUY8)B$#\XR3D:G\IY!/H\!^(GF)T;S*+E9(E%(%^+CW91ZC* MR"(?N%K6)/<($.N)PMK^>"QM611B(?+H=4DV^<#5DJ:;@#6F+IF;JJ541BM6 MFO#=OT:I?M'DD>N.Y<@%+7;HH!Z'JA%'JD,22`$H=N"`#WA5(-::$)P.:]QBX9?T.99=/C&NY^$]9_==B\JE`'3\(4*8 M&7'-@J/&M.6XQR#AK[/?F89SRHUW'-.A)L.W'0B24S!'&(2ZFL1+,:E#%1W% MJ[9\#^PE,M@5`L0[[BEF96N._0[L2CQU5&B=+(X*]U5Y,5)7#N/[>IX@*6Q%+,>` M1,F55=7P#"J)IX\13S@=K5JZ?(=.&;V/V"E!A[%\(E*W?W*U+^,(5@!./5<( MI??5$R>`?((R$\B%9;$'LYHVR'=4A,LDEY[D'9C"4LD'C?M^[W@#-W'2R*#4 MC74J"Z9::F33MVG$22*77E?F13YHW)=_I_+Q==BH!R7^\!V8:XYEBW2B&&0U MG``+^0G".\METFI_"6TV3+&4;K4P3W!KAV0_AW:CG=K"@:.X3=6@I"SSJ34H M/%?UQ0N2)D#'K*40JT6:F,3;9V&E3%GU$[]Y,TN$@&KCK0.SISXY)*K;)33J M&&MD>6ZAAX/J':15RE6E7,LCK_ISJ/X/=J^JNN6TB\/3\VTFWS M/O66S=PR@\*#M;ZBKC@L_$D]Y;06=5JK7/3MBG-D_.7X5?%WZ`904Z*;%CNU MQ(:GWA&PF<#=@_;4?3G=?"2L<1CO=*B?JL2;$@I,&@$HQZ.55S_U^[T_/K__ M=/SG'[_K:^?Q"WSZPOA^A#<*7?O#U>?9L9SOKJ;^W; MSQ8R-S-D/#M#;T\W7SZ\N+ZQCM^"Y^_/CP?&H68\G^DW']Y?Y^.%J]?_]D;W][T^U67DW]ZOP"Q$[YL MDP&.`S6J84J3PBS4984G`1M6C^OYN0DU^AEPP9J'L-LK:,`N3K2%:4NL(FQ$ MRL6%4$M?'77@7-;*7/2T.D\>-"C9!\8;A`RF/U<(@M7:0ANP[>!WAS5(*)L4 MWB"H.)O/@2YFHO.R],-K!K?,HLV#*@3<2PTN``DS3@AP5Y_P=4:EPNYR0[8[ MB"B+#X<\`JYHI.GFS8/\^05,WEXA8K(6HBOK!%0U/8V=-2\`*W>=9I(,.P,/ MZ0N"KFG/)RBMPXX(@460K&,#/$G"K<[:*41#$DM0_:'$EL0TYLW6)+LI!FO- M--PN%8$S`'&V][6`0.>7C8Z/?,Y:7_E7E6(Z^A* MFJU14VW3?/@0$)7?ZXI#Z8O-V"V^8F;IF9\9\#O0AZQ$,Q+-H2]S1HJ4;![D MM5P=F209<.U?OM&,:.-$?^#)FL!73#A"UP3L!#=^N6YTTZMO!OD?6+0YF/,T MGLY+21`'L\MFFW21XD1_8($F\*VC6W[QW+V@^J>BU*56?1=6]EBE5&%HJ]3>FJ"FT-_.'.E_.R8&=);2>6EOII8&W2MCZ*_KE:`+RTM0[Z8$R\#+W0XL M8YU-8;E!$Y9&7:H)*Z_Q!6Q9*L8UEKUORX#J,&5Y@W7+E.7"$NG16[6\40?` M<$DQCLCU?$Q=5S'=X+.)R=Q$*JF$L7+%+/1JZ4WMSV/6K8W-16@DVM"+-%EY M9+LJL"*(UK'%?D,CP2TI,&.+KM_RY)*Y.=4UOH#3D8HQ=T3`*+GLD27SA.XUB[$]!=AD5W=$ M`Q(1(BU%O_U[?N7@C#3$K]I&)97BB*H0QANJ+9\T2\P&0C'"'>A:4!!!7U@O M*N:JW`N,768TZP+.$5YYQW3*^/7[QFAW(>U>!`)G@W/+U/-=6,,[,QA2)N:WZ MF*@^)JJ/B>ICHOJ8I`GC&B\TZ)_MW#66\LYF3ZDE9K8D".3LY32NF;"!G6SF.;4\KB!"/9L@]5CS)EVY5M5[9=V?:&;'OF-G)#=KL4 M_?;G396F5ME;ILRMVP7M2'+FD6J$VTJ,W%*]@MK MU&)Z)E/93&4SEWL"6*15+63E6U]5"J7LK[*_ MROXJ^]M8*93':-#;:XJ(C8%M8I>Q4P`I+HV5,U?FI;5'Y_A1CG>::=PBJWHI M99.5358V6=GDQFSRF8:A"1>L\X`;KPDUNMG$NK!KFP-5"[9DAZIV2ME/93^5 M_53VLTG[>>H0UL..C-%J9D+W,&A#$6Q!RIW('Q=%L0598U7]I.RLLK/*SBH[ MVZB=]>_4F6K8WH0N.6XJ75R&?"1DWOK3,C MX&^'[H M<_R81D9KK2N=_.[D/D\I$,<.9JFO<^I_:]87H.$S:$PH!_R`9H[,A6+R4I"/BH_E)Q/1E1>@:C>6YI->AR=+@P2RU$,_;M/I)/ MHWYD!2@G@.C87-NAP*D&1,.CMMMW2`?"A_=9)=_!7U_HF)C=^&6`QW=@4]O2 M&QNVS7%$#AC5+]T.#>J9TANP1IAE^Q@S3H[37A+H]-%;ODSD(\-S;>AN]$_( MB4X`_2%7/.U=:%Q;')@^;-M7 MC@PP`H2/*KK'P;"[V/*<_E+#^IPU<,MM828>`=#5H[OHT)XOVP_(2M5_&K`QIQI!+@/_A]02P,$%`````@`2$0*/Z!6VI8D*```P?(! M`!4`'`!I:&-H+3(P,3$P-C,P7VQA8BYX;6Q55`D``\=Z0D['>D).=7@+``$$ M)0X```0Y`0``W3UK<]NVLM_OS/T/.+UGSB1SY%I.VJ9)VS,CRW*C5I%424Z: MZ9SI4!1LLZ%)E:2GX`R,_8?]VG;`U(O07^W(>83H=]XC#-"_T=_OHVC_ZOS\ MX\>/7]IH:&@[`0S]0V##$/\"G)W]!^#__O=_OL=(Q@'$*%Z!=PC/Z'`'+H;@ MXMFKY\-7%\_`S68,G@TO+N)):(;K>!^V5@C!IP?7"W_X(H?LTS9PO_2#N_-G MP^'S\W3@%_'(5Y_P+PKC/SXGHR]>OGQY3OZ:#0T=VD`$]N+\US>SM7T/'ZPS MQPLCR[,Q@M!Y%9)?SGS;BAS?$Z`+,$?@?YVEP\[PK\XNGIT]O_CR4[C[XC_Q MS@'P?>"[<`5O`2']573 M8BP7WV`L_Y?\>N-'ECNSMM#]`N#A-ZLIFFY6.K6]Q!&HVT8X2^PN'MX[AG^:(;?/!^2O9&$AC8B)193 M4R`W_91E]@"IA1`FC&FPRM_=K4L^433=NT/L\,YNUE_\9[R87TWFZ\D50#^M M%[/IU6B#_G$YFHWFXPE8OYY,-M^?$XP%/N!?C((B,ZS`3DE$/]:L+1EQ;ON( MTGUTYN97>!OX#ZILC'REK2'RVRKCW%9X-E1D&O@MA?+?C']_5^8-<]I'6$D< MPK,[R]K_/@I#&(5T99!L`%G\K15NR0XD$\^QDCB';A2FOR%JXVQXD9PV_\?` MP]!`+V(]VFQSEGJ3,UG*HT&UOD9CP46&?PJ]_GH5[:\33\I M5N;B=)Z`+"*HIUUQBZG?TV>XWXT.K;$5WH^\'?[?Y,^#\VBY"$14NOA>RBCW% ML()(AAT;F6-T7%U(72U.O0)71PY#UD[3B+29E3!1-N:%2VC=JG(ULFW_@("L MH`T1P*T+YS!*M&*W;PH*.D!+-J?>(@/C!$4'L0A0+\/6JLCQJAJ"E0QQ(!"<\[/.B*?R[2HU',P+S@U2V]@OB\#N+>=2U$F#[#Q!$>*A9 MPYC&#PK_3XMJ=)PDT":?]CC:W?5Q0L>F_3BADE$C(#`>'.(4N1_N'7RH_'FP M7"IE1.&O1L-M$KY[-)AH1BU2QCB\YHO*SGGR?#1 MPV(8SR!IZ>A))`_Y\P1!'*KL\"BBX]/M%(+5I.U>$ ML90SC;T7ZKYS#*3+.$X!01=2%.4*>>K7R)`=4M/#%A-S"4%>2*6R+G4Y6`;^ M'@;1<8EV)4(2AL.&>^P<=A13X>+3KVO8Q##MGG@*T2XP'4\B?,9S]"*\+*J7 MFN6KB]45O(5(/'?7CH_N8!`B@7)L!WKV4:J"10J@OEHP:=H8+\<^O%[.KR6K]+VOOA]^!J\GU=#R=S,?OS54>JK`UJ]F0WJ;S MBJ7?B;97(HY64B/%1'K!S=^;H\/R"2Y=^Y;'J%``1YMNI`J.0DA-*9Q[FM&' M>C@.(\I%6JRUZJ^,8U#"*X_+;WO?:N2:\Z!1M=S,\6"XN!TCZ]#I,F5+Q:/I M;.#1P*Q'>O3=1\>[0[+C09S;M\DLT]$K'KORUA]SJ7FK2JD&:6D=<8!50_51 M"9/>_!R=B+IZHWT\VK13P&45K3"(LDK5U-WD8>_Z1PA7T"4WX$XZJT.1J4>J M.^I02Q%;E((#KH+T'W#`F5SZ)'&N+?20.1:93>$),SB95:<:CA7TE3,%39&6'R*50=T\3'CXHL(3.M6-)'`F>_= M;6#P@'.?IP1A9_J'@4ZO4<2AA),9'@`O&]:'\C@^YRJJAK->51-H&?B[@QV] MLP)D$49'HLPLMPO986#27)CJ%Z%P[52I0IKP:HB,[:( M.S@@76]>Y(^&.L%O-4X]4MS=?2Q'S@G;LC;EX(O!/,[/+CNGIMO<#$DC" MEQLO!A=?#>.[C>C'YQ>LJXUF[G8+"D3Q7K?(]JF?C+FCMF/#27^=2PXYUTSJ MI7E48Q.LU-(]B4L#31:<8`V/D) M`Z)IPL,VA'\>L"K",1?S99H"O"VHF)H=4>H$U$)!E4`)E=8B*J6RJ?RDI,)F ME\U]9>9`DF!0EJ47*X;24RNA5OO$YP2CDC>UK:+G1 MO6T%\#5"A'1#./7L%K[O9ACT%D4UHI49,$YA@A-0D$(=``3W2Q`*Z@\3LMJ* MB&2BW'R+-99K-2:6IJ%:$`CC30?[*!C-.JXAZ\CW")+NFJN5<>B\4%M&SK&" MD9--Q&\`_CG\\,>TC+.9HR@*G.TAPB?HQB]N7I>BU!)E703GY56:"NE<-?BY M:;@F4L77BLI;VT:E7^DJ;W>G=2W.]D..,EEM*DVBJ>XX=RDHT(:3X5R&,S+D M[,U1KH-/NVM?^\%5TEN[VGVZR]IX*0)TU\O+$,=R5VKZES]Q/'"%E(H5A$]- MWU95DH9"O$=ZPY1U)Z.*J$-1K<&H63;YU-3T-D5[C;TX8D$FCA*,M1=2R!%73Z2]X8E`@E^RHI/<.&H0`C M&8)%7;YR@7<9[I0D-K7(4H)*>S$WG0X9*8JSOWU24C3F<>4GMVCUN&`%ZN*4 M"]D\NVJI8?6( MR,0G?9+BE>F@:"WW"I>UN>O56F##)85VE%#VGG9>?-X\&#:Y6&IM_6#D[9+& M:`GX3I)T=$QZ8RQT(EB7PBS7"M(47*7WG:%L&Y=?A1P;>ZFJH91U\K9HAU)2 M1J$Y^%M"SQ*,9)1A66"PHW#X4]:C;"PN`__1"9'U20D^3FC8"1-A9:K[!WX&&C7_PDR#X]9E85+,3KQ.#DH=/MV3QB.&V'?,K MQHW9VSDB7*QT`>(MO$E3S7T`;8?XR@CZZ`$GA_\B_^Q"GGCH=+?79%+"["1U MFD$L'2LWQZB%+,#$8DM-_M*5'X(MV]Y:7%P3-6L5(A@B8UC-L/C!=9C:$8&X MZ>;,#[L5@AR:]I\@$I:"$Q6UD8WD?>@G+AK\M"?B4>4554!*JU1^6(:<9ND3 MG3(I&^I$[4D9&A5DUBLPE=6B\:,2<"@[!,J'4VHV7B,BXG9\ M!V1.GE+TE_#6#V"N37_Y>B)R4HM0XLLO;V!T[Z._/*(AI-U?-^>=/O(->+(: ME\?3H%N")/6.(NM3FD8RZR(9D-WBH:^7.:I>?X8_41F7,>^Z^QRKJ#K4^?6? M3X6].17K7CK_!UT[NX1C-$C#*P[ M6+G1+F4B"@/3[LB)4L9Z*C.9#JQX/K>/@?9S4I:'V>$GM2O:'$,9JFA6D0"S M^F+A:.%<@X*K$IKYX6$+@\5M!5UG)HH<`28N_TI16&O:Q-,,%\PJ<3U_3LGO M2=L2FIR,6CKTR)+00?6#HI"R2!0PH\J"VB,YK>.]@*1R-T;I7S*XFJS68_'(SW;SO=W>8>HD0[A)3LZ'Z M8F/-"%5M#41A?3_>V^N-"#0)5^7ZH77>UYV)JW41WL/`\7<3CUNPP"*':>:Y MN&VT\;+8.HXQNMTQ7E=1;335<>O-:K]-_?(AT&LSD0FZ\6](/NH::]*Z:>JU M9RL%6K2C(5<&5+J&:+RV1ZCHK-'SI^7ZV"MH![A-."Z-O7+".,6!*VM954&O MXZ^]BT^S-=H,>%)MT2[YVA+8Y6$;UQ!M2Q?OS:9&.]R)KS:VPOMKU__8;B/6 M*M3V;WHW(`M/?\EF0,I:.0=/!+9X?O]-[ MZGQD92",-=54XN-)X&1V1E\S9PFJJ.I#A&&F.W'J8]Q03]"-Z5M<,/REPMV< MS\1/NE#QDPC'1KL_#LF]P(V_@I@ZQ\7WP#%H9%[""/.4M+G;P=WE\08=`U.O MJ5)N'ZLV_[L;^EF/RIWPX#+&(,6$>UK$-R[PA1[TLXUURS[!![9'\.2`4"+G MZ6G=N:!=N70F<9D6ZH8[>GK6=;<`VI'4F7SUQ?C]3(6M'/?2$]BI:19($R!N MHT3\[""2&;34Z$C^"/\\.'N\58;K#=MMHMB@N"@/:G%[[7@6DA[O#O?_Q(_` M7CEA=YV$A7'K?HQ5D"[6D5D2P!W<1N3E+I)CL/T^O-LNR_;"TZLRVV/B"K-0 MAR'F50YJ?Z6_5W>E1DF-M&0>[G[T_1WF^-SWX,/>]8\P>\ID@_8OQ*>Q[Z4> MV>3V%MK=*)*F)&E_[*89O9RT!3:22*7MV1:#QW>2<`.-6!A,]\=O1WXJ MN="&^ZGZ8-P]8@$,\_94&$*B"///J4O%"^5`ZO4[Y8AC!0YC(,AXS]ON!`ZQ MTMP3))-^HAIO3Z$H^:W2Z.')4T>-*$IPLB\>F7:V-CINIUZ<>4TSL%.O^LQ] M%V>J$%Z=UQ1%"&)9Y,E`'%Y(1AJWP&7X6FJ-);8-K+Q[OW1^_FZO#QQQ?!RQ<_/_OC9G,,W1>/]E]#]Z?HW^>S;T.%=O7]A#.+=7/SU_^+#='?;S/ZT/_W9] MY[CU=]],_)\NC^]_>;E8N<]_@M^^N7Y^OKNP=M]N[=4O/\Z^]KR?OOWXXJOG MXQ;B\.P]NO%J$S&SKC7S\>UA]_^.&_8+Q>G9VIM\DN[R;I><_PL##<3O+!7OK:*P%ASQW^5\8=2.:5/16 M42P#N+><'6G8J4?D"A@[B-TA6=CZLB*7)XKY,A@9DFL,VS\=3N,F7\0J"V_0 M^9\!N\.7!VMQ&B@_K:.I1KS29\'`&;CWP[V#==J?!POY#4?L.AT"$B>^A;T5 M/L[+AD);TZ#S+\/T1;Z7F=.51X")!)H4A0PY?*M5GM MJ\XK>`N#('L(-D4S+^A@'K.P#@N]% M20QK0'X7#X]_TS>1EQ$C(45=O\7MFJ?I)[>TCOI#62E2K=>OASL5J]<@6PQ#`[E%"/]3?9^ M2&6]`/`%M&:'VE6+J1I>P4?H'32IQ3)2W7GQ6HH8HGCC02OPD"P&\3`IUZHO MXLG@.%\F:?O3IM),/O+EUNDMEI.:59(FBFO,Z\X.0MHR0JX-O\>;-WI,1K*GN0B8EL!MXY$V<.LY;'I+5_H95J+PXE.Y2R6R8VFWZ_+6X^"6V MEBZT\H"9O=#*H4SP0JN30NCGA58!/M+O1=;MC)D+K354B5QHI3*L?Q=:NV)< MHU>]RR?F"N(V'S;R=#$)>FRK$LX63R^I5Q:Y5+%J%9+AN(E4_--37!499'/) MF=:WF`B=R7Q3BK(=JAD]Y!@D]]9&]I\')X#+Y++6$NTM?DYTDM[7ZD+^)+`; MD41Q^IB7=W=.;-]'?OT].#//GTE+0.%Y-+D=4A53AH5&T<8:S7T:]OZ8^Q3J MZLS]Q,*G'N*FQ51>`@0L?-8>-;?PLTMY;5CX/&!F+7P.98(6_FT*H9\6O@`? MZ89BW.CS=N%Y[D%HI_.U7TM6)K0QY','=I>%CQXN%F!0CXQ_@ M":KQTU]%%@H/6O("B)YQH[0-Q<$1_1YO;7/@%4=*;N< M1#;6^"(\C*_M3KU;/WB(.]C)A"+K8.AM?U-##4/!YVV7(_I!A3A:F M$EFZQOXU`N30%#.3%8SN-'\+OC1L0!/[YTO+Z>2-J`)\/0)$0\U+&)!K8FAG MLZB,Z704C2?%I'UI80VNW)Z*>+OB?Q&%Y@!Q";V@&%`:!!@JZ*"QIU2_45F? MVFF^".XL+^G[>7J'(^Y(NT1LP1JHT!/4 MO!FMWI,W.J<_SJ?7T_%HO@&C\7AQ,]],YS^"Y6(V'4\G:Z-YT:ZE+SM/.^61 MK,8_PS>C5:KT7RS-FO5 MM2D1.>77TEXJ1PB:4-"-%FU`CV;/OPFM3'6<@@0YF,163*""$]AZH]'T$T3J M,D5_G4AQG]4<]2P&WE3'"P'29EV*4,/3SU\C_3R=(PT]`9O1KX;CNS(\RK2N M\`XTZCK#1-%I.JP/%BB/&'Z'(S2GGYZP"#^I^;.6[5+R9M6][^Y@$&)O.CHB M/7AZR"J[V:JDIY2!:]-=JA3R]-DW2)_%AB;2:I/Y9OIV`I:ST=S@$U)-N7RJ M\FBR7^K:3Q9M%QI1F@8CS_E)$,BJ$LN!^9>U]\/O0`R-&(WKW*M^V6V,WOCX MJG)2><5/=AL5M>\2>F&<,R+=C9<^^EI@Y`0D3729-#!MG,9IBD1+8+P54GEJ M^052RZO)9KJ:X(Q.22,;2>NTQ/Q3BJ>-W6M0HJ>*OY/,CRHM.M^24R62E1"* MP1$]30""(D20@NQE?+:I]!3R1$TV5N$+()_?Q`KP?0I\CX0<%VK:NAZ*UN!L M+3D\E?OMR;-?3E9@_7JTFIC5N<(\RI2JV`8HATN9X+M0BFQDF@.=3$(8TI2. M!VA";(+V1V_5*KI M)5)-;T>KZ>AR-D$Z:C-93=8;@+WUS7MSN6XU5F:Z2F%[U'UR,61=J#%!S+K] M;S&R&$*93@:YV?V,7,KQ/:_\)#9(T9].WL186D%TW`26%^([]K[7V(56@:M- M*2H0QRW4'Q)'>3;:3*[`KT7P]&N.Z?;/9F0;\S92DZG:I:TH)C%VH M2QGTNG6F!&T,F4T@``("Y&$(9+/-=(B1EH9BBQBY'5/4I+'?;.$W&)"ZWEO> M\81`KHFC&"2-9>-"!'$U)+[+]'JQ7DXWHQGXY68TF^*"\?7Z!NG)\01<3R:X MCOS'U>B-P9R/%`=/UXZ$-Z=)73@72Q<9^Q[N:PL]NX7"2D70^I(G:@1R%=VSI'1R MNL$YD_BBYGA!KF-.YN6[F`9ZG3;B]JGSJ?K&-O,U?'S30Q4600;D^+B*K5\YW,,%W4K+#1*8YW\$DA-FI M*1T/X@E,%66FS*:.B85Z&N[:E06IV*@X[33S!CYL8="%+''QZ0Z;\(@1:^R< MS@&_Q;/,"Y4(0PM]1^OV0#U@AT]0WUM'2$B[$Z@J$KU=IRKX.5:4[P$RD"8M MIHPD*H/*=E!U@:HMJ-8V]*S`\6^\<`]MY]:!NRO_P7*\3@XN)C+=!Q>+$-;! ME8P?@-P,\%L\Q[R.J65BX>#BKEW=`DK;@*3P1Y^<3F)>=$0ZO3@J!2S)2<<. M0#H:_(;'&TYWDDW^.Y.)3Y"K8%2+BDU3\U9 M+L"3SAP/)-.HAHX)@1)B:5ZPZO>A22@^$]NXUAT'9'V/Q`ZZ5DM4A%HEC$M* MO9Y*KD6NUJ.A',['4\ M&&05CCVQL/E,*R:DF>M5M;5)@NBD]CH_]+CX=/OV/&*XZ<'1)Y_4>L$+`=+7W$F`&E9SB&1JW#J,3`:YV;WI M12[#N5,K%-%]T7L\C,(01N'X$.#T-ZL]?#QH`))AI@V*`LU4$[6Z*`6G9P>= MWV-6Y4(WI$P^7!RB,$)2B@X8]@$00OO+.__Q',&)=3_ZH:SR!7'H4OIBY+!N M1<1?;#Y`-XAO1X0@-]N4],BQ$XN3Q&YH]1-DWPOB/L5#?LB!&8`8$$@A@2FPZR:WUD::HY.(>DJ7/1&-+D'+&)+/R#'1!0_>6EM7;CQZ0D'Y@L?.>B% M:_0#D*$!"1Z01P0B'S"2->;CIZUL&=T%;8\9>@_T=]"YNX_@;O0(`^L.S@_8 M3L4/C+H']%NJ]J+)2PH&)'!`#`AWWJZJ]`%(P)N-C4HNG<9WI=W3VZDW;?C@ MCVPDF`%D-J%EL3;KDX&^[`0&*#7O'12[]YI^TUEXR326RFZ8_NK;R:<]],*X MUI3&L-B?3D<99D:!8J:_7%Q2,^,;<2;`CSCMX*>?X;$U>[L$5E,FDTE`C5$= M#P9D-$##C810:IE2LIHI*]1=M9E8[86CG&D3YSP7FJED^$%#QFIJ:@TH*]?) M@[)=/?66`<1/1B4:@L4+BO>!'X%-)J?*T/0S4]RET1@CMAU:CR"&R5.Q=2ZM MT+%;,A<)+,,'F=2Z)6Q%WL;I=05FCK5U7-(YMB;`EQO9FRA?E7H:$UAKU%R8 MA&S*6R>:^2'3B,//62==0)_@<4];<;P-O9J1K)5J;I=V0J_(+Y!E;^$+!K4V M=3JP:E<;L:K+=%,M:_KBM)X62(QQ_`QQ^='9P=WE\2:$NZDW]1Z17!::5?,^ M!!)T3&&`[1$\P6#0`?\49)!RC!G)FJ-^7GZT'K/3\JB M)?C)W#+ITDSL0:7IPF7ZG/N5%65,5_=]Z6`U^KY4`NKRP4E&`HT&>+@QWY?+ ME-3W9:_0K-]%XC(K:$/G$9L7S.^9X7G%0:CCO_;-/,@6+6_SB%LD4DUJO&9:_Q=9U[DBU#E-S MGB#@N`=Y>2S.L,?5;P0,R,$QZG&(+Y?V=:A:]"X+>ZU!DAMK)J19QXV*=5)>G>XP M\^G0=;"B]G;A&\?S`U*?Q"\`6^9-DW3RH*<1YOIE4D//HKNC5]_%":%I&![@ MCEF>1\8,0#S*\!73'+VT;:ZNIY$U<.V$MN7&T9)K]#O.+3]9TZ`*6IL^9))0 M9S7$$]*0%YEBLF*ZEDMEHX*^8,UZ$IFS<:X-YZ&:E,U6LG:?1XI.>OT,GT!E M$V5OV6'A25*WL>R\AU;06L";"5GGE0H6$:P6)_'P5!7@"=78MWY54,>D5!-P M5ZLU$)`K#L"/I@D7@N7F986P^?(O0UY)W7)JZB,X6Z"WYC5-E)VT2WV6OJ"$ M39?`5A?`3=>7U]F/U$+Z&I5Z2BA+,YQ>^&+DA_J5=:"L7"X#P=PZO8[%2:ZN MT>`EO_0!FC_7"BC^$5E*$$FN%-S"ZQW>B<(4"<:DXDI&S MC3`#P(D.<"($;`DE:8^*&#[((1BD7S@AE14/\$5HB9P[`B2:WR2"NLTF43W3^BXZ MO)`ZO79$V& M#?0<)34^4;-$3LR:Y6'K.O:UZUM16]]4'J2NU&8%,_]#B@<",M)<\H;)@>+7 M4UY5$S5*/L"Q%<$[/VCM-F(1J/YV'P7\?,:3H2`=:_@>(I491=Y7E]9"N@*' MM3I)5IP`ZZLB8U`@F*D@X':V& M;X,#W.5"86KE]?E(9;7$OA_\8JY5.-+-VRK-Z?QRQ#*E$P'R,R2BJ M=!17F9V4R3+07S^D2T&_0O_:(B.1?)O_#U!+`P04````"`!(1`H_;Q`)#007 M``!=F`$`%0`<`&EH8V@M,C`Q,3`V,S!?<')E+GAM;%54"0`#QWI"3L=Z0DYU M>`L``00E#@``!#D!``#M76UOVS@2_G[`_0=?[LL=#JF=9-NT1;N`8R=MVC3) M)FF[Q>&PD"7:5BN++BDE<7_]D7JQ)5F228H4I4#[95O7Y@R?&0X?#LGAFW_L M[_?>`1<@PP-6;[+JV:-_>8M_]_9[([A8WIIV[]SUR+^:GGT/R&?N/4#D[^3? MYYZW?-WO/SP\/#/)5[%I(X"ACTR`Z0>]_?W?>_2_O__M#14R0H"*>-W[2N0, M_5GO8-`[.'Q]-'A]<-C[?#?J'0X.#L(?D5\XMOMC8F#0>UPX+GZ[EQ#V.$'. M,XAF_M4/_G7]56SG?9$T>]#_\]/% MK3D'"V/?=K%GN"85@.W7./CP`IJ&9T.70:]>X3?HW_;CK^W3C_8/#O>/#IX] M8FOO]Q"Y7N\-@@ZX`=->H/IK;[4$;_>PO5@Z5*/@LSD"T[=[]MR<[U,,!R^. M!K2-?])/_B(6P]"Q+8K]B>'0GMS.`?#V>K3ASS?GJ3[8\[D-36J^/OWG?N&O M^[\KU>ZO:P,!UYL#SS8-!U=3-MN8`MW/7:(%N/7(GQ=$%+^^V0;ZO\LQ_^V< M]'T.'0L@?/K3M[W5'6GB$*(C-AU+?M^/A[=<*$<&GI\Y\($?P_4O`\UDZ'4) M/<"F1_!-28Y%VQJPBQW([>^`1_1`IA>$+7*)'T@;*%%[?-+C[LM4@%.#@52O M$U%`NO\)*:'"$\44D>^3@GHH\4Y1713XJ;`J:CQ67!U9OCN&ID_9P]"U3EV/ MS-7G[A2B14!5V10K;2'A34M"]8&Y^2/6*FV&RF)H9%QO"%*=\!`9JP3^>.6UZ577]$W^LM@;;!OSFUG[;!3 M!!<"ON3!8L-"1!CTV[V#9XG8(VZ#6Q.X!K+A\-%6:X:4H(V3UVB%\I&2"WD: MG33R8KA'#7YV\1*8]M0&UA@N#-M5@GVAL$W\U6R"//=+6:(8K\@:@V>#9"AJ MMC\E(EZD_F&E83S$&'@X?R:2XT,9"0U!>FOF2**=!27A*#VB]!0@!*R+$,A" MI0*-/(`P"+[)/>!'/J*]*3-0$57(_:76B)G?"XIY03>U0!YK2Y,WA'72_]$\ MT[WA$`WQT!L9"*UL=_;%<'PE!(E-<'*TU\E!RAPR.7P8X1,WL1-;5S3JW0"B MO6U&>;IM7578=J?,IIMU-V@)>E.W18>F"7VBQ`TP`5&(3*.7P(NZIF16*Y.G M;9FP.]RRX27!D$)6/'?OB7R(5I=`B=52[6L:;SP>F[18&AN-P?/*FP.TT1JK M'6@ETO0R&D[SE:$F)6X*V?(:@:5A6^$QTN;T<4FS=JK#8[ZT5@VS,M0B8_Y6_X#+!NTZ M)K@6VBV%4&2MY]K"8^0^9($2*!=R887A,E^>_C6`6``M0"^RZHMJ`;5*CE+E M8BXE0+OE6/QX.UV9#9_O3MY%K#B.1)W9+N6](X@]?`E=,W0S1:;<+;0%]F1`3@(_K1!* MU<50O>2%V66WHZ?,L,EEF0O;F-B.[=D`DZ%_ZT'S1W3$E?3&-FW@FBNNW1^N M!O7NQA4/)3Y4Q!<(Z3DMT1*$-=PO5=V2/RZ`,Z$G).XN/2N2#319<[;#, M%=420Q8B)2NKM%Z!I%8$U2*4I.2?*XX[>B,OV-NH8^1M"6L' MDRD!2T926GP'(5*LGBEQA\1VF'(7;#+2T8(+BCILV"0>P^?)Z95%H>&J9UG$ M1^,%=&=W`"W&8.)MLD/*AF*!.$TSHN@:GPE!&:L/T1T'RS>]KP8BG,M;!5YJ M.(KV&O(DM=2:1;C)6&H(GKQ>VG28`P.#JXECSP(4L=IANENHMN!;U<`,>$I9 MEU2=2Q5/HGJW)9B=NF#RU+8WL>X`7"QLC^Y(4B\<0=>SW1EQ/46&*Q/7TD!; MBJ",]267727L,C'L*[7)3HP[3`+KQ\PV!I>=:+6K65`,ZSTP'&]NDGZ_)TH2 MW\%DE2O!C-4D:(FJ[$:M")^\K2OQJ`O=0$MU%\ZR,EJU\5B,E(3\@%B^SK)L M"ICA7`>'QJ.I/Z&@DL3=;JEZ-_J+7#F5O6.`3N.MEZ17AL7':.&46W^"360O M`T*W.6FIPLA\"NB^G\]B<4Y(!;(+KT+CNV`6;*I56YO>`,^P76"=&LBE4PA9 M+?L+/]BN"\.4DL4I@]3FCVT6Z.1L;TH:V_4,8/U)77:?+A^X\I:H0@;\9+L0 M!16B"/4"6,E`W)*A-Z?`,.JV4=%U['3;80C_=GS*Q*\A"F#S/&1/?(^&^CM( M4R-DC4PDD]9F*JTJ23/=TVW1`"@?M6)&T'Z_H'BYH"YX[Y2I^;HDBP/LQDU\ M`R=G=^Y-/UN9+_Z'>BKV94LM=P7\N@)^70&_KH!?X4CI"OAU!?S:5\#/<>`# MC2)G$(VA/_&FOK-]]5?EJ4$N!1KC=ELS3RH7R0>JMLL2!3O+"JV]0V([S+L+ M-FWGF!*K>D)>KU#0'2M8X%\#%+Q_H7@7J%!L2RS+`J"^TTT;[0)5\-#WYF39 M]FNSVE%DUBUQFI>KW-;^98T((Q4G+N5$@RWY7O MT7>U:":L%ALFY;75D"G,I-3\T9=2JY!&3@W%DD;HD4I=$ZI)(3>A,_4FD6\,!.+KV>@O0O6T&!6J5 M.%.!J);PH$*DY!Q-$[S6%L9_=Q:5C%/ZGD>QL,9$@U(+EH!58?NSPBGO]?:L M,8%HZ%I1"8A(/26;V?F2-.<$=GIQ:B^[`"P)PU`L@OK+I6,#K-!J61&ZAQN7 MO;;PT5BIYAK!>QL3H'*R^RH,5RI/^[S'9<9RZ+0E5H-;R;3<'ZV>&79CW2TE M0*S6:`DQ#5F$LZTADO"(SWX5#!:$[[A2 M.$]V.?>'NBEE.?KY?16?HN1Z1%]1R$]P%(V%`U6!.M-WM9G0>'>/V<*F5:XR/:8\,SN)(9 MN3]L-NKY?8UP/ZX[F4&M?DWW`8)3GE2O]!CF**7%]UB1`KG:YL4R]PT>-5(! MLJPJ96)O?D1E0^*>GQC8-E4$TWQ!>HJ5J1LJJ0=!\J'5F3#+JC2V'=]3<^VA M2)2^0KQZK+Z&N/8K:5^!/9L3T<-[LJ:;@:U#_UQAGKDQ77/VKM#-CH:T,V1B M8S2CZ*6_F`!T-=U26%FDYE-`E[UYO3LY1CDAUCI!%^@:A95:;C_QJJ`IY:G` M(XI1EALDZKHR%70D53'HCC1T"-'1G@"KV'6I95N:U-M3),4GGM&2+EL"6.X&CODL9+TXGY5GGYX4)9#>'GN5N< MNX$2SXTM`;*A=>HF#P&(KK@4EW#:KMO4=(/EEFH22%;E&:D[6:7X9)7(_9/L MV0$YKS",@8EHB45ZO&]LXW"[C)X.+#H3]#Z,#BH,+$VW5@Q@>9:0?+M&1W6O MD8'G9PY\V..GD;LRAG'3<@M[;;=:/5AZ9GWX=/OW!-5:R--<9K`,(9S9MA]YVI2H1&@T\ZF1!?1Q"5$]6GS&M*UMU_,F7VHSI M-=?:"B#6OB;NZM@H&SB\=6^TQ?2NWEAM?L!4GZS6>6.]'9QPR:OIF>T:I/_N MC%;>HJ_QC6VLSB&89>MB<;7X!KL%M-6QZTJ2:)D[6.N9\&1!I3X]'M\``M8[ M""WJK9?0!8NE`U=@78;X#ADN)GTD9HG7.Z?3*3#5Q)2J*CUMGZIL,!WOHXSF MACL#.-E9C$$0')-/QW+E#_B:;/#BA!<._GW-U^P4Y%8&"2 MJ\708OZ=J3S"@*F4.YI__]N;?^SO]_[[]=.7H__]]T]SZ3]^?_L7+X84[?3R>7?U)8LN?7W\L MOGZ:O+`6Q_;XR[$Y`)?FS8>CQ8^)Y2\O?QH__N-`>S6!UHM3^.%D]>V/5U_+K[A+]\F%W^`[Q/D M83`8@\?3CV/_\M?\(/)%>ZHGL90KHWM%D M'1YL_#078JU7TPO[-XX4B8N;1IJ'`Z+6H%"N24-.%I1NG(J"K.NI@&('OC96 M]:]88Z':M\FK#1:V$+%&N&%AX31*FT5//27FPWJZ8H$/^D':($=5F);VD) M0>PCPS5!G?PQ*_1)^\(6PKK((_O6G:*#E:S2-=\A8AXDF2.8S.!6()"5:O2G MCOF&1>0E'7TN:TQWHH#CZ',I)A4JLRO*#]T`>E7-C.YPU1.Z,S)UY0,Y/;D\ M0F=QE%EY7?1,I+&*CF`,S9^^C0`)+"24>*MKQW"#MRC)ITOZ%24G)-FEM]`! M>+`56,O)=H6"F26GTS5.VWG2-4_;_$.&8?[.15G>_"T^?:_/9\J8OLL::]'T M78I)A2<;9)UR-P&P`D5I5_#5=$0T4/,T4K$P;3NVG,Z;.;5>!)VN]^SC8$.K MV-*`X5I;3SBIG)C+Q+;2PBQPRIR+!8N6+3=Z@@F=4Z+J:!>42%Y-''L6ON^E MPO8U<;#;[:L[/[,3'7=2(F7"#0,M)JY MD[#(>1=-=-]BLPFNRD1I$;J6P$)FRJ`CZR6SNDH)7D(/[''3YBLT,]SHLOFF MOEM8G>(ZH=_Z(KKAK(,4IE?1'8A]!.Z(NB=$P@^N6*Q,>/K6E@&>E>UL*M:V,2JA7'#LB.1"B^4KF-CG+=T+2O?-#)(>]U4<"!01KIP MH[XJT1-J6'QP=A2NN12NBH]QT;..G77LK&-G3>A,_>R,)\@H.O;#+K\A5BKE M5'R`2CH,5"M=&HB\#4UWTJMRHUUM5'X>H2-!C2-!C'[#PWP^L6>HH M7W5B(T%0MY/W5!F0/"_L=NV:,K%U1*DC2LTF2N)11PV;JJ!/8YQR!^.J`GDK M=]Y"4L;GH>OC9U59%U-#74[IZ3$J'@_J$DO-F-\ZOM3QI2;SI;*8HL*C2N6U M),54CEE[\TS1#AG?A1WZO-`<.J3/F&X9>BO"_#9O#JTKA0@Q'>'&._;S]-A/ M54_K&%$S9K".$76,J,F,B#?.*/$R7AU:PISXL6TSFQ(ZH`U<'!YD#ZK?7D,R MB0'/1@&V)\`%4[OZK;S*0JK3EHY@-8Y@R7(]=J+5T:R.9G4TJPF=T7"`6S#: MJ/`V85V:$0Q**9C]5!O(2.>I\:R+7=&2U\%5!2,6ZUNY7NP-/3Y$_, M_M.=9FK*I-:1I(XD-9DD%884%>Y4+*PQ[E3*=$K`:NLAHX'`Z>\3']/"W7@$ M%Q/;#12JFB_B;++;?7MZY$;,J[H]MV;,2QW/Z7A.DWD.6W11X5N,DENRO\:* M8ZMWU40.7T>/!U\;R%O=(FF MS%T=%^JX4).Y4&%(4>).A<(:XTZE)*<$K+:=F1Y#,R@]2=\N(5S-6R6>!>8^ M+U36&%^);):&>".G!>R_PM9NP,RFC;C>I;$HX388F,]F\+Y/?ADZ-_E#UJ<+ M6]432GA,0%VZ&)2*_(`V'"MS1[Y7'>54:UKF?1%PTQAD8C4WHB,?4>7.R%+* M<+X!`YVZUIB$K.KH%K:LKQ2Z`-K%^$3('XGM@VZ&"5W@0O?6(]$^N"^#KWP/ M>X9KD76NK$A2*J-5]F#!+++,;U4M<^U/'-L\:=:F\,L(GL9<"ZY,&;;+4]="0? ME`CKXPIT)`I&I&5D..>$)C]^!"MI,3O3K*Z53(4HG04F@ORE0)8BT6HX(]^` M)40T%TQ76'Y)@H@3]?S66Q12RE&*3/!*.,*$S7^!CD\@0*LSVP%(&OK99MOG M\UO`Q*N>@>A4&;8;-#'P9?`$X/_?$,J"U+= M;_JTS8F!0?#7_P-02P,$%`````@`2$0*/P)'@C]@"0``:4D``!$`'`!I:&-H M+3(P,3$P-C,P+GAS9%54"0`#QWI"3L=Z0DYU>`L``00E#@``!#D!``#M7&US MVK@6_GYG[G_P\FEW=B@0FI)DFLP86?BG(.M)SSJ.C6H6JO%0EQB2L^H M,X$^4*:^A^G9=!AZZ+RT,J=H^4#"<>6H6JU7$*8,8`>6YOUQY"?W=EE88;,` M5G@/&"*GI#`0CB'K`1_2`#AP30Q-)H@X0IV*@%?]5*\N9IC2M9[/]0686N5K MMV-)\$LT!.<`1'!Y"2J60Q-GDA=/1,MBF%=4(T"'GIQ7Y=-%UJ^+Q$%!.`/2@#S&[)*'?AB,0>>R\]","'AHAZ)96 M^'39V/.;!X8?.,A%%Q`Z(?%@MI$J04@" M[AB(6_G5$O$`6]+KAA./*WQ.Z'5>(9B7*\;G1!@EJ/5>2CG`^^5*\3F=R$LD:UTMT=OFBBCBP\#4T_8F.2J/%91X MR!6[?A-X8G>V)A"RDH+<6.MOJ5V6KK\Z^ZOM+_@NRR.0Q1>8W&M$M#)Z;:UG M:6WQR3(Z>ENU^9>FVE%[+4VQKC7-_ES9'"=AEHA"U\`7\O/F,IX/,.^2+;N^ M4C8E=TR\P*P:`[Z-B5VLWGT!C:5W]>G M^2.1W@/!B03KF#?#ICDTB//*>ZW?'R13=OQ&VAKJ=:U?>(LM!%U/$*C$/(O/I]L=L)&IH#2^]IEJ6H/4[0 MH-M5S0?I5?I53[_46RIG2VVUC$'/UGM72I^3V=*U1,X.E*U05MW@K+K+AQJ) MC(F\I&^*^&0_2(K$!M<7/I2<;!PX6.5@BX3J[A!TDLA#77I.,\GJ!Y.OF7S; MYM4\:=MIHMD_RF#2[?*]RK*-UA?E7C5-OB4=8D8>)A*HD%QD$5&K)A(A(KS> MXU1HBJU^3=[_#P1L$9#$0'5W^*[5$DD003UV`TX%#P'ZG:;T^8'T$(SS4)'( MQ:ZP7#M*9$($:U.S=3-.9_\M),CW*'_==^_J?__UU0FBZ0,^/G5?&D_CAQD> MM*/GJT9XVOAR]'U@SZC7>')>JMX-^[/2.5$[>#1MC(VO#D-?[Q_]^^[PD^LW M4/NNX51ASS%OZO[CT(V"W@_P^*='T&Q(W$\:N6G.'FY/#=.KW\"3[F6]XM:` M>S)TS-NKSC'&-R?/C8_U5J/1?.D\T+N'8><6?A^&C,)J&TZU+^VH]S+IS6Z^ M!YIQ[)$AC7I?U#8\:?CJRVU7!4:U.?K>NK^R!KCZA;3A^/S\;Z5EF?.W0.^P MZ))7W>X\I%9/7'@GK_LPSPGCL^\A%N:D(H6+//E)[6,B'2)KN5--76UV-,Z+ MK9F:92MB:TZ\A#B0DD!*&BN[4Y7CY$-N56[.'7GET%?%P'";E"D*D-M>&U==MM:/<#M2.+DZVEC4PY=N8WR=<.,NT1!R_=%@E.?#O4,N0=D-8[7`#MQTX&/3D2@>0+"9D?6(.F MI=T.1`JJW1WNA';1TB9.)&ZH5>QJF"$VT_&(A+X$$5.4V6-'.*ING9P7HRE\ M."4>3UD9\-_#UN?*6J%,7%-3V2JJ6=;:(#\@(5-P8DE46MU57*[5(8X<+T-$ M?"LOY,JBJ5P[*M=K'Z;47=8<[`E#*!Y7/>P'8R'W)AC9!58I0"2(558Y=>QEHCVM,QVJ5L>XVQ*"=.<"M/4/OT\D-42M_W`$-S+P),#46*) M6=[ELA`0DQ]OFV%>\B9G/2^U"'8AYLZ95A^A#BD3%94E):X*DL6-9[P-X;'. MH"^\MZ2`>:_S$@LC4<\C>P7IMOW`Z"V)D51[F]T*[N98G4K8Y6&!4SL*626'3:J8Z?HFO\<_/2])VG[6E9"&",C@#'R(BWL_3%G+0R#36"H M30,Q9'&43$25I48?AK)PJ0T8*(X:B:BRU.@02KE0B_@^P5)491SW,&)B>IOL MX0?%L<(_H=1&UK9NQ7N(QA,^G/K$76$,Y934B)@X,HA1BV.:W$BS%LVN'6&[ MHJ\X!O@)[)E+8->XB]*X`KG)_I`S,K-%W\N0^/.(P%>3^!%6T?*TO$BS/$!U MOT>4B09J$Q,Z!#O(@SW(Q-9C$_Y!3-,/R1-R^?ED-J"B-KG0=GE_E=*SH`G` M8TA7I>-3#W:+F=KOAS==[]6EI^,G2(NZ&'(CS0P3JX-<(LS/Z/\/ZF8AS5+7 MBH(@;@#>RJUM<;3A#KCUK$-A\56>!?` M5']I\KWRG(X+%-73':_M*P=5_!RTR_2#^M98-IH6V0RZ4Z5=\ MV^<)[,K&)N`95!_,XI2K>'J_&7FJ+?K\M!'OK?*ZI4^X`&0HE'V:$,,1*GB\ M^&D-TD]0&@BQN(!87.$44/O=$#/=O1E1A"&E+>(/>305LQ6:[#WQIBY[$WKB M9-T'/'C:(K[ MB"T")4\HQ:D)\K2QX*'^C;C3-S.+3PQ_1+Q!>RIJ>-L),7,SRZK\*8Z2N5!* MMY7E-7%Q0;R^_P=02P$"'@,4````"`!(1`H_F6VC`]F<```6J`8`$0`8```` M```!````I($`````:6AC:"TR,#$Q,#8S,"YX;6Q55`4``\=Z0DYU>`L``00E M#@``!#D!``!02P$"'@,4````"`!(1`H_5,CG&\(*``"EA```%0`8```````! M````I($DG0``:6AC:"TR,#$Q,#8S,%]C86PN>&UL550%``/'>D).=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`2$0*/^[[2?L[%0``;V4!`!4`&``````` M`0```*2!-:@``&EH8V@M,C`Q,3`V,S!?9&5F+GAM;%54!0`#QWI"3G5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`$A$"C^@5MJ6)"@``,'R`0`5`!@````` M``$```"D@;^]``!I:&-H+3(P,3$P-C,P7VQA8BYX;6Q55`4``\=Z0DYU>`L` M`00E#@``!#D!``!02P$"'@,4````"`!(1`H_;Q`)#007``!=F`$`%0`8```` M```!````I($RY@``:6AC:"TR,#$Q,#8S,%]P&UL550%``/'>D).=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`2$0*/P)'@C]@"0``:4D``!$`&``` M`````0```*2!A?T``&EH8V@M,C`Q,3`V,S`N>'-D550%``/'>D).=7@+``$$ ?)0X```0Y`0``4$L%!@`````&``8`&@(``#`'`0`````` ` end XML 23 R13.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 7 - RETIREMENT PLAN
3 Months Ended
Jun. 30, 2011
Pension and Other Postretirement Benefits Disclosure [Text Block]
NOTE 7 - RETIREMENT PLAN

The Company has a 401(k) plan for its employees. All employees with 90 days of service are eligible to participate, unless they are covered by a collective bargaining agreement which precludes coverage. The Company matches employee contributions up to 3% of the employee's compensation, subject to IRS limits. During the three months ended June 30, 2011 and 2010, the Company incurred expenses of $774 and $758, respectively, which are included in salaries and benefits in the accompanying unaudited condensed consolidated statements of operations.  At June 30 and March 31, 2011, accrued compensation and benefits in the accompanying unaudited condensed consolidated balance sheets included $1.6 million and $3.8 million, respectively, in accrued employer contributions.

XML 24 R6.htm IDEA: XBRL DOCUMENT  v2.3.0.11
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)
3 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Net loss $ (2,735) $ (1,778)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization of property and equipment 1,090 1,044
Provision for doubtful accounts 9,697 8,908
Amortization of debt issuance costs 410 130
Loss on warrants 3,270 1,900
Noncash share-based compensation expense   14
Changes in operating assets and liabilities:    
Accounts receivable (3,471) (5,831)
Inventories of supplies (150) (90)
Due from governmental payers 932 4,979
Prepaid income taxes (5,200)  
Prepaid expenses - hospital quality assurance fees (15,100)  
Hospital quality assurance fees receivable 1,815  
Prepaid insurance, other prepaid expenses and current assets, and other assets (1,835) (2,496)
Accounts payable (3,799) (3,322)
Accrued compensation and benefits (1,696) (3,253)
Unearned revenues - hospital quality assurance fees 17,245  
Income taxes payable (6,306)  
Accrued insurance retentions and other current liabilities 418 1,098
Net cash provided by (used in) operating activities (5,415) 1,303
Cash flows from investing activities:    
Decrease (increase) in restricted cash 12 (6)
Additions to property and equipment (419) (571)
Net cash used in investing activities (407) (577)
Cash flows from financing activities:    
Proceeds from revolving line of credit, net 919  
Noncontrolling interests distributions (500) (1,250)
Payments on capital lease obligations (289) (200)
Net cash provided by (used in) financing activities 130 (1,450)
Net decrease in cash and cash equivalents (5,692) (724)
Cash and cash equivalents, beginning of period 20,539 10,159
Cash and cash equivalents, end of period 14,847 9,435
Supplemental information:    
Cash paid for interest 2,191 1,701
Cash paid for income taxes $ 6,300  
XML 25 R9.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 3 - DEBT
3 Months Ended
Jun. 30, 2011
Debt Disclosure [Text Block]
NOTE 3 - DEBT

On April 13, 2010 (the “Effective Date”), the Company entered into an Omnibus Credit Agreement Amendment (the “Omnibus Amendment”) with SPCP Group IV, LLC and SPCP Group, LLC (together, “Silver Point”), Silver Point Finance, LLC, as the Lender Agent, PCHI, Ganesha Realty LLC (“Ganesha”), Dr. Chaudhuri and KPC Resolution Company (“KPC”).  KPC and Ganesha are companies owned and controlled by Dr. Chaudhuri, who is the majority shareholder of the Company.  Ganesha is a member of PCHI with a 49% membership interest in PCHI.

The Company entered into the Omnibus Amendment in connection with the Loan Purchase and Sale Agreement, dated as of January 13, 2010, as amended, by and between KPC and the previous lender’s receiver.  Under the Loan Purchase Agreement and as approved by the Court on April 2, 2010, KPC agreed to purchase all of the Credit Agreements from Medical Capital Corporation’s receiver for $70.0 million.  Concurrent with the closing of the Loan Purchase Agreement, KPC sold its interest in the Credit Agreements to Silver Point, and KPC purchased from Silver Point a 15% participation interest in the Credit Agreements.  On April 13, 2010, concurrent with the effectiveness of the Omnibus Amendment and the closing of the Loan Purchase Agreement, Silver Point acquired all of the Credit Agreements, including the security agreements and other ancillary documents executed by the Company in connection with the Credit Agreements, and became the “New Lender” under the Credit Agreements.

The following are material terms of the Omnibus Amendment:

 
The stated maturity date under each Credit Agreement was changed to April 13, 2013.  The Credit Agreements were otherwise due to mature on October 8, 2010.
     
 
Affirming release of prior claims between the Company and the previous lender’s receiver, Silver Point agreed to waive any events of default that had occurred under the Credit Agreements and waived claims to accrued and unpaid interest and fees of $6.4 million under the Credit Agreements as of April 13, 2010.
     
 
The $80.0 million Credit Agreement was amended so that the $45.0 million term note (the “$45.0 million Loan”) and $35.0 million non-revolving line of credit note (the “$35.0 million Loan”) will each bear a fixed interest rate of 14.5% per year.  These loans previously bore interest rates of 10.25% and 9.25%, respectively.  In addition, the Company agreed to make certain mandatory prepayments of the $35.0 million Loan when it received proceeds from certain new financing of its accounts receivable or provider fee funds from Medi-Cal under the Hospital Quality Assurance Fee program (“QAF”) (Note 11).  The $35.0 million non-revolving line of credit was refinanced on August 30, 2010 (see below).

 
The $50.0 million Revolving Credit Agreement was amended so that Silver Point will, subject to the terms and conditions contained therein, make up to $10.0 million in new revolving funds available to the Company for working capital and general corporate purposes.  Each advance under the $50.0 million Revolving Credit Agreement will bear interest at an annual rate of Adjusted LIBOR (calculated as LIBOR subject to certain adjustments, with a floor of 2% and a cap of 5%) plus 12.5%, compared to an interest rate of 24.0% that was previously in effect under the $50.0 million revolving credit agreement.  In addition, the Company agreed to make mandatory prepayments of the $50.0 million Revolving Credit Agreement under the conditions described above with respect to the $80.0 million Credit Agreement.  The financial covenants under the $50.0 million Revolving Credit Agreement were also amended to increase the required levels of minimum EBITDA (as defined in the Omnibus Amendment) from the levels previously in effect under the $50.0 million Revolving Credit Agreement. This $50.0 million revolving line of credit was refinanced on August 30, 2010 (see below).
     
 
The $10.7 million Credit Agreement was amended so that the $10.7 million convertible term note will bear a fixed interest rate of 14.5% per year, compared to the interest rate of 9.25% previously in effect and to eliminate the conversion feature of the loan.  In addition, the Company agreed to make mandatory prepayments of the $10.7 million Credit Agreement under the conditions described above with respect to the $80.0 million Credit Agreement. This $10.7 million term note was refinanced on August 30, 2010 (see below).

In connection with the sale of the Credit Agreements, all warrants and stock conversion rights issued to the previous lender were cancelled.  In connection with the Omnibus Amendment, the Company issued new warrants (Note 4).

On August 30, 2010, the Company (excluding PCHI) entered into a Credit and Security Agreement (the “New Credit Agreement”) with MidCap Financial, LLC, a commercial finance lender specializing in loans to middle market health care companies, and Silicon Valley Bank (collectively, the “AR Lender”).

Under the New Credit Agreement, the AR Lender committed to provide up to $40.0 million in loans to the Company under a secured revolving credit facility (the “New Credit Facility”), which may be increased to up to $45.0 million upon the Company’s request, if the AR Lender consents to such increase.  Upon execution of the New Credit Agreement, the AR Lender funded approximately $39.7 million of the New Credit Facility, which funds were used primarily to repay approximately $35.0 million in loans outstanding to affiliates of Silver Point (“Term Lender”).  Upon such repayment, each of the Company’s $35.0 million non-revolving line of credit loan, $50.0 million revolving credit agreement and $10.7 million credit agreement with the Term Lender were fully repaid and terminated.  The only loan currently outstanding to the Term Lender consists of a $45.0 million Term Note issued under the Company’s $80.0 million Credit Agreement.

The New Credit Facility is secured by a first priority security interest on substantially all of the Company’s assets, including the equity interests in all of the Company’s subsidiaries (excluding PCHI).  The availability of the AR Lender’s commitments under the New Credit Facility is limited by a borrowing base tied to the Company’s eligible accounts receivable and certain other availability restrictions.

Loans under the New Credit Facility accrue interest at LIBOR (subject to a 2.5% floor) plus 5.0% per annum, subject to a default rate of interest and other adjustments provided for in the New Credit Agreement.  For purposes of calculating interest, all payments the Company makes on the New Credit Facility are subject to a six business day clearance period. The Company also pays a collateral management fee of .0625% per month on the outstanding balance (or a minimum balance amount equal to 85% of the monthly average borrowing base (the “Minimum Balance Amount”), if such amount is greater than the outstanding balance), a monthly minimum balance fee equal to the highest interest rate applicable to the loans if the Minimum Balance Amount is greater that the outstanding balance, and an unused line fee equal to .042% per month of the average unused portion of the New Credit Facility.  The Company paid to the AR Lender a non-refundable origination fee of 1.0% of the AR Lender’s commitments under the New Credit Facility at closing.

The New Credit Agreement contains various affirmative and negative covenants and customary events of default, including payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to similar obligations, events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, and the occurrence of events which have a material adverse effect on the Company.

Amendment to $80.0 million Credit Agreement – Concurrently with the execution of the New Credit Agreement, on August 30, 2010 the Company entered into an amendment to its existing $80.0 million Credit Agreement, as amended (the “Original Credit Agreement”), with the Term Lender, PCHI, and Ganesha  (the “Amendment”).  Under the Amendment, the Company agreed with the Term Lender to the following material changes to the Original Credit Agreement:

 
In the event of a mandatory prepayment of the Company’s accounts receivable based financing facility under the Original Credit Agreement, the outstanding loans under such agreement shall not be required to be prepaid below $10.0 million.  There is also a floor of $10.0 million below which commitments under such accounts receivable based facility would not be mandatorily reduced as a result of such prepayment.
     
 
The Original Credit Agreement was amended to add an affirmative covenant requiring the Company to deliver financial statements and other financial and non-financial information to the Term Lender on a regular basis, and a negative covenant requiring that the Company maintain a minimum fixed charge coverage ratio of 1.0 and minimum levels of earnings before interest, tax, depreciation and amortization (“EBITDA”).
     
 
The Company agreed to the provisions of an Intercreditor Agreement executed on August 30, 2010 by and between the AR Lender and the Term Lender with respect to shared collateral of the Company that is being pledged under both the New Credit Agreement and the Original Credit Agreement.  Under the Intercreditor Agreement, among other things the Term Lender consented to the AR Lender having a first priority lien on substantially all of the Company’s assets while the Term Lender retained a second lien on such assets, in addition to the Term Lender’s first priority lien on the Company’s leased properties owned by PCHI.

On October 29, 2010, the Company entered into Amendment No. 1 (the “Amendment”) to the New Credit Agreement, dated as of August 30, 2010, by and among the Company and the AR Lender.

Under the Amendment, the AR Lender committed to increase the total revolving loan commitment amount under the New Credit Agreement from $40.0 million to $45.0 million, and the Company agreed to pay to the AR Lender a non-refundable origination fee of 1.0% of the AR Lender’s increased commitment under the Amendment, or $50.

Also under the Amendment, the AR Lender agreed to allow the inclusion in Eligible Accounts that are used to determine the Company’s Borrowing Base of up to $33.6 million in aggregate federal or state matching payments to the Company related to QAF (Note 11), which amount was increased from $11.8 million for the first matching payment.

In addition, the optional prepayment and permanent commitment reduction provisions of the New Credit Agreement were amended to change the minimum Revolving Loan Commitment Amount to $20.0 million from $5.0 million.  In addition, the prepayment fee calculation under the New Credit Agreement was changed so that the prepayment fee is based on $40.0 million rather than the amount of the permanent revolving loan commitment reduction amount.

Lastly, under the Amendment, in the event the Company permanently reduces its Revolving Loan Commitment Amount to $20.0 million (and assuming there is no Event of Default at the time), the Company would be permitted to transfer funds that are swept into the Lender’s account from the Company’s lockbox accounts to a different bank account designated by the Company. Effective March 1, 2011, the Company reduced its Revolving Loan Commitment Amount to $20.0 million.  Beginning in April 2011, the funds that were previously swept into the Lender’s account were swept directly to the Company’s main account.

As of June 30, 2011, the Company had the following Credit Agreements:

 
A $45.0 million Term Note issued under the $80.0 million Credit Agreement, bearing a fixed interest rate of 14.5% per year ($45.0 million outstanding balance at June 30, 2011). If any event of default occurs and continues, the lender can increase the interest rate to 19.5% per year.
     
 
A $20.0 million Revolving Credit Agreement, bearing an interest rate of 5.0% plus LIBOR, with a 2.5% floor, per year (7.5% at June 30, 2011) and an unused commitment fee of 0.625% per year ($20.0 million outstanding balance at June 30, 2011).  For purposes of calculating interest, all payments the Company makes on the New Credit Facility are subject to a six business day clearance period.  As of June 30, 2011, the Company was in compliance with all financial covenants.

The Company's outstanding debt consists of the following:

   
June 30,
 2011
   
March 31,
 2011
 
             
Current: 
               
Revolving line of credit 
 
$
20,000
   
$
19,081
 
                 
 Noncurrent:
               
 Secured term note
 
$
45,000
   
$
45,000
 

XML 26 R10.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 4 - COMMON STOCK WARRANTS
3 Months Ended
Jun. 30, 2011
Derivative Instruments and Hedging Activities Disclosure [Text Block]
NOTE 4 - COMMON STOCK WARRANTS

On April 13, 2010, the Company issued warrants (the “Omnibus Warrants”) to purchase its common stock for a period of three years at an exercise price of $0.07 per share in the following denominations: 139.0 million shares to KPC or its designees and 96.0 million shares to the Term Lender or its designees. The Omnibus Warrants also provide the holders with certain pre-emptive, information and registration rights. As of April 13, 2010, the Company recorded warrant expense and the related warrant liability of $2.9 million, representing fair value.  As of June 30, 2011, the fair value of the Omnibus Warrants was $2.0 million.

In addition, on April 13, 2010, the Company issued a three-year warrant (the “Release Warrant”) to acquire up to 170.0 million shares of common stock at $0.07 per share to Dr. Chaudhuri who facilitated a release enabling the Company to recover amounts due from the Company’s prior lender and a $1.0 million reduction in principal of its outstanding debt, among other benefits to the Company. As a result, the Company recorded the fair value of the Release Warrant ($2.1 million) as an offsetting cost of the recovery of amounts due from the Company’s prior lender. The Release Warrant also provides the holder with certain pre-emptive, information and registration rights. As of June 30, 2011, the fair value of the Release Warrant was $1.4 million.

The Omnibus Warrants and the Release Warrant are collectively referred to as the “April Warrants.” The net loss recorded related to the April Warrants for the three months ended June 30, 2011 and 2010 was $3.3 million and $1.9 million, respectively.

The fair value of warrants issued by the Company is estimated using the Black-Scholes valuation model, which the Company believes is the appropriate valuation method under the circumstances. Since the Company’s stock is thinly traded, the expected volatility is based on an analysis of the Company's stock and the stock of eight other publicly traded companies that own hospitals.

The risk-free interest rate is based on the average yield on U.S. Treasury notes with maturity commensurate with the terms of the warrants. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not anticipate paying cash dividends in the foreseeable future.  The assumptions used in the Black-Scholes valuation model are as follows.

   
June 30, 2011
   
April 13, 2010
 
             
Expected dividend yield
   
0.0%
     
0.0%
 
Risk-free interest rate
   
0.4%
     
1.7%
 
Expected volatility
   
43.0%
     
68.4%
 
Expected term (in years)
   
1.8
     
3.0
 

XML 27 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 28 R18.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 12 - COMMITMENTS AND CONTINGENCIES
3 Months Ended
Jun. 30, 2011
Commitments and Contingencies Disclosure [Text Block]
NOTE 12 - COMMITMENTS AND CONTINGENCIES

GUARANTEE - At June 30, 2011, the Company accrued $1.8 million for a guarantee extended to a state supported teaching institution to accept the transfer of an uninsured patient for a necessary higher level of care.  The agreement and the institution’s practice are being reviewed.

OPERATING LEASES - On April 13, 2010, the Company and PCHI entered into a Second Amendment to Amended and Restated Triple Net Hospital Building Lease (the “2010 Lease Amendment”).  Under the 2010 Lease Amendment, the annual base rent to be paid by the Company to PCHI was increased from $5.4 million to $7.3 million, but if PCHI refinances the $45.0 million Term Note, the annual base rent will increase to $8.3 million. This lease commitment with PCHI is eliminated in consolidation.

CAPITAL LEASES - In connection with the Hospital Acquisition, the Company also assumed the leases for the Chapman facility, which include buildings and land with terms that were extended concurrently with the assignment of the leases to December 31, 2023. The Company leases equipment under capital leases expiring at various dates through December 2015. Assets under capital leases with a net book value of $7.1 million and $7.5 million are included in the accompanying unaudited condensed consolidated balance sheets as of June 30 and March 31, 2011, respectively. Interest rates used in computing the net present value of the lease payments are based on the interest rates implicit in the leases.

INSURANCE - The Company accrues for estimated general and professional liability claims, to the extent not covered by insurance, when they are probable and reasonably estimable. The Company has purchased as primary coverage a claims-made form insurance policy for general and professional liability risks. Estimated losses within general and professional liability retentions from claims incurred and reported, along with incurred but not reported (“IBNR”) claims, are accrued based upon projections and are discounted to their net present value using a weighted average risk-free discount rate of 5%. To the extent that subsequent claims information varies from estimates, the liability is adjusted in the period such information becomes available. As of June 30 and March 31, 2011, the Company had accrued $12.6 million and $14.0 million, respectively, which is comprised of $5.7 million and $6.6 million, respectively, in incurred and reported claims, along with $6.9 million and $7.4 million, respectively, in estimated IBNR.  Estimated insurance recoveries of $2.2 million and $2.7 million are included in other prepaid expenses and current assets in the accompanying unaudited condensed consolidated balance sheets as of June 30 and March 31, 2011, respectively.

The Company has also purchased occurrence coverage insurance to fund its obligations under its workers' compensation program. The Company has a "guaranteed cost" policy, under which the carrier pays all workers' compensation claims, with no deductible or reimbursement required of the Company. The Company accrues for estimated workers' compensation claims, to the extent not covered by insurance, when they are probable and reasonably estimable. The ultimate costs related to this program include expenses for deductible amounts associated with claims incurred and reported in addition to an accrual for the estimated expenses incurred in connection with IBNR claims. Claims are accrued based upon projections and are discounted to their net present value using a weighted average risk-free discount rate of 5%. To the extent that subsequent claims information varies from estimates, the liability is adjusted in the period such information becomes available. As of June 30 and March 31, 2011, the Company had accrued $770 and $836, respectively, comprised of $392 and $434, respectively, in incurred and reported claims, along with $378 and $402, respectively, in estimated IBNR.

In addition, the Company has a self-insured health benefits plan for its employees. As a result, the Company has established and maintains an accrual for IBNR claims arising from self-insured health benefits provided to employees. The Company's IBNR accruals at June 30 and March 31, 2011 were based upon projections. The Company determines the adequacy of this accrual by evaluating its limited historical experience and trends related to both health insurance claims and payments, information provided by its insurance broker and third party administrator and industry experience and trends. The accrual is an estimate and is subject to change. Such change could be material to the Company's unaudited condensed consolidated financial statements. As of June 30 and March 31, 2011, the Company had accrued $2.0 million and $1.8 million, respectively, in estimated IBNR. The Company believes this is the best estimate of the amount of IBNR relating to self-insured health benefit claims at June 30 and March 31, 2011.

The Company has also purchased umbrella liability policies with aggregate limits of $25 million. The umbrella policies provide coverage in excess of the primary layer and applicable retentions for insured liability risks such as general and professional liability, auto liability, and workers compensation (employers liability).

As of June 30, 2011, the Company finances various insurance policies at an interest rate of 4.03% per annum. The Company incurred finance charges relating to such policies of $12.4 and $16.7 for the three months ended June 30, 2011 and 2010, respectively. As of June 30 and March 31, 2011, the accompanying unaudited condensed consolidated balance sheets include the following balances relating to the financed insurance policies.

   
June 30,
2011
   
March 31,
2011
 
             
Prepaid insurance
 
$
2,282
   
$
3,108
 
                 
Accrued insurance premiums
 
$
1,523
   
$
1,951
 
(Included in other current liabilities)
               

CLAIMS AND LAWSUITS – The Company and the Hospitals are subject to various legal proceedings, most of which relate to routine matters incidental to operations. The results of these claims cannot be predicted, and it is possible that the ultimate resolution of these matters, individually or in the aggregate, may have a material adverse effect on the Company's business (both in the near and long term), financial position, results of operations, or cash flows. Although the Company defends itself vigorously against claims and lawsuits and cooperates with investigations, these matters (1) could require payment of substantial damages or amounts in judgments or settlements, which individually or in the aggregate could exceed amounts, if any, that may be recovered under insurance policies where coverage applies and is available, (2) cause substantial expenses to be incurred, (3) require significant time and attention from the Company's management, and (4) could cause the Company to close or sell the Hospitals or otherwise modify the way its business is conducted. The Company accrues for claims and lawsuits when an unfavorable outcome is probable and the amount is reasonably estimable.

The following is a summary of material developments in the matter involving Orange County Physicians Investment Network, LLC (“OC-PIN”) that was identified in our Form 10-K filed on June 24, 2011.  There have been no material developments in the other matters identified in the Form 10-K.

On April 24, 2009, a conglomeration of several OC-PIN members led by Ajay G. Meka, M.D. filed a lawsuit against Dr. Shah, other OC-PIN members, and various attorneys, alleging breach of fiduciary duty and seeking damages as well as declaratory and injunctive relief relating to the control of OC-PIN.  After a number of demurrers were filed by the defendants, Plaintiffs filed a Sixth Amended Complaint on May 5, 2011, to which the Company is not a party.  On May 19, 2011, Judge Nancy Wieben-Stock appointed Dr. Anil Shah and Dr. John Glavinovich as interim managers of OC-PIN and signed a formal order to this effect on June 27, 2011.  On July 20, 2011, OC-PIN’s attorney placed a demand on the Company to seat two directors – Mr. Brahmbhatt himself and one AmerZarka, M.D. – on the Board of Directors.  The Company declined this request based on its non-compliance with the Global Settlement Agreement and asked for additional information.  On August 3, 2011, the Company filed a lawsuit in the Orange County Superior Court asking for declaratory relief as to how it must respond to this request.

XML 29 R11.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 5 - INCOME TAXES
3 Months Ended
Jun. 30, 2011
Income Tax Disclosure [Text Block]
  
NOTE 5 - INCOME TAXES

The utilization of NOL and credit carryforwards is limited under the provisions of the IRC Section 382 and similar state provisions. Section 382 of the IRC of 1986 generally imposes an annual limitation on the amount of NOL carryforwards that may be used to offset taxable income where a corporation has undergone significant changes in stock ownership. In fiscal year 2009, the Company entered into the amended purchase agreement which resulted in a change in control. The Company conducted an analysis and determined that it is subject to significant IRC Section 382 limitations. For both Federal and State tax purposes, the Company's utilization of NOL and credit carryforwards is subject to significant IRC Section 382 limitations. The Company evaluates its ability to utilize the net operating losses each period with regard to the limitations imposed under IRC 382 and also considering the continuing expiration of statutes of limitation for prior years; and in the prior year determined that a portion of the federal and state net operating losses were no longer realizable, and removed from the schedule of deferreds those net operating losses in excess of the IRC 382 limitation and also considering prior years statutes now closed.

The difference between the reported income tax benefit and the amount computed by multiplying income before income tax benefit in the accompanying unaudited condensed consolidated statements of operations for the three months ended June 30, 2011 and 2010 by the statutory federal income tax rate primarily relates to the impact of a full valuation allowance reserving the net deferred assets, permanently nondeductible expenses, state and local income taxes, and variable interest entity.

The Company received QAF (Note 11) payments in the first quarter of the current fiscal year and expects additional payments in subsequent periods.  The application of FIN 18 requires the Company to compute the interim period income tax expense (benefit) by applying the estimated annual effective tax rate to the first quarter income (loss) from continuing operations, which resulted in the recognition of a tax benefit for the first quarter.

The Company evaluated its historical and projected sources of income to determine the extent to which the net deferred tax assets projected at June 30, 2011 could be realized, and based on this analysis the Company concluded that there was not sufficient positive evidence to support the realization of the net deferred tax assets, and therefore will continue to maintain a full valuation allowance against its net deferred assets for the three months ended June 30, 2011.

The Company’s California Enterprise Zone credits are currently under examination by the California taxing authority.  As a result of the examination, the Company recorded a liability of approximately $18.9 million for unrecognized tax benefits.  The Company's utilization of these credits is also subject to significant IRC Section 383 limitations, and these limitations have been incorporated into the tax provision calculation.

PCHI TAX STATUS - PCHI is a limited liability company. PCHI's taxable income or loss will flow through to its owners and be their separate responsibility. Accordingly, the accompanying unaudited condensed consolidated financial statements do not include any amounts for the income tax expense or benefit, or liabilities related to PCHI's income or loss.

XML 30 R5.htm IDEA: XBRL DOCUMENT  v2.3.0.11
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY (USD $)
3 Months Ended
Jun. 30, 2011
Mar. 31, 2011
Balance $ (21,796) $ (18,561)
Net income (loss) (2,735)  
Noncontrolling interests distributions (500)  
Common Stock [Member]
   
Balance 255 255
Balance (in Shares) 255,307 255,307
Additional Paid-in Capital [Member]
   
Balance 62,911 62,911
Other Additional Capital [Member]
   
Balance (882) (882)
Retained Earnings [Member]
   
Balance (82,150) (79,280)
Net income (loss) (2,870)  
Noncontrolling Interest [Member]
   
Balance (1,930) (1,565)
Net income (loss) 135  
Noncontrolling interests distributions $ (500)  
XML 31 R7.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 1 - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Jun. 30, 2011
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
NOTE 1 - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION - The accompanying unaudited condensed consolidated financial statements of Integrated Healthcare Holdings, Inc. and its wholly owned subsidiaries (the "Company") have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial reporting. Accordingly, the accompanying statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, these statements include all adjustments that are of a normal and recurring nature necessary to present fairly the Company’s consolidated financial position, results of operations and cash flows. The results of operations for the three months ended June 30, 2011 are not necessarily indicative of the results for the entire 2012 fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2011 filed with the SEC on June 24, 2011.

The Company has determined that Pacific Coast Holdings Investment, LLC ("PCHI") (Note 9), is a variable interest entity as defined by GAAP and, accordingly, the financial statements of PCHI are included in the accompanying unaudited condensed consolidated financial statements.

All significant intercompany accounts and transactions have been eliminated in consolidation. Unless otherwise indicated, all amounts included in these notes to the consolidated financial statements are expressed in thousands (except per share amounts, percentages and stock option prices and values).

LIQUIDITY - As of June 30 and March 31, 2011, the Company had a total stockholders’ deficiency of $21.8 million and $18.6 million, respectively, and a working capital deficit of $20.6 million and $21.3 million, respectively.  For the three months ended June 30, 2011 and 2010, the Company had a net loss of $2.9 million and $1.9 million, respectively. At June 30, 2011, the Company had no additional availability under its revolving credit facility (Note 3).

DESCRIPTION OF BUSINESS - Effective March 8, 2005, the Company acquired four hospitals (the "Hospitals") from subsidiaries of Tenet Healthcare Corporation (the "Acquisition"). The Company owns and operates the four community-based hospitals located in southern California, which are:

 
282-bed Western Medical Center in Santa Ana
 
188-bed Western Medical Center in Anaheim
 
178-bed Coastal Communities Hospital in Santa Ana
 
114-bed Chapman Medical Center in Orange

RECLASSIFICATION FOR PRESENTATION - Certain amounts previously reported have been reclassified to conform to the current period's presentation with no impact on the reported net loss of the Company.

CONCENTRATION OF RISK - The Hospitals are subject to licensure by the State of California and accreditation by the Joint Commission. Loss of either licensure or accreditation would impact the ability to participate in various governmental and managed care programs, which provide the majority of the Company's revenues.

Substantially all net operating revenues come from external customers. The largest payers are Medicare and Medicaid, which combined accounted for 55% and 57% of the net operating revenues for the three months ended June 30, 2011 and 2010, respectively. No other payers represent a significant concentration of the Company's net operating revenues.

The Company receives all of our inpatient services revenue from operations in Orange County, California. The economic conditions of this market could affect the ability of our patients and third-party payers to reimburse us for our services, through its effect on disposable household income and the tax base used to generate state funding for Medicaid programs.

USE OF ESTIMATES - The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Principal areas requiring the use of estimates include third-party cost report settlements, income taxes, accrued insurance retentions and self-insurance reserves, and net patient receivables. Management regularly evaluates the accounting policies and estimates that are used. In general, management bases the estimates on historical experience and on assumptions that it believes to be reasonable given the particular circumstances in which its Hospitals operate. Although management believes that all adjustments considered necessary for fair presentation have been included, actual results may materially vary from those estimates.

REVENUE RECOGNITION - Net operating revenues are recognized in the period in which services are performed and are recorded based on established billing rates (gross charges) less estimated discounts for contractual allowances, principally for patients covered by Medicare, Medicaid, managed care, and other health plans. Gross charges are retail charges based on the Company’s Charge Description Master. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and therefore are not displayed in the unaudited condensed consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the federal government and state government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop-loss payments). Because Medicare requires that a hospital's gross charges be the same for all patients (regardless of payer category), gross charges are also what the Hospitals charge all other patients prior to the application of discounts and allowances.

Revenues under the traditional fee-for-service Medicare and Medicaid programs are based primarily on prospective payment systems. Discounts for retrospectively cost based revenues and certain other payments, which are based on the Hospitals' cost reports, are estimated using historical trends and current factors. Cost report settlements for retrospectively cost-based revenues under these programs are subject to audit and administrative and judicial review, which can take several years until final settlement of such matters are determined and completely resolved. Estimates of settlement receivables or payables related to a specific year are updated periodically and at year end and at the time the cost report is filed with the fiscal intermediary. Typically no further updates are made to the estimates until the final Notice of Program Reimbursement is received, at which time the cost report for that year has been audited by the fiscal intermediary. There could be several years’ time lag between the submission of a cost report and receipt of the Final Notice of Program Reimbursement. Since the laws, regulations, instructions and rule interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates recorded by the Hospitals could change by material amounts. The Company has established settlement receivables of $994 and $456 as of June 30 and March 31, 2011, respectively, which are included as due from government payers in the accompanying unaudited condensed consolidated balance sheets.

The Hospitals receive supplemental payments from the State of California to support indigent care (Medi-Cal Disproportionate Share Hospital payments or "DSH") and from the California Medical Assistance Commission ("CMAC") under the SB 1100 and SB 1255 programs. The Hospitals received supplemental payments of $4.9 million and $11.1 million during the three months ended June 30, 2011 and 2010, respectively. The related revenue recorded for the three months ended June 30, 2011 and 2010, was $3.4 million and $6.4 million, respectively. As of June 30 and March 31, 2011, estimated DSH receivables were $2.4 million and $3.9 million, respectively, which are included as due from government payers in the accompanying unaudited condensed consolidated balance sheets.

The following is a summary of due from governmental payers:

   
June 30,
 2011
   
March 31,
 2011
 
Medicare
 
$
994
   
$
456
 
Medicaid
   
2,426
     
3,896
 
   
$
3,420
   
$
4,352
 

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers. The payers are billed for patient services on an individual patient basis. An individual patient's bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. The Hospitals estimate the discounts for contractual allowances utilizing billing data on an individual patient basis. Management believes the estimation and review process allows for timely identification of instances where such estimates need to be revised. The Company does not believe there were any adjustments to estimates of individual patient bills that were material to its net operating revenues.

The Hospitals provide charity care to patients whose income level is below 300% of the Federal Poverty Level. Patients with income levels between 300% and 350% of the Federal Poverty Level qualify to pay a discounted rate under AB 774 based on various government program reimbursement levels. Patients without insurance are offered assistance in applying for Medicaid and other programs they may be eligible for, such as state disability, Victims of Crime, or county indigent programs. Patient advocates from the Hospitals' Medical Eligibility Program ("MEP") screen patients in the hospital and determine potential linkage to financial assistance programs. They also expedite the process of applying for these government programs. The estimated costs (based on direct and indirect costs as a ratio of gross uncompensated charges associated with providing care to charity patients) for the three months ended June 30, 2011 and 2010 were approximately $1.3 million and $1.9 million, respectively.

Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending under the MEP, with appropriate contractual allowances recorded. If the patient does not qualify for Medicaid, the receivables are reclassified to charity care and written off, or they are reclassified to self-pay and adjusted to their net realizable value through the provision for doubtful accounts. Reclassifications of Medicaid pending accounts to self-pay do not typically have a material impact on the results of operations as the estimated Medicaid contractual allowances initially recorded are not materially different than the estimated provision for doubtful accounts recorded when the accounts are reclassified. All accounts classified as pending Medicaid, as well as certain other governmental receivables, over the age of 90 days were reserved in contractual allowances as of June 30 and March 31, 2011 based on historical collections experience.

The Company receives payments for indigent care under California section 1011. As of June 30 and March 31, 2011, the Company established a receivable in the amount of $1.4 million and $1.6 million, respectively, related to discharges deemed eligible to meet program criteria.

The Company is not aware of any material claims, disputes, or unsettled matters with any payers that would affect revenues that have not been adequately provided for in the accompanying unaudited condensed consolidated financial statements.

PROVISION FOR DOUBTFUL ACCOUNTS - The Company provides for accounts receivable that could become uncollectible by establishing an allowance to reduce the carrying value of such receivables to their estimated net realizable value. The Hospitals estimate this allowance based on the aging of their accounts receivable, historical collections experience for each type of payer and other relevant factors. There are various factors that can impact the collection trends, such as changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients, volume of patients through the emergency department, the increased burden of copayments to be made by patients with insurance and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends and the estimation process.

The Company's policy is to attempt to collect amounts due from patients, including copayments and deductibles due from patients with insurance, at the time of service while complying with all federal and state laws and regulations, including, but not limited to, the Emergency Medical Treatment and Labor Act ("EMTALA"). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, until the legally required medical screening examination is complete and stabilization of the patient has begun, services are performed prior to the verification of the patient's insurance, if any. In nonemergency circumstances or for elective procedures and services, it is the Hospitals' policy, when appropriate, to verify insurance prior to a patient being treated.

CASH AND CASH EQUIVALENTS - The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.

Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All of the non-interest bearing cash balances were fully insured at June 30, 2011 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, and the Company’s non-interest bearing cash balances may again exceed federally insured limits.

INVENTORIES OF SUPPLIES - Inventories of supplies are valued at the lower of weighted average cost or market.

PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and any impairment write-downs related to assets held and used. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Capital leases are recorded at the beginning of the lease term as property and equipment and a corresponding lease liability is recognized. The value of the property and equipment under capital lease is recorded at the lower of either the present value of the minimum lease payments or the fair value of the asset. Such assets, including improvements, are amortized over the shorter of either the lease term or their estimated useful life, where applicable.

The Company uses the straight-line method of depreciation for buildings and improvements, and equipment over their estimated useful lives of 25 years and 3 to 15 years, respectively.

LONG-LIVED ASSETS - The Company evaluates its long-lived assets for possible impairment whenever circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future cash flows. However, there is an evaluation performed at least annually. Fair value estimates are derived from established market values of comparable assets or internal calculations of estimated undiscounted future net cash flows. The estimates of future net cash flows are based on assumptions and projections believed by the Company to be reasonable and supportable. These assumptions take into account patient volumes, changes in payer mix, revenue, and expense growth rates and changes in legislation and other payer payment patterns.

DEBT ISSUANCE COSTS - On August 30, 2010, the Company entered into a new revolving credit facility (Note 3) under which it incurred debt issuance costs consisting of a $450 origination fee for the Company's $40 million Revolving Line of Credit (new debt) and $469 in legal and other expenses paid to third parties. These amounts are amortized over the credit facility’s three year life using the straight-line method. Subsequently, the $40 million Revolving Line of Credit was reduced to $20 million, resulting in an acceleration of the amortization of the related debt issuance costs.  Debt issuance costs of $410 (including $334 in accelerated amortization) and $130 were amortized during the three months ended June 30, 2011 and 2010, respectively.  At June 30 and March 31, 2011, prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheets included $153 and $300, respectively, as the current portion of debt issuance costs.

FAIR VALUE MEASUREMENTS - The Company's financial assets and liabilities recorded in the unaudited condensed consolidated balance sheets include cash and cash equivalents, restricted cash, receivables, debt, accounts payable, and other liabilities, all of which are recorded at book value which approximates fair value.

GAAP has established a hierarchy for ranking the quality and reliability of the information used to determine fair values and requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

 
Level 1:
Unadjusted quoted market prices in active markets for identical assets or liabilities.
     
 
Level 2:
Unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability.
     
 
Level 3:
Unobservable inputs for the asset or liability.

The Company utilizes the best available information in measuring fair value.  Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company currently has no financial or nonfinancial assets or liabilities subject to fair value measurement on a recurring basis except for warrants issued in April 2010 (Note 4).

The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis and where they are classified within the hierarchy as of June 30, 2011:

   
Total
   
Level 1
   
Level 2
   
Level 3
 
                         
Warrant liability
 
$
3,437
     
-
     
-
   
$
3,437
 

Warrant liability - fair value measurements using significant unobservable inputs (Level 3)

Balance at March 31, 2011 - Fair value of warrants issued and vested
 
$
167
 
Change in fair value of warrant liability included in earnings
 
       3,270
 
         
Balance at June 30, 2011
 
$
3,437
 

 WARRANTS - The Company has entered into complex transactions that contain warrants (Notes 3 and 4). If an instrument (or an embedded feature) that has the characteristics of a derivative instrument under this standard is indexed to an entity’s own stock, it is still necessary to evaluate whether it is classified in stockholders’ equity (or would be classified in stockholders’ equity if it were a freestanding instrument). Effective April 1, 2009, the Company adopted this standard, and at the time of adoption, this standard did not have an effect on the Company’s consolidated financial statements.  Subsequent to the Company’s adoption of this standard, the Company issued the April Warrants, which are accounted for as liabilities (Note 4).

LOSS PER COMMON SHARE - Loss per share is calculated under two different methods, basic and diluted. Basic loss per share is calculated by dividing the net loss by the weighted average shares of common stock outstanding during the period. Diluted loss per share is calculated by dividing the net loss by the weighted average shares of common stock outstanding during the period and dilutive potential shares of common stock. Dilutive potential shares of common stock, as determined under the treasury stock method, consist of shares of common stock issuable upon exercise of stock warrants or options, net of shares of common stock assumed to be repurchased by the Company from the exercise proceeds (Note 8).

INCOME TAXES - Deferred income tax assets and liabilities are determined based on the differences between the book and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws using the asset and liability method. The Company assesses the realization of deferred tax assets to determine whether an income tax valuation allowance is required. The Company has recorded a 100% valuation allowance on its deferred tax assets.

There is a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and California. Certain tax attributes carried over from prior years continue to be subject to adjustment by taxing authorities. Penalties or interest, if any, arising from federal or state taxes are recorded as a component of the income tax provision.

SEGMENT REPORTING - The Company operates in one line of business, the provision of healthcare services through the operation of general hospitals and related healthcare facilities. The Company's Hospitals generate substantially all of its net operating revenues.

The Company's four general Hospitals and related healthcare facilities operate in one geographic region in Orange County, California. The region's economic characteristics, the nature of the Hospitals' operations, the regulatory environment in which they operate, and the manner in which they are managed are all similar. This region is an operating segment, as defined by GAAP. In addition, the Company's general Hospitals and related healthcare facilities share certain resources and benefit from many common clinical and management practices. Accordingly, the Company aggregates the facilities into a single reportable operating segment.

SUBSEQUENT EVENTS - The Company’s accompanying unaudited condensed consolidated financial statements are considered issued when filed with the SEC.  The Company has evaluated subsequent events to the filing date of this Form 10-Q with the SEC.

NEW ACCOUNTING STANDARDS – In August 2010, the FASB approved certain modifications to existing accounting standards that will directly affect health care entities in the future. The first change provides clarification to companies in the healthcare industry on the accounting for professional liability insurance. Specifically, it states that receivables related to insurance recoveries should not be netted against the related claim liability and such claim liabilities should be determined without considering insurance recoveries. The second change clarifies that disclosures regarding the level of charity care provided by a health care entity must (i) represent the direct and indirect costs of providing such services, and (ii) include a description of the method used to determine those costs. Additionally, disclosures about charity care must now include information regarding any related reimbursements received by a health care entity. The modified accounting standards are required to be adopted for fiscal years that begin after December 15, 2010. The charity care disclosure change must be applied on a retrospective basis; however, the accounting change for insurance recoveries may be applied on either a prospective or retrospective basis (the Company has applied the accounting change for insurance recoveries on a retrospective basis). The Company adopted the modified accounting standards during the three months ended June 30, 2011, which did not have a material impact on the unaudited condensed consolidated financial statements.

In January 2010, the FASB issued guidance to amend the disclosure requirements related to recurring and nonrecurring fair value measurements. The guidance requires new disclosures on the transfers of assets and liabilities between Level 1 (quoted prices in active market for identical assets or liabilities) and Level 2 (significant other observable inputs) of the fair value measurement hierarchy, including the reasons and the timing of the transfers. Additionally, the guidance requires a rollforward of activities on purchases, sales, issuance, and settlements of the assets and liabilities measured using significant unobservable inputs (Level 3 fair value measurements). Disclosures regarding transfers are required beginning January 1, 2010 and the Level 3 rollforward is to be disclosed in reporting periods beginning after December 15, 2010.

XML 32 R16.htm IDEA: XBRL DOCUMENT  v2.3.0.11
NOTE 10 - RELATED PARTY TRANSACTIONS
3 Months Ended
Jun. 30, 2011
Related Party Transactions Disclosure [Text Block]
   
NOTE 10 - RELATED PARTY TRANSACTIONS

PCHI - The Company leases substantially all of the real property of the acquired Hospitals from PCHI. PCHI is owned by various physician investors and Ganesha, which is managed by Dr. Chaudhuri. As of June 30 and March 31, 2011, Dr. Chaudhuri and Mr. Thomas are the beneficial holders of an aggregate of 447.5 million shares of the outstanding stock of the Company. As described in Note 9, PCHI is a variable interest entity and, accordingly, the Company has consolidated the financial statements of PCHI in the accompanying unaudited condensed consolidated financial statements.

XML 33 R2.htm IDEA: XBRL DOCUMENT  v2.3.0.11
CONDENSED CONSOLIDATED BALANCE SHEET (USD $)
Jun. 30, 2011
Mar. 31, 2011
Current assets:    
Cash and cash equivalents $ 14,847 $ 20,539
Restricted cash 12 24
Accounts receivable, net of allowance for doubtful accounts of $22,008 and $20,076, respectively 46,312 52,538
Inventories of supplies, at cost 6,095 5,945
Due from governmental payers 3,420 4,352
Prepaid insurance 2,282 3,108
Prepaid income taxes 5,200  
Prepaid expenses - hospital quality assurance fees 15,100  
Hospital quality assurance fees receivable   1,815
Other prepaid expenses and current assets 8,695 8,885
Total current assets 101,963 97,206
Property and equipment, net 53,580 54,251
Debt issuance costs, net 182 445
Total assets 155,725 151,902
Current liabilities:    
Revolving line of credit 20,000 19,081
Accounts payable 40,169 43,968
Accrued compensation and benefits 17,011 18,707
Accrued insurance retentions 15,373 16,642
Unearned revenue - hospital quality assurance fees 17,245  
Income taxes payable 6,494 12,800
Other current liabilities 6,244 7,261
Total current liabilities 122,536 118,459
Debt, noncurrent 45,000 45,000
Warrant liability, noncurrent 3,437 167
Capital lease obligations, net of current portion of $1,140 and $1,131, respectively 6,548 6,837
Total liabilities 177,521 170,463
Commitments, contingencies, and subsequent event    
Common stock, $0.001 par value; 800,000 shares authorized; 255,307 shares issued and outstanding 255 255
Additional paid in capital 62,911 62,911
Receivable from stockholders (882) (882)
Accumulated deficit (82,150) (79,280)
Total Integrated Healthcare Holdings, Inc. stockholders' deficiency (19,866) (16,996)
Noncontrolling interests (1,930) (1,565)
Total stockholders' deficiency (21,796) (18,561)
Total liabilities and stockholders' deficiency $ 155,725 $ 151,902
XML 34 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.11 Html 19 116 1 false 5 0 false 3 true false R1.htm 000 - Disclosure - Document And Entity Information Sheet http://www.ihhioc.com/role/DocumentAndEntityInformation Document And Entity Information false false R2.htm 001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET Sheet http://www.ihhioc.com/role/ConsolidatedBalanceSheet CONDENSED CONSOLIDATED BALANCE SHEET false false R3.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parentheticals) Sheet http://www.ihhioc.com/role/ConsolidatedBalanceSheet_Parentheticals CONDENSED CONSOLIDATED BALANCE SHEET (Parentheticals) false false R4.htm 003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS Sheet http://www.ihhioc.com/role/ConsolidatedIncomeStatement CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS false false R5.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY Sheet http://www.ihhioc.com/role/ShareholdersEquityType2or3 CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY false false R6.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Sheet http://www.ihhioc.com/role/ConsolidatedCashFlow CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS false false R7.htm 006 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.ihhioc.com/role/Note NOTE 1 - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R8.htm 007 - Disclosure - NOTE 2 - PROPERTY AND EQUIPMENT Sheet http://www.ihhioc.com/role/Note0 NOTE 2 - PROPERTY AND EQUIPMENT false false R9.htm 008 - Disclosure - NOTE 3 - DEBT Sheet http://www.ihhioc.com/role/Note00 NOTE 3 - DEBT false false R10.htm 009 - Disclosure - NOTE 4 - COMMON STOCK WARRANTS Sheet http://www.ihhioc.com/role/Note000 NOTE 4 - COMMON STOCK WARRANTS false false R11.htm 010 - Disclosure - NOTE 5 - INCOME TAXES Sheet http://www.ihhioc.com/role/Note0000 NOTE 5 - INCOME TAXES false false R12.htm 011 - Disclosure - NOTE 6 - STOCK INCENTIVE PLAN Sheet http://www.ihhioc.com/role/Note00000 NOTE 6 - STOCK INCENTIVE PLAN false false R13.htm 012 - Disclosure - NOTE 7 - RETIREMENT PLAN Sheet http://www.ihhioc.com/role/Note000000 NOTE 7 - RETIREMENT PLAN false false R14.htm 013 - Disclosure - NOTE 8 - INCOME PER SHARE Sheet http://www.ihhioc.com/role/Note0000000 NOTE 8 - INCOME PER SHARE false false R15.htm 014 - Disclosure - NOTE 9 - VARIABLE INTEREST ENTITY Sheet http://www.ihhioc.com/role/Note00000000 NOTE 9 - VARIABLE INTEREST ENTITY false false R16.htm 015 - Disclosure - NOTE 10 - RELATED PARTY TRANSACTIONS Sheet http://www.ihhioc.com/role/Note000000000 NOTE 10 - RELATED PARTY TRANSACTIONS false false R17.htm 016 - Disclosure - NOTE 11 - HOSPITAL QUALITY ASSURANCE FEE PROGRAM Sheet http://www.ihhioc.com/role/Note0000000000 NOTE 11 - HOSPITAL QUALITY ASSURANCE FEE PROGRAM false false R18.htm 017 - Disclosure - NOTE 12 - COMMITMENTS AND CONTINGENCIES Sheet http://www.ihhioc.com/role/Note00000000000 NOTE 12 - COMMITMENTS AND CONTINGENCIES false false R19.htm 018 - Disclosure - NOTE 13 - SUBSEQUENT EVENT Sheet http://www.ihhioc.com/role/Note000000000000 NOTE 13 - SUBSEQUENT EVENT false false All Reports Book All Reports Warning: The equity rendering routine was not applied to 004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY. None of the elements feature the 'periodStartLabel' preferred label role. Process Flow-Through: 001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET Process Flow-Through: Removing column 'Jun. 30, 2010' Process Flow-Through: Removing column 'Mar. 31, 2010' Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parentheticals) Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2010' Process Flow-Through: 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS ihch-20110630.xml ihch-20110630.xsd ihch-20110630_cal.xml ihch-20110630_def.xml ihch-20110630_lab.xml ihch-20110630_pre.xml true true EXCEL 35 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]B-&5A,S)A,U]B960S7S0Y,#E?.3@S8E]A,3'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I7;W)K#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DY/5$5?-%]#3TU-3TY?4U1/ M0TM?5T%24D%.5%,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/5$5?.%])3D-/345?4$527U-(05)%/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!);F9O M2!296=I2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,3`U M,30X.#QS<&%N/CPO'0^665S/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^3F\\2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^4VUA;&QE3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4\+W1D/@T*("`@("`@("`\=&0@ M8VQA&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)FYB M'0^)FYB3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E'!E;G-E'!E;G-E'!E;G-E.CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$"!B96YE9FET/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XU+#(P,#QS<&%N/CPO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]B-&5A,S)A,U]B960S7S0Y,#E?.3@S8E]A M,3'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B-&5A,S)A,U]B960S7S0Y,#E?.3@S M8E]A,3'0O:'1M;#L@8VAA MF%T:6]N(&]F(&1E8G0@:7-S=6%N8V4@8V]S=',\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S65R&5S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B@U+#(P,"D\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E6UE;G1S(&]N(&-A M<&ET86P@;&5A&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD M(#8L,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]B-&5A,S)A,U]B960S7S0Y,#E?.3@S8E]A,3'0O:'1M;#L@8VAAF%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N M9"!02<^ M#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SY"05-)4PT*("`@("`-"B`@("`@($]&(%!215-%3E1!5$E/3B`M(%1H92!A M8V-O;7!A;GEI;F<@=6YA=61I=&5D(&-O;F1E;G-E9`T*(`T*("`@("`@8V]N M2P@=&AE(&%C8V]M<&%N>6EN9R!S=&%T96UE;G1S(&1O M(&YO="!I;F-L=61E(&%L;`T*(`T*("`@("`@;V8@=&AE(&EN9F]R;6%T:6]N M(&%N9"!N;W1E2!'04%0(&9O6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=) M3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J=7-T:69Y)SX-"B`@(`T*("`@ M("`@/&9O;G0@2<^#0H@("`-"B`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY!;&P-"B`@ M(`T*("`@("`@'!R97-S960@:6X@=&AO=7-A;F1S("AE>&-E M<'0@<&5R('-H87)E#0H@(`T*("`@("`@86UO=6YT2!H860@82!T;W1A;`T*(`T*("`@("`@2P@ M86YD(&$@=V]R:VEN9R!C87!I=&%L(&1E9FEC:70@;V8@)FYB2!H860@80T*("`-"B`@("`@(&YE="!L;W-S(&]F("9N8G-P M.R0R+CD@;6EL;&EO;B!A;F0@)FYB2!H860@;F\@861D:71I;VYA;"!A=F%I;&%B:6QI='D-"B`@("`-"B`@("`@ M('5N9&5R(&ET6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T M.R!415A4+4%,24=..B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@2!A8W%U:7)E9`T*(`T*("`@("`@9F]U6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`-"B`@("`@("`@ M("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$=&]P('=I9'1H M/3-$-24^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$:G5S=&EF>3X-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(SDV-SD[/"]F;VYT/@T*("`-"B`@ M("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=VED=&@],T0Y,"4^ M#0H@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`-"B`@("`@("`@ M("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$=&]P('=I9'1H M/3-$-24^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXQ,30M8F5D#0H@#0H@("`@("`@("`@("`@($-H87!M86X@365D:6-A M;"!#96YT97(@:6X@3W)A;F=E/"]F;VYT/CPO9F]N=#X-"B`@(`T*("`@("`@ M("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`\+W1R/@T*("`@("`-"B`@("`@(#PO=&%B;&4^/&)R+SX\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=( M5#H@,'!T.R!415A4+4%,24=..B!J=7-T:69Y)SX-"B`@#0H@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^4D5#3$%34TE&24-!5$E/ M3@T*(`T*("`@("`@1D]2(%!215-%3E1!5$E/3B`M($-E2<^#0H@("`-"B`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)SY#3TY#14Y44D%424].#0H@("`-"B`@ M("`@($]&(%))4TL@+2!4:&4@2&]S<&ET86QS(&%R92!S=6)J96-T('1O(&QI M8V5N2!T:&4@4W1A=&4-"B`@(`T*("`@("`@;V8@0V%L:69O2!T:&4@2F]I;G0@0V]M;6ES0T*("`@#0H@("`@("!A;&P@;F5T(&]P97)A=&EN9R!R979E;G5E65R2=S(&YE="!O<&5R871I;F<@6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P M=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4 M+4%,24=..B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@2!O M9B!O=7(-"B`@("`-"B`@("`@('!A=&EE;G1S(&%N9"!T:&ER9"UP87)T>2!P M87EE2<^#0H@("`-"B`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY54T4-"B`@(`T* M("`@("`@3T8@15-424U!5$53("T@5&AE(&%C8V]M<&%N>6EN9R!U;F%U9&ET M960@8V]N9&5N2!C;W-T(')E<&]R="!S971T;&5M96YT M&5S+"!A8V-R=65D(&EN2!V87)Y(&9R;VT@ M=&AO28C.#(Q-SMS($-H87)G92!$97-C65D(&EN('1H92!U;F%U9&ET960@8V]N9&5N7!I8V%L;'D@<&%I9"!A;6]U;G1S('1H870@87)E#0H@(`T* M("`@("`@;F5G;W1I871E9"!W:71H(&EN2<^ M#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SY2979E;G5E2!O;B!P2!R97-O;'9E9"X@17-T:6UA=&5S(&]F('-E='1L96UE;G0-"B`-"B`@("`@ M(')E8V5I=F%B;&5S(&]R('!A>6%B;&5S(')E;&%T960@=&\@82!S<&5C:69I M8R!Y96%R(&%R90T*(`T*("`@("`@=7!D871E9"!P97)I;V1I8V%L;'D@86YD M(&%T('EE87(@96YD(&%N9"!A="!T:&4@=&EM92!T:&4@8V]S=`T*("`@#0H@ M("`@("!R97!O2X@5'EP:6-A;&QY(&YO#0H@("`@(`T*("`@("`@9G5R=&AE2!T:&4@9FES8V%L#0H@(`T*("`@("`@:6YT97)M961I87)Y+B!4:&5R92!C M;W5L9"!B92!S979E2P@ M=VAI8V@@87)E(&EN8VQU9&5D(&%S(&1U92!F6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@ M,'!T.R!415A4+4%,24=..B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@ M6UE;G1S(&]F M("9N8G-P.R0T+CD@;6EL;&EO;B!A;F0@)FYB2X@07,@;V8@2G5N92`S M,"!A;F0@36%R8V@@,S$L(#(P,3$L#0H@("`-"B`@("`@(&5S=&EM871E9"!$ M4T@@65R2<^#0H@("`-"B`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4:&4-"B`@(`T*("`@("`@9F]L M;&]W:6YG(&ES(&$@2!O9B!D=64@9G)O;2!G;W9E65R6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B`@#0H@("`@("`@(#QT6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9"<^#0H@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY*=6YE#0H@(`T*("`@("`@ M("`@("`@("`S,"P\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+V1I=CX-"B`@ M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A% M24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[,C`Q,3PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@ M("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@"<^#0H@("`-"B`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@"<^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@ M6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^36%R8V@-"B`@(`T*("`@("`@("`@("`@("`S M,2P\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[,C`Q,3PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`\+V1I=CX- M"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@"<^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@ M("`\='(@6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!, M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@ M("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@ M,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@ M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^365D:6-A6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!, M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@ M("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@ M,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@ M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)FYB6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX- M"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#DE/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!, M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@ M("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@ M,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXT-38\+V9O;G0^#0H@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`- M"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T* M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^ M#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P M<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!, M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^365D:6-A:60\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@ M("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@"<^ M#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@ M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N M,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/@T*("`-"B`@("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,BPT,C8\+V9O M;G0^#0H@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@ M("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@ M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D"<^#0H@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T* M("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`\+W1R/@T*("`@ M("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T M>6QE/3-$)U!!1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T* M("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX- M"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#1P>"!D;W5B;&4G/@T*("`@#0H@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXS+#0R,#PO9F]N=#X-"B`@(`T*("`@ M("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D"<^#0H@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@ M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)SX-"B`@(`T*("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[ M($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S M='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$58 M5"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=( M5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O M;G0@"<^#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@ M("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`\+W1R/@T*("`@("`-"B`@("`@ M(#PO=&%B;&4^/&)R+SX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E' M2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J=7-T M:69Y)SX-"B`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^4F5V96YU97,-"B`@(`T*("`@("`@=6YD97(@;6%N86=E9"!C87)E M('!L86YS(&%R92!B87-E9"!P65R65R2!T:&4@<&%Y97)S(&9O;&QO=VEN9R!T:&5I2!I9&5N=&EF:6-A=&EO;B!O9@T*(`T*("`@("`@:6YS=&%N M8V5S('=H97)E('-U8V@@97-T:6UA=&5S(&YE960@=&\@8F4@2<^#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SY4:&4-"B`@(`T*("`@("`@2&]S<&ET86QS('!R M;W9I9&4@8VAA2!C87)E('1O('!A=&EE;G1S('=H;W-E(&EN8V]M92!L M979E;`T*("`@#0H@("`@("!I2!A(&1I2!B92!E;&EG:6)L92!F;W(L('-U8V@@87,-"B`@(`T*("`@("`@2P@5FEC=&EM2!A;'-O(&5X<&5D:71E('1H92!P2!P871I96YT&EM M871E;'D@)FYB6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z M(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J=7-T:69Y M)SX-"B`@(`T*("`@("`@/&9O;G0@2!F;W(@365D:6-A:60L('1H92!R96-E:79A M8FQE2!C M87)E(&%N9"!W2!A2!A;F0@861J=7-T960@=&\@=&AE M:7(@;F5T(')E86QI>F%B;&4-"B`@(`T*("`@("`@=F%L=64@=&AR;W5G:"!T M:&4@<')O=FES:6]N(&9O2!R96-O M6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U( M14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J M=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@6UE;G1S(&9O0T*(`T*("`@("`@97-T86)L:7-H960@ M82!R96-E:79A8FQE(&EN('1H92!A;6]U;G0@;V8@)FYB6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P M=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4 M+4%,24=..B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@65R6EN9R!U;F%U9&ET960@8V]N9&5N2!P2!EF%B;&4@=F%L=64N(%1H92!(;W-P:71A;',@ M97-T:6UA=&4-"B`@#0H@("`@("!T:&ES(&%L;&]W86YC92!B87-E9"!O;B!T M:&4@86=I;F<@;V8@=&AE:7(@86-C;W5N=',-"B`@(`T*("`@("`@'!E65R(&%N9"!O=&AE2!D97!A M6UE;G1S('1O M#0H@#0H@("`@("!B92!M861E(&)Y('!A=&EE;G1S('=I=&@@:6YS=7)A;F-E M(&%N9"!B=7-I;F5S0T*("`@(`T*("`@("`@8VAA;F=E(&%N9"!C86X@:&%V92!A;B!I;7!A M8W0@;VX@8V]L;&5C=&EO;B!T6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[ M($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J=7-T:69Y)SX-"B`@ M(`T*("`@("`@/&9O;G0@2P@87,@2!C:7)C=6US=&%N8V5S M(&]R(&9O2P@=VAE;B!A M<'!R;W!R:6%T92P@=&\-"B`-"B`@("`@('9E2!I;G-U2!C;VYS:61E0T*("`-"B`@ M("`@(&QI<75I9"!D96)T(&EN=F5S=&UE;G1S('!U2<^ M#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SY#87-H#0H@("`@#0H@("`@("!A;F0@8V%S:"!E<75I=F%L96YT2!E>&-E960@9F5D97)A M;&QY(&EN'!E2!F961E28C.#(Q-SMS(&YO M;BUI;G1E2!I;G-U2<^#0H@("`-"B`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY)3E9%3E1/4DE%4PT* M(`T*("`@("`@3T8@4U504$Q)15,@+2!);G9E;G1O6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E' M2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J=7-T M:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@2!A;F0@97%U:7!M96YT(&%R92!S=&%T960@870@8V]S="P-"B`@ M("`@#0H@("`@("!L97-S(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@ M86YY(&EM<&%I'!E;F1I='5R M97,@9F]R(&UA:6YT96YA;F-E(&%N9"!R97!A:7)S(&%R92!C:&%R9V5D('1O M#0H@(`T*("`@("`@97AP96YS92!A2!A;F0@97%U:7!M96YT(&%N M9"!A#0H@#0H@("`@("!C;W)R97-P;VYD:6YG(&QE87-E(&QI86)I;&ET>2!I MF5D+B!4:&4@=F%L=64@;V8@=&AE#0H@("`-"B`@("`@('!R M;W!E2<^#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SY4:&4-"B`@(`T*("`@("`@0V]M<&%N>2!U2X\+V9O;G0^#0H@("`-"B`@("`\ M+V1I=CX\8G(O/CQD:78@2X@1F%I<@T*("`@#0H@("`@("!V86QU92!E2<^ M#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SY$14)4#0H@("`@#0H@("`@("!)4U-504Y#12!#3U-44R`M($]N($%U9W5S M="`S,"P@,C`Q,"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O#0H@("`-"B`@ M("`@(&$@;F5W(')E=F]L=FEN9R!C'!E;G-E65AF5D(&1U'!E;G-E6EN9PT*("`@#0H@("`@("!U;F%U9&ET960@8V]N M9&5N6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E' M2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J=7-T M:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@2!F;W(@2!A;F0-"B`@#0H@("`@ M("!R96QI86)I;&ET>2!O9B!T:&4@:6YF;W)M871I;VX@=7-E9"!T;R!D971E M6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$:G5S=&EF>3X-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY5;F%D:G5S=&5D#0H@("`-"B`@ M("`@("`@("`@("`@<75O=&5D(&UA6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED M=&@],T0X."4^#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`\+W1R/@T*("`@("`-"B`@("`@("`@ M/'1R/@T*("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N M/3-$=&]P('=I9'1H/3-$-24^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0W)3X-"B`@(`T*("`@("`@("`@ M("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U! M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY,979E M;`T*("`@#0H@("`@("`@("`@("`@(#,Z/"]F;VYT/@T*("`@("`-"B`@("`@ M("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@ M("`@("`@("`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.#@E/@T*(`T*("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N M,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU2<^#0H@(`T*("`@("`@/&9O M;G0@F5S('1H92!B97-T(&%V86EL86)L92!I;F9O2!H M87,@;F\-"B`@("`-"B`@("`@(&9I;F%N8VEA;"!O6QE/3-$)U!!1$1)3D"<^ M#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&-O M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^3&5V96P-"B`@(`T* M("`@("`@("`@("`@("`Q/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@/"]D M:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT@"<^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE M/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^3&5V96P-"B`@ M(`T*("`@("`@("`@("`@("`R/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@ M/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@"<^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^3&5V96P- M"B`@(`T*("`@("`@("`@("`@("`S/"]F;VYT/@T*("`@(`T*("`@("`@("`@ M("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@ M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B M;W1T;VT^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO M='(^#0H@("`@(`T*("`@("`@("`\='(@"<^#0H@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@ M3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@ M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z M(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@ M("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)U!!1$1)3D6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#1P>"!D;W5B;&4G/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P M<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!, M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXS+#0S-SPO9F]N=#X-"B`@(`T*("`@("`@("`@ M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D"<^#0H@#0H@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F M;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)SX-"B`@(`T*("`@("`@("`@("`@ M/&9O;G0@"<^#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO M=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`-"B`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G/@T*("`@#0H@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)SX-"B`@(`T*("`@("`@("`@ M("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U! M4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL M93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U) M3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1')I9VAT/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^+3PO9F]N=#X-"B`@("`- M"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]D:78^ M#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@-'!X)SX-"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F M;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@ M("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G/@T*("`@#0H@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS+#0S-SPO9F]N M=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@ M("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE. M+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^0F%L86YC90T*("`-"B`@("`@("`@ M("`@("`@("!A="!-87)C:"`S,2P@,C`Q,2`M($9A:7(@=F%L=64@;V8@=V%R M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO M='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY#:&%N9V4-"B`-"B`@("`@("`@ M("`@("`@("!I;B!F86ER('9A;'5E(&]F('=A6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$U)3X-"B`-"B`@("`@("`@ M("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1'1O<"!W:61T:#TS1#$U)2!S='EL93TS1"="3U)$15(M0D]45$]- M.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1'1O<"!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)V)A8VMG"<^#0H@(`T*("`@("`@("`@("`@/&1I=B!S M='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$58 M5"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=( M5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P M=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG M;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G/@T*(`T*("`@("`@("`@ M("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U! M4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL M93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U) M3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1')I9VAT/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,RPT,S<\+V9O;G0^#0H@ M("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]D M:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@-'!X)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@2<^#0H@(`T*("`@("`@/&9O;G0@2!T;R!E M=F%L=6%T90T*("`@("`-"B`@("`@('=H971H97(@:70@:7,@8VQA2`H;W(-"B`@("`-"B`@ M("`@('=O=6QD(&)E(&-L87-S:69I960@:6X@2!A9&]P=&5D('1H:7,@28C.#(Q M-SMS#0H@("`@(`T*("`@("`@8V]N2<^ M#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SY,3U-3#0H@("`@#0H@("`@("!015(@0T]-34].(%-(05)%("T@3&]S2!D M:79I9&EN9R!T:&4@;F5T(&QO2!D:79I9&EN9R!T:&4@;F5T(&QO M&5R8VES92!O9B!S=&]C:R!W87)R86YT2!F&5R8VES92!P`T*("`-"B`@("`@ M(&)A"!A`T* M(`T*("`@("`@=F%L=6%T:6]N(&%L;&]W86YC92!I2<^#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SY4:&5R90T*("`@("`-"B`@("`@(&ES(&$@"!P;W-I=&EO;B!T86ME;B!O<@T*(`T*("`@("`@97AP96-T960@ M=&\@8F4@=&%K96X@:6X@82!T87@@`T*("`@("`-"B`@("`@(&%T=')I8G5T97,@8V%R65A&5S(&%R90T*("`@(`T*("`@ M("`@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=( M5#H@,'!T.R!415A4+4%,24=..B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O M;G0@2!O<&5R871E2=S($AO2<^#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SY4:&4-"B`@(`T*("`@("`@0V]M<&%N>2=S(&9O M=7(@9V5N97)A;"!(;W-P:71A;',@86YD(')E;&%T960@:&5A;'1H8V%R90T* M("`-"B`@("`@(&9A8VEL:71I97,@;W!E2P-"B`@(`T*("`@("`@0V%L:69O M2!E;G9I2!O<&5R871E+"!A;F0@=&AE(&UA;FYE2!'04%0+B!);B!A9&1I=&EO;BP@=&AE($-O M;7!A;GDG2P@=&AE($-O;7!A;GD@86=G6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@ M3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%, M24=..B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@&ES=&EN9R!A8V-O=6YT:6YG#0H@("`@(`T*("`@("`@2!A9F9E8W0@:&5A;'1H(&-A2!A;F0@2!A(&AE86QT:"!C M87)E#0H@("`@(`T*("`@("`@96YT:71Y+B8C,38P.U1H92!M;V1I9FEE9"!A M8V-O=6YT:6YG('-T86YD87)D65A2!H87,-"B`@#0H@("`@("!A<'!L:65D('1H92!A8V-O M=6YT:6YG(&-H86YG92!F;W(@:6YS=7)A;F-E(')E8V]V97)I97,@;VX@80T* M(`T*("`@("`@2<^#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)SY);@T*("`-"B`@("`@($IA;G5A2P@ M=&AE(&=U:61A;F-E(')E<75I7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`V-"XX<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E' M2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^3D]410T*("`@#0H@("`@("`R("T@4%)/4$525%D@04Y$ M($5154E0345.5#PO9F]N=#X-"B`-"B`@("`\+V1I=CX\8G(O/CQD:78@6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E' M2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^2G5N90T*(`T*("`@("`@("`@("`@("`S,"P\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/&9O M;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^ M#0H@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^36%R8V@-"B`@#0H@("`@ M("`@("`@("`@(#,Q+#PO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO9&EV/@T* M("`@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M5T5)1TA4.B!B;VQD)SXR,#$Q/"]F;VYT/CPO9F]N=#X-"B`@ M(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^ M#0H@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@("`@ M(`T*("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^0G5I;&1I;F=S/"]F;VYT M/@T*("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@ M/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT M/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@ M("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/@T*("`@#0H@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS-"PV,S<\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@ M("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T* M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z M(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=) M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"B`@(`T*("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=) M3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS M1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1% M3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T M)R!A;&EG;CTS1')I9VAT/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,3,L-3(S/"]F;VYT/@T*("`@ M(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I M=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F M;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`\+W1R M/@T*("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T* M("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"B`@(`T*("`@("`@("`@("`@/&1I M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU2 M24=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z M(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A M;&EG;CTS1')I9VAT/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,3,L-C,U/"]F;VYT/@T*("`@(`T* M("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX- M"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/@T*("`@#0H@("`@("`@("`@ M("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%2 M1TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ,RPR-C8\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO M9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO M='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SY#;VYS=')U8W1I;VX-"B`@#0H@("`@("`@("`@ M("`@("`@:6X@<')O9W)E6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3X-"B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z M(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX- M"B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U( M14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT M/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^,2PT,#0\+V9O;G0^#0H@("`-"B`@("`@("`@("`@("`@ M/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@ M("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Y)3X-"B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS M1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1% M3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T M)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E. M12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I M9VAT/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^,2PS-S4\+V9O;G0^#0H@("`-"B`@("`@("`@("`@ M("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@ M("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^07-S971S#0H@#0H@ M("`@("`@("`@("`@("`@=6YD97(@8V%P:71A;"!L96%S97,\+V9O;G0^#0H@ M("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\ M+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"B`@(`T* M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z M(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=) M3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/@T*("`-"B`@("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^-S0L,#`V M/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@ M("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@ M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T* M("`@("`@("`\+W1R/@T*("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A M8VMG6QE/3-$)U!!1$1) M3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SY,97-S#0H@("`@#0H@("`@("`@("`@("`@("`@86-C M=6UU;&%T960@9&5P6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D"<^#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^ M#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T* M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z M(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=) M3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/@T*("`-"B`@("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*#$Y+#"<^#0H@#0H@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE. M+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#X-"B`@("`-"B`@("`@ M("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@ M(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`\+W1R/@T*("`@("`- M"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#DE/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@ M("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Y)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@ M("`@("`\='(@"<^#0H@(`T*("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N M,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[ M(%1%6%0M24Y$14Y4.B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*("`-"B`@("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^4')O<&5R='D- M"B`@(`T*("`@("`@("`@("`@("`@(&%N9"!E<75I<&UE;G0L(&YE=#PO9F]N M=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@ M("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@ M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#1P>"!D;W5B;&4G/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y% M+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXU,RPU.#`\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@ M("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@"<^ M#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@ M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`-"B`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G/@T*("`@#0H@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE. M+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)U!!1$1)3D2<^ M#0H@(`T*("`@("`@/&9O;G0@2X\+V9O;G0^#0H@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@3X-"B`@(`T*("`@("`@/&9O;G0@2!E87)T:'%U86ME(&EN2!L:6UI="!O9B`F;F)S<#LD-3`N,"!M:6QL:6]N+B!!('-I M9VYI9FEC86YT#0H@("`-"B`@("`@(&5A6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E. M12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=. M.B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@0T* M(`T*("`@("`@2<^#0H@ M("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4 M:&4-"B`@(`T*("`@("`@4W1A=&4@;V8@0V%L:69O&-E<'1I;VX@;V8@ M;VYE("AA;@T*(`T*("`@("`@861M:6YI'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@#0H@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U( M14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)SY/;@T*("`-"B`@("`@($%P2!E;G1E2!,3$,@*"8C.#(R,#M'86YE2`H)B,X,C(P.TM00R8C.#(R,3LI+B8C,38P.R8C M,38P.TM00R!A;F0-"B`-"B`@("`@($=A;F5S:&$@87)E(&-O;7!A;FEE2!$2XF(S$V,#LF(S$V,#M'86YE6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[ M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4:&4-"B`@ M(`T*("`@("`@0V]M<&%N>2!E;G1E2!T:&4@0V]U&5C=71E9"!B>2!T:&4@0V]M<&%N>2!I;@T*("`@(`T* M("`@("`@8V]N;F5C=&EO;B!W:71H('1H92!#3X-"B`@(`T*("`@("`@/&9O;G0@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SX-"B`@(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@ M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=( M5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X- M"B`-"B`@("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^/&9O;G0@ M6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SY4:&4-"B`@("`-"B`@("`@("`@("`@("`@("`@ M('-T871E9"!M871U2!D871E('5N9&5R(&5A8V@@0W)E9&ET($%G6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y% M+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S M=&EF>3X-"B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY!9F9I2!A;F0@=&AE#0H@("`-"B`@("`@("`@ M("`@("`@("!P6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T* M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`- M"B`@("`@("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@=VED=&@],T0U M)3X-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(SDV-SD[/"]F;VYT/@T*("`-"B`@("`@("`@("`\+W1D/@T* M("`-"B`@("`@("`@("`\=&0@=VED=&@],T0Y,"4^#0H@("`-"B`@("`@("`@ M("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^/&9O;G0@2!A9W)E960@=&\@;6%K92!M86YD M871O0T*("`@#0H@("`@("`@("`@("`@("`@("!I;B!E9F9E8W0@=6YD97(@=&AE M("9N8G-P.R0U,"XP(&UI;&QI;VX@4F5V;VQV:6YG#0H@(`T*("`@("`@("`@ M("`@("`@("`@0W)E9&ET($%G6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`-"B`@("`@("`@("`\+W1D/@T*("`- M"B`@("`@("`@("`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-24^#0H@("`@ M(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^5&AE#0H@(`T* M("`@("`@("`@("`@("`@("9N8G-P.R0Q,"XW(&UI;&QI;VX@0W)E9&ET($%G M65A2!I;B!E9F9E8W0@86YD#0H@("`-"B`@("`@("`@("`@ M("`@("!T;R!E;&EM:6YA=&4@=&AE(&-O;G9E2!A9W)E960@=&\-"B`-"B`@("`@("`@ M("`@("`@("!M86ME(&UA;F1A=&]R>2!P6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SY);@T*("`-"B`@("`@(&-O;FYE8W1I;VX@=VET M:"!T:&4@&-L=61I;F<@4$-(22D@96YT97)E9"!I;G1O(&$-"B`@ M#0H@("`@("!#FEN9R!I;B!L;V%N M6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!4 M15A4+4%,24=..B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@2!U;F1E2!T;R!R97!A>2!A<'!R;WAI;6%T96QY("9N8G-P.R0S-2XP(&UI;&QI;VX@ M:6X@;&]A;G,-"B`@#0H@("`@("!O=71S=&%N9&EN9R!T;R!A9F9I;&EA=&5S M(&]F(%-I;'9E0T*("`@#0H@("`@("!R97!A:60@86YD('1E6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P M=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4 M+4%,24=..B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@2!A;&P@ M;V8@=&AE($-O;7!A;GDF(S@R,3<[2!I;G1E2!I6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U( M14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J M=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@2!M86ME0T*("`@(`T*("`@("`@8VQE87)A;F-E('!E6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=( M5#H@,'!T.R!415A4+4%,24=..B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O M;G0@6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T M)R!A;&EG;CTS1&IU6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[(%1%6%0M1$5#3U)!5$E/3CH@=6YD97)L:6YE)SY!;65N9&UE;G0- M"B`@(`T*("`@("`@=&\@)FYB0T*("`@#0H@("`@ M("!W:71H('1H92!E>&5C=71I;VX@;V8@=&AE($YE=R!#6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y% M+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S M=&EF>3X-"B`@(`T*("`@("`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^/&9O;G0@6UE;G0@;V8@=&AE#0H@ M("`-"B`@("`@("`@("`@("`@("`@("`@0V]M<&%N>28C.#(Q-SMS(&%C8V]U M;G1S(')E8V5I=F%B;&4@8F%S960-"B`-"B`@("`@("`@("`@("`@("`@("`@ M9FEN86YC:6YG(&9A8VEL:71Y('5N9&5R('1H92!/6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@ M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T* M("`-"B`@("`@("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@=VED=&@] M,T0U)3X-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^5&AE#0H@("`@#0H@("`@("`@("`@("`@("`@("!/6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`- M"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(^#0H@#0H@("`@ M("`@("`@("`\=&0@=VED=&@],T0U)3X-"B`@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^5&AE#0H@("`@#0H@("`@("`@("`@ M("`@("`@("!#;VUP86YY(&%G2!L:65N(&]N('-U8G-T86YT:6%L;'D@86QL(&]F('1H90T* M("`@("`-"B`@("`@("`@("`@("`@("`@($-O;7!A;GDF(S@R,3<[2!0 M0TA)+CPO9F]N=#X\+V9O;G0^/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@ M("`@/"]D:78^#0H@("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T6QE/3-$)TU!4D=)3BU,1494 M.B`P<'0[(%1%6%0M24Y$14Y4.B`S-G!T.R!-05)'24XM4DE'2%0Z(#!P=#L@ M5$585"U!3$E'3CH@:G5S=&EF>2<^#0H@("`@#0H@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY/;@T*("`@(`T*("`@("`@("!/ M8W1O8F5R(#(Y+"`R,#$P+"!T:&4@0V]M<&%N>2!E;G1E2!A;F0-"B`-"B`@("`@("`@=&AE($%2($QE M;F1E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY5;F1E<@T*("`@("`-"B`@ M("`@('1H92!!;65N9&UE;G0L('1H92!!4B!,96YD97(@8V]M;6ET=&5D('1O M(&EN8W)E87-E('1H92!T;W1A;`T*("`-"B`@("`@(')E=F]L=FEN9R!L;V%N M(&-O;6UI=&UE;G0@86UO=6YT('5N9&5R('1H92!.97<@0W)E9&ET#0H@("`@ M(`T*("`@("`@06=R965M96YT(&9R;VT@)FYB2<^#0H@("`-"B`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)SY!;'-O#0H@("`@#0H@("`@("!U;F1E M28C.#(Q-SMS($)O6UE;G0N M/"]F;VYT/@T*("`@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@6UE;G0@86YD('!E6UE;G0@9F5E#0H@#0H@("`@("!C86QC=6QA=&EO;B!U;F1E6UE;G0@9F5E(&ES(&)A6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U( M14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J M=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@2P-"B`@#0H@("`@("!U;F1E2!W;W5L9"!B92!P M97)M:71T960@=&\@=')A;G-F97(@9G5N9',@=&AA="!A28C.#(Q-SMS#0H@#0H@("`@("!L;V-K8F]X(&%C8V]U;G1S M('1O(&$@9&EF9F5R96YT(&)A;FL@86-C;W5N="!D97-I9VYA=&5D(&)Y#0H@ M("`@(`T*("`@("`@=&AE($-O;7!A;GDN($5F9F5C=&EV92!-87)C:"`Q+"`R M,#$Q+"!T:&4@0V]M<&%N>2!R961U8V5D(&ET2!H860@=&AE(&9O;&QO=VEN9R!#6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@(`T*("`@("`@("`@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`@#0H@ M("`@("`@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^00T*("`- M"B`@("`@("`@("`@("`@("`@("`@("`F;F)S<#LD-#4N,"!M:6QL:6]N(%1E M&5D M(&EN=&5R97-T(')A=&4@;V8@,30N-24@<&5R('EE87(@*"9N8G-P.R0T-2XP M#0H@(`T*("`@("`@("`@("`@("`@("`@("`@(&UI;&QI;VX@;W5T6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y% M+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S M=&EF>3X-"B`@("`-"B`@("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$:G5S=&EF>3X-"B`-"B`@("`@("`@("`@("`@("`@(#QD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^00T*("`-"B`@("`@ M("`@("`@("`@("`@("`@)FYB6UE;G1S('1H92!#;VUP86YY M#0H@(`T*("`@("`@("`@("`@("`@("`@("!M86ME2!C;&5A2!W87,@:6X@8V]M<&QI86YC92!W:71H(&%L;"!F:6YA;F-I86P- M"B`@("`@#0H@("`@("`@("`@("`@("`@("`@(&-O=F5N86YT2<^#0H@("`@#0H@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE#0H@ M("`-"B`@("`@($-O;7!A;GDG6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@ M,2XR-3L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SY*=6YE#0H@(`T*("`@("`@("`@("`@("`S,"P\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[,C`Q,3PO M9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@"<^ M#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T M;VT@"<^#0H@("`-"B`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^36%R M8V@-"B`@(`T*("`@("`@("`@("`@("`S,2P\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[,C`Q,3PO9F]N=#X-"B`@ M("`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B M;W1T;VT@"<^#0H@("`-"B`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@("`@ M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@("`@ M(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY#=7)R96YT.B8C,38P M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@ M("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/@T*("`@ M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T* M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@ M(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@ M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X- M"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P M<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!, M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^4F5V;VQV:6YG#0H@("`@#0H@("`@("`@("`@("`@ M("`@;&EN92!O9B!C"<^#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^ M#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)SX- M"B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U( M14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[ M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\ M+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D M;W5B;&4G/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=( M5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXQ.2PP.#$\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`@(#PO M9&EV/@T*("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@ M("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@"<^#0H@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`\+W1R/@T*("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@ M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`\+W1R/@T*("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG M6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE. M+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[3F]N8W5R6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@ M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T* M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@ M(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@ M(`T*("`@("`@("`\+W1R/@T*("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$ M)V)A8VMG6QE/3-$)U!! M1$1)3D6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#M396-U6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G/@T*("`@#0H@ M("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@ M,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$ M)U!!1$1)3D"<^#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO M=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE M)SX-"B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E. M12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N M,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO M='(^#0H@("`@(`T*("`@("`@/"]T86)L93X\8G(O/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O M;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^3D]410T*("`@#0H@("`@("`T("T@0T]-34].(%-43T-+(%=!4E)! M3E13/"]F;VYT/@T*("`@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@65A28C.#(Q-SMS('!R:6]R(&QE;F1E2<^#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SY4:&4-"B`@(`T*("`@("`@3VUN:6)U0T*("`@("`-"B`@("`@(&)E;&EE=F5S(&ES('1H M92!A<'!R;W!R:6%T92!V86QU871I;VX@;65T:&]D('5N9&5R('1H90T*(`T* M("`@("`@8VER8W5M'!E M8W1E9"!V;VQA=&EL:71Y(&ES(&)A6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E. M12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=. M.B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X- M"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$T)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@ M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SY*=6YE#0H@(`T*("`@("`@("`@("`@("`S M,"P@,C`Q,3PO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`- M"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P M=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG M;CTS1&-E;G1E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO M='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@("`@("`@/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,"4^#0H@ M(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0S)3X-"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0S)3X-"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F M="!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H@ M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@ M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,R4^#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`\+W1R/@T*("`@("`-"B`@("`@("`@ M/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X- M"B`@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E M/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^ M#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T M)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY2:7-K+69R964- M"B`@("`-"B`@("`@("`@("`@("`@("!I;G1E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*("`@#0H@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H@("`@#0H@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,3AP=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/@T*("`@#0H@("`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"B`@("`- M"B`@("`@("`@("`@(#QD:78@6QE/3-$)V)A8VMG M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"B`@("`-"B`@("`@("`@("`@(#QD M:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*("`@#0H@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F M;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H@("`@#0H@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXV."XT)3PO9F]N=#X- M"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\ M+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*("`@#0H@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`\ M+W1R/@T*("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^17AP96-T960-"B`@(`T*("`@("`@("`@("`@ M("`@('1E6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#0E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T* M("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q,"4^#0H@("`@#0H@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP M=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG M;CTS1')I9VAT/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#0E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@ M(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q,"4^#0H@("`@#0H@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXS+C`\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`- M"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,R4^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T* M("`@("`@/"]T86)L93X\8G(O/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M"!$:7-C;&]S=7)E(%M497AT($)L M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=CX-"B`@ M#0H@("`@("`F(S$V,#LF(S$V,#L\8G(@+SX-"B`@("`-"B`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^3D]410T*("`@#0H@("`@("`U("T@24Y#3TU%(%1!6$53/"]F;VYT/@T* M(`T*("`@(#PO9&EV/CQB2<^#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)SY4:&4-"B`@(`T*("`@("`@=71I;&EZ871I;VX@;V8@3D], M(&%N9"!C2!B M92!U2!E=F%L=6%T97,@:71S(&%B:6QI='D@=&\@=71I;&EZ90T* M("`@#0H@("`@("!T:&4@;F5T(&]P97)A=&EN9R!L;W-S97,@96%C:"!P97)I M;V0@=VET:"!R96=A65A M65AF%B;&4L(&%N9"!R96UO=F5D(&9R;VT@=&AE('-C:&5D=6QE M(&]F(&1E9F5R65A6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U! M4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J=7-T:69Y)SX-"B`@(`T* M("`@("`@/&9O;G0@`T*("`-"B`@("`@(&)E;F5F:70@:6X@=&AE(&%C8V]M<&%N>6EN9R!U M;F%U9&ET960@8V]N9&5N2!F961E'!E;G-E2X\+V9O;G0^#0H@(`T*("`@(#PO9&EV/CQB2<^#0H@("`-"B`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)SY4:&4-"B`@(`T*("`@("`@0V]M<&%N M>2!R96-E:79E9"!1048@*$YO=&4@,3$I('!A>6UE;G1S(&EN('1H92!F:7)S M="!Q=6%R=&5R#0H@(`T*("`@("`@;V8@=&AE(&-U`T* M("`@#0H@("`@("!E>'!E;G-E("AB96YE9FET*2!B>2!A<'!L>6EN9R!T:&4@ M97-T:6UA=&5D(&%N;G5A;"!E9F9E8W1I=F4-"B`@#0H@("`@("!T87@@2<^ M#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SY4:&4-"B`@(`T*("`@("`@0V]M<&%N>2!E=F%L=6%T960@:71S(&AI'1E;G0@=&\@=VAI8V@@=&AE(&YE M="!D969E6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E. M12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=. M.B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@&EM871E;'D@)FYBF%T:6]N(&]F('1H97-E(&-R961I M=',@:7,@86QS;R!S=6)J96-T('1O('-I9VYI9FEC86YT#0H@#0H@("`@("!) M4D,@4V5C=&EO;B`S.#,@;&EM:71A=&EO;G,L(&%N9"!T:&5S92!L:6UI=&%T M:6]N2!C;VUP86YY+B!00TA))W,-"B`@(`T*("`@ M("`@=&%X86)L92!I;F-O;64@;W(@;&]S2!A;6]U;G1S(&9O"!E>'!E;G-E(&]R M(&)E;F5F:70L(&]R#0H@("`-"B`@("`@(&QI86)I;&ET:65S(')E;&%T960@ M=&\@4$-(22=S(&EN8V]M92!O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX-"B`@#0H@("`@("`F(S$V,#LF(S$V,#L\ M8G(@+SX-"B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^3D]410T*("`@#0H@("`@("`V M("T@4U1/0TL@24Y#14Y4259%(%!,04X\+V9O;G0^#0H@("`@#0H@("`@/"]D M:78^/&)R+SX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N M,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4:&4- M"B`@(`T*("`@("`@0V]M<&%N>2=S(#(P,#8@4W1O8VL@26YC96YT:79E(%!L M86X@*'1H92`B4&QA;B(I+"!W:&EC:"!I65A2!P65A2P@ M87,@;V8@2G5N92`S,"P@,C`Q,2P@=&AE(&UA>&EM=6T@86=G0T*("`@#0H@("`@("!B96QI979E M2!O9B!T:&4@9W)A;G0-"B`@#0H@("`@("!D M871E+"!A;F0@86X@861D:71I;VYA;"`Q+S$R(&]F('1H92!S:&%R97,@=F5S M="!O;B!E86-H#0H@(`T*("`@("`@2DN($-E65A3X-"B`@ M(`T*("`@("`@/&9O;G0@'!E8W1E9"!T97)M(&ES M(&-A;&-U;&%T960@8GD@=&%K:6YG('1H92!S=6T@;V8-"B`@#0H@("`@("!T M:&4@=F5S=&EN9R!T97)M('!L=7,@=&AE(&]R:6=I;F%L(&-O;G1R86-T=6%L M('1E2!B M>2!T=V\N/"]F;VYT/@T*("`@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@3X-"B`@(`T*("`@("`@/&9O;G0@&5R8VES960-"B`@("`@#0H@("`@("!D=7)I M;F<@=&AE('1H2!O9B!S=&]C:R!O<'1I;VX@86-T M:79I='D@9F]R('1H92!T:')E92!M;VYT:',@96YD960-"B`-"B`@("`@($IU M;F4@,S`L(#(P,3$@:7,@<')E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X- M"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9"<^#0H@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^4VAA6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY796EG:'1E9"T\ M+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N M,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#ME>&5R8VES93PO9F]N=#X-"B`@("`-"B`@ M("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#MP6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SY796EG:'1E9"T\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]D M:78^#0H@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@ M3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS M1&-E;G1E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#MG6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@ M("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U! M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=( M5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T* M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[879E6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[8V]N M=')A8W1U86P\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@ M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E' M2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^06=G M6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#MI;G1R:6YS:6,\+V9O;G0^#0H@("`@(`T*("`@("`@ M("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS M1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1% M3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T M)R!A;&EG;CTS1&-E;G1E6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`-"B`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Y)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`-"B`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"B`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)3X-"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X-"B`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`-"B`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X- M"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^3W5T6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@ M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N M,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/@T*("`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@ M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T* M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@ M(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/@T* M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@ M(`T*("`@("`@("`\+W1R/@T*("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$ M)V)A8VMG6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^1W)A;G1E9#PO9F]N=#X- M"B`@("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@ M(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@ M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X-"B`@(`T*("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N M,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/@T*("`-"B`@("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^+3PO9F]N=#X- M"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@ M/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@ M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/@T*("`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`\+W1R/@T*("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X-"B`@(`T*("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[ M($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S M='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$58 M5"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=( M5#H@,'!T)R!A;&EG;CTS1')I9VAT/@T*("`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^+3PO9F]N=#X-"B`@ M("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]D M:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/@T*("`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@ M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#@E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z M(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX- M"B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U( M14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT M/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^*#(P/"]F;VYT/@T*(`T*("`@("`@("`@("`@("`\+V1I M=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=( M5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`- M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^*3PO9F]N=#X-"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@ M(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^ M#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX- M"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#@E/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!, M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@ M("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@ M,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXP+C(U/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@ M(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^ M#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO M=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0X)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#DE/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@ M(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0X)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SY/=71S=&%N9&EN9RP-"B`@#0H@("`@("`@("`@("`@("`@2G5N92`S,"P@ M,C`Q,3PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@ M("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@ M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)SX-"B`@ M(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@ M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T* M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)SX-"B`@(`T* M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z M(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=) M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/@T*("`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G/@T*("`@#0H@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)V)A8VMG6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^17AE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@ M9&]U8FQE)SX-"B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P M=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`- M"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E' M2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@ M#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#@E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@ M(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G M/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y% M+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)FYB6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1&IU7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA3X-"B`@ M(`T*("`@("`@/&9O;G0@65R#0H@#0H@("`@ M("!C;VYT7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M3D]410T*("`@#0H@("`@("`X("T@24Y#3TU%(%!%4B!32$%213PO9F]N=#X- M"B`@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@ M3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%, M24=..B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@2!D:79I9&EN9R!T:&4@;F5T(&EN M8V]M92!B>2!T:&4@=V5I9VAT960@879E2!I;F-U7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^3D]410T*("`@#0H@ M("`@("`Y("T@5D%224%"3$4@24Y415)%4U0@14Y42519/"]F;VYT/@T*("`@ M#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U( M14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J M=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@2=S("9N8G-P.R0T-2XP#0H@("`- M"B`@("`@(&UI;&QI;VX@5&5R;2!.;W1E+B!4:&4@0V]M<&%N>2!R96UA:6YS M('!R:6UA2!L:6%B;&4@87,-"B`@("`@#0H@("`@("!T:&4@8F]R2!S=6)S=&%N=&EA;&QY(&%L;"!O9B!T:&4@0V]M<&%N>2=S#0H@ M("`@(`T*("`@("`@87-S971S(&%N9"!A;&P@;V8@=&AE(')E86P@<')O<&5R M='D@;V8@=&AE($AO2!E;G1I='D@=&AA="!I2!O9B!F:6YA;F-I86P@6UE;G1S+"!R96UA:6YI;F<@<')I;6%R:6QY#0H@ M("`-"B`@("`@(&QI86)L92!U;F1EF%T:6]N(&]F('1H92!#;VUP86YY)W,@;F]N+7)E86P@97-T871E#0H@("`- M"B`@("`@(&%S2P-"B`@("`@#0H@("`@("!T:&4@ M9FEN86YC:6%L('-T871E;65N=',@;V8@4$-(22!A6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T M.R!415A4+4%,24=..B!J=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@"<^#0H@ M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@ M"<^#0H@("`-"B`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^2G5N90T* M("`-"B`@("`@("`@("`@("`@,S`L/"]F;VYT/@T*(`T*("`@("`@("`@("`@ M/"]D:78^#0H@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P M=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG M;CTS1&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B M;W1T;VT^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^ M#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^0V%S:#PO9F]N=#X-"B`@#0H@("`@("`@("`@ M("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@ M("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P M<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!, M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@ M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#DE/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P M<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!, M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXS,S`\+V9O;G0^#0H@#0H@("`@("`@("`@("`@ M(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@ M("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@ M("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY0 M2P-"B`@("`-"B`@("`@("`@("`@("`@("!N970\+V9O;G0^#0H@ M("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]D M:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/@T*("`@#0H@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXT,2PY-3$\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@ M(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@ M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y% M+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F M=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^3W1H97(\+V9O;G0^#0H@("`-"B`@("`@("`@("`@("`@ M/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ-#(\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO9&EV M/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXW,#PO9F]N=#X-"B`@ M("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO M9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@ M("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`\+W1R/@T*("`@("`-"B`@("`@ M("`@/'1R('-T>6QE/3-$)V)A8VMG"<^#0H@(`T*("`@("`@("`@ M("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U! M4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL M93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U) M3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G/@T*("`@#0H@ M("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@ M,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$ M)U!!1$1)3D"<^#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO M=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE M)SX-"B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E. M12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N M,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO M='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/@T*("`@#0H@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F M;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"B`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO M='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@ M(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T* M("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O M;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/@T*("`@#0H@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SY$96)T#0H@("`@#0H@("`@("`@("`@("`@("`@ M*&%S(&=U87)A;G1O6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T* M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A% M24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X- M"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)FYB6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@ M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#DE/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P M<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!, M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXT-2PP,#`\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`- M"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T* M("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^3W1H97(\+V9O;G0^ M#0H@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@ M/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=( M5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXV,3<\+V9O;G0^#0H@#0H@("`@("`@("`@("`@(#PO9&EV/@T* M("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D M/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@"<^#0H@#0H@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=( M5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXV,S0\+V9O;G0^#0H@#0H@("`@("`@("`@("`@(#PO9&EV/@T* M("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D M/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@"<^#0H@#0H@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`\ M+W1R/@T*("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T* M("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Y)3X-"B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL M93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U) M3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@ M,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@ M3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS M1')I9VAT/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^-#4L-C,T/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@ M(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`\+W1R/@T*("`@("`- M"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#DE/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@ M("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Y)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@ M("`@("`\='(@"<^#0H@(`T*("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N M,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@("`@("`@/&1I M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y% M+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXH,RPS,C4\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@ M("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@"<^ M#0H@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A% M24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO M9F]N=#X-"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@ M("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y% M+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXH,BPY-C$\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@ M("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@"<^ M#0H@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A% M24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO M9F]N=#X-"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@ M("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`\+W1R/@T*("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG M"<^#0H@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P M=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)SX-"B`- M"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E.12U(14E' M2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@ M#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B M;&4G/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!, M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@ M("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@ M,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@ M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)FYB6QE/3-$)U!!1$1)3D"<^#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T* M("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`T<'@@9&]U8FQE)SX-"B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS M1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1% M3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T M)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@3$E. M12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE M9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@/"]T86)L93X\8G(O/CQD M:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY!2!N;W0@8F4@86)L92!T;PT*("`@("`-"B`@("`@ M('!E2=S(&UA>&EM=6T@ M97AP;W-U2<^#0H@("`- M"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY00TA) M#0H@("`@#0H@("`@("!R96YT86P@:6YC;VUE(&%N9"!T:&4@0V]M<&%N>28C M.#(Q-SMS(')E;&%T960@2X\+V9O;G0^#0H@("`@ M#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U( M14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!J M=7-T:69Y)SX-"B`@(`T*("`@("`@/&9O;G0@7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA2!43X-"B`@(`T*("`@("`@/&9O;G0@2!V87)I;W5S#0H@("`-"B`@ M("`@('!H>7-I8VEA;B!I;G9E2!H87,@8V]N6EN9R!U;F%U9&ET960@8V]N9&5N7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA3X-"B`@(`T*("`@("`@/&9O;G0@2!T:&4@:&]S<&ET86P@:6YD M=7-T0T*("`@(`T*("`@("`@ M0TU3+B!,96=I6UE;G1S(')E8V5I=F5D(&)Y($UE M9&DM0V%L#0H@#0H@("`@("!M86YA9V5D(&-A6EN9R!U;F%U9&ET960@8V]N9&5N M'!E;G-E3X-"B`@(`T*("`@("`@/&9O;G0@'1E;G-I;VX@;V8@=&AE(%%!1@T* M("`@#0H@("`@("!F;W(@=&AE('-I>"!M;VYT:"!P97)I;V0@9G)O;2!*86YU M87)Y(#$@=&AR;W5G:"!*=6YE(#,P+"`R,#$Q#0H@("`-"B`@("`@("@F(S@R M,C`[,C`Q,2!1048F(S@R,C$[*2X\+V9O;G0^#0H@("`-"B`@("`\+V1I=CX\ M8G(O/CQD:78@3X-"B`@(`T*("`@ M("`@/&9O;G0@6UE M;G1S#0H@("`-"B`@("`@(&9O'!E;G-E2`F;F)S<#LD,34N."!M:6QL:6]N(&%N9"!R96-E M:79I;F<@87!P0T*("`@("`-"B`@("`@("9N8G-P.R0S,2XV M(&UI;&QI;VX@:6X@;F5T(')E=F5N=65S(&9R;VT@=&AE('-T871E("@F;F)S M<#LD,3@N,2!M:6QL:6]N#0H@#0H@("`@("!F2!H87,-"B`-"B`@("`@(')E8V5I=F5D M("9N8G-P.R0Q-RXR(&UI;&QI;VX@9G)O;2!T:&4@9F5E+69O6EN9R!U;F%U9&ET M960@8V]N9&5N6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z M(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4 M:&4-"B`@(`T*("`@("`@0V]M<&%N>2!C86YN;W0@<')O=FED92!A;GD@87-S M=7)A;F-E3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]B-&5A,S)A,U]B960S7S0Y,#E?.3@S8E]A M,3'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS M1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1% M3E0Z(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T M)R!A;&EG;CTS1&QE9G0^#0H@("`@(`T*("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A M;&EG;CTS1&IU6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SY'54%204Y4144F(S$V,#LM#0H@("`@(`T*("`@ M("`@070@2G5N92`S,"P@,C`Q,2P@=&AE($-O;7!A;GD@86-C3X-"B`@ M(`T*("`@("`@/&9O;G0@3X-"B`@(`T*("`@("`@/&9O M;G0@'1E;F1E9"!C M;VYC=7)R96YT;'D@=VET:"!T:&4@87-S:6=N;65N="!O9B!T:&4@;&5A6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E. M12U(14E'2%0Z(#$N,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU M6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)SY)3E-54D%.0T4-"B`@("`-"B`@("`@("T@5&AE($-O;7!A;GD@ M86-C2!C;&%I;7,L('1O('1H92!E>'1E;G0@ M;F]T(&-O=F5R960@8GD@:6YS=7)A;F-E+`T*("`@(`T*("`@("`@=VAE;B!T M:&5Y(&%R92!P2!E2!F;W(@9V5N97)A;"!A;F0@<')O9F5S0T*("`-"B`@("`@(')I6EN9R!U;F%U9&ET960@8V]N9&5N3X-"B`@(`T*("`@("`@/&9O;G0@2!H87,@ M82`B9W5A2!I;G-U2!A2!E'!E;G-E2!I6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY);@T*("`-"B`@("`@(&%D M9&ET:6]N+"!T:&4@0V]M<&%N>2!H87,@82!S96QF+6EN2!H87,@97-T86)L:7-H960-"B`- M"B`@("`@(&%N9"!M86EN=&%I;G,@86X@86-C2!D971E0T*(`T*("`@("`@;V8@=&AI2=S('5N875D:71E9`T*("`@#0H@("`@("!C;VYD96YS960@ M8V]N2!H860@86-C0T*("`@("`-"B`@("`@(&)E;&EE M=F5S('1H:7,@:7,@=&AE(&)E3X-"B`@(`T*("`@ M("`@/&9O;G0@2!L87EE2!R:7-K2P@86YD#0H@(`T*("`@("`@=V]R:V5R65R2!F:6YA;F-E6EN9R!U;F%U9&ET960@8V]N M9&5N6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SX-"B`@#0H@("`@("`@(#QT6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@ M("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SY*=6YE#0H@(`T*("`@("`@("`@("`@("`S,"P\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,C`Q,3PO9F]N=#X- M"B`@("`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@"<^#0H@("`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@"<^#0H@("`-"B`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^36%R8V@-"B`@ M(`T*("`@("`@("`@("`@("`S,2P\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+V1I=CX-"B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^,C`Q,3PO9F]N=#X-"B`@("`@#0H@("`@("`@ M("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@"<^#0H@("`-"B`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@ M("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@("`@("`@/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T M;VT^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SY06QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\ M+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#DE/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T* M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A% M24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXR+#(X,CPO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\ M+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@ M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#DE/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G M/@T*(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y% M+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXS+#$P.#PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@ M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@ M("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`\+W1R/@T*("`@("`-"B`@("`@ M("`@/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#DE/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO M=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@ M(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Y)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\ M='(@6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y% M+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M06-C6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S M<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@ M("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/@T* M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A% M24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ M+#4R,SPO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@ M("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@ M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X- M"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@ M#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE M/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y% M+4A%24=(5#H@,2XR-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXQ+#DU,3PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@ M#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^ M#0H@(`T*("`@("`@("`\+W1R/@T*("`@("`-"B`@("`@("`@/'1R('-T>6QE M/3-$)V)A8VMG6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR M-3L@34%21TE.+5))1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*$EN8VQU9&5D#0H@ M("`@#0H@("`@("`@("`@("`@("`@:6X@;W1H97(@8W5R6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^ M#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y M)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO M=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@ M(#PO=&0^#0H@(`T*("`@("`@("`\+W1R/@T*("`@("`-"B`@("`@(#PO=&%B M;&4^/&)R+SX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N M,C4[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU2!A;F0@=&AE($AO2!H879E(&$@ M;6%T97)I86P@861V97)S92!E9F9E8W0@;VX@=&AE#0H@("`-"B`@("`@("`@ M0V]M<&%N>2=S(&)U2!A9V%I;G-T#0H@("`-"B`@("`@("`@8VQA:6US(&%N9"!L87=S=6ET6UE;G0@ M;V8@2!T:&4@=V%Y M(&ET0T*("`-"B`@("`@ M("`@97-T:6UA8FQE+CPO9F]N=#X-"B`@#0H@("`@("`\+V1I=CX\8G(O/CQD M:78@3X-"B`@("`@#0H@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4:&4-"B`@("`@ M#0H@("`@("`@(&9O;&QO=VEN9R!I2!0:'ES:6-I86YS($EN=F5S=&UE;G0-"B`- M"B`@("`@("`@3F5T=V]R:RP@3$Q#("@F(S@R,C`[3T,M4$E.)B,X,C(Q.RD@ M=&AA="!W87,@:61E;G1I9FEE9"!I;@T*("`@("`-"B`@("`@("`@;W5R($9O M3X- M"B`@("`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)SY/;@T*("`@(`T*("`@("`@("!!<')I;"`R-"P@,C`P.2P@82!C;VYG M;&]M97)A=&EO;B!O9B!S979E2!'+B!-96MA+"!-+D0N(&9I;&5D(&$@;&%W7,L(&%L;&5G:6YG#0H@ M(`T*("`@("`@("!B2`R,"P@,C`Q,2P-"B`@ M(`T*("`@("`@("!/0RU024XF(S@R,3<[2!P;&%C960@82!D M96UA;F0@;VX@=&AE($-O;7!A;GD@=&\-"B`@("`@#0H@("`@("`@('-E870@ M='=O(&1I2!R96QI968@87,@=&\@:&]W(&ET(&UU7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6QE/3-$)T9/3E0M M5T5)1TA4.B!B;VQD)SY.3U1%(#$S)B,Q-C`[+2!354)315%514Y4#0H@(`T* M("`@("`@159%3E0\+V9O;G0^/"]F;VYT/@T*("`@#0H@("`@/"]D:78^/&)R M+SX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,S9P=#L@3$E.12U(14E'2%0Z(#$N,C4[($U! M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY/;@T*("`-"B`@ M("`@($IU;'D@,2P@,C`Q,2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O('-O M9G1W87)E(&%N9"!S97)V:6-E2!S M>7-T96US+CPO9F]N=#X-"B`-"B`@("`\+V1I=CX\8G(O/CQD:78@3X-"B`@(`T*("`@("`@/&9O;G0@2!W:71H(&$-"B`@(`T*("`@("`@=F%R:65T>2!O9B!S97)V:6-E2!S>7-T96US+B8C M,38P.R8C,38P.TUC2V5S2!H87,@96YT97)E9"!I;G1O('1H90T*(`T*("`@("`@87)R86YG96UE;G0@ M=&\@96YH86YC92!I=',@8VQI;FEC86P@:6YF;W)M871I;VX@3X-"B`@(`T*("`@("`@/&9O;G0@2!M87D@8F4@=&5R;6EN M871E9"!B>2!T:&4@0V]M<&%N>2!P2`V,"4@;V8@=&AE(&9E97,-"B`@(`T*("`@("`@87)E(&9O M3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]B-&5A,S)A,U]B960S7S0Y,#E?.3@S8E]A,3&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U&UL/@T*+2TM M+2TM/5].97AT4&%R=%]B-&5A,S)A,U]B960S7S0Y,#E?.3@S8E]A,3